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Abstract 
Background: Data from epidemiological studies demonstrate an inverse association 
between high intakes of anthocyanins and risk of cardiovascular disease. The human 
and animal dietary intervention studies also showed that consumption of anthocyanin-
rich extracts and foods causes beneficial changes in lipid profiles. However, the 
potential mechanisms of action are yet to be fully elucidated; in particular, is it the 
anthocyanins per se or their metabolites that cause the changes, and what are the 
gene/protein targets in the lipoprotein metabolic pathways? Therefore, the aim of this 
research was to develop a mechanistic understanding of how anthocyanins and/or 
their metabolites alter lipid/lipoprotein metabolism and improve HDL function.  
Approaches: Using cultured macrophages, the effects of the two main dietary 
anthocyanins and a large number of their metabolites on the expression of key genes 
involved in reverse cholesterol transport (RCT), and on the expression and enzyme 
activities of paraoxonase-1 (PON1) (marker of HDL function) were tested at 
physiologically relevant concentrations. The effects of anthocyanin consumption on 
cholesterol efflux transporters was investigated by quantifying the expression of 
ABCA1 and ABCG1 in aortic and liver tissues from ApoE-/- mice that had consumed 
diets supplemented with anthocyanin-expressing tomatoes compared to mice that 
had consumed diets supplemented with anthocyanin-free (control) red tomatoes. The 
broader effects of three major anthocyanin metabolites was assessed using RNA seq 
to study genome-wide changes in gene expression in cultured human macrophages. 
A randomized placebo-controlled crossover human intervention study was conducted 
using purified anthocyanin extracts to investigate the effects of consuming 
anthocyanins on lipid/lipoprotein profiles and biomarkers of HDL function and 
interactions with PON1 genotype.  
Results: None of the tested anthocyanins or their metabolites significantly altered the 
expression of cholesterol transporter (ABCA1, ABCG1) or scavenger receptor 
(MSR1, SCARB1 and CD36) genes (the key genes involved in RCT), nor did they 
affect the expression of the PON1 gene or the activities of the enzyme. In addition, 
RNA seq analysis revealed that treatment with the three major anthocyanin 
metabolites did not cause any significant changes in the expression of macrophage 
genes or affect pathways related with atherosclerosis. In the human dietary 
intervention with high doses of isolated anthocyanins, no significant changes in lipid 
profiles, ApoA1, ApoB1, HDL subfractions and biomarkers of glycemic control were 
observed compared to the placebo after 4 weeks of intervention. The human 
II 
 
intervention also showed no significant interaction between the consumption of 
anthocyanin, biomarkers of HDL function, PON1 activities and PON1 genotype.   
Conclusion: In conclusion, the data in this thesis do not support the notion that 
anthocyanins or their metabolites improve lipid/lipoprotein profiles and biomarkers of 
HDL function.    
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1.1. Structure of the thesis 
The data presented in this thesis is about the underlying molecular mechanisms by 
which anthocyanins and their metabolites would provide atheroprotective effects with 
the main focus on lipid metabolism using in-vitro and in-vivo models. Chapter one 
introduces anthocyanins, their bioavailability and metabolism, their related health 
benefits. It defines the gaps in knowledge which need to be investigated and details 
the aims and objectives of this thesis. Chapters two and three present the results of 
in-vitro models that were used to investigate the effects of anthocyanins and their 
selected metabolites on markers related to reverse cholesterol transport and HDL 
function. Chapter four presents RNA transcriptomic analysis as a non-targeted in-vitro 
approach to identify other possible atherosclerosis-linked genes and the pathways 
affected by the anthocyanins. Chapter five, on the other hand, presents the results of 
a human intervention trial conducted to investigate the effects of two different types 
of purified anthocyanin extracts on lipid/lipoprotein profiles and quality, and markers 
of HDL function.     
1.2. What are (poly)phenols 
(Poly)phenols are a diverse group of phytochemicals containing single or multiple 
phenol rings [1]. They are distributed in the plant kingdom, including fruits and 
vegetables [2]–[5]. (Poly)phenols are secondary metabolites arising from the 
shikimate and acetate-malonate (malonyl-CoA) biosynthetic pathways in plants [6]–
[8]. There are more than 8,000 phenolics and (poly)phenols are classified into 
subgroups according to their chemical structure. Flavonoids, phenolic acids, lignans 
and stilbenes are the main subgroups of (poly)phenols [9], [10]. The flavonoids 
subgroup can be further classified into anthocyanins, flavan-3-ols, flavanones, 
flavonols, flavones and isoflavones [11]. Fig 1.1 and 1.2 demonstrate the main 
(poly)phenols and flavonoids classes. Although, (poly)phenols are found in all plant 
tissues, they are usually most concentrated in fruits and leaves [12]. The main sources 
of (poly)phenols in food are fruits, vegetables, tea, wine, beverages, chocolate and 
other cocoa products [11], [13], [14]. The main focus of my project was anthocyanins; 
thus this class will be described in more detail.    
1.3. Anthocyanins, what they are? 
Anthocyanins are a subgroup of flavonoid-type bioactive compounds that belong to 
the overarching phytochemical group called (poly)phenols [15]. Anthocyanins are one 
of the most important plant pigments that are responsible for red, pink, violet and blue 
colours of fruits, seeds, flowers and other parts of many plants [16], [17].  
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Figure 1. 1: Chemical structure of (poly)phenols.  
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Figure 1. 2: Chemical structure of flavonoids. 
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The word anthocyanin is derived from the two Greek words anthos (= flower) and 
kianos (= blue) [18]. Their water-soluble nature makes them the most commonly used 
colourants in the food industry [19]. Anthocyanins are predominately present in the 
skin of fruits, although in berries, they are found in the skin and flesh [20]. 
Anthocyanins are involved in many functional roles in plants such as attracting the 
pollinators and seed dispersing animals ; and protecting against UV light and other 
environmental stress factors [21], [22].  Anthocyanins have two absorption peaks, one 
in the UV range between 270 to 280 nm and another which is in the visible region 
between 465 to 550 nm [23], [24].  
1.3.1. Chemical structure of anthocyanins 
Chemically, anthocyanins consist of an aglycon called anthocyanidin bound to several 
sugar moieties [25]. Anthocyanidins are polyhydroxy or polymethoxy derivatives of 2-
phenylbenzopyrylium and have the same C6-C3-C6 general backbone structure of 
flavonoids [26]. Anthocyanidins consist of three aromatic rings; the A-, B- and C-rings  
(Fig 1.3) [27]. The A-ring and C ring are fused together and bonded by a carbon–
carbon bond to the B-ring [28]. To form the glycoside form (anthocyanins), a sugar 
molecule glycosidically linked to a hydroxyl group on the anthocyanidin (aglycon), at 
the 3-position on the C-ring or the 5, 7-position on the A-ring [29]. The sugar 
molecules are usually glucose, rhamnose, galactose or arabinose and are attached 
as mono-, di-, or trisaccharide forms [30].  
1.3.2. Types and distribution of anthocyanins 
There are many types of anthocyanins in nature. To date, more than 500 
anthocyanins and 17 anthocyanidins have been reported and the number is still rising 
[31]. The main differences between them are the number and positions of hydroxyl 
and methoxyl groups attached to anthocyanidin structure; the nature and the number 
of the sugar moiety bonded with anthocyanidin; and the position of these bonds [32], 
[33]. Among the 17 anthocyanidins present in nature, only six are common in food; 
cyanidin, delphinidin, pelargonidin, peonidin, petunidin, and malvidin (see Fig 1.3)  
[34]. The distribution of these aglycons is: Cyanidin 50%, delphinidin 12%, 
pelargonidin 12%, peonidin 12%, petunidin 7% and malvidin 7% [35]. These six 
aglycons differ chemically at the 3` and 5` position of the B-ring (see Fig 1.3). 
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Figure 1. 3: Chemical structures of anthocyanins 
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Anthocyanins also differ in colour according to the substitution at the B-ring with colour 
goes toward  more bluish if more hydroxyl groups are present or goes toward redness 
if more methoxyl groups are present [36], [37]. The non-methylated anthocyanidins 
(cyanidin, delphinidin, and pelargonidin) are found in 80% of pigmented leaves, 69% 
in fruits and 50% in flowers. Moreover, 3-monoglycosides, 3-diglycosides, and 3,5-
diglycosides are most commonly sugars bound to anthocyanidins. Furthermore, 3-
monoglycosides occurrence is 2.5 times higher than other glycosides and cyanidin-3-
glucoside is the most abundant anthocyanin type found in nature [17]. 
1.3.3. Anthocyanins sources and daily intake 
Fruits including red and blue berries, blackcurrant, blood orange and red grape, 
vegetables with coloured skin, as well as red wine, are the most common sources of 
anthocyanins amongst a long list of other human dietary sources [10].  
Within different plants, anthocyanins content ranges from 0.25 mg/100 g Fresh 
Weight (FW) in pear to 500 mg/100 g FW in blueberries [38]. Also, anthocyanin levels 
noticeably vary in the same plant according to the cultivar, season and agronomic 
factors [39]. In fruit, the major sources of anthocyanin were found to be elderberry, 
chokeberry, bilberry, raspberry, blueberry, blackberry and red grape, while, purple 
corn and red cabbage are the main anthocyanin sources in vegetables. Table 1.1 
shows the total anthocyanin content of some fruits and vegetables.   
Not only the anthocyanin content but also the anthocyanin type is quite different 
among food sources. For instance, black raspberry contain the highest levels of 
cyanidin-type anthocyanins (669 mg/ 100 g FW), while, black currant contain the 
highest levels of delphinidin-type anthocyanins (333 mg/100g FW) [40].  
The average daily intake of anthocyanins strongly depends on various factors like the 
dietary habits of a population, season and culture. Therefore, there are big differences 
in the reported anthocyanins intake [40] . In Europe, the mean intake of 
anthocyanidins for men ranged from 19.8 mg/day (Netherlands) to 64.9 mg/day (Italy), 
whereas for women the range was 18.4 mg/day (Spain) to 44.1 mg/day (Italy). 61 % 
of habitual intake comes from fruit, while wine contributed to 14.4-24.5% of intake. 
Higher consumption by Italians may result from their Mediterranean diet, which 
includes berries, and other red and blue-coloured fruits, and red wine [15]. In Finland, 
on the other hand, the daily intake of anthocyanins was suggested to be 82 mg/day 
[18]. The anthocyanins daily intake in USA was estimated to be 12.5 mg/day based 
on the concentration data and updated food intake data from NHANES 2001−2002 
[40]. On the other hand, some reports suggested that the daily consumption of 
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anthocyanins is anywhere from 3 to 215 mg/day as previous data were derived from 
questionnaires and dietary recall which often underestimate intakes. Doses ranging 
from 400 to 500 mg of anthocyanins can easily be obtained from one serving of berries 
and some juices [41].  
 
Table 1. 1: Anthocyanins content in common dietary sources 
Food 
Total anthocyanins content 
(mg/100 g fresh weight) 
Reference 
Elderberry 200-1816 [27], [40] 
Chokeberry 410-1480 [37] 
Red grape 30-750 [42] 
Bilberry 300-698 [43]–[45] 
Raspberry 20-687 [46], [47] 
Blueberry 25-495 [48]–[50] 
Blackberry 82.5-325.9 [51], [52] 
Plum 2-25 [26] 
Strawberry 13-36 [51], [53] 
purple corn 1642 [54] 
Eggplant 750 [55] 
Cabbage 322 [35] 
Black rice 23-207 [56]–[60] 
Port Wine 14-110 (mg/100mL) [61] 
Red wine 16.4-35 (mg/100mL) [62], [63] 
Pomegranate (Juice) 44 (mg/100mL) [64], [65] 
 
 
10 
 
1.4. Bioavailability and metabolism of anthocyanins 
Bioactive compounds such as anthocyanins need to be bioavailable in order to exert 
their activity. Therefore, it is not only important to know the concentration of nutrients 
in food, but it is even more important to know the fate of these nutrients in the body 
and how much is bioavailable. The term “bioavailability” means the proportion of the 
nutrient that is digested, absorbed and reaches the circulation intact after oral 
administration. Other definitions included both intact and metabolised forms  [38].  
The biological activities of anthocyanins are strongly linked to their absorption and 
metabolism in vivo.  Anthocyanins can be rapidly absorbed and detected in circulation 
within minutes of consumption in their parent forms as a result of absorption through 
gastrointestinal tract, in particular from the small intestine [66], [67]. Anthocyanins 
required 0.5 to 2 h to reach Cmax in plasma which is far faster than other flavonoids 
[27]. Some researchers suggested that the anthocyanin metabolism start in the oral 
cavity as a result of interaction with salivary proteins and digestive enzymes [19], [46]. 
In saliva samples that collected from healthy volunteers following a human 
intervention with black raspberry, several derivatives of black raspberry anthocyanins 
were detected including their hydrolysed from (aglycon), glucuronidated conjugates 
and few quantities of protocatechuic acid resulting from the activity of β-glycosidase 
derived from bacteria and oral epithelial cells or as a result of oral microbiota [46]. 
However, there is no information about the absorption of anthocyanins in the oral 
cavity [18].  
In the stomach, given the quick appearance of anthocyanin in the circulation after 
ingestion (approximately 30 min), it was suggested that anthocyanins able to cross 
the gastric system and reach to the circulation [19], [27]. This suggestion was 
supported with in vivo and in situ models (using mainly rat model) and reported that 
about 20% of the total absorbed anthocyanins were absorbed from the stomach in 
their intact forms [68]–[70]. The reason could be that the acidic gastric juice increased 
the stability of glycoside forms [52], [69]. In fact, there is ambiguous information 
whether the stomach is only an absorption organ or metabolizing organ and the 
mechanism of anthocyanin gastric absorption remains unknown [19]. Although the 
reported absorption of anthocyanin in stomach, the vast majority of animal and human 
studies suggest that the intestine is the major site of anthocyanin absorption [71]. 
After passing the stomach, anthocyanins arrive in the small and large intestine. 
Following entry into the small intestine where more basic conditions are present, the 
intact as well as methylated and conjugated forms of anthocyanins were quickly 
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absorbed [52]. The absorption is associated with the action of several hydrolysis 
releasing enzymes such as lactase phlorizin hydrolase in the brush border of the small 
intestine. The aglycones usually undergo phase II transformation in the enterocytes, 
producing sulphate, glucuronides, and/or methyl forms through the respective action 
of sulfotransferases, uridine-5`-diphosphate glucuronosyltransferases and catechol-
O-methyltransferases [71]. Unabsorbed anthocyanins then reach the colon where 
substantial structural modification takes place including ring fusion and phase 11 
metabolism leading to the production of many smaller molecules such as phenolic 
acids and their conjugates. Microbiota most likely play an essential role in this 
biotransformation [15].  
In general, the absorption of anthocyanins is dependent on their molecular structure. 
In human and rat, the glycosylated forms are less absorbed than the hydrolysed forms  
[72]. Probably because the glycosylated forms have higher molecular weight. 
Moreover, anthocyanins carrying the same sugar moiety were absorbed as following: 
delphinidin > cyanidin > malvidin. This may be a result of the greater number of 
hydroxyl groups in delphinidin or the greater hydrophobic nature of malvidin. Similarly, 
anthocyanins with the same aglycone type were absorbed in the order: galactoside > 
glucoside > arabinoside [72].  
Comparing the amount of the intact anthocyanins absorbed and excreted in urine to 
the total ingested doses; anthocyanins appear to have low bioavailability, with a 
recovery of < 1% of consumed doses of anthocyanins in the majority of studies [73]. 
Manach et al. (2005) reviewed 97 human interventions that investigated the kinetics 
and extent of polyphenol absorption [74]. They found that the concentration of 
anthocyanins measured in plasma were ranged from 10-50 nmol/L and the mean time 
to reach Cmax was 1.5 h (range: 0.75-4 h) for plasma and 2.5 h for urine. They also 
found that concentration of anthocyanins excreted in urine were 0.1% of the intake. 
Other reported concentrations of anthocyanins 1 – 100 nmol/L in plasma and urine 
following consumption of berries and grapes [27]. Furthermore, Czank et al. (2013) 
found that only 36.47 ng of cyanidin-3-glucoside were recovered in plasma, urine and 
faeces after consumption of 500 mg of 13C-labelled cyanidin-3-glucoside [75]. Table 
1.2 adapted from Kay (2006) [76] summarises the measured bioavailability of intact 
anthocyanins in human.  
The most pressing issue is how to explain the high bioactivity of anthocyanin despite 
the reported low recovery (bioavailability). Some researcher suggest that the 
bioavailability of anthocyanins was underestimated [77]. The reason for this 
suggestion was that the main methods used in analysis were based on measuring 
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anthocyanins in their coloured acidified forms (flavylium ions) and therefore, other 
colourless forms have not been quantified [77]. However, this suggestion doesn’t 
explain entirely the low recovery. Other suggest that the reason of the reported low 
bioavailability of anthocyanins is that anthocyanins expose to extensive metabolism 
and biotransformation, and therefore, the concentration of the intact forms are very 
low [19]. In fact, the degradation of anthocyanins into smaller molecules such as 
phenolic acid is the most likely event. There are several reports supporting this notion. 
For example, Prior and Wu (2006) reported that 60–90% of the anthocyanins 
disappeared from the gastrointestinal tract within 4 h after a meal;  and just very low 
concentrations of intact compounds were observed, suggesting that anthocyanins 
transformed into other forms [27]. In addition, 30 to 44% of blood orange anthocyanins 
were found as protocatechuic acid (PCA) in plasma supporting suggesting that 
anthocyanin underwent extensive metabolism [78]. This notion was confirmed using 
use of isotopically labelled anthocyanins. Czank, et al. (2013) [75] and de Ferrars, et 
al. (2014) [73] confirmed this notion when they identified a substantial number and 
amount of breakdown products derived from 13C-labelled anthocyanins and about 
43% of the 13C dose was recovered.  
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Table 1. 2: Bioavailability of anthocyanins following single dose administration in humans* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- * 
Cmax, maximum concentration derived from serum or plasma data; tmax, time to reach maximum concentration derived from serum or plasma data; 
t1/2, half-life of elimination. Table 1.2 is adapted from Kay (2006) [76]
Source 
Period 
(h) 
Dose 
(mg) 
Urinary 
recovery (%) 
Cmax 
(nmol/l) 
tmax 
(h) 
t1/2 
(h) 
Reference 
Chokeberry 24 721 0·15 96·1 2·8 1·5 [79] 
Hibiscus extract 7 147 0·018 7·6 1·5 2·6 [80] 
Red grape juice 7 283 0·23 222·7 0·5 1·8 [81] 
Red wine 7 280 0·18 95·5 1·5 2·0 [81] 
Blackcurrant 7 145 0·04 – – 1·7 [82] 
Elderberry 7 147 0·37 – – 1·7 [82] 
Chokeberry 24 1300 0·048 592 – – [83] 
Strawberries 24 77 1·9 – – – [84] 
Blackcurrant 4 716 0·05 35·6 0·7 – [85] 
Blueberry 4 1200 0·003 29·2 4·0 – [86] 
Blackcurrant 7 1000 0·039 – – – [87] 
Elderberry 24 720 0·08 97·4 – – [88] 
Blueberry 6 690 0·004 – – – [88] 
Elderberry – 500 0·05 – – – [89] 
Blackcurrant 5 153 0·03 – – – [90] 
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Based on the reported fact that anthocyanins undergo extensive metabolism and few 
quantities of intact form were detected in human fluids, a significant question remains 
about the biologically active form of anthocyanins. Either anthocyanin parent 
compounds are very active at low nanomolar concentration which is not reported 
anywhere; or their metabolites which are found in 6 to 42-fold higher abundance are 
responsible for the biological activity of anthocyanins. Therefore, the relative 
biological activity of the parent compounds and their metabolites remains to be 
studied.   
1.4.1. Metabolism of cyanidin-3-glucoside 
Czank et al. (2013) studied the metabolism of 13C-labelled cyanidin-3-glucoside in 
human participants and found that the major metabolites in serum were phase II 
conjugates of PCA, ferulic acid, and hippuric acid. The maximum concentration for 
phase II conjugates of PCA was 2.35 µM, while the maximum concentration of 
cyanidin-3-glucoside was 0.14 µM [75]. Similar findings were observed when the 
metabolism of 13C-labelled cyanidin-3-glucoside was studied by de Ferrars et al. 
(2014) [73]. A total 35 of metabolites were identified, of which 17 were found in the 
plasma, 31 in the urine, and 28 in the faeces. In the serum, PCA, 13 derivatives of 
PCA, phloroglucinaldehyde (PGA) and one derivative of PGA were identified. The 
concentration ranged from 11 nM for PCA-3- glucuronide to 1962 nM for hippuric acid, 
while the concentration of the parent compound (cyanidin-3 glucoside) reached 141 
nM. Eight sulphated and glucuronidated forms of PCA and methylated PCA (vanillic 
acid) were identified within the serum. Apart from hippuric acid, vanillic acid (1845 
nM), ferulic acid (827 nM), 4-hydroxybenzaldehyde (667 nM), vanillic acid sulphate 
(430 nM) and PCA sulphate (157 nM) were the predominant metabolites present in 
serum. In addition, the methylated form; peonidin-3-glucoside as well as the 
glucuronide form were also detected after consumption of cyanidin-3-glucoside, 
although in low concentrations [73]. 
1.4.2. Metabolisms of other anthocyanin types 
The metabolism of other anthocyanin types such as delphinidin and pelargonidin type 
has also been studied. However, anthocyanin-rich dietary sources were used instead 
of pure or isotope labelled compounds.  
Mueller et al. 2017 [91] studied the metabolism of bilberry extract powder that contain 
mainly trihydroxylated-B ring anthocyanins as well as cyanidin-3-glucoside in humans 
with and without colon. They found that the main metabolites in ileostomy fluid, which 
represent the compounds available to the colon from the small intestine, were PCA, 
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gallic acid and PGA. Gallic acid was suggested to originate from B-ring of delphinidin 
glycosides. On the other hand, syringic acid (a partially methylated form of gallic acid) 
and vanillic acid (a methylated form of PCA) were the predominant metabolites in the 
plasma of healthy subjects, with concentrations represent 45 and 24.6 % of total 
metabolites, respectively. It was difficult to decide whether syringic acid and vanillic 
acid derived from the methylation of gallic acid and PCA; or if they originated from 
methylated anthocyanins that present in bilberry extract such as petunidin, peonidin 
and malvidin glycosides.  
Azzini et al. (2010) studied the metabolism of pelargonidin-3-glucoside in humans by 
using strawberry fruit as a dietary source [92]. In serum, 4-hydroxybenzoic acid as 
well as coumaric acid were identified, while 4-hydroxybenzoic acid was described as 
the major metabolite.  The concentration of 4-hydroxybenzoic acid and coumaric acid 
were 2.5 and 0.37 µM, respectively. However, a low amount of the parent compounds, 
both as aglycones and glucuronide conjugates were identified in urine. Moreover, 
Mullen et al. (2008) identified pelargonidin-O-glucuronide at a maximum 
concentration of 274 nM, together with traces of pelargonidin-3-glucoside in human 
plasma after strawberry consumption as a source of pelargonidin-3-glucoside [93]. 
In addition to that, there are several recent human interventions that measured the 
anthocyanin metabolites. For instance, a recent human intervention detected about 
63 metabolites in plasma following the consumption of aronia crude extract. Most of 
the detected metabolites were present in nanomolar concentrations except for 
hippuric acid, benzoic acid, phenylacetic acid, and 3-(4-hydroxyphenyl) propionic 
acid, which were present at micromolar concentrations [94].  
Overall, the concentration and stability of anthocyanin metabolites in biological fluid 
is higher than the parent compounds suggesting that high bioactivity of anthocyanins 
is more likely to be mediated by the metabolites. However, the biological activity of 
these metabolites, which compounds are more beneficial and at which concentrations 
is yet to be investigated. In addition, these metabolites are found in mixtures and the 
interaction between these metabolites is most likely to take place, thereby it needs to 
be examined.  
1.5. Anthocyanins and cardiovascular disease (CVD) 
Growing evidence suggests that diets rich in fruits are one of the most important 
factors for reducing the rate of some chronic diseases such as CVD. This is most 
likely because of the abundance of bioactives such as (poly)phenols including 
anthocyanins in these foods [95].  Numerous studies highlight the beneficial effect of 
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flavonoids, anthocyanins in particular, as key constituents in lowering CVD risk factors 
[15]; and therefore the current project focused on the relation between anthocyanins 
and the reduction in CVD risk.  
CVD is the biggest cause of mortality worldwide [96], [97]. It accounts for 30 % of all 
deaths worldwide [98] and the number of people dying from CVD is expected to reach 
to 23.6 million in 2030 [99]. In UK, around 7.4 million people live with heart and 
circulatory disease and around 168 thousand died from CVD in 2017 which account 
for 28% of all deaths in UK. The total annual healthcare cost of heart and circulatory 
disease in the UK was estimated as £9 billion [100]. Although CVD term involves all 
disease affecting heart and/or blood vessels, atherosclerosis is the main CVD type 
[101] and thereby, atherosclerosis will be the main focus in this thesis.  
1.5.1. Pathobiology of atherosclerosis 
Atherosclerosis is a chronic, progressive and inflammatory disease in which the 
arteries become hard and narrow as a result of being clogged up by fatty substances 
called plaques or atheroma [102]. The key cellular players in the development of this 
disease are endothelial cells, leukocytes, platelets and intimal smooth muscle [103], 
[104]. Atherosclerosis is associated with principal CVD such as coronary heart 
disease (CHD), carotid artery disease, and peripheral arterial disease which lead to a 
decrease of blood flow and oxygen supply and which may result in acute 
cardiovascular events such as a heart attack or stroke and can eventually lead to 
death [105]–[108].  Elevated cholesterol level is the main CVD risk that drives the 
development of atherosclerosis; however, other risk factors such as hypertension, 
diabetes, smoking, male gender, and inflammatory markers appear to accelerate the 
progress of the disease [109].  
Atherosclerosis begins as an inflammatory response to endothelial injury caused by 
oxidized low-density lipoprotein (ox-LDL) within the endothelium. Ox-LDL 
accumulates as a result of high low-density lipoprotein (LDL) and cholesterol levels in 
blood. This injury triggers the monocytes, T-cells, chemokines and membrane 
adhesion molecules; and attracts immune cells to the site. The adhesion molecules 
then change the endothelial cells permeability and facilitate the migration of monocyte 
into the injury site. In response to potent cytokines and mitogens, monocyte mature 
into macrophages which then scavenge the ox-LDL and dead cells through 
phagocytosis forming what are called cholesterol-laden macrophages or foam cells, 
the hall mark of atherosclerosis.  
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The accumulation of living and dead foam cells, endothelial cells and smooth muscle 
cells increase the vessel thickness and decrease the lumen. At a later stage, the 
plaque can be ruptured, close up the lumen, compromise the blood flow and reduce 
or block the flow of blood to the organs which may lead to death [95], [110]–[113].  
Healthy diet (e.g. a diet rich in fruits and vegetables) and healthy lifestyle (e.g. physical 
activity, no smoking) are the most important protective factors against atherosclerosis. 
In addition, high-density lipoprotein (HDL) and its major apolipoprotein (Apo) ‘(Apo 
A1)’ play a significant role in attenuation of atherosclerosis by reducing the 
atherogenic modification of LDL and promoting the process of reverse cholesterol 
transport (RCT) which slows down the foam cell formation by lowering cholesterol 
accumulation [114], [115].  
Promotion of RCT is the main mechanism which lowers the cholesterol accumulation 
in foam cells, and it may be the target of anthocyanins treatments. Therefore, more 
studies are required to understand the interaction between anthocyanins and/or their 
metabolites and RCT and how anthocyanins treatments may contribute to the 
enhancement of RCT and HDL function. For more details about the role of RCT in 
foam cell formation and atherosclerosis development, see sections 2.2.  
Many epidemiological, meta-analysis and clinical studies suggest that the 
consumption of anthocyanins-rich fruit and vegetables are associated with reduced 
atherosclerosis risk.   
1.5.2. Epidemiological association between anthocyanins and lowering 
CVD risk. 
Several epidemiological studies have studied the association between food rich in 
anthocyanins (such as berries and red wine) and CVD outcomes or biomarkers [116]. 
Cassidy et al. (2016) recently found that anthocyanins intake is inversely associated 
with nonfatal myocardial infraction (MI) but not  with fatal MI in a study that followed 
43,380 healthy men for 24 years (Health Professionals Follow-Up Study [117]). The 
association was stronger in normotensive participants. Another recent study followed 
93,600 women aged 25-42 years for 18 years. An inverse association between higher 
intake of anthocyanins and risk of MI was observed [118]. In this study, the reduction 
in the risk was 32% comparing the participants who consume the highest versus the 
lowest quantity of anthocyanins. Median intakes in this study were 12 mg/day 
anthocyanins with a continual dose-response at higher levels of intakes with 17% 
reduction in MI for every 15 mg/day increase in anthocyanins intake in the multivariate 
model [118]. In another study by Cassidy et al. (2011), it was found that anthocyanin 
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consumption (predominantly from blueberries and strawberries) was correlated with 
an 8% reduction in risk of hypertension in a study which followed 87,272 individuals 
for 14 years. The reduction increased to 12% in participants ≤ 60 year of age [119]. 
Furthermore, the association between anthocyanins intake and CVD mortality was 
investigated. The Iowa Women’s Health study which followed 34,489 
postmenopausal women for 16 years found an association with anthocyanin intake 
and reduced risk of CHD and CVD-related mortality [120]. Anthocyanin intake 
reduced the risk of CHD, CVD and CVD-related mortality by 12, 9 and 10%, 
respectively. The significant reduction was correlated with the consumption of one 
portion of strawberry and blueberries once a week [120]. Similarly, McCullough et al. 
(2012) found that high intake of anthocyanidins (the aglycon form of anthocyanins) 
and other classes of flavonoids were associated with a lower risk of fatal CVD. The 
risk reduced by 18% in high intake compared to the low intake of anthocyanidins and 
flavonoids [121].    
Moreover, several epidemiological studies provide mechanistic support for the 
association between high intake of anthocyanins and observed decrease in CHD. For 
instance, higher intake of anthocyanins improved arterial stiffness and blood pressure 
[119]. Moreover, high intake of anthocyanins was correlated with a 4 mmHg decrease 
in central systolic blood pressure which is similar to those who stopped smoking, a 
2.3 mmHg decrease in medium arterial pressure and a 0.4 m/s decrease in pulsive 
wave velocity [122]. In a recent study, Jennings et al. (2014) found that higher habitual 
intake of anthocyanins resulted in a 0.7 mlU/L reduction in insulin concentrations in 
blood which is similar to the effect of 1 h/day walking and a low-fat diet [123].  
In contrast, some other epidemiological studies found no association between 
anthocyanin intake and CVD risk factors. For instance, Mursu et al. (2008) found no 
association with high anthocyanins intakes and CVD mortality after following Finnish 
men aged 42-60 years over 15 year [124]. Additionally, there was no significant 
association with flavonoids consumption and CVD risk factor in a study with 38,445 
healthy female [125]. Moreover, Cassidy et al. (2012) found no association between 
anthocyanin intake and ischemic control after following 69,622 women for 14 year 
from the Nurses’ Health Study, although, a non-significant modest inverse association 
between a higher intake of flavones and anthocyanins and risk of total and ischemic 
stroke was observed [126]. The discrepancies between studies may result from a 
failure to accurately assess intake in human populations due to insufficient information 
from the questionnaires used in these studies, limited information in food composition 
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databases and/or the nature of the studied population, e.g. populations with a high 
baseline intake showed no association [116].  
1.5.3. Evidence from meta-analysis studies 
There are several systematic reviews and meta-analysis studies that reported an 
association with the consumption of anthocyanins and reduction in CVD risk factors. 
In a very recent systematic review and meta-analysis of 17 randomized clinical trials 
that reported the effect of crude and purified anthocyanins on lipid profile and 
inflammatory markers, fifteen studies reported significant in biomarkers related to 
CVD [127]. Except for total cholesterol, all other lipid profile parameters such as LDL, 
HDL-cholesterol and triglyceride were positively influenced by anthocyanin treatment. 
In the same study, a significant reduction in TNF-α  was also reported after 
anthocyanin consumption [127]. In another recent meta-analysis of 45 randomized 
clinical trials that included 2,053 patients has reported a correlation between the 
intake of berries and a reduction in LDL-cholesterol, triglyceride and blood pressure 
and increase in HDL-cholesterol level [128]. The study presumed that the dual 
beneficial effect of consumption of berries on lowering LDL and increasing HDL is 
linked to the CETP inhibition [128]. Additionally, a meta-analysis study that included 
50 prospective cohort trials reported a relationship between fruit and vegetable intake 
and a reduction in CVD risk factors. The dose-response analysis showed that people 
who consumed 800 g per day of fruit and vegetables had the lowest risk of CVD [129]. 
On the other hand, a recent systematic review and meta-analysis of nineteen 
randomized clinical trials reported no significant effects of anthocyanin supplementation 
on reducing LDL-cholesterol and increasing HDL-cholesterol in the pooled results of all 
nineteen trials [130]. However, when the authors sub-grouped the trials by dose and 
duration, they reported a positive influence of anthocyanin intake on total and LDL-
cholesterol at doses ≥ 300 mg/day for more than 12 weeks duration[130]  
1.5.4. Evidence from dietary intervention studies 
Several randomized clinical trials have examined the effect of consumption of 
anthocyanin on several CVD biomarkers including lipid profile, blood pressure, 
endothelial dysfunction, inflammation, arterial stiffness, and platelet activation. 
1.5.4.1. Effect of anthocyanin consumption on blood pressure  
In a very recent study, Rodriguez-Mateos et al. (2019) found that consumption of 500 
ml of blueberry drink that contain 150 mg anthocyanins for more than 28 days 
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significantly reduced 24h ambulatory systolic blood pressure by -5.6 mmHg, although 
no significant difference in diastolic blood pressure was observed [131]. In another 
recent study, a significant decrease in diastolic blood pressure was observed after 
consumption of 500 mL anthocyanin-rich orange juice corresponding to 250 mg/day 
anthocyanins for 16 weeks [132]. Moreover, Aviram et al. (2001) observed a 
significant 5% reduction in systolic blood pressure after consumption of pomegranate 
juice for 14 days in hypertensive individuals. In the same study, the reduction was 
increased to 21% in systolic blood pressure after one-year consumption of 
pomegranate juice in larger group of participants with asymptomatic severe carotid 
artery stenosis [133]. However, 240 ml/day of pomegranate juice for 90 days did not 
significantly change blood pressure in another study [134]. Probably because Aviram 
et al. (2001) used in-house produced pomegranate juice unlike the other group that 
used a commercial juice with no information about anthocyanins content [135]. 
Furthermore, a supplementation using Medox™ (purified anthocyanins) capsules, 
corresponding to 320 mg/day anthocyanins for 12 weeks, decreased systolic blood 
pressure by 5% [136]. Additionally, a reduction in both systolic and diastolic blood 
pressure was observed with after chronic intakes (more than 500 mg/day 
anthocyanins) of freeze-dried blueberries and mixed berries [137], [138].  
In contrast, several other trials reported no significant changes in blood pressure after 
anthocyanin consumption.  In very recent studies, blueberries [139], bilberries [140], 
anthocyanin-rich orange juice [141], chokeberry juice [142], cranberry juice [143] and 
aronia extract [144] did not affect blood pressure. This might be because office blood 
pressure was measured in most of these studies rather than 24 h ambulatory blood 
pressure (the gold standard technique for blood pressure measurement) [116].  
1.5.4.2. Effect of anthocyanins consumption on endothelial function 
Endothelial dysfunction - especially the reduction in bioavailability of endothelium-
derived nitric oxide (eNO) - is established as one of the important early events in 
atherosclerosis [145], [146]. Lack of bioavailable eNO leads to arterial stiffness and 
an increase in vasoconstriction and thereby increased blood pressure [147]. 
Measurement of  flow-mediated vasodilation (FMD) and arterial stiffness reflect the 
activity of NO and the endothelial function [148], [149].  
In several human interventions, the consumption of anthocyanins was linked to 
increased FMD and decreased arterial stiffness. In a very recent study, Curtis et al. 
(2019) reported that 1 cup per day of blueberries juice (corresponding to 364 mg 
anthocyanins) for 6 months improved endothelial function. FMD increased by 1.45%, 
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while arterial stiffness decreased by 2.24% in 138 obese and overweight volunteers 
[139]. Moreover, Istas et al. (2019) observed an increase in FMD after consumption 
of either aronia whole fruit or aronia extract for 12 weeks compared to the baseline of 
day 1 and the placebo [94]. Acute improvement in FMD was also observed. About 
1.4% and 1.7% increase in FMD after 2h consumption of aronia extract compared to 
baseline and placebo, respectively. A correlation between anthocyanins metabolites 
found in plasma after aronia consumption, especially isoferulic, dihydroferulic and 
hydroxybenzoic acids, was suggested as the cause of this improvement. However, 
no significant changes in arterial stiffness were observed in the same study [94]. 
Another study published this year found an increase in FMD by 2.3% following 2 and 
6 h after the consumption of 150 mg anthocyanins derived from Medox™ or blueberry 
extract. The improvement was also dose dependant and correlated with phenolic 
metabolites present in circulation after the intervention. No changes in arterial 
stiffness was found [131]. Furthermore, in hypertensive postmenopausal women, 
freeze-dried blueberry containing 470 mg of anthocyanins for 2 months decreased 
brachial-ankle pulse wave velocity (1,401±122 cm/second; p<0.01; baseline levels 
were 1,498±179 cm/second) which was similar to another study which examined the 
effect of six week consumption of dehydrated powder of blueberry on arterial stiffness 
[150], [151].       
On the other hand, many other studies reported non-significant changes after 
anthocyanin-rich fruit and vegetable consumption [152]–[155]. For instance, Hollands 
et al. (2018) found that anthocyanin-rich orange juice did not affect the carotid-femoral 
pulse wave velocity and brachial-ankle pulse wave velocity which are measurements 
reflect the arterial stiffness nor affect NO concentration in plasma [141].   
1.5.4.3. Effect of anthocyanins consumption on lipid profile. 
Elevated levels of lipid - mainly LDL - are the key risk factor for initiation and 
development of atherosclerosis [156], [157]. On the other hand, HDL has a protective 
role by promoting reverse cholesterol transport; the process by which cholesterol is 
transported to liver for excretion and thereby reducing the progress of atherosclerosis 
[158]–[160]. Thus, the effects of anthocyanin consumption on lipid profiles have 
received much attention [161]–[163]. Several human interventions observed an 
improvement in lipid profile after the intake of fruit and vegetables and anthocyanin-
rich extracts. Wallace et al. (2016) systematically reviewed many randomized 
controlled trials reporting the effect of anthocyanins on CVD biomarkers [164]. Of 
twelve eligible assessed articles, ten studies investigated the effect of anthocyanins 
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on lipid profile. Nine of the ten studies included LDL as an outcome.  Four of these 
nine articles reported a significant decrease in LDL [162], [165]–[167]. The reduction 
varied from 10.72 to 22.9 %. Interestingly, only the trials conducted in participants with 
initially elevated cholesterol levels showed a significant decrease in LDL. Moreover, 
total cholesterol was significantly reduced in three studies [162], [166], [168]. 
Triglyceride significantly decreased only in two reviewed articles. Those two studies 
were conducted in hyperlipidemia subjects [162], [166]. On the other hand, six articles 
reported a significant increase in HDL circulating levels [62], [162], [168], [169]. Three 
of them were conducted with hyperlipidemia subjects and the increase varied from 
3.6 to 34 %. It seems that the people with hypercholesterolemia or with elevated risk 
biomarkers were influenced more by anthocyanin since the significant improvements 
were reported mainly in trials conducted with dyslipidemics.   
In addition to the trials that were reviewed by Wallace et al. (2016), an additional ten 
trials were recently published (Table 1.3). Two of three articles that showed a 
significant decrease in cholesterol and LDL were conducted in obese patients or 
former smokers. As shown in Table 1.3, bilberries caused the highest improvement 
in lipid profile with an increase in HDL by 22% and reduction in total cholesterol, LDL 
and triglyceride by 8.5, 16.2 and 17.8%, respectively. However, the trial was 
conducted without a control group. The population in this study was composed of 
healthy subjects [140].  
Most trials used a whole food material or (poly)phenolic-rich extracts that might have 
contained several bioactives alongside anthocyanins. To the best of my knowledge, 
only seven trials have been reported to use a mixture of purified anthocyanins 
extracted from bilberry and blackcurrant called Medox™ [136], [165], [167], [170]–
[173].  None of them reported a significant decrease in total cholesterol, while LDL 
significantly decreased in four reports [136], [165], [167], [170]. The participants in all 
these four reports were hypercholesterolemic supporting the notion that the people 
with cholesterol levels higher than normal are the most influenced by anthocyanin 
treatment.    
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Table 1. 3: Overview of effects of dietary anthocyanins on lipid profile in randomized controlled trials 
 
- Values are % of change compared to control group. * = significant changes; (ns) = not significant; ‡ = no control groups; ≠ = the control group was blond 
orange; ND = not determined; ¥ = the change in blood lipid levels after intervention were not mentioned in the text; §  = dose was estimated based on 
the given dose of 150 g three times a week of bilberries (3038 mg/kg material) 
-  
Material 
Doses 
(mg/day) 
Duration Participants Cholesterol LDL HDL TAG Ref 
Red orange 
juice ‡ 
250 12 weeks 11 obese women -7.1 (ns) -10.8 * -4.5 (ns) +2.9 (ns) [132] 
Medox™ 160 16 weeks 
27 cognitive 
impairment 
Ns ns ns ns [173] 
Blueberry juice 
364 
6 months 115 obese 
+3.5 (ns) +1.5 (ns) +5* +5.6 (ns) 
[139] 
182 0 -1.5 (ns) +1.6 (ns) +15.9* 
Bilberries ‡ ~200 § 6 weeks 
11 healthy men -16.2* -8.5* +22.1* -17.8* 
[140] 
25 healthy women -10.8* -13.7* +11.8* -36.5* 
Red orange ≠ 50 28 days 41 healthy 0 -3.0 (ns) +7.4 (ns) -7.7 (ns) [141] 
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Continued 
Material 
Doses 
(mg/day) 
Duration Participants Cholesterol LDL HDL TAG Ref 
Aronia extract 30 
12 weeks 66 healthy 
-4.6 (ns) -4 (ns) 0 -10(ns) 
[94] Aronia whole 
fruit 
3.3 -7.5 (ns) -9.1 (ns) -7.7 (ns) 0 
Chokeberry 
juice 
113.3 
4 weeks 84 healthy 
-1.2 (ns) -0.3 (ns) ND +1.6 
[142] 
28.3 -1.4 (ns) +0.3 (ns) ND -2.2 
Wild blueberry 
drink ¥ 
 28 days 40 healthy (ns) (ns) (ns) (ns) [131] 
Medox™ 320 28 days 16 healthy -5.9 (ns) 0 -4.8 (ns) -10.2 9ns) [172] 
Aronia extract 45.1 12 weeks 
49 healthy, former 
smokers 
-8* -11* +3.2 (ns) +3.5 (ns) [144] 
 
- Values are % of change compared to control group. * = significant changes; (ns) = not significant; ‡ = no control groups; ≠ = the control group was blond 
orange; ND = not determined; ¥ = the change in blood lipid levels after intervention were not mentioned in the text; §  = dose was estimated based on 
the given dose of 150 g three times a week of bilberries (3038 mg/kg material) 
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Although the randomized control trials showed that anthocyanins have the potential 
to reduce the risk of CVD and atherosclerosis, there was inconsistency within studies 
due to the limitations in many of these trials. The main reasons for this inconsistency 
could be that many of these trials were conducted without a proper control group [42], 
[174]–[181]; the doses used hugely varied within studies from 0.5 to 512 mg/day [42], 
[182], and the duration varied from two weeks to one year [64], [183]; the health status 
of subjects were varied within studies, and most importantly, whole materials that 
contain several bioactives were used in most of these trials instead of using purified 
anthocyanins which make the effectiveness of anthocyanins on CVD biomarkers is 
inconclusive. Thus, further investigations using suitable controls and purified 
anthocyanins are still required.  
1.5.5. Atherosclerosis and HDL function 
HDL is well recognized as having an important role in protecting against 
atherosclerosis [184]. Many epidemiological and clinical studies confirmed that high 
levels of HDL in circulation is inversely associated with the incidence of CVD, mainly 
CHD [185]–[188]. However, several recent studies suggest that the anti-
atheroprotective effect of HDL is more complex [189]. Studies that were conducted in 
participants with some mutations that cause decreases in HDL concentration showed 
enhanced anti-atherogenicity [190], [191].   
Moreover, patients given an inhibitor of cholesteryl-ester transfer protein (CETP) 
enzyme – an enzyme which facilitates the transport of cholesterol ester between 
lipoproteins - showed a higher risk of CHD although the substantial increase in HDL 
levels suggesting that the anti-atheroprotective effects of HDL is beyond the 
concentration and its more related with HDL properties and functions [192]. Therefore, 
HDL function is gaining more attention and it is becoming more accepted that HDL 
quality is more important than quantity [193].  
HDL has many anti-inflammatory, anti-atherogenic and anti-oxidative functions [194]–
[196]. One of the most established functions is cholesterol efflux from foam cells, the 
hall mark of atherosclerosis, through reverse cholesterol transport pathway [197]–
[199]. The more cholesterol transferred by HDL, the slower atherosclerotic plaque 
size can grow. In fact, apolipoprotein A1 (Apo A1), the major apolipoprotein presents 
in HDL, plays a central role in this pathway. The lipid-poor Apo A1 increases the 
affinity of HDL to bind with cholesterol transporters in macrophages such as the ATP-
binding cassettes A1 (ABCA1) and the ATP-binding cassettes G1 (ABCG1) and then 
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rapidly acquire phospholipid and unesterified cholesterol from peripheral tissues, 
thereby facilitating cholesterol efflux. The overexpression of ApoA1 promotes RCT 
and maturation of HDL [200]–[203]. For more details about the role of HDL in RCT, 
see sections 2.2. HDL-associated enzymes such as CETP protein and lecithin-
cholesterol acyl transferase (LCAT) play essential roles in the net transfer of 
cholesterol from foam cells to HDL, and in modulating HDL shape [204], [205].  
The second key function of HDL is antioxidation activity. HDL can protect LDL from 
oxidation and thereby attenuate the progress of atherosclerosis. HDL-associated 
antioxidant enzymes such as paraoxonase 1 (PON1) seem to be the main mediators 
of this property. PON1 can protect LDL from oxidation as well as hydrolysing the ox-
LDL. It was also found that high levels of PON1 increased the cholesterol efflux 
capacity of HDL. In addition to PON1, other enzymes were found to contribute to 
antioxidation such as acetyl-hydrolase platelet activation factor [206]–[208]. For more 
details about the role of PON1 as biomarker of HDL function in protecting LDL from 
oxidation, see section 3.2. 
Another important property of HDL related to its anti-atherogenicity is the 
heterogeneity of HDL particles. HDL has two subclasses; HDL2 and HDL3; based on 
the density of the HDL particle. HDL2 is larger and less dense than HDL3 [197]. HDL3 
was found to have a strong inverse association with CHD [209]. Furthermore, 2-
dimensional electrophoresis revealed at least 12 subspecies of HDL.  Pre-β-1 and α-
3 particle were strongly associated with CHD, while, α-1, pre-α-3 and pre-α-1 were 
lower in CHD patients [210].  
On the other hand, dysfunctional HDL may exert pro-atherosclerotic and pro-
inflammatory functions. An increase in ApoA-associated enzyme myeloperoxidase 
decrease the cholesterol efflux capacity of HDL. Additionally, serum amyloid A 
clusterin was higher in dysfunctional HDL [211]–[213]. Fig 1.4 summarize the key 
important properties of anti-atherogenic and dysfunctional HDL.    
Several human interventions have reported an improvement in HDL biomarkers after 
consumption of anthocyanins. For instance, Zhu et al. (2014) reported an increase in 
cholesterol efflux capacity and PON1 activity after consumption of purified 
anthocyanins. Similarly, Qin et al. (2019) found that anthocyanins increased 
cholesterol efflux capacity and decreased serum CETP mass and activity [165], [170]. 
In addition, blueberry anthocyanins increased Apo A1 levels and the density of HDL 
particles [139].  
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Although, the importance of HDL function in attenuation of atherosclerosis is 
apparent, little research has investigated the effect of anthocyanins consumption on 
the key elements of HDL function, and the mechanism by which anthocyanins might 
improve HDL function has yet to be studied; and more investigation is still required.  
 
 
 
Figure 1. 4: Scheme demonstrate the key elements of antiatherogenic vs 
proatherogenic HDL. 
ApoA1= apolipoprotein A1, PON1= paraoxonase 1, CETP= cholesteryl-ester transfer protein, 
LCAT= lecithin-cholesterol acyl transferase. 
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1.6. Thesis aims 
Considering the previous literature summarized in this chapter, there are several 
questions that need to be investigated. Firstly, the mechanisms of action by which 
anthocyanins would exhibit their effect still have not been elucidated and more 
research is still required. Secondly, with all limitations of previous clinical trials, it is 
hard to draw general conclusions regarding the effectiveness of anthocyanins and 
therefore, conducting rigorous trials with purified anthocyanins is essential. In 
addition, anthocyanins are rapidly degraded producing a wide range of metabolites 
suggesting that the metabolites may be more beneficial, but the biological activities of 
most of them have not been investigated or were investigated individually ignoring the 
possibility of interaction. The tested concentrations were often higher than the 
physiologically achievable one, thus, more research still requited to fill this gap. Since 
high lipid levels are the main CVD risk that drives the development of atherosclerosis, 
this project focused on the effect of anthocyanins on lipid/lipoprotein profile and quality 
and the pathways related to that. To address these questions and progress the 
research from previous current literature, the overall aims and objectives are outlined 
below. 
• Overall aim of this project is to develop a mechanistic understanding of how 
anthocyanins alter lipid/lipoprotein metabolism. 
• The overall hypothesis is that anthocyanins and/or their metabolites, will affect 
lipid/lipoprotein metabolism and/or quality by altering the expression of key genes 
involved in reverse cholesterol transport (RCT) and/or the quality of circulating 
lipoproteins. 
RCT was proposed to be the target of anthocyanin treatment. There are different 
elements involved in RCT. However, the cholesterol transporters, scavenger receptors 
and HDL function are the key ones. Therefore, these three elements were the main 
focus of the project.  To test the overall aim and hypothesis, the following objectives 
were addressed: 
1- To study the effects of anthocyanins and their metabolites on the 
expression of key genes involved in RCT 
Two important elements in RCT were studied in this objective; the effects of the parent 
anthocyanins and their metabolites on cholesterol transporters and scavenger 
receptors, using physiologically-relevant concentrations. The upregulation of 
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cholesterol transporters and the downregulation of scavenger receptors should result 
in a promotion in RCT and a reduction in cholesterol accumulation in the foam cell. 
Chapter two of this thesis aims to address this question using in-vitro and in-vivo 
models.   
2- To determine the effects of anthocyanins and their metabolites 
on PON1 gene expression and PON1 enzyme activities as a 
marker of HDL function 
HDL function is important to promote RCT. HDL carries the cholesterol back to the 
liver for excretion and therefore, improvement in HDL function should result in an 
increase in its capacity to carry more cholesterol from foam cells and attenuate the 
progress of atherosclerosis. PON1 contribute in many functions of HDL. Thereby, an 
increase in PON1 gene expression or activities may enhance the functions of HDL. 
Due to the little research that has been carried out to understand this effect, the main 
objective for chapter three was to address this question using an in-vitro models. 
3- To detect any atherosclerosis-linked genes and pathways affected 
by the anthocyanins using RNA sequencing.  
It is important to understand the mechanism(s) by which anthocyanins deliver their 
beneficial effects. Because, anthocyanins may target several pathways, non-targeted 
approaches such as RNA sequencing would be useful to elucidate the possible 
underlying molecular mechanism(s) for further in-vitro and in-vivo investigation. In-
vitro cell model was used to address this objective which was presented in chapter 
four. 
4- To compare the effects of 4-week consumption of cyanidin-type 
anthocyanins and delphinidin-type anthocyanins on 
lipid/lipoprotein profiles and markers of HDL function using a 
randomized placebo-controlled cross-over human trial. 
This objective was addressed in chapter five by conducting a randomized cross-over 
placebo-controlled trial. The trial was designed to compare the effects of two types of 
anthocyanins on lipid profile/HDL function in a population with elevated cholesterol 
levels using two purified anthocyanin-rich extracts. The trial was also conducted to 
translate the in-vitro findings in previous chapters to an in-vivo situation and to gain 
insight into the interaction between anthocyanins treatment, PON1 genotype, PON1 
activities and markers of HDL function.  
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Chapter two: The effects of dietary 
anthocyanins and their metabolites on 
the expression of key genes and the 
function of reverse cholesterol 
transport (RCT) 
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2.1. Abstract 
Data from various epidemiological studies, human interventions and animal 
interventions studies indicate that dietary anthocyanins consumption has the potential 
to lower the risk of cardiovascular disease (CVD) and modulate cholesterol 
metabolism, however, the mechanisms remain undeciphered. It has also been shown 
that anthocyanins are rapidly degraded, and it is most likely that its metabolites are 
responsible for high bioactivity. Upregulating reverse cholesterol transport (RCT) was 
proposed as a mechanism by which anthocyanins exhibit their effects on cholesterol 
level. Therefore, the aim of the research described in this chapter was to investigate 
the ability of anthocyanins and their metabolites to enhance the expression of ABCA1 
and ABCG1 genes, and downregulate the expression of scavenger receptor genes 
which are key genes involved in RCT. Two approaches have been used, in vitro and 
in vivo. For in vitro, human and mouse macrophages were treated with two 
predominant types of anthocyanins and 18 of their recently identified metabolites at 
physiologically relevant concentrations. In addition, the effects of 8 pure synthetic 
phase II conjugates of anthocyanin metabolites on RCT key genes were investigated.  
In vivo effects were investigated by quantifying gene expression in the liver and aorta 
tissues isolated from Apo E-/- mice that had been fed for 16 weeks with anthocyanin- 
and flavonol-rich tomatoes, compared to mice consuming anthocyanin-free red 
tomatoes and anthocyanin-free but flavonol-rich tomatoes. The expression of RCT 
key genes was quantified using qPCR.  None of the anthocyanins or their metabolites 
affected the expression of RCT key genes in macrophages. Furthermore, there were 
not any synergistic effects as a mixture of anthocyanins and various of their 
metabolites also did not cause changes in gene expression. The in vitro model was 
validated using two positive controls which stimulated ABCA1/G1 expression, 
showing that the model was working properly. Moreover, these findings were 
consistent with the lack of effect of the anthocyanin-supplemented mouse diets on the 
expression of these genes in liver and aortic tissue, compared to red tomato. There 
was a small increase in ABCG1 gene expression in aortic tissue of the anthocyanins-
rich tomato fed group compared to the control group, but this was not statistically 
significant. These data do not support the notion that anthocyanins and their 
metabolites affect the gene expression of cholesterol transporters and receptors in 
macrophages and mouse tissue.  
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2.2. Introduction 
Numerous reported animal studies, epidemiological surveys and clinical observations 
have revealed a positive relationship between LDL and total cholesterol levels in blood 
and CVD incidence [159]. Any excess cholesterol can accumulate in peripheral 
tissues and lead to pathological consequences as cholesterol cannot be catabolized 
in organs and tissues, only in the liver and steroidogenic tissues which can convert 
cholesterol to bile acids or steroid hormones. Therefore, cells need to maintain 
cholesterol homeostasis and regulate utilization of intra-and extracellular cholesterol 
sources [214]. Many cells do that by regulating the activities of the 
hydroxymethylglutaryl-CoA (HMG-Co-A) synthase and reductase enzymes, and 
regulating LDL-receptor synthesis, thereby preventing any further intracellular 
cholesterol synthesis or extracellular LDL-cholesterol entry [215]. 
In contrast, macrophages (phagocytes which can take up dead cells, modified 
lipoproteins, and other extracellular debris such as aggregated lipoproteins) can 
accumulate a large amount of cholesterol. Because of its toxicity, free cholesterol (FC) 
is usually esterified to cholesteryl esters (CE) which can be stored as cytosolic lipid 
droplets. As macrophages progressively scavenge more and more cholesterol, they 
take the appearance of foam cells because of the foamy appearance of cytoplasmic 
cholesteryl esters inclusions. The accumulation of cholesterol-laden macrophages 
(foam cells) in the intima of arteries is the early hallmark of atherosclerosis [156] 
As such, the limitation of cholesterol accumulation to reduce the atherosclerosis 
progression in macrophages is necessary and the only way to do this is to efflux or 
eliminate the accumulated cholesterol by a process called reverse cholesterol 
transport (RCT) [156] . 
2.2.1. Reverse Cholesterol Transport 
Reverse cholesterol transport (RCT) is the process by which excess cholesterol is 
effluxed from peripheral tissues and is delivered to HDL and then transported to the 
liver for elimination and excretion as bile acids. Cholesterol-laden macrophages (foam 
cells) are the main cell type which participates in plaque formation and usually RCT 
is studied as a macrophage-specific phenomenon in relation to atherosclerosis. Active 
cholesterol efflux is the main way by which macrophages efflux cholesterol to the 
extracellular acceptor. ATP-binding cassette (ABC) transporters are the key players 
in this mechanism [158], [216]. 
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2.2.2. ATP-Binding Cassette transporters and RCT. 
ATP-Binding Cassette transporter type A1 (ABCA1) and type G1 (ABCG1), belong to 
the large ABC transporter family and are the main regulators of RCT in macrophages. 
These transporters bind with ATP to provide the required energy for active 
transportation. The role of ABCA1 in RCT was not known until it was reported that 
ABCA1 knockout mice show similar symptoms as patients suffering from Tangier 
disease – low HDL levels in plasma, low ApoA1 levels and high accumulated CE, 
which are related to the deficiency in cholesterol transport to Apo A1 [214]. 
2.2.3. RCT mode of action 
Fig 2.1 summarizes the main steps of the RCT process and the role of ABCA1 and 
ABCG1 transporters. The main cause of foam cell generation is the internalization of 
modified LDL-cholesterol. This triggers the enzyme machinery of macrophages such 
as acyl coenzymeA:cholesterol acyltransferase-1 (ACAT1) which aids in the 
esterification of cholesterol and produce cholesterol esters (CE) for storage [217], 
[218]. When CE becomes highly accumulated in macrophages, cholesteryl ester 
hydrolase and lysosomal acid lipase convert CE to free cholesterol. ABCA1 and 
ABCG1 only transport free cholesterol [218]. Excess of free cholesterol leads to 
production of oxysterol (an oxidized derivative of cholesterol). Oxysterol is a liver X 
receptor (LXR) ligand which is required to upregulate ABCA1 and ABCG1 
synthesis[214]. 
As a result of ABCA1 synthesis, a direct interaction occurs between ABCA1 and lipid-
poor or lipid-free apolipoprotein A1 (mainly produced by the liver). This binding 
triggers a multi-step process by which free cholesterol (unesterified) and 
phospholipids are transferred to Apo A-1 to produce a nascent HDL particle. After 
that, lecithin:cholesterol acyl transferase (LCAT) present in HDL particles triggers 
what is called HDL maturation by esterifying the cholesterol that has been transported 
to HDL. This results in the production of globular HDL particles with a normal CE core, 
thereby, reducing free cholesterol at the surface of HDL and increasing further the 
capacity of HDL to accept additional cholesterol [214], [219]. Subsequently, ABCG1 
acts to transport cholesterol from inside to the surface of the macrophage where it is 
accepted by the HDL particle, thus completing cholesterol elimination. ABCG1 
transports additional cholesterol to HDL producing what are called mature HDL 
particles [220]. The mature HDL then travels to the liver or steroidogenic tissues 
where a selective uptake of HDL-cholesterol can occur mediated by scavenger 
receptor type B1 (SR-B1) [214].  
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Once cholesterol is returned to the liver, cholesterol can be used as a precursor for 
bile acids production in a process mainly mediated by the cytochrome P450 enzyme, 
cholesterol 7 ɑ-hydroxylase (CYP7A1). Bile acids subsequently are secreted into bile 
duct and may be excreted via the faeces or retaken up from the intestine via a process 
called enterohepatic recirculation [221]. 
 
  
 
 
Figure 2. 1: A model depicting the principal process of reverse cholesterol 
transport in macrophages and the role of ABCA1 and ABCG1. 
To prevent the progress of foam cell formation, cholesterol laden macrophages transfer 
cholesterol via ABCA1 to lipid-poor apo A-I forming nascent HDL particles which are subjected 
to further lipidation via ABCG1 to produce mature HDL particles. Mature HDL particles deliver 
cholesterol to the liver by SR class B type I (SR-BI) for bile acid production.  
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2.2.4. Scavenger receptors 
Scavenger receptors (SR) play a significant role in atherosclerosis [222]. While native 
LDL can enter into cells via LDL receptors which can be negatively regulated by 
cholesterol stores, modified LDL such as ox-LDL or acetylated-LDL can only bind with 
scavenger receptors leading to foam cell formation [223]. Scavenger receptors can 
bind with different ligands and therefore they can be classified into several 
subfamilies. However, the class A and class B are the principal receptors for binding 
modified LDL in macrophages.  
SR-A1 (belonging to class A) and CD36 (belonging to class B) account for 75 to 90% 
of the uptake of acetylated and ox-LDL [224]. The downregulation of SR-A1 and CD36 
in Apo E-/- mice reduced foam cell formation by reducing modified LDL uptake [225].   
2.2.5. Effect of anthocyanins on cholesterol efflux and ABCA1/G1 gene 
expression. 
A few recent reports have described the effect of anthocyanins and their metabolites 
on cholesterol efflux and ABCA1/G1 gene expression. Wang, Y (2012) investigated 
the effects of the anthocyanin C3G in apolipoprotein E-deficient mice (Apo E-/-) and 
reported that C3G (2 g/kg diet) upregulated ABCG1 protein expression in the aortic 
tissue of the mice [226]. In vitro, Wu (2014) investigated the effect of some 
anthocyanin metabolites such as ferulic acid, gallic acid and vanillic acid at relatively 
low concentrations on cholesterol efflux in RAW264.7 mouse macrophages and 
reported that ferulic acid and gallic acid increased cholesterol efflux from the mouse 
macrophages at 10 µM by 1.4 and 1.3 fold, respectively, whereas, vanillic acid had 
no effect on cholesterol efflux [227]. Wang, D. (2012) studied the effect of C3G and 
PCA on cholesterol efflux and ABCA1/G1 gene expression in mouse and human-
derived macrophages at concentrations very close to that found in vivo and reported 
that C3G had no effect on cholesterol efflux at concentrations between 0.25 to 1 µM, 
while PCA significantly increased the cholesterol efflux at the same concentrations in 
both mouse and human-derived macrophages. Additionally, it was reported that PCA 
but not C3Gat concentrations between 0.25 and 1 µM upregulated both ABCA1 and 
ABCG1 gene expression by 2.5 and 4-fold, respectively, in human-derived 
macrophages (THP-1 macrophages). It was also reported that PCA down-regulated 
the presence of the microRNA miRNA-10b, which is responsible for the repression of 
ABCA1/G1 gene expression [221].  
The results of these studies support the notion that anthocyanins achieve their 
biological action via their metabolites. However, these studies did not take into 
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account that anthocyanin metabolites are found in blood as a complex mixture and it 
is possible that synergistic interactions action may take place. In addition, there are 
no reports of the activities of metabolite phase-2 conjugates. Therefore, additional 
studies using mixtures of anthocyanin metabolites and metabolite conjugates are still 
needed. 
 
 
 
 
2.3. Objectives 
The overall aim of the experiments described in this chapter was to investigate the 
impact of anthocyanins and their metabolites on processes involved in reverse 
cholesterol transport. The specific objectives for this chapter were to (1) investigate 
the ability of anthocyanins and their metabolites to upregulate the expression of 
cholesterol transporters genes; (2) to investigate the ability of anthocyanins and their 
metabolites to downregulate the expression of scavenger receptors and (3) to 
investigate the influence of feeding anthocyanin-expressing purple tomatoes in 
comparison to anthocyanin-free red tomatoes on the expression of cholesterol 
transporters and scavenger receptors in aorta and liver using the Apo E-/- mouse 
model. 
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2.4. Materials and methods 
2.4.1. Cell cultures 
THP-1 human monocytes were obtained from the European Collection of 
Authenticate Cell Cultures (ECACC). The cells were routinely cultured as suspended 
cell in bicarbonate-buffered RPMI-1640 media containing 2 mM glutamine (Sigma-
Aldrich, Cat. # R8758), 10% Fetal Bovine Serum (FBS) (v/v), penicillin (100 U/ml) and 
streptomycin (100 µg/ml) (Thermofisher, Cat# 15140122) according to the 
manufacture’s protocol and incubated at 37°C in 5% CO2. Once the cells had grown 
to confluence (0.8 x 106 cell/ml), they were split or seeded for differentiation. THP-1 
monocytes were chemically differentiated to macrophages by phorbol 12-myristate 
13-acetate (PMA, from Sigma-Aldrich, Cat. # P8139). For differentiation, THP-1 
monocytes were seeded at 5 x 105 cell/ml in 12-well plates and treated with 100 ng/ml 
PMA for 48 hr followed by a 24-hr rest time in culture media without PMA (Fig 2.2). 
This differentiation process was monitored by following the morphological transition 
of the monocytes from suspended to adherent cells. All experiments were conducted 
between passages 9 to 15.  
J774A.1 mouse macrophages was obtained from European Collection of Authenticate 
Cell Cultures (ECACC) and routinely cultured in the same conditions as mentioned 
with THP-1. For seeding, the cells were harvested at 80% confluency using a cell 
scraper and centrifugation for 5 min at 200 X g and seeded in 12-well plates. The cells 
then were left to attach to the plate for 48 hr. Because J774A.1 cells are already 
macrophages, the differentiation step was not required. 
The differentiated THP-1 cells and J774A.1 macrophages were then preloaded with 
25 µg/ml acetylated -LDL (ac-LDL) (Alfa Aesar, Cat. # J65029) for 24 hr prior the 
treatments (Fig 2.2). The non-preloaded cells were treated with full growth media free 
from ac-LDL. All procedures were performed according to Wang et al. 2012 [228] 
2.4.2. Treatments 
The major human metabolites arising from cyanidin-3-glucoside and the predicted 
metabolites of delphinidin-3-glucoside were assessed at concentrations of 1 and/or 
10 µM for 24 hr (Fig 2.2). Standard solutions were initially prepared in 100% DMSO 
at concentrations of 10 mM followed by dilution to the final concentrations using FBS-
free cell culture media, immediately prior to application to cells. Final treatment 
concentration of DMSO was 0.1%. The vehicle control was preloaded cells treated 
with DMSO at concentration of 0.1%. Kaempferol (10 µg/ml, 30 µM) and cyclic- 
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adenosine monophosphate (c-AMP) (300 µM) served as positive control (+ve), while, 
the negative control (-ve) was non-preloaded cells treated with DMSO. Treatments 
were conducted in triplicate and the experiments were repeated two times.  
C3G and D3G were purchased from Extrasynthese. PGA, PCA, gallic acid, ferulic 
acid, vanillic acid, 4HBA, sinapic acid, hippuric acid, 5HFA, c-AMP and kaempferol 
were purchased from Sigma Aldrich. Syringic acid purchased from Alfa Aesar and 
phloroglucinol was purchased from Across Organics. PCA conjugates and gallic acid 
conjugates were synthesised inhouse using the method by [229]. 
 
 
 
 
 
 
Figure 2. 2: Graphic demonstration of THP-1 differentiation, preloading and 
treatment.  
PMA = phorbol 12-myristate 13-acetate. Ac-LDL = acetylated- DL 
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2.4.3. Selection of anthocyanins and their metabolites 
There are many types of anthocyanins that produce a large number of metabolites. 
C3G alone produced 35 metabolites in serum, urine and faeces which makes it 
difficult to test all anthocyanins metabolites [73]. Therefore, it was essential to 
establish a list of metabolites of interest that will be examined based on their presence 
in serum and their concentrations. Cyanidin and delphinidin are the most common 
anthocyanidins found in human diet, thus, C3G, D3G and their metabolites were the 
main focus of my project [17].  
It was well established that C3G degrades into phloroglucinaldehyde (PGA) and 
protocatechuic acid (PCA) following the deglycosylation of C3G and releasing the 
aglycone (cyanidin) at physiological pH and temperature. PGA is derived from the A-
ring, while, PCA is derived from the B-ring [230][41] . Therefore, the effects of 
cyanidin, PGA and PCA were investigated.  
Additionally, about 17 metabolites have been identified in serum when pure 13C-
labelled C3G was fed to humans. Although, PCA was not the major metabolite in this 
study, 13 derivatives of PCA were detected with hippuric acid, vanillic acid, ferulic acid 
and 4-hydroxybenzaldehyde (4HBA) representing the predominant metabolites in 
serum [73]. Therefore, the effects of vanillic acid, ferulic acid, 4-hydroxybenzaldehyde 
were studied. Moreover, C3G and its metabolites undergo a subsequent conjugation 
via phase II metabolisms in liver producing wide range of glucuronides, sulphates and 
methyl forms. Phase II conjugates of PCA including PCA glucuronides , PCA 
sulphates and methylated PCA (such as vanillic acid) reached to 2.35 µM in serum 
after feeding with isotope-labelled C3G to human [75]. Therefore, PCA-3-glucuronide 
(PCA-3GlcA), PCA-4-glucuronide (PCA-4-GlcA), PCA-3-sulphate (PCA-3-Sulph) and 
PCA-4-sulphate (PCA-4-Sulph) were included to the list of metabolites of interest.  Fig 
2.3 demonstrates the possible pathways of C3G and PCA biotransformation.  
Since ferulic is one of the most abundant metabolites of C3G present in serum, it was 
considered that ferulic acid was released directly from C3G as caffeic acid that was 
subsequently methylated to ferulic acid rather than a derivatization of PCA (Fig 2.3). 
If this pathway was taken into account, phloroglucinol would be released as the A-ring 
product. So far no one has reported phloroglucinol as an anthocyanin metabolite.  
However, in our lab we could identify phloroglucinol in the urine of humans who had 
consumed purified anthocyanin-rich extracts (data unpublished) supporting the notion 
that C3G may degrade into ferulic acid and phloroglucinol (Fig 2.3). Phloroglucinol, 
therefore, was added to the list of compounds of interest. 
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Figure 2. 3: Structures and proposed pathway for C3G metabolism.  
PCA-3-sulph= PCA-3-sulphate, PCA-4-Sulph= PCA-4-sulphate, PCA-4-GlcA= PCA-3-
glucuronide, PCA-4-GlcA= PCA-4-glucuronide. AccelrysDraw (version 4.2 for windows) was 
used to draw the chemical structures.  
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On the other hand, no human intervention feeding solely pure D3G to participants has 
been reported. However, there is evidence from studies feeding D3G-rich fruit 
extracts that supports the idea that D3G metabolism follows a similar pattern as that 
of C3G degradation. D3G degrades rapidly to gallic acid and PGA in culture media 
(pH=7.4, temperature 37°C) [231]. Gallic acid originates from the B-ring of delphinidin 
(Fig 2.4). Gallic acid per se can undergo phase II metabolism to produce 3-O-
methylgallic acid (3MeGA) and 4-O-methylgallic acid (4MeGA) [232] and possibly 
gallic acid-3-glucuronide (GA-3-GlcA) and gallic acid-4-glucuronide (GA-4GlcA). 
Therefore, the effect of gallic acid and gallic acid conjugates were also tested. 
In addition, syringic acid was found to be the major degradant in human plasma after 
consumption of anthocyanin-rich bilberry extract which contains mainly 
trihydroxylated-B ring anthocyanins such as D3G [91]. It has been suggested that 
syringic acid originated from methylation of gallic acid [91][233] (Fig 2.4). Thus, the 
effect of syringic acid was also tested. In this study, vanillic acid, HBA, PGA, gallic 
acid and hydroxybenzoic acid were also reported as bilberry’s anthocyanin 
metabolites.  
Similar to C3G, phloroglucinol might be generated from the A-ring of D3G, thus, 
sinapic acid would be one of the B-ring metabolites of D3G. Moreover, sinapic acid 
might produce 5-hydroxy ferulic acid (5HFA) after undergoing demethylation, the 
process that can occur easily in presence of microbiota (Fig 2.3). Although, I am not 
aware of any previous studies reporting sinapic acid and 5HFA as anthocyanin 
metabolites, they might be present in circulation for a short time and cause an effect 
before fast derivatization into other compounds. Therefore, these two metabolites 
were also added to the list. 
The concentrations of metabolites detected human plasma after consumption of 13C-
labelled C3G ranged from 0.1 - 2 µM, with cumulative concentrations of metabolites 
reaching 10 µM. Therefore, the selected metabolites were tested at 1 and 10 µM as 
representative of low and high physiological concentrations.  
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Figure 2. 4: Structures and proposed pathway for D3G metabolism.  
3MethGA= 3-O-methylgallic acid, 4MethGA= 4-O-methylgallic acid, GA-4-GlcA= gallic-3-
glucuronide, GA-4-GlcA= gallic acid-4-glucuronide. AccelrysDraw (version 4.2 for windows) 
was used to draw the chemical structures. 
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Based on the justifications provided above, 20 compounds of anthocyanins and their 
metabolites were chosen and tested at two different physiologically relevant 
concentrations (1 and 10 µM). These compounds are: C3G, D3G, PCA, PGA, ferulic 
acid, vanillic acid, 4HBA, gallic acid, syringic acid, sinapic acid, 5HFA, PCA-3-GlcA, 
PCA-4-GlcA, PCA-3-Sulph, PCA-4-Sulph, GA-3-GlcA, GA-4-GlcA, 3MethGA and 
4MethGA. Since there was not a human study that used solely pure D3G, it was 
difficult to confirm whether syringic acid, sinapic acid, 5HFA and phloroglucinol were 
from D3G or from other bilberry’s anthocyanins. Therefore, these metabolites have 
been tested as predicted (potential) metabolites at a concentration of 10 µM.  
There are many other metabolites that might be important and need to be examined 
such as vanillic acid sulphate that was detected at considerable amounts (430 nM) 
following 13C-labelled C3G consumption [73]. However, it was not available in our lab. 
Only PCA and gallic acid conjugates were available in our lab when the experiment 
was conducted and therefore, the project focused on them. In addition, there are new 
metabolites that discovered recently while writing this thesis after conducting the 
experiment and there was not enough time to examine them. For instance, in a very 
recent study, phenylacetic acid and 3-(4-hydroxyphenyl) propionic acid were detected 
following the consumption of aronia crude extract. These compounds and others 
should be investigated in future work [94]. 
2.4.4. RNA extraction 
RNA was extracted from treated THP-1-derived macrophages and J774A.1 mouse 
macrophage using RNeasy® Mini Kit (Qiagen Ltd, Cat# 74106) according to the 
manufacturer’s protocol. Briefly, cell culture media was removed, and cells were 
washed once with cold PBS (Thermofisher, Cat# 14190094). Cells layer were then 
harvested using a cell scraper and centrifuged for 1 min at 1000 x g. The pellets were 
initially lysed using the provided RLT Buffer and further homogenised using a 
QIAshredder (Qiagen Ltd, Cat. # 79654,). The quantity of RNA, as well as 260/280 
and 260/230 ratios were measured using the NanoDrop ND-1000 spectrophotometer. 
Three readings for RNA quantification were obtained per sample and the average 
RNA concentration was then calculated. RNA samples were aliquoted and stored at 
-80°C until use.  
2.4.5. Animal study 
The study was approved by the Animal Welfare and Ethical Review Body (AWERB) 
at the University of East Anglia and conducted in compliance with the provisions of 
 46 
 
the Animals (Scientific Procedures) Act 1986 (ASPA) and the LASA Guiding 
Principles for Preparing and Undertaking Aseptic Surgery. 
The experiment protocol and procedures were described by Day et al. 2018 [234]. 
Briefly, 92 male homozygous ApoE-deficient mice were purchased from Jackson 
Laboratories (Charles River Laboratories, Kent, United Kingdom) and were kept in 
acclimatisation on standard breeding diet AIN-93G (Testdiets, Kent, United Kingdom). 
At age 8 weeks, the mice were then randomly divided into five groups and fed ad 
libitum supplemented with 10% tomato powder. The tomatoes were genetically 
modified to express one type of polyphenol. The five group of mice were fed with 10% 
tomato powder that express either flavonols (n=20), a mixture of anthocyanins and 
flavonols (n=20), resveratrol (n=20), isoflavones (n=12) or control low- or no- 
polyphenol red tomato powder (control, n=20) for 17 weeks. The body weight and 
food consumption of the mice were measured three times a week and mice were 
sacrificed by exsanguination under isoflurane anaesthesia. The organs were washed 
with 0.9% saline and EDTA by direct injection in the heart’s left ventricle. Aortic and 
hepatic tissue for gene expression was then collected immediately and stored in 
RNAlater (Life Technologies, Paisley, UK) overnight and stored at -20 °C until further 
processing. The study was conducted by Mark Winterbone at QIB and my role was to 
process the tissues, extract RNA and do the assays.  
2.4.6. RNA extraction from aorta and liver 
Aortas were placed in RNAlater to remove the surrounding adipose tissue using 
SZ40 Olympus Zoom dissecting microscope. Two to three aortas were then pooled 
for total RNA extraction to obtain enough RNA for gene expression. Total RNA was 
extracted using miRNeasy Mini Kits (Qiagen Ltd, Cat. # 217004) according to the 
manufacturer’s instructions. The tissue was lysed using QIAzol Lysis Reagent 
(Qiagen Ltd, Cat. # 79306). The homogenization step was done by using Precellys 
24 lysis & homogeniser at 6000 rpm for 4 cycles for 30 s (Bertin Technologies, 
France) and QIAshredder. 
Livers were processed into a homogeneous powder using a pestle and mortar 
under liquid nitrogen. Total RNA was extracted using miRNeasy Mini Kits according 
to the manufacturer’s protocol. The lysis step was performed by adding 700 µl 
QIAzol Lysis Reagent to 25 mg homogenized sample followed by a homogenisation 
step similarly to aortas tissues. RNA quantity, 260/230 ratio and 260/280 ratio were 
measured as previously mentioned.  
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2.4.7. Gene expression quantification 
For the quantification of gene expression of ABCA1 and ABCG1 in THP-1 and in 
mouse cells and tissues, Precision OneStepPLUS qRT-PCR master mix 
(Primerdesign, Cat. # OneStepPLUS and OneStepPLUS-LR) and the pre-designed 
probe/primers for the genes ABCA1, ABCG1, GAPDH, 18S, YWHAZ and RPL4 
(from IDT technology) were used. The sequences for forward and reverse primers 
and probes are given in Table 2.1 and 2.2. The preparation of the samples and 
reaction mixes for the RT-PCR was done using the CAS-1200 robot and Robotics 
4 software (Corbett Life Sciences) in 96 well Semi-Skirted fast plates with final 
volume 20 µl contains 20 ng total RNA and appropriate concentrations of primers 
and probes. RNAse-free water (Qiagen Ltd, Cat. # 129112) was used as a no 
template control (NTC). Each sample was run as three technical replicates. 
RT-qPCR was performed using ABI StepOne Plus machine (Applied Biosystems) 
with conditions of 48°C for 30 min for reverse transcription followed by one cycle at 
95°C for10 min and then 40 cycles of 95 °C for 15 sec and 60 °C for 1 min. In this 
technique, RNA can be used as starting material and within one step the 
complimentary DNA is produced, and the target gene amplified. A fluorescent 
signal is generated by the use of dual labelled probes and Taq polymerase.  
For scavenger receptors gene expression in (MSR1, SCARB1 and CD36), reverse 
transcription was carried out to produce c-DNA using 1 μg of total RNA and the 
Precision NanoScript Reverse Transcription kit (Primerdesign, Cat. #  RT-
NanoScript2) in a final volume of 20 µl according to the manufacturer’s instructions. 
Appropriate concentrations of primers were used. RNAse-free water (Qiagen Ltd, 
Cat. # 129112) was used as a No Template control (NTC). Each sample was run 
as three technical replicates. primers were designed according to Day et al. 2018 
[234] using either the Roche probe library software 
https://lifescience.roche.com/en_gb/brands/universal-probe-library.html or the 
PubMed primer designing tool https://www.ncbi.nlm.nih.gov/tools/primer-blast/ and 
checked for specificity using BLAST https://blast.ncbi.nlm.nih.gov/Blast.cgi  Table 
2.1 and 2.2. Gene expression analysis was carried out according to Day et al. 2018 
using the VIIA™ 7 PCR System (Life Technologies, UK) in a fina l reaction volume 
of 10 µl, and comprised of 1 X ImmoMix PCR MasterMix (Bioline, Cat. # BIO-
25022), SYBR Green (0.06ul of 100x stock), ROX reference dye (175 nM) 
magnesium (0.5 mM), BSA (50 µg/ml) and 10 nM forward and reverse primers 
[234]. The following PCR cycling conditions were used; one cycle at 95°C for 10 
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min for initial denaturation, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 
min and then the melt curve. For each gene, the melt curves and standard curves 
were performed to determine the primer specificity and linearity respectively. 
Target genes were normalized against housekeeping genes. (1) GAPDH for THP-
1, (2) 18S for J774A.1, (3) YWHAZ for liver and RLP4 for aorta. The fold expression 
of the target genes was quantified relative to the control sample (DMSO for cell 
model or red tomato for mice tissues) using 2-∆∆Ct method.  
2.4.8. Statistical analysis 
All data and statistics were carried out by using GraphPad Prism (version 5.04 for 
Windows, GraphPad Software, La Jolla California USA, www.graphpad.com). All 
values are given as means ± SD. Any statistical difference between the groups was 
determined with one-way ANOVA coupled with Dunnett’s Multiple Comparison Test 
comparing all sample groups to control (DMSO in cell model or red tomato in mouse 
tissues). Values of p ≤ 0.05 were considered significant.
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Table 2. 1: Primer and probe sequences of genes analysed in THP-1 human 
macrophages  
 
Gene name Sequence 
ABCA1 Forward AGA TAA TCC CCT GAA CCC AAG 
Reverse GCT ACC CAC CCT ATG AAC AAC 
Probe 5`-/56-FAM/TTC CAA ATA/ZEN/AAG CCA TGC 
CCT CTG C/3IABkFQ/-3` 
ABCG1 Forward TGG TCT GAG TCA CAC ATG C 
Reverse GTC TGA ACT GCC CAA CCT AC 
probe 5`-/56-FAM/TGC AAC CTC /ZEN/CAT GAC AAA 
ATC TGC TG/3IABkFQ/-3 
GAPDH Forward TGT AGT TGA GGT CAA TGA AGG G 
Reverse ACA TCG CTC AGA CAC CAT G 
probe 5`-/56-FAM/AAG GTC GGA/ZEN/GTC AAC GGA 
TTT GGT C/3IABkFQ/-3 
MSR1 Forward TTT GAT GCT CGC TCA ATG AC 
Reverse TTG AAG GGA AGG GCT GTT TT 
SCARB1 Forward TAT GCC CAG TAC GTC CTC CT 
Reverse CTG GCT CAC GGT GTC CTC 
CD36 Forward TGG AAC AGA GGC TGA CAA CTT 
Reverse TTG ATT TTG ATA GAT ATG GGA TGC 
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Table 2. 2: Primer and probe sequences of genes analysed in mice tissue and 
J774A.1 mouse macrophages. 
Gene name Sequence 
ABCA1 Forward CCA TAC CGA AAC TCG TTC ACC 
Reverse CCG CAG ACA TCC TTC AGA ATC 
probe 5`-/56-FAM/CGT ACG TGC/ZEN/AGA TCA TAG 
CAA AGA GCT/3IABkFQ/-3 
ABCG1 Forward ACT GTT CTG ATC CCC GTA CT 
Reverse TCT CCA ATC TCG TGC CGT A 
probe 5`-/56-FAM/TGC CAC TTC/ZEN/CAT GAC AAA 
GTC TGC T/3IABkFQ/-3 
RPL4 Forward CTT GCC AGC TCT CAT TCT CTG 
Reverse TGG TGG TTG AAG ATA AGG TTG A 
probe 5`-/56-FAM/CTG AAC AGC/ZEN/CTC CTT GGT 
CTT CTT GTA/3IABkFQ/-3 
YWHAZ Forward AGC TTG GCC TTC TGC AC 
Reverse AGA TCA GGG ACA GAG TCT CAG 
probe 5`-/56-FAM/ACC CAC TCC/ZEN/GGA CAC AGA 
ATA TCC A/3IABkFQ/-3 
18S Forward CTT TGG TCG CTC GCT CCT C 
Reverse TCA CCG GGT TGG TTT TGA TC 
probe 5`-/56-FAM/TGC CGA CGG/ZEN/GCG CTG ACC 
/3IABkFQ/-3 
MSR1 Forward CTG GAC AAA CTG GTC CAC CT 
Reverse GTC CCC GAT CAC CTT TAA CA 
SCARB1 Forward CGT TGT CAT GAT CCT CAT GGT 
Reverse ACA GGC TGC TCG GGT CTA T 
CD36 Forward TTG AAA AGT CTC GGA CAT TGA G 
Reverse TCA GAT CCG AAC ACA GCG TA 
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2.5. Results 
2.5.1. The in vitro effect of anthocyanins and their metabolites on 
cholesterol transporters gene expression. 
2.5.1.1. Effect of anthocyanins parent compounds on ABCA1 and 
ABCG1 genes expression in THP-1 macrophages 
The effect of two anthocyanin parent compounds, C3G and D3G, on the expression 
of ABCA1 and ABCG1 genes was examined by incubating preloaded THP-1-
macrophages with 1 and 10 µM of C3G and D3G for 24 hr (Fig 2.5 A and B). The cells 
were preloaded with 25 µg/ml ac-LDL for 24 hr prior to treatment to initiate foam cell 
formation and to stimulate the RCT process. The expression of ABCA1 and ABCG1 
(the cholesterol transporters) was quantified using qPCR.  As shown in Fig 2.5 A and 
B, there was no significant effect of C3G or D3G on ABCA1 and ABCG1. C3G at 10 
µM slightly increased ABCG1 expression by 14% when compared to 1 µM, but it was 
not significant (Fig 2.5-B).  
Kaempferol (the positive control) significantly induced the expression of the ABCA1 
and ABCG1 genes by 2.7- and 4.2-fold, respectively (p ≤ 0.001). On the other hand, 
the expression of ABCA1 and ABCG1 genes in the negative control (cells treated with 
DMSO but not preloaded with ac-LDL) was 40-50% lower than the ac-LDL pre-loaded 
control (p ≤ 0.001, Fig 2.5 A&B). This indicates that the model is working and sensitive 
to treatment and that the ac-LDL preloading step does indeed increase the expression 
of the cholesterol efflux transporters ABCA1 and ABCG1 in THP-1 macrophages. 
Therefore, these data clearly show that treatment of the macrophages with 
anthocyanin parent compounds does not alter ABCA1 and ABCG1 gene expression. 
This was consistent with previous findings that C3G did not change ABCA1 and 
ABCG1 gene expression and indicated that the biological activity of anthocyanins may 
be attributed to their metabolites [228]. Therefore, the effect of anthocyanin 
metabolites on cholesterol transporters, ABCA1 and ABCG1, was investigated. 
 52 
 
ABCA1
G
e
n
e
 e
x
p
re
s
s
io
n
 f
o
ld
 C
h
a
n
g
e
-V
e 
C
on
tr
ol
C
3G
D
3G +V
e
0.0
0.5
1.0
1.5
3.0
1M
10M
***
***
ABCG1
G
e
n
e
 e
x
p
re
s
s
io
n
 f
o
ld
 C
h
a
n
g
e
-V
e
C
on
tr
ol
C
3G
D
3G +V
e
0
1
2
4
5 1M
10M
***
***
A
B
 
Figure 2. 5: Effect of anthocyanins parent compounds on (A) ABCA1 and (B) 
ABCG1 gene expression.  
THP-1 derived macrophages were preloaded with ac-LDL (25 µg/ml) and then treated; control 
= DMSO, C3G = cyanidin-3-glucoside, D3G = delphinidin-3-glucoside and +Ve = is the positive 
control, kaempferol (10 µg/ml, 30 µM). -Ve is the negative control which is cells treated with 
DMSO without preloading step. The fold change was calculated relative to the ac-LDL 
preloaded vehicle control. Data are shown as means ± SD. *** p ≤ 0.001 as compared to 
control using one-way ANOVA coupled with Dunnett’s multiple comparison test. 
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2.5.1.2. Effects of anthocyanin metabolites on ABCA1 and ABCG1 gene 
expression in THP-1 macrophages. 
Preloaded THP-1 macrophages were treated with 1 and 10 µM of PGA, PCA, gallic 
acid, ferulic acid, vanillic acid and 4HBA for 24 hr prior to RNA extraction and 
quantification of ABCA1 and ABCG1 gene expression (Fig 2.6 and 2.7). Similar to the 
parent compounds, there were no statistically significant differences observed at 
either of the concentrations tested on either ABCA1 or ABCG1 gene expression.  
These data contradict with what has previously been reported, i.e. that 1 µM PCA 
upregulated both ABCA1 and ABCG1 gene expression in THP-1 macrophages by 2.6 
and 4 fold, respectively [228]. Therefore, a series of experiments were carried out to 
confirm the sensitivity and reliability of the model and to validate my results. The data 
from these experiments has been presented later in this chapter.  
Interestingly, ferulic acid (one of the main C3G metabolites) increased ABCA1 gene 
expression by 22% at the lower concentration tested which was similar to the 
concentration reported in serum (0.827 µM) after consumption of labelled-C3G [73]. 
However, this was not statistically significant (Fig 2.6). Unexpectedly, 4HBA at the 
higher but not the lower concentration reduced ABCG1 by 26% but again the change 
was not significant. 
To further investigate the potential active compounds accounting for anthocyanin 
biological activity, syringic acid, sinapic acid, phloroglucinol and 5HFA were examined 
at concentration 10 µM (see Fig 2.8 A and B). However, no significant differences 
were found. Phloroglucinol, 5HFA and hippuric acid slightly decreased ABCG1 gene 
expression but the effect did not reach statistical significance (Fig 2.8 B).  
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Figure 2. 6: Effect of anthocyanins metabolites on ABCA1 gene expression.  
THP-1 derived macrophages were preloaded with ac-LDL (25 µg/ml) for 24 hr prior treatment. 
Control = DMSO, PGA = phloroglucinaldehyde, PCA = protocatechuic acid, 4HBA = 4-
hydroxybenzaldehyde and +Ve = the positive control, kaempferol (10 µg/ml, 30 µM). -Ve is the 
negative control which is cells treated with DMSO without preloading step. The fold change 
was calculated relative to control. Data are shown as means ± SD. *** p ≤ 0.001 as compared 
to control using one-way ANOVA coupled with Dunnett’s multiple comparison test. 
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Figure 2. 7: Effect of anthocyanins metabolites on ABCG1 gene expression.  
THP-1 derived macrophages were preloaded with ac-LDL (25 µg/ml) for 24 hr prior treatment. 
Control = DMSO, PGA = phloroglucinaldehyde, PCA = protocatechuic acid, 4HBA = 4-
hydroxybenzaldehyde and +Ve = the positive control, kaempferol (10 µg/ml, 30 µM). -Ve is the 
negative control which is cells treated with DMSO without preloading step. The fold change 
was calculated relative to control. Data are shown as means ± SD. *** p ≤ 0.001 as compared 
to control using one-way ANOVA coupled with Dunnett’s multiple comparison test. 
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Figure 2. 8: Effect of anthocyanins potential metabolites on (A) ABCA1 and (B) 
ABCG1 gene expression.  
THP-1 derived macrophages were preloaded with ac-LDL (25 µg/ml) for 24 hr prior treatment. 
Control = DMSO, 5HFA = 5-hydroxyferulic acid and +Ve = the positive control, kaempferol (10 
µg/ml, 30 µM). -Ve is the negative control which is cells treated with DMSO without preloading 
step. The fold change was calculated relative to control. Data are shown as means ± SD. *** 
p ≤ 0.001 as compared to control using one-way ANOVA coupled with Dunnett’s multiple 
comparison test. 
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2.5.1.3. Effect of anthocyanin metabolite conjugates and mixtures on 
ABCA1 and ABCG1 gene expression in THP-1 macrophages. 
PCA conjugates and gallic acid conjugates were investigated for their effect on the 
gene expression of the ABCA1 and ABCG1 cholesterol transporters using the same 
model as for the unconjugated metabolites of anthocyanins (Fig 2.9 and 2.10). To 
study the effect of metabolite conjugates, the cells were treated with a combination of 
PCA glucuronides (PCA-3-GlcA and PCA-4-GlcA, 1 µM each), and combination of 
PCA sulphates (PCA-3-Sulph and PCA-4-Sulph, 1 µM each) for 24 hr.  
A mixture of C3G, PCA and PCA conjugates (1 µM each) was also incubated with 
cells to investigate the synergistic effect of C3G and PCA conjugates. Following the 
treatments, there was no significant changes on the gene expression of ABCA1 and 
ABCG1 with any of PCA conjugates (Fig 2.9). In addition, a mixture of C3G and PCA 
conjugates did not induce any changes in either of the cholesterol transporter genes 
(Fig 2.9).   
To investigate the effect of gallic acid conjugates on ABCA1 and ABCG1 gene 
expression, the preloaded THP-1 macrophages were treated with a combination of 
gallic acid glucuronides (GA-3-GlcA and GA-4-GlcA, 1 µM each), a combination of 
methylated gallic acid (3MethGA and 4MethGA, 1 µM each) and a mixture of D3G, 
gallic acid and gallic acid conjugates, 1 µM each. Consistent with PCA conjugates, no 
significant change was seen with any of gallic acid conjugates or the mixture of D3G 
and gallic acid conjugates (Fig 2.10).  
The data presented here show that none of the tested anthocyanin parent compounds 
or their metabolites caused significant changes in the expression of either the ABCA1 
or ABCG1 genes. Apart from PCA, all of the data is novel in that there are no existing 
published reports describing the effects of any of these metabolites on the expression 
of RCT cholesterol transporter gene expression. However, since my data show that 
PCA did not induce the expression of ABCA1 or ABCG1 genes which contradicted a 
previously published report by Wang et al [228], additional experiments were 
conducted to examine the reliability and sensitivity of the model that was used in this 
current study.  
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Figure 2. 9: Effect of PCA conjugates on ABCA1 and ABCG1 gene expression.  
THP-1 derived macrophages were preloaded with ac-LDL (25 µg/ml) for 24 hr prior treatment. 
Control = DMSO, PCA-GlcAs = 1 µM of PCA-3-glucuronide and PCA-4-glucuronide, PCA-
Sulphs = 1 µM of PCA-3-sulphate and PCA-4-sulphate, PCA-Mixture = 1 µM of C3G, PCA 
and PCA conjugates. +Ve = is the positive control, kaempferol (10 µg/ml, 30 µM). -Ve is the 
negative control which is cells treated with DMSO without preloading step. The fold change 
was calculated relative to control. Data are shown as means ± SD. *** p ≤ 0.001 as compared 
to control using one-way ANOVA coupled with Dunnett’s multiple comparison test. 
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Figure 2. 10: Effect of gallic acid conjugates on ABCA1 and ABCG1 gene 
expression.  
THP-1 derived macrophages were preloaded with ac-LDL (25 µg/ml) for 24 hr prior treatment. 
Control = DMSO, GA-GlcAs = 1 µM of gallic acid-3-glucuronide and gallic acid-4-glucuronide, 
MethGA = 1 µM of 3-O- Methylgallic acid and 4-O- Methylgallic acid, GA-Mixture = 1 µM of 
D3G, gallic acid and gallic acid conjugates. +Ve = is the positive control, kaempferol (10 µg/ml, 
30 µM). -Ve is the negative control which is cells treated with DMSO without preloading step. 
The fold change was calculated relative to control. Data are shown as means ± SD. *** p ≤ 
0.001 as compared to control using one-way ANOVA coupled with Dunnett’s multiple 
comparison test. 
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2.5.1.4. Repeatability and assay sensitivity 
It has been reported that PCA upregulated both ABCA1 and ABCG1 gene expression 
by 2.6 and 4 fold, respectively, in preloaded THP-1 derived macrophages at a 
concentration of 1 µM [228]. It was also reported in the same paper that PCA 
treatment increased ABCA1 and to a lesser extent ABCG1 gene expression in ac-
LDL-loaded mouse peritoneal macrophages (MPMs).  
2.5.2.4.1. Using different cholesterol transporter inducer 
Although kaempferol (the positive control) consistently increased both ABCA1 and 
ABCG1 gene expression in THP-1 at concentration 10 µg/ml in the current 
experiment, as expected, it is useful to examine whether the model is sensitive to any 
other RCT stimulators. Cyclic adenosine monophosphate (c-AMP) is a well-known 
ABCA1 inducer [235][236][237]. Therefore, the effects of c-AMP on ABCA1 gene 
expression was tested using the current model. Preloaded THP-1-derived 
macrophages were treated with c-AMP at a concentration of 300 µM and PCA at a 
concentration of 1 µM (Fig 2.11). c-AMP significantly upregulated ABCA1 gene 
expression by 1.8-fold, while, PCA did not significantly affect the gene expression (Fig 
2.11, p ≤ 0.001). This shows that the model is sensitive to treatment with at least two 
known agonists (kaempferol and c-AMP) but that expression of the ABCA1 and ABG1 
genes is not altered by treatment with PCA. 
2.5.2.4.2. The importance of the preloading step 
In vivo, foam cell macrophages in arteries contain large quantities of esterified 
cholesterol deriving from the internalization of modified LDL [238]. To mimic the in 
vivo situation, THP-1 macrophages were preloaded with modified-LDL (ac-LDL). This 
preloading step stimulated RCT and increased the expression of the cholesterol 
transporter genes as evidenced by the results from the experiments comparing the 
negative control treatment (non-preloaded macrophages) with the control (preloaded 
macrophages) (Fig 2.5 to 2.10). However, the model might be over-stimulated in the 
sense that the model became sensitive only to the strong agonists and is not able 
anymore to detect the effect of secondary weak stimuli. Hence, further investigations 
were carried out to explore this possibility.  
Therefore, the effect of c-AMP (the well-known RCT agonist) on ABCA1 gene 
expression was tested with and without preloading step (Fig 2.12).  THP-1 
macrophages were incubated with media containing 25 µg/ml ac-LDL (preloaded) or 
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media without ac-LDL (non-preloaded) for 24 hr prior treatment with c-AMP and 
ABCA1 gene expression quantified. Firstly, c-AMP with preloading resulted in 1.9-fold 
increase compared to DMSO with preloading indicating that there was not a problem 
with c-AMP (Fig 2.12). Interestingly, c-AMP without preloading resulted in 40% 
reduction in ABCA1 gene expression compared to DMSO with preloading and 130% 
reduction compared to c-AMP with preloading which shows that c-AMP was not able 
to induce the RCT process if the macrophages had not been pre-loaded with LDL-
cholesterol (Fig 2.12).  
Moreover, there was no significant difference between c-AMP without preloading and 
DMSO without preloading suggesting that the model without the preloading step was 
not sensitive even to the known agonist. Therefore, preloading with ac-LDL is 
necessary to ensure the macrophages were converted to foam cells and the RCT 
process was initiated (Fig 2.12). 
Since preloading with ac-LDL is necessary for completion of foam cells formation, it 
was thought (although it is not likely) that the concentration of ac-LDL  used in this 
experiment was not enough for foam cell process completion and perhaps increasing 
the concentration of ac-LDL might enhance further the sensitivity of the model. 
Therefore, THP-1 macrophages were preloaded with 25 and 50 µg/ml of ac-LDL prior 
treatment to examine the effect of concentration of ac-LDL on stimulation of the 
model.  
In addition, non-preloaded cells treated only with the vehicle DMSO were included to 
assess the effect of the preloading step as the non-preloaded cells usually give lower 
gene expression compared to the preloaded cells. The results show that increasing 
the ac-LDL concentration did not enhance further the sensitivity of the model as there 
was no statistical differences in ABCA1 gene expression between treatments at either 
of the two concentrations of ac-LDL tested (Fig 2.13). Moreover, ABCA1 gene 
expression in non-preloaded cells treated with DMSO was significantly lower than the 
preloaded cells which mean that the preloading step worked fine and succeeded in 
stimulating the model. This finding confirmed that the concentration of ac-LDL (25 
µg/ml) that had been used in the experiments reported in this chapter was sufficient 
and there was no need to increase the ac-LDL concentration.   
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Figure 2. 11: ABCA1 gene expression in THP-1 macrophages stimulated by c-
AMP.  
THP-1 derived macrophages were preloaded with ac-LDL (25 µg/ml) for 24 hr prior treatment. 
Control = DMSO, c-AMP= cyclic adenosine monophosphate (300 µM), PCA= 1 µM 
protocatechuic acid. The fold change was calculated relative to control. Data are shown as 
means ± SD. *** p ≤ 0.001 as compared to control using one-way ANOVA coupled with 
Dunnett’s multiple comparison test. 
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Figure 2. 12: Effect of preloading with ac-LDL on THP-1 model stimulation.  
THP-1 derived macrophages were either preloaded with ac-LDL (25 µg/ml) for 24 hr or non-
preloaded prior treatment with DMSO (vehicle control) or with c-AMP (300 µM). The fold 
change was calculated relative to DMSO + Preloading. Data are shown as means ± SD. *** p 
≤ 0.001, ** p ≤ 0.01 as compared to DMSO + Preloading using one-way ANOVA coupled with 
Dunnett’s multiple comparison test
 64 
 
 
 
A
B
C
A
1
 g
e
n
e
 e
x
p
re
s
s
io
n
 f
o
ld
 c
h
a
n
g
e
DMSO ac-LDL+DMSO ac-LDL+cAMP
0.0
0.5
1.0
1.5
2.0
2.5 25g/ml ac-LDL
50g/ml ac-LDL
a
b b
c
c
 
 
Figure 2. 13: Effect of ac-LDL concentration on THP-1 model stimulation. 
THP-1 derived macrophages were preloaded with two ac-LDL concentrations (25 and 50 
µg/ml) for 24 hr prior treatment with DMSO (vehicle control) or c-AMP (300 µM). DMSO without 
preloading treatment has been done by incubating the macrophages with media free from ac-
LDL for 24 hr before treatment with DMSO. The fold change was calculated relative to ac-LDL 
+ DMSO. Data are shown as means ± SD. Bars for treatments with different superscript letters 
are significantly different (p ≤ 0.001) compared to ac-LDL + DMSO using one-way ANOVA 
coupled with Dunnett’s multiple comparison test. 
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In the current model, the preloading step (24 h) occurs before exposing the cells to 
treatments to make sure the cells were converted to foam cells and started to efflux 
cholesterol. In vivo however, the cholesterol uptake (represented by the preloading 
step) may occur in parallel to cholesterol efflux (represented by stimulation of 
cholesterol transporters) to maintain cholesterol homeostasis [219]. Therefore, it was 
hypothesised that applying treatments simultaneously with the ac-LDL loading may 
improve the response of the model to putative treatments. To test this, THP-1 
macrophages were treated with 25 µg/ml ac-LDL at the same time as the treatment. 
The treatments were PCA (1 µM), c-AMP and kaempferol and also a control (DMSO). 
ABCA1 and ABCG1 genes expression were quantified and normalized to control 
treatment.  
As shown in Fig 2.14, PCA did not significantly change the expression of either gene 
which is consistent with the results presented earlier in this chapter. However, when 
both treatment and preloading were performed in combination with each other, both 
c-AMP and kaempferol significantly induced ABCA1 and ABCG1 gene expression 
(Fig 2.14). But, the magnitude of induction was far less than what was seen when 
preloading and treatment had been done successively (Fig 2.5 to 2.13). For instance, 
adding the treatment alongside the preloading reduced the effect of kaempferol on 
ABCA1 and ABCG1 by 100 and 140%, respectively, compared to the effect when the 
preloading had been done before the treatment (see Fig 2.14 and Fig 2.5 to 2.10). 
Similar observations were seen with c-AMP which hardly affected gene expression 
(Fig 2.14). The reason for this may be that foam cell formation was not complete which 
meant there was a lower capacity of the cells for cholesterol efflux. This finding 
confirmed that including a preloading step prior treatment is better for model 
sensitivity. 
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Figure 2. 14: The influence of doing the treatment alongside the preloading step 
on model sensitivity.  
THP-1 derived macrophages were preloaded with ac-LDL (25 µg/ml) simultaneously with the 
treatments for 24 hr. The treatments were control=DMSO, PCA= protocatechuic acid (1 µM), 
c-AMP = cyclic-AMP (300 µM) and kaempferol (10 µg/ml, 30 µM). The fold change was 
calculated relative to the control. Data are shown as means ± SD. *** p ≤ 0.001, ** p ≤ 0.01 
and * p ≤ 0.05 as compared to the control using one-way ANOVA coupled with Dunnett’s 
multiple comparison test. 
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2.5.2.4.3. The influence of cell passage number 
It was recommended that THP-1 should be differentiated at passage numbers lower 
than 20 to get completely differentiated THP-1 macrophages [238]. In the current 
model, THP-1 cells were used at passage number from 9 to 15 which is considered a 
low passage number. However, it is possible that using cells from a lower passage 
number, even lower than 9, might increase the sensitivity of the model to treatments. 
Therefore, THP-1 cells were differentiated as previously described at passage 
number 4. After preloading, differentiated cells were treated with 1 µM PCA and 
kaempferol. The gene expression of ABCA1 was quantified and normalized to control 
treatment (DMSO). The analysis showed that there were no significant differences 
between PCA and the control (DMSO) (Fig 2.15). In addition, kaempferol induced the 
ABCA1 by 2.4-fold similar to what was previously found when the higher passage 
numbers had been used (Fig 2.5 to 2.10). Based on that, using passage number lower 
than previously used has no influence in the model reliability and sensitivity. 
2.5.2.4.4. The influence of presence versus absence of fetal bovine serum 
(FBS) 
FBS has been used as a supplement in basal growth medium in cell culture for 
decades [239]. Therefore, the cell growth, cell differentiation and preloading steps 
have been performed in media contain 10% FBS. However, lipoproteins found in FBS 
can bind with polyphenols and suppress their action [240]. Hence, the treatments 
were performed in FBS-free media which is opposite to what is happening in vivo in 
which macrophages are subjected to the stimuli in the presence of serum. Therefore, 
conducting the treatments in the presence of FBS was further investigated. After 
growing, differentiating and preloading THP-1 macrophages in media containing 10% 
FBS, the cells were then treated with 1 µM PCA, kaempferol and vehicle control 
(DMSO) using media in the presence or absence of FBS. The -ve (negative control) 
was non-preloaded cell treated with DMSO. As shown in Fig 2.16 A and B, kaempferol 
significantly increased ABCA1 and ABCG1 gene expression in both the presence and 
absence of FBS (p ≤ 0.001). However, the effect in the absence of FBS was higher 
than the effect in the presence of FBS (Fig 2.16 A and B). In fact, the effect of 
kaempferol on ABCG1 in the absence of FBS was two times higher than the effect in 
the presence of FBS (Fig 2.16 B). Probably, lipoproteins in serum bind with 
kaempferol and attenuate its action [240]–[242]. Again, no significant changes in 
ABCA1 and ABCG1 gene expression were observed after PCA treatment using any 
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of these conditions (Fig 2.16 A and B). These data indicated that conducting the 
treatment in the presence of FBS negatively influenced the sensitivity of the model, 
probably because it contains components that can bind the treatment compounds and 
reduce their efficacy.  
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Figure 2. 15: The influence of using THP-1 at low passage number on model 
sensitivity.  
THP-1 derived macrophages at passage number 4 were preloaded with ac-LDL (25 µg/ml) for 
24 hr prior treatment. Control = DMSO, PCA= 1 µM protocatechuic acid and kaempferol (10 
µg/ml, 30 µM). The fold change was calculated relative to control. Data are shown as means 
± SD. *** p ≤ 0.001 as compared to control using one-way ANOVA coupled with Dunnett’s 
multiple comparison test. 
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Figure 2. 16: The influence of the presence of fetal bovine serum (FBS) on model 
sensitivity. (A) ABCA1 gene expression and (B) ABCG1 gene expression.  
THP-1 derived macrophages were preloaded with ac-LDL (25 µg/ml) for 24 hr prior treatment. 
Control = DMSO, PCA= 1 µM protocatechuic acid and kaempferol (10 µg/ml, 30 µM). -Ve is 
the negative control which is cells treated with DMSO without preloading step. The fold change 
was calculated relative to control. Data are shown as means ± SD. *** p ≤ 0.001 as compared 
to control using one-way ANOVA coupled with Dunnett’s multiple comparison test. 
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2.5.2.4.5. Using different cell line 
Wang et al. have previously reported that 1 µM of PCA increased ABCA1 and ABCG1 
expression in human (differentiated THP-1) and mouse macrophages (J744.1) [228]. 
So far work in this chapter has only focused on human macrophages, and so 
experiments were undertaken to test the effects of PCA on ABCA1 and ABCG1 gene 
expression in mouse macrophages. J744A.1 mouse macrophages were grown, 
preloaded as previously described. J744A.1 cells are semi-detach macrophages and 
does not require a differentiation step. The preloaded J774A.1 macrophages were 
then treated with 1 µM PCA, c-AMP and the DMSO. No significant changes were 
observed in ABCA1 gene expression after PCA treatment (Fig 2.17). On the other 
hand, c-AMP induced ABCA1 gene expression by 1.8-fold (p ≤ 0.001). This was 
consistent with data reported earlier in this chapter with human macrophages. These 
data show that PCA has no effect on cholesterol transporter gene expression in either 
human- or mouse-derived macrophages. 
In summary, from these series of experiments that focused on examining the 
repeatability, sensitivity and reliability of the model using different conditions and 
parameters, it has been shown that the current model was working well and produced 
reliable and repeatable results. It has been shown that the ac-LDL preloading step 
was necessary to increase the response of the ABCA1 and ABCG1 genes to known 
effectors, but it was not over stimulated as both the tested positive controls increased 
both ABCA1 and ABCG1 gene expression. Increasing the ac-LDL concentration did 
not enhance further the sensitivity meaning that the concentration used was (near) 
optimal. Applying the treatments simultaneously to the ac-LDL substantially reduced 
the sensitivity indicating that the order in the current model is the best for model 
stimulation. No further enhancement was observed with cells at lower passage 
number, adding FBS to media for treatment reduced the sensitivity and finally, using 
different cell line did not change the fact that the model produces repeatable results 
and PCA has no effect on cholesterol transporters gene expression. Based on these 
findings, anthocyanins and their metabolites did not significantly change the 
expression of the cholesterol transporter genes ABCA1 and ABCG1 in THP-1-derived 
macrophages.  
Having eliminated ABCA1 and ABCG1 as putative targets for anthocyanins and / or 
their metabolites, the search for other putative targets in the RCT pathway were 
investigated. The first was cellular cholesterol uptake.      
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Figure 2. 17: ABCA1 gene expression in J774A.1 treated with PCA and c-AMP.  
J774A.1 macrophages were preloaded with ac-LDL (25 µg/ml) for 24 hr prior treatment. 
Control = DMSO, c-AMP= cyclic adenosine monophosphate (300 µM), PCA= 1 µM 
protocatechuic acid. The fold change was calculated relative to control. Data are shown as 
means ± SD. *** p ≤ 0.001 as compared to control using one-way ANOVA coupled with 
Dunnett’s multiple comparison test. 
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2.5.2. The in vitro effect of anthocyanins and their metabolites on the 
expression of genes involved in cholesterol uptake 
The scavenger receptors (SR) play a vital role in meditating the uptake and 
internalization of modified-LDL that initiates foam cell formation [225]. Inhibiting the 
expression of SR may attenuate foam cell formation [224]. Therefore, the effect of 
anthocyanins and their metabolites on the gene expression of three members of the 
SR family (MSR1, SCARB1 and CD36) were investigated. The preloaded THP-1-
derived macrophages were treated with 10 µM of C3G and D3G for 24 hr as 
representative anthocyanin parent compounds. To investigate the effect of 
anthocyanin metabolites, the cells were treated with 10 µM of PCA, PGA, ferulic acid, 
vanillic acid, 4HBA and gallic acid for 24 hr. The gene expression of MSR1, SCARB1 
and CD36 were quantified using RT-qPCR.   
For anthocyanin parent compounds, C3G and D3G slightly increased the expression 
of the MSR1 and SCARB1 genes (Fig 2.18-2.19), although the effect was not 
significant. The expression of CD36 was not changed compared to control (Fig 2.20). 
Unexpectedly, PCA at a concentration of 10 µM significantly increased the expression 
of the MSR1 gene by 1.4-fold change (Fig 2.18, p ≤ 0.05). Furthermore, PCA caused 
a small but non-significant increase in expression of the SCARB1 gene (Fig 2.19), 
whereas PCA did not change the expression of the CD36 gene (Fig 2.20). No 
significant changes were observed in the expression of any of the three genes after 
4HBA treatment (Fig 2.18-2.20). No statistically significant changes were observed 
with other treatments.   
Based on these results, there was not a direct interaction between anthocyanins and 
their metabolites with genes driving either cholesterol transporter or cholesterol 
uptake in the in vitro model used in the previous experiment. However, a secondary 
effect of anthocyanins on these genes is not excluded. Therefore, exploring the effects 
using an in vivo model was suggested. Therefore, the gene expression of cholesterol 
transporters and cholesterol uptake were investigated in tissues isolated from mice 
treated with anthocyanins. 
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Figure 2. 18: Effect of anthocyanins and their metabolites on MSR1 gene 
expression.  
THP-1 derived macrophages were preloaded with ac-LDL (25 µg/ml) for 24 hr prior treatment. 
Control = DMSO, C3G = cyanidin-3-glucoside, D3G = delphinidin-3-glucoside, PGA = 
phloroglucinaldehyde, PCA = protocatechuic acid and 4HBA = 4-hydroxybenzaldehyde. The 
fold change was calculated relative to control. Data are shown as means ± SD. * p ≤ 0.05 as 
compared to control using one-way ANOVA coupled with Dunnett’s multiple comparison test. 
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Figure 2. 19: Effect of anthocyanins and their metabolites on SCARB1 gene 
expression.  
THP-1 derived macrophages were preloaded with ac-LDL (25 µg/ml) for 24 hr prior treatment. 
Control = DMSO, C3G = cyanidin-3-glucoside, D3G = delphinidin-3-glucoside, PGA = 
phloroglucinaldehyde, PCA = protocatechuic acid and 4HBA = 4-hydroxybenzaldehyde. The 
fold change was calculated relative to control. Data are shown as means ± SD. No significant 
differences detected compared with control using one-way ANOVA coupled with Dunnett’s 
multiple comparison test. 
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Figure 2. 20: Effect of anthocyanins and their metabolites on CD36 gene 
expression.  
THP-1-derived macrophages were preloaded with ac-LDL (25 µg/ml) for 24 hr prior treatment. 
Control = DMSO, C3G = cyanidin-3-glucoside, D3G = delphinidin-3-glucoside, PGA = 
phloroglucinaldehyde, PCA = protocatechuic acid and 4HBA = 4-hydroxybenzaldehyde. The 
fold change was calculated relative to control. Data are shown as means ± SD. No significant 
differences detected compared with control using one-way ANOVA coupled with Dunnett’s 
multiple comparison test. 
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2.5.3. The effect of anthocyanins consumption on the gene expression 
of cholesterol transporters in vivo. 
To test the in vivo effect of anthocyanins on ABCA1 and ABCG1 gene expression (the 
cholesterol transporters), tissues from ApoE-/- mice that were fed high-polyphenol 
tomatoes were used. Four groups of mice were fed four types of tomatoes that were 
high in either flavonols, a mixture of anthocyanins and flavonols (ANCs + Flavonols), 
resveratrol or isoflavones. The effects of consumption of these different types of high-
polyphenol tomatoes were compared to control group in which the mice were fed 
normal red tomatoes (low polyphenol tomato). The animal intervention was conducted 
by Mark Winterbone. I only completed the analysis of the relative gene expression in 
the liver and aorta tissues. I undertook the removal of the fat from the tissue and 
further tissue processing, the extraction of RNA from aorta and liver tissue samples, 
and the analysis of gene expression.  
With regard the outcome of the animal feeding study, the primary outcome was the 
size of plaques in the aortic arch. This data indicated that the diets supplemented with 
tomatoes expressing a mixture of anthocyanins and flavonols and the tomatoes 
expressing resveratrol caused reductions in atherosclerotic plaque size in mouse 
aortic sinuses by 31 and 26%, respectively (data unpublished), compared to the diet 
supplemented with control red tomato. Since removal of cholesterol from plaques is 
a key process underpinning reduction in plaque size, it was hypothesised that RCT 
key genes in these two groups would be altered by the diets.  
For ABCA1 and ABCG1 gene expression in aorta, ANCs + Flavonols tomatoes 
increased ABCG1 gene expression by 1.4-fold compared to the control tomatoes, 
although this was not significant, while, ABCA1 remained unchanged (Fig 2.21 A and 
B). Resveratrol tomatoes increased both ABCA1 and ABCG1 by 1.4- and 1.3-fold, 
respectively; however, the increases were not significant. Surprisingly, ABCA1 gene 
expression was significantly increased by 1.9-fold following consumption of isoflavone 
tomatoes, whereas flavonol tomatoes non-significantly increased ABCG1 by 1.7-fold 
(Fig 2.21 A-B, p ≤ 0.05). According to these findings, anthocyanin-containing 
tomatoes did not influence ABCA1 and ABCG1 gene expression in aortas which is 
consistent with the results obtained from the in vitro work with cultured macrophages.  
For liver tissues, ANCs + Flavanols tomatoes did not alter ABCA1 and ABCG1 gene 
expression compared to the red control tomatoes (Fig 2.22 A and B). Unexpectedly, 
isoflavone-expressing tomatoes significantly reduced ABCA1 by 25% (Fig 2.22 A, p 
≤ 0.05). No significant changes were observed with other treatments. 
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Figure 2. 21: The gene expression of (A) ABCA1 and (B) ABCG1 in aorta tissue 
isolated from Apo E-/- mice fed with high-polyphenol tomatoes.  
Control = red tomatoes (polyphenol-free tomatoes), ANCs + Flavonols = a 
combination of anthocyanins and flavonols. The fold change was calculated relative 
to control. Data are shown as means ± SD. * p ≤ 0.05 as compared to control using 
one-way ANOVA coupled with Dunnett’s multiple comparison test. 
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Figure 2. 22: The gene expression of (A) ABCA1 and (B) ABCG1 in liver tissue 
isolated from Apo E-/- mice fed with high-polyphenol tomatoes. 
Control = red tomatoes (polyphenol-free tomatoes), ANCs + Flavonols = a combination of 
anthocyanins and flavonols. The fold change was calculated relative to control. Data are 
shown as means ± SD. * p ≤ 0.05 as compared to control using one-way ANOVA coupled with 
Dunnett’s multiple comparison test. 
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2.5.4. The effect of anthocyanins consumption on the gene expression 
of cholesterol uptake in vivo 
The gene expression of scavenger receptors MSR1, SCARB1 and CD36 in aorta, 
were quantified using the same aorta RNA extracts that had been used in analyses 
described in the section above. None of the polyphenol-rich tomato groups 
significantly influenced MSR1 or SCARB1 gene expression, although the 
consumption of isoflavone-expressing tomatoes slightly increased MSR1 gene 
expression (Fig 2.23A, B). Anthocyanin-containing tomatoes slightly increased CD36, 
albeit this was not significant. Similarly, flavonols and resveratrol tomatoes increased 
CD36 gene expression, but this was not significant (Fig 2.23C)  
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Figure 2. 23: The gene expression of (A) MSR1, (B) SCARB1 and (C) CD36 in 
aorta tissue isolated from Apo E-/- mice fed with high-polyphenol tomatoes. 
Control = red tomatoes (polyphenol-free tomatoes), ANCs + Flavonols = a combination of 
anthocyanins and flavonols. The fold change was calculated relative to control. Data are 
shown as means ± SD. * p ≤ 0.05 as compared to control using one-way ANOVA coupled with 
Dunnett’s multiple comparison test. 
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2.6. Discussion  
Data from dietary interventions with human participants and in animal models has 
shown that anthocyanins have the potential to modify circulating lipoprotein profiles, 
specifically by reducing total and LDL-cholesterol levels and increasing the levels of 
HDL-cholesterol [164]. However, the mechanisms behind this effect remain elusive: 
First, it is not known whether the anthocyanin parent compounds per se or one or 
more of the myriad of smaller phenolic acid-type metabolites that interact with cells 
and tissues to alter lipoprotein metabolism, and second it is not known where in the 
pathway they act (i.e. with which components of the RCT pathway and in what 
manner). The in vitro work with cultured macrophages described in this chapter 
represents a fairly comprehensive investigation to find out which 
anthocyanins/metabolites were responsible and with which components of the RCT 
pathway they interacted. This research goes well beyond the current state-of-the-art 
which is limited to a single report describing increases in the expression of the ABCA1 
and ABCG1 cholesterol efflux transporters in human and mouse-derived 
macrophages by PCA [228].  
The main findings were that (1) none of the two major anthocyanin parent compounds 
or their metabolites significantly affected the expression of cholesterol transporters 
genes (ABCA1 and ABCG1); (2) none of the parent compound of anthocyanins or 
their metabolites altered the gene expression of the scavenger receptors (MSR1, 
SCARB1 and CD36), although PCA slightly increased the gene expression of MSR1.  
The data presented in this chapter contradict with what Wang et al. 2012 has 
previously reported [228]. They reported that PCA but not C3G increased ABCA1 and 
ABCG1 by 2.6 and 4 fold, respectively which support the idea that anthocyanin 
metabolites are more beneficial [228]. However, the data in this chapter did not 
support this notion. In the current study, C3G did not affect the gene expression which 
was consisted with the previous report. However, PCA did not alter the gene 
expression of either ABCA1 and ABCG1, although the model used in this experiment 
was very similar to the model used by Wang et al. (2012) [228]. The only difference 
could be that they used an isolated ac-LDL made inhouse, while a commercially 
available ac-LDL was used in the current study. Probably (although it is unlikely), the 
isolated ac-LDL that they used contains other molecules that affect the response to 
the treatment. Another possibility could be using serum free media in treatment 
preparation. It is not mentioned whether FBS-free/containing media was used in 
Wang et al. (2012) paper and may be this condition affect the respond. I tried to 
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contact the authors to find out what is the conditions they used but I have not got any 
response. It was obvious that the current model used in this chapter was highly 
sensitive and the data was reliable as both the positive controls and negative control 
worked well.    
Apart from C3G and PCA [228], the effect of all other tested metabolites in this study 
on RCT gene expression were investigated for the first time. The pharmacokinetics 
study of isotope-labelled C3G [73] showed that PCA wasn’t the main metabolite of 
C3G but ferulic acid, vanillic acid and hippuric acid were the main ones. The reported 
concentration of PCA in human plasma was 146 nm, while the concentration of vanillic 
acid, ferulic acid, hydroxybenzaldehyde were 1845, 827 and 667 nm, respectively 
which is higher than PCA by at least 4.5 to 12-fold [73]. However, the effect of these 
metabolites on ABCA1 and ABCG1 remained unexplored. In the previous report 
[228], it was totally ignored that PCA is subject to phase II conjugation and the effects 
of PCA conjugates has not been investigated yet. In addition, the fact that anthocyanin 
metabolites are found in mixture and there is high possibility of synergistic effect was 
unexplored. Moreover, no one has investigated the effect of D3G and its potential 
metabolites and there is a gap of knowledge which needs further investigation. 
Therefore, the effect of two major anthocyanin types, C3G and D3G, and 18 of their 
metabolites including their recently identified human metabolites of C3G and the 
predicted metabolites of D3G on the gene expression of key elements of RCT have 
been investigated for the first time. Most of these metabolites have been recently 
identified and their biological effects are still relatively unknown which make the data 
presented here novel. To the best of my knowledge, this is the first in vitro study to 
examine the effects of the pure synthetic phase II conjugates of anthocyanins on RCT 
at physiologically relevant concentrations. This is the first in vitro study to include the 
concept that anthocyanin metabolites are present in mixtures and they may 
synergistically operate to exhibit their effects. Moreover, one of the main strengths of 
the work presented in this chapter was the concentrations of the tested metabolites. 
This study examined the effects of anthocyanins and their metabolites at two different 
physiologically-relevant concentrations, 1 µM and 10 µM which were within the peak 
concentrations of anthocyanin metabolites found in human plasma after consumption 
of 13C-labelled C3G (ranged from 0.1 - 2 µM, with cumulative concentrations of 
metabolites reaching 10 µM) [73], [75].  
The reason for using THP-1 cell as a model to investigate the underlying mechanisms 
by which anthocyanins and their metabolites exhibit their effect was due to the vital 
role that human macrophages play in atherosclerosis. Foam cells found in 
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atherosclerotic vascular lesion are derived from macrophages [243]. Like in the case 
of blood monocyte-macrophages, THP-1 cells increase in number in monocyte stage 
and it can be easily differentiated chemically into macrophage stage in which the cells 
stop dividing [244]. Thereby, THP-1 cells were used in this model. THP-1 monocytes 
were originated from the peripheral blood of a leukemic one-year-old male. THP-1 
can be differentiated into macrophages by using PMA. After differentiation, THP-1 
convert to adherent cells and stop dividing [245]. To mimic physiological status of the 
cholesterol-laden macrophages (foam cells) which contain large quantities of 
esterified cholesterol, THP-1-derived macrophages should be preloaded with a 
modified LDL such as ac-LDL. Ac-LDL increased the quantity of esterified cholesterol 
by several folds in THP-1 macrophages [238]. Therefore, ac-LDL has been used in 
the preloading step to stimulate the model. The data in this chapter clearly showed 
the preloading step was successful and the foam cell formation process was 
completed as there was a clear significant difference in the gene expression of 
preloaded and non-preloaded cells (negative control).    
Despite the fact that the model used in this study is sensitive to treatments, the 
contradiction with Wang et al. 2012 lead to further examination of the sensitivity of the 
current model at different conditions and the use of different parameters to confirm 
the repeatability and reliability of the results obtained. Firstly, both kaempferol and c-
AMP, the well-known ABCA and ABCG1 agonists, increased the gene expression of 
ABCA1 and ABCG1 similar to what have been previously reported [236], [237] 
indicating that the model was sensitive. Additionally, changing the conditions of the 
preloading reduced the sensitivity of the model even to the well-known agonists 
suggesting that the current conditions of preloading step were optimum. Furthermore, 
the passage number that used in this model has no influence on the model sensitivity. 
It can be concluded from this further optimisation that the current model is sensitive 
to treatments and the model successfully worked with two different cell lines.  
Since none of the anthocyanins or their metabolites affected the gene expression of 
cholesterol transporters, the effect on the gene expression of scavenger receptors, 
another element of RCT, were investigated. Scavenger receptors are responsible for 
internalization of modified-LDL[246]–[248]. Scavenger receptors have different 
families according to their structure and therefore they can bind with different ligands 
in addition to LDL derivatives. However, in this study, only three members that belong 
to family A and family B which mainly bind with LDL and its derivatives as a ligand 
were investigated [225]. These three members were: (1) MSR1 (also known as SR-
AI), (2) SCARB1 (also known as SR-BI) and CD36. These three receptors were 
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chosen as they all can use ac-LDL which was used in preloading step as a ligand. 
PCA increased MSR1 gene expression by 1.4-fold change. Otherwise, none of the 
tested metabolites changed the gene expression of any of selected scavenger 
receptors. Although it was expected to observe a reduction in gene expression, there 
was non-significant slight increase on MSR1 with some metabolites on MSR1. 
Probably because the chemical differentiation and preloading steps that used in THP-
1 model. Several studies have reported an increase in the expression of scavenger 
receptors in THP-1 cell after treatment with PMA and ac-LDL which used in the 
differentiation and preloading step [238].  
There are several explanations that may explain why the tested metabolites did not 
show any effects. One reason (although it is unlikely) could be that the more effective 
metabolites have not been tested [73], [91]. Although, wide range of anthocyanin 
metabolites were tested in this study, there are other compounds have not been 
tested. Phenylacetic acid and 3-(4-hydroxyphenyl) propionic acid are good example 
for newly discovered metabolites that should be considered in future work [94]. 
Another example, in our lab, high concentration of homoprotocatechuic acid (3,4 
dihydroxyphenyl acetic acid) was identified for the first time after incubation of C3G 
with human faeces from a donor using the colon model (unpublished data). The 
differences in microbiota was suggested as a reason for producing this new 
compound. For instance, in 13C-labelled C3G study which conducted with 8 
participants [73], vanillic acid was identified only in two participants, while, the other 
six participants did not produce it which means that the metabolisms differ from one 
person to another or from one status to another and there are un-identified 
metabolites which may contribute to the biological activity of anthocyanins. Therefore, 
it is expected that different metabolites may be derived by the action of different 
microbiota and one of these compounds might be responsible for the biological activity 
of anthocyanin. Therefore, exploring the newly discovered metabolites would explain 
the biological activity of anthocyanins. Another explanation is that the interaction 
between anthocyanin metabolites play the crucial role and they interact all together to 
deliver the action of anthocyanins. Due to time and cost, only a mixture of some but 
not all C3G and D3G metabolites were examined. The mixture of C3G metabolites 
were analysed separately from the mixture of D3G metabolites, while, they are found 
together in food and their metabolites are present together in plasma. Is possible that 
if all C3G and/or D3G metabolites were mixed together, an effect on cholesterol 
transporter genes might be observed.  
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Although, there was not any significant effect observed in RCT key genes in vitro, 
anthocyanins might target different pathways and different cell lines. For instance, 
Krga et al. (2018) found that the anthocyanins and their gut metabolites 
downregulated the monocyte adhesion and trans-endothelial migration pathways in 
HUVECs cell line [249]. Similarly, anthocyanin metabolites significantly reduced IL-6 
protein levels and VCAM-1 protein production in HUVECs [250]. IL-6 and VCAM-1 
play a key role in the progression of atherosclerosis [250]. Therefore, more work is 
still required to investigate more pathways. 
Since it is possible that the reported changes in circulating lipoprotein profiles in 
dietary intervention studies in human participants [164] and animal models [251], 
[252] are caused by secondary effects rather than direct interactions between 
anthocyanins/metabolites and components of the RCT pathway such as scavenger 
receptors and cholesterol efflux transporter proteins, the effects of dietary 
interventions with anthocyanins was also investigated. It is challenging to determine 
the specific mechanisms if effects are caused by a secondary rather than primary 
effect. Possible routes for secondary effects include via the gut microbiota (e.g. the 
anthocyanins/metabolites alter the structure and function of the gut microbiome which 
in turn affects lipoprotein metabolism, perhaps by changing bile acid metabolism and 
rates of enterohepatic recirculation). It should be noted that investigating possible 
secondary effects was not within the scope of this thesis chapter or indeed the PhD 
project. Therefore, the effect of consuming anthocyanin-expressing tomatoes on the 
gene expression of cholesterol transporters and scavenger receptors were 
investigated in aorta and liver tissues isolated from ApoE-/- mice.  
In this intervention, the mice fed with genetically modified tomato enriched in different 
type but the same concentration of polyphenols. It was found in this intervention that 
flavonols + anthocyanins containing tomatoes and resveratrol tomatoes significantly 
reduced the size of the atherosclerotic plaque in mouse aortic sinuses by 31 and 26%, 
respectively (unpublished data). After quantifying the gene expression of key 
elements of RCT in the liver and aorta, the main findings were that (1) anthocyanin-
expressing tomatoes did not significantly changed the gene expression of ABCA1 and 
ABCG1 in aorta and liver, although a slight non-significant increase was observed in 
ABCG1 gene expression in aorta and (2) anthocyanin-containing tomatoes did not 
significantly affect the scavenger receptors gene expression in aorta. It should be 
noted that anthocyanin-containing tomatoes express both anthocyanins and 
flavanols.  Isoflavones-containing tomatoes increased ABCA1 in aorta. However, the 
impact of this effect is not understood as the same treatment did not change the lipid 
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profile in the plasma or in the liver tissue and reduced ABCA1 gene expression in 
liver. Further investigation is still required to understand the effect of isoflavones on 
lipid metabolism.  
In summary, PCA did not affect the expression of ABCA1 or ABCG1 gene which 
contradicts a single report in the literature. The data presented in chapter described 
a comprehensive study of the effects of all the main human metabolites of C3G and 
the known and predicted metabolites of D3G and have demonstrated that none of 
these have any significant effect on the expression of the two macrophage cholesterol 
efflux transporters or on the scavenger receptors that mediate cholesterol uptake by 
macrophages. In addition to the in vitro data, the possible effects of anthocyanin-
supplemented diets versus anthocyanin-free control diets on the expression of the 
cholesterol efflux transporter genes in aortic and liver tissues was quantified and saw 
no significant differences, even though the anthocyanin-supplemented diets had 
caused favourable changes in circulating lipoprotein profiles in the animals. 
As mentioned elsewhere in this chapter that RCT has different key steps and 
therefore, anthocyanins and their metabolites may target different level such as HDL 
function. Therefore, the effect of anthocyanins and their metabolites on paraoxonase 
1 (PON1) (marker of HDL function) was investigated and presented in chapter three.   
 
 
2.7. Conclusions.  
Taken together, the data presented here do not support the notions that the effects of 
anthocyanins on lipoprotein metabolism are caused by interactions between 
anthocyanin parent compounds or one or more of their phenolic-type metabolites with 
key transporters involved in the RCT process both in vitro and in vivo. However, it 
doesn’t exclude the possibility that other untested or unidentified metabolites would 
affect the gene expression. Future work should consider testing more anthocyanins 
metabolites individually and in mixtures that contain all anthocyanins metabolites. 
Both the in vitro and in vivo data did not exclude the possibility that anthocyanins 
would target another level of RCT such as HDL function and therefore the next 
chapter will explore the effect of anthocyanins and their metabolites on PON1 (marker 
of HDL function) gene expression and activities.  
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Chapter three: The effects of 
anthocyanins and their metabolites on 
PON1 as a marker of HDL function 
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3.1. Abstract 
 
High HDL quantity and functions are inversely associated with CVD risk. Paraoxonase 
1 (PON1) contributes to many atheroprotective functions of HDL such as promoting 
the reverse transport of cholesterol process and reducing the levels of oxidized LDL. 
PON1 activities are influenced by several factors, most importantly, diet and genetic 
polymorphisms. Randomized controlled trial data indicates that anthocyanin 
consumption increased PON1 activity. However, the underlying molecular 
mechanisms by which anthocyanin induce PON1 activity are not understood. In the 
current study, it was proposed that anthocyanins may increase PON1 through 
upregulation of gene expression or as activator for the enzyme itself. Therefore, the 
aim of this research was to investigate the ability of anthocyanins and their 
metabolites to increase PON1 gene expression and enzyme activities. The effect of 
the two predominant dietary anthocyanins and 18 of their recently identified microbial 
metabolites including their phase II conjugates on PON1 gene expression was studied 
using a PON1-Huh7 stably-transfected cell line and reporter gene assay. The effects 
of these compounds on PON1 arylesterase and lactonase activities was investigated 
using two isoforms of the PON1 enzyme that are the phenotyps of the 192Q/R 
polymorphism (PON-RR and PON-QQ). None of the compounds caused significant 
changes in PON1 promoter activity (p ≥ 0.05). further, none of the compounds caused 
significant changes in arylesterase and lactonase activity regardless of the phenotype 
at physiological concentrations. However, cyanidin reduced the lactonase activity of 
PON-RR at high concentrations but not at physiologically-achievable concentrations. 
In conclusion, no evidence was found that anthocyanins and/or their metabolites 
could affect PON1 gene expression or enzyme activity. Future work should focus on 
investigating the effects of anthocyanins on LDL oxidation status and PON1 secretion, 
and to consider other atherosclerotic-related pathways.  
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3.2. Introduction  
More recent studies have suggested that the relationship between HDL and CVD 
markers extends beyond the concentration of HDL alone and that the function of HDL 
may be more important than HDL concentration in protecting against CVD diseases 
[253]. HDL possesses a number of atheroprotective functions such as mediating 
cholesterol efflux, protecting against oxidation and inflammation, and promoting nitric 
oxide [220].  
HDL can protect LDL from oxidation and therefore attenuate atherosclerosis 
development by preventing the production of oxidized LDL. This protective effect 
could be attributed to enzymes associated with HDL including paraoxonase 1 (PON1) 
[254]. PON-1 has been the focus of research activities because of its capacity to 
stimulate cholesterol efflux and protect HDL and LDL from oxidative modifications, 
thus inhibiting atherosclerosis [255]. 
3.2.1. Paraoxonase 1 (PON1) 
PON1 is an HDL-associated enzyme secreted by the liver and found to have 
significant anti-oxidative and anti-inflammatory properties through its lactonase, 
peroxidase and esterase activities [256].  Low PON1 activity has been found in 
numerous pathological conditions associated with atherosclerosis, such as diabetes, 
hypercholesterolaemia, obesity and metabolic syndrome [257]. It also found that 
PON1 knockout mice showed increased levels of plaque formation and oxidative 
stress in atherosclerotic lesions as well as having altered anti-inflammatory activity of 
HDL. This advocates PON1 as a potential anti-atherosclerotic agent [258]. The 
antiatherogenicity of PON1 was suggested to be related to its ability to hydrolyse 
oxidized cholesteryl esters, oxidized phospholipids, phosphatidylcholine core 
aldehydes, and degrade hydrogen peroxide, thus protecting lipoprotein particles from 
any further oxidative modification [259]. 
3.2.2. PON1 activities 
PON1 has different enzyme activities based on the substrate used. PON1 can be 
evaluated as paraoxonase when the substrate used is paraoxon from which PON1 
got its name [260]. It can be referred to as an arylesterase (when arylesters such as 
phenyl acetate or p-nitrophenyl acetate are used as substrates) or as diazoxonase 
(when diazoxon is used as substrate) or as lactonase (when lactones are used as 
substrate) [261]. Despite the fact that PON1 was traditionally described as an 
arylesterase/paraoxonase and its activity was measured accordingly, lactonase has 
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been recently shown to be PON1’s native activity [254].  Impairing the lactonase 
activity of PON1, e.g. via mutations of its catalytic dyad, diminished the ability of the 
enzyme to prevent LDL oxidation, reduced HDL-mediated cholesterol efflux and 
abolished lysophosphatidylcholine (LPC) formation from phospholipid in 
macrophages suggesting that the actual biological antiatherogenic functions of PON1 
may be mediated by its lactonase activity [262]. PON1 lactonase activity was also 
reported to hydrolyse homocysteine thiolactone, a toxic metabolite of homocysteine, 
which has been reported to be involved in homocysteine-induced vascular damage 
[263].   
Because arylesterase and paraoxonase are possibly not physiologically relevant 
activities, whereas lactonase is the native physiologically relevant activity, it is 
important to study PON1 as a lactonase when investigating its role in 
antiatherogenesis. However, the majority of studies haven’t focused on lactonase 
activity and therefore more studies are still required using appropriate substrates such 
as lipophilic lactones.  
3.2.3. Paraoxonase polymorphism 
Nearly 200 single nucleotide polymorphisms (SNPs) have been identified in the 
human PON1 gene.  However, the SNPs that alter amino acids located at position 55 
(leucine/L or methionine/M) and at the position 192 (glutamine/Q or arginine/R) of 
PON1 are more associated with lipoprotein oxidation and CHD risk and seem to be 
more involved in the differences in PON1 activity between individuals [264]. People 
with the 192-Q/Q genotype gain greater protection against CVD. The 192-Q/Q 
genotype is associated with high HDL and decreased level of cholesterol, LDL, 
triglyceride and apo B protein [265]. The 192- Q/Q enzyme was more potent than R/R 
in decreasing the levels of oxidized lipids in human atherosclerotic lesions [266]. The 
PON1 L55M polymorphism has also been associated with variation in serum PON1 
activity levels but has a weaker effect [267]. In a healthy non-diabetic population, both 
PON1 activity and specific activity are affected by the L55M polymorphism [265]. The 
effect of polymorphisms also varies depending upon the substrate leading to different 
phenotypes. For instance, the 192- R/R polymorphism hydrolyses paraoxon 
approximately 9 times faster than 192- Q/Q, while the opposite happens when 
diazoxon and sarin were used as a substrate [268]. Thereby, conducting a 
comparison between individuals regardless of the differences in 
genotypes/phenotypes could lead to a false interpretation, especially, when 
substrates that are strongly influenced by polymorphisms such as paraoxon are being 
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used [260]. Therefore, it is recommended to compare between values of PON1 levels 
within each different genotype/phenotype instead of general comparison of all 
population.  
There are many other PON1 polymorphisms that have been reported to be associated 
with risk of CVD and other chronic diseases. For instance, rs 3735590 at the 3′ UTR 
of the PON1 gene which is within a miRNA binding site was reported to be associated 
with ischaemic stroke and thinner carotid artery intima-media thickness (IMT). This 
SNP affects the binding of the negative regulator miRNA-616 which inhibits PON1 
expression [269]. Another example is the SNP that is located at the -107 position of 
the promoter region of the PON1 gene. It is referred as T (-107) C and was reported 
to affect both PON1 gene expression and serum activity [270].  
Although the wide range of PON1 activity among individuals is usually interpreted as 
genotype differences, there are additional environmental factors that could modulate 
PON1 activity, and diet and lifestyle are the major ones among those factors [271]. 
For instance, vitamins A, E, and C supplementation restored the decreased 
paraoxonase activity [272]. Furthermore, there is an interaction between PON1 
genotype and the environmental factors such as diet. It was reported that there is a 
significant association between anthocyanin intake and increased HDL levels in 4 
from 18 independent tagging SNPs in the PON1 gene which have been linked to lipid 
profiles and cardiovascular risk [273]. 
3.2.4. Effect of polyphenols on paraoxonase 1 
Several dietary intervention studies in humans and animals have reported that 
polyphenol consumption has promising effects on PON1 activity. This was shown in 
a study by Zhu et al. (2014) in which a total of 122 hypercholesteraemic human 
subjects were given 320 mg/day anthocyanins or placebo (n = 61 per group) for 24 
weeks. They reported that anthocyanin consumption increased the activity of HDL-
PON1 by 17.4% compared with placebo [170]. Aviram et al. (2000) observed a similar 
effect on serum PON1 in humans after they fed pomegranate juice (1.5 mmol total 
polyphenols per day) for two weeks [274]. On the other hand, quercetin consumption 
did not significantly change PON1 activity in serum collected from 35 healthy normal-
weight volunteers after two weeks supplementation with doses of 50, 100 and 150 
mg/day [275]. 
In animal studies, polyphenol consumption has been linked to improved PON1 
activity. For instance, Fuhrman et al. (2002) found that supplementation with 50 
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µg/day catechin and quercetin for 6 weeks increased serum PON1 activity by 113% 
and 75%, respectively in Apo E-/- mice [276]. This increase might be attributed to the 
upregulation in PON1 gene expression in liver as the hepatic PON1 mRNA increased 
by 2-fold after 2 weeks consumption of quercetin using C57BL/6 mice [275]. In 
another dietary intervention study in 28 male rats, the consumption of soy isoflavones 
for 8 weeks significantly increased plasma PON1 activity [277]. 
In addition to studies in humans and animals, several cell model experiments also 
have shown positive effects of polyphenols on PON1 activity and gene expression. 
For instance, Esatbeyoglu, et al. (2017) studied the effect of polyphenols derived from 
purple sweet potatoes (PSP) which were fractionated into two fractions, anthocyanin- 
and copigment-rich fractions. Treatment of PON1-Huh7 cells with PSP-copigment-
rich fraction resulted in significant dose-dependent induction of PON1 transactivation, 
while PSP-anthocyanins-rich fraction was a weak inducer [278]. In the previous study 
[278], a mixture of phenolic compounds was tested and it is difficult to identify which 
phenolic compound was responsible for the observed increase. However, many 
studies have also been conducted using pure phenolic compounds to investigate their 
effect on PON1. Gouedard et al. (2004) studied the effect of resveratrol, which 
belongs to a class of polyphenolic compounds called stilbenes found predominantly 
in grape skin. The report describes the effects on PON1 enzymatic activity, gene 
expression and PON1 promoter activity using Huh7 cell line. They reported that 10 
µM resveratrol for 48 hr resulted in a significant increase of both PON1 secretion 
(62%), cell-based enzyme activity (50%) and gene expression (> 2-fold). They also 
found that PON1 promotor activity was increased in a dose-dependent manner [279]. 
These findings have been confirmed in HepG2 cells by Gupta et al. (2014) who 
reported that resveratrol increased PON1 secreted enzymatic activity in a dose-
dependent manner with highest activity at 15 µM, and also increased the gene and 
protein expression of PON1 [280]. In another study, resveratrol induced 
PON1promotor activity by 3.4-fold compared with control [275]. The effect of flavonols 
such as quercetin and its methylated derivative isorhamnetin on PON1 have also 
been investigated. Isorhamnetin induced a 2.7-fold increase in PON1 promotor 
activity, while, quercetin increased PON1 promotor activity by 1.4-fold as compared 
to control [275]. Quercetin (10 µM) also increased the cell-based PON1 activity by 
50% in Huh7 cell line [281]. Gouedard et al. (2004) tested the effect of other phenolics 
on PON1 gene expression in Huh7. They found that naringenin, flavone, catechin and 
quercetin increased PON-1 mRNA by about two fold but that catechin was a poor 
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inducer [281]. Conversely, Mahrooz et al. (2011) reported that 10  µM naringenin 
inhibited both paraoxonase and arylesterase of purified human PON1 activity [254].     
In summary, data in the literature shows that some phenolic compounds could act as 
PON-1 inducers. However, only two human intervention studies which were 
conducted with Medox™ [170] pomegranate juice [274], and one in vitro study that 
used PSP-anthocyanins [278] have reported the effect of anthocyanins on PON1 
[278]. The Zhu et al. (2014) study was the only report that reported the effects of 
purified anthocyanins on PON1 serum activity in humans [170]. Nevertheless, they 
used a proprietary product, Medox™, which is a combination of 17 different natural 
anthocyanins which did not allow any conclusion to be drawn about which 
anthocyanin or anthocyanins were responsible. Moreover, they completely ignored 
the influence of polymorphisms in PON1 which would mean a range of unknown 
phenotypes within the study population. Additionally, none of these studies have 
investigated the effects of anthocyanin metabolites or investigated how anthocyanins 
mediated the increase in PON1 activity. Therefore, further investigation is still needed 
to explore the effects of anthocyanins and their metabolites on PON1 gene expression 
and activities with considering the differences between PON1 phenotypes.  
3.3. Objectives 
The overall aim of this chapter was to explore the molecular mechanisms by which 
anthocyanins induce PON1 activity as a marker of HDL function. The specific 
objectives of the research described in were to: (1) investigate the effect of 
anthocyanins and their metabolites on PON1 gene expression and (2) investigate the 
effect of anthocyanins and their metabolites on arylesterase and lactonase activities 
using two different PON1 phenotypes. 
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3.4. Materials and methods 
3.4.1. Reporter gene assay 
The effect of anthocyanins and their metabolites on PON1 gene expression was 
evaluated using a reporter gene assay (Bioluminescence firefly luciferase assay) in 
cultured hepatocytes. PON1-Huh7 is a Huh7 liver hepatoma cell line that had been 
stably transfected with a reporter plasmid containing 1009bp [-1013, -4] of the PON1 
gene promoter cloned into the firefly luciferase reporter vector pGL3 basic. The 
luciferase reporter vector is commonly used to study gene expression and any other 
post-translational modifications  [275], [282]. Briefly, once the PON-1 promoter is 
activated (e.g. by treatment), the reporter gene (luciferase gene) will be expressed 
and therefore, luciferase enzyme will be produced (Fig 3.1). The activity of the 
luciferase enzyme can be then easily measured by using a chemiluminescence assay 
of a protein extract. The more the treatment has the capacity to induce PON1 
promoter, the more luciferase activity can be obtained (Fig 3.1). The light intensity 
reflects the gene expression which is a function of the promoter activity. 
3.4.1.1. Cell culture 
PON1-Huh7 cells were kindly provided by Prof Gerald Rimbach, Institute of Human 
Nutrition and Food Science, University of Kiel, Germany. The cells were maintained 
following the protocol as previously described [282]. Briefly, PON-Huh7 cells were 
cultivated in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma-Aldrich, Cat. # 
D5671) supplemented with 10% FBS (v/v), penicillin (100 U/ml) and streptomycin 
(100 µg/ml) (Thermofisher, Cat# 15140122), glutamine 2 mM (Sigma-Aldrich, Cat. # 
59202C) and 100 µg/ml G418 disulphate (Sigma-Aldrich, Cat. # G8168) at 37°C in 
5% CO2 until reaching 80-90 % confluency with the media changed every two days. 
The cells were then detached by adding trypsin-EDTA (Thermofisher, Cat# 
25300054) for 2-3 min at 37°C. A complete DMEM that contain 10% FBS was then 
added to inhibit the trypsin. The trypsinised cell suspension was collected and the 
cells were either split or seeded for treatments. In 24-well plates, cells were seeded 
at an initial density of 0.15 x106 cells/well and left to attach for 24 hr. After that, the 
media was removed and new pre-warmed media containing anthocyanins treatment 
was added to the appropriate wells and incubated at 37 °C, 5% CO2 for 48 hr.  
3.4.1.2. Treatments  
In this experiment, the same metabolites that were tested in the previous chapter were 
used. The treatments were prepared as previously described earlier in section 2.4.2. 
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The only differences are that (1) the treatments were prepared in complete DMEM 
growth media containing 10% FBS and (2) 20 µM of curcumin (Fisher Scientific, Cat# 
AC218580100) was used as a positive control alongside the anthocyanins and their 
metabolites treatments. After treatment, the luciferase activity was measured as a 
marker of PON1 promoter activity. Treatments were conducted in quadruplicate and 
the experiments were repeated at least two times.  
 
 
 
Figure 3. 1: Principle of a simple reporter gene assay.  
The reporter plasmid vector contains the target promoter sequence and a luciferase gene. 
After triggering the promoter, the luciferase gene will be expressed in the living cells and 
produce luciferase protein which catalyzes a reaction with luciferin to produce light. The 
amount of expressed luciferase protein can be estimated from measuring the light intensity 
which reflects the promoter activity in living cells.  
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3.4.1.3. Luciferase assay 
Luciferase activity was measured using the Luciferase Assay System (Promega, Cat# 
E1500) according to the manufacturer’s instructions. Briefly, after 48 h treatment, the 
media was removed and the cell layer was washed twice with cold calcium- and 
magnesium-free PBS (Thermofisher, Cat# 14190094). The lysis buffer was then 
added to the cell layer and the cells were scraped. Immediately, the lysate was 
collected and centrifuged for 2 min at 12,000 XG at 4ºC. After that, in 96-well white 
plates, 100 µl of luciferase assay reagent was add to 20 µl cell lysate. The 
luminescence was immediately measured over 20 sec using a plate reader; 
FLUROstar Optima (BMG labtech, UK). The plate reader is capable of injecting the 
reagent automatically and can perform multiwell reading. The luminescence was 
expressed as total light intensity which was collected over 20 sec. Results were 
normalised to the total cell protein content. The total protein in each sample was 
determined using the bicinchoninic acid (BCA)-Reducing Agent Compatible assay as 
per manufacturer’s protocol (Thermofisher, Cat# 23252). 
3.4.1.4. PON1 promoter activity calculation 
First, the light intensity which reflect the promoter activity was normalized to the 
total protein content in the cell lysate. 
Promoter activity = Total light intensity / total protein content (µg/ml)  
The fold change of PON1 was calculated relative to the control (DMSO).  
3.4.2. PON1 enzyme activities  
The direct effect of anthocyanins on PON1 activities has been measured using a 
commercially available purified PON1 that has been phenotyped into two phenotypes 
based on Q192R polymorphism. PON1 phenotype QQ (PON-QQ) and phenotype RR 
(PON-RR) were purchased from ZeptoMetrix (Cat# 0801384). In this experiment, the 
same metabolites that tested in the previous chapter were used. The treatments were 
prepared as previously described earlier in section 2.4.2. The only difference is that 
the treatments were diluted in the assay buffer. Arylesterase and lactonase PON1 
activities were measured using colourimetric assays as described below. 
3.4.2.1. PON1 arylesterase 
PON1 arylesterase activity was quantified by measuring the hydrolysis rate of p-
nitrophenyl acetate, the colourless substrate, into p-nitrophenol that has yellow colour 
and measuring the increase in absorbance using a spectrophotometer (Fig 3.2 A) 
[283]. PON1 arylesterase was measured as described elsewhere [254], [284], [285]. 
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First, PON-RR and PON-QQ were diluted in assay buffer consisting of 20 mM Tris-
HCl buffer, pH=8 and 1 mM CaCl2 just prior to conducting the assay. The dilution 
factors for PON-RR and PON-QQ were 10- and 15-fold, respectively. These two 
dilutions were chosen after a series of dilutions were tested to obtain a linear phase 
of the enzyme reaction.  
Just prior the assay, the treatments were prepared and diluted in the assay buffer. 
While diluting the enzymes and treatments, it was considered that a further dilution 
will occur in the assay plate when the treatments will mix together with enzyme, 
substrate and the assay buffer. Briefly, the assay was developed with a final volume 
of 200 µl in 96-well polystyrene plate. 20 µl of diluted enzyme and 20 µl of treatment 
mix together with 140 µl pre-warmed assay buffer. The plate was then sealed to 
prevent evaporation and incubated at 37°C for 10 min. Just prior to adding the 
substrate, the stock solution of p-nitrophenyl acetate (0.5M) (Sigma-Aldrich. Cat# 
N8130) was diluted into 5 mM in pre-warmed assay buffer. Quickly, 20 µl of diluted 
substrate was added to the previous reaction mixture and the increase in absorbance 
was measured Immediately at 410 nm for 10 min using FLUROstar Optima (BMG 
labtech, UK). So, the final concentration of reactants would be 1% PON-RR / 0.7% 
PON-QQ, 1 mM p-nitrophenyl acetate and 1 or 10 µM anthocyanins treatments. The 
final concentration of DMSO was 0.1% in all treatments. The control treatment was 
enzyme treated with DMSO at final concentration of 0.1%. The slope of the reaction 
rate was calculated using the instrument software. Blanks without enzymes or 
treatments were used to correct for the spontaneous nonenzymatic hydrolysis of p-
nitrophenyl acetate by subtracting blanks from the hydrolysis rate of treatments.  The 
% of change was calculated relative to the control as following: 
% 𝑜𝑓 𝐶ℎ𝑎𝑛𝑔 =
𝑅𝑎𝑡𝑒 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 − 𝑅𝑎𝑡𝑒 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
𝑅𝑎𝑡𝑒 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
 𝑥 100 
Treatments were conducted in triplicates and the experiments were repeated at least 
two times. The purity of the enzymes was determined by measuring the activity of 
enzymes with 100 µM of 2-hydroxyquinoline (2-HQ), the PON1-potent inhibitor 
(Sigma-Aldrich, Cat# 270873). 
3.4.2.2. PON1 lactonase 
PON1 lactonase activity was measured spectrophotometrically by monitoring the 
hydrolysis of the synthetic lipolactone substrate, 5-thiobutyl butyrolactone (TBBL) 
[286], [287]. TBBL was synthesised inhouse using the method described elsewhere 
[288]. The principle of this assay is that the enzyme releases a colourless thiol moiety 
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upon hydrolysis of the oxo-lactone ring of TBBL, the colourless substrate (Fig 3.2 B). 
The release of thiol can be detected by adding a chromogenic probe such as 5,5′-
dithiobis (2-nitrobenzoic acid) (DTNB) that produces a yellow colour with thiol. 
Therefore, the enzyme rate can be measured by monitoring the increase in 
absorbance after adding DTNB to the reaction mixture (Fig 3.2 B).  
Lactonase activity was measured as described previously [288], [289]. Briefly, PON-
RR and PON-QQ were diluted to 50- and 80-fold, respectively in the assay buffer that 
consisted of 50 mM Tris-HCl, 1 mM CaCl2, 50 mM NaCl and pH=8. These two dilutions 
were chosen after a series of dilutions were tested to obtain a linear phase of the 
enzyme reaction. The treatments were prepared as previously mentioned in 
arylesterase section (3.8.2.1). Using 96-well polystyrene plates, 20 µl of enzyme and 
20 µl of treatment were mixed together with 60 µl pre-warmed assay buffer. 50 µl of 
DTNB (4 mM) was mixed with the reaction mixture. The plate was sealed to prevent 
evaporation and incubated for 10 min at 37°C. A solution of TBBL (2 mM) was 
prepared in pre-warmed assay buffer contain 2% acetonitrile just before use and 50 
µl of TBBL (2 mM) was added to the reaction mixture and the absorbance was 
measured immediately at 412nm using a FLUROstar Optima plate reader (BMG 
labtech, UK). The final volume was 200 µl and the concentration of reactant were 
0.2% PON-RR / 0.125% PON-QQ, 1 mM DTNB, 0.5 mM TBBL and 1 or 10 µM 
treatments. The lactonase activity was calculated as described in the arylesterase 
section (3.8.2.1). Treatments were conducted in quadruplicate and the experiments 
were repeated at least two times. The purity of the enzymes was determined by 
measuring the activity of enzymes with 100 µM of 2-hydroxyquinoline (2-HQ). 
3.4.3. PON1 gene expression and enzyme activity in HepG2 cell. 
3.4.3.1. Cell culture 
Human hepatoma cell line HepG2 was maintained in minimum essential medium with 
Earle′s Balanced Salts (EMEM) containing 2mM L-glutamine (Sigma-Aldrich, Cat# 
51411C) supplemented with 10% FBS, penicillin (100 U/ml) and streptomycin (100 
µg/ml) in 75T flask at 37°C in a humidified incubator with atmosphere containing 5% 
CO2.  
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Figure 3. 2: The principle of measuring PON1 (A) arylesterase and (B) lactonase 
activities.  
The figure demonstrates the hydrolysis of p-nitrophenyl acetate (arylesterase substrate) and 
5-thioalkyl butyrolactones (lactonase substrate) by PON1 enzyme. DTNB =5,5′-Dithiobis (2-
nitrobenzoic acid). 
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3.4.3.2. Secreted PON1 activity 
HepG2 were seeded in 6-well plates (0.5 x 106 cell/well) using complete media for 48 
hr. After that, the medium was removed, and cells were washed twice with pre-
warmed PBS. The cell layer was then treated with compound of interest using serum-
free medium for 48 h. The media, then was collected and used as source of PON1 
enzyme. PON1 arylesterase activity was measured as described early in section 
3.8.2.1. 
3.4.3.3. Cell-based PON1 activity 
The cells were seeded as previously described. After 48 h, the cells were incubated 
with compound of interested prepared in media for additional 48 h. At the end of the 
incubation period, the media was discarded, and the cells then were washed twice 
with pre-warmed PBS. Cell-based PON1 activity was measured by adding the 
reaction mixture that contain the substrate to the cell layer and monitoring the change 
in absorbance. The reaction was initiated by the addition of 1 ml of buffer containing 
p-nitrophenyl acetate to yield final concentration of 1mM. The reaction mixture was 
incubated at 37°C and the absorbance was recorded at 410 nm at the end of 20 min 
incubation. At the same condition,1 ml of reaction mixture containing 100 µM 2-HQ 
was added to number of treated wells to correct for PON-1 specific activity. 
Autohydrolysis background activity was also determined by the addition of reaction 
mixture to cell-free well 
3.4.3.4. PON1 gene expression in HepG2 
The cells were treated with DMSO and 10 µM of PCA as early mentioned. RNA 
extraction and qRT-PCR reaction were performed as described in section 2.4.3 and 
2.4.6. PON1 gene expression was normalized against GAPDH. The sequences of 
forward and reverse primers were: 5`-TTCA CCCGATGGCAAGTATG-3` and 5`-
ACGAGGGTATTAAAGTCAAGGG-3`, respectively. 
3.4.4. Statistical analysis 
All data and statistics were analysed using GraphPad Prism (version 5.04 for 
Windows, GraphPad Software, La Jolla California USA, www.graphpad.com). All 
values are given as means ± SD. Any statistical difference between the groups was 
determined with one-way ANOVA coupled with Dunnett’s multiple comparison test 
comparing all sample groups to control (DMSO 0.1%). Values of p ≤ 0.05 were 
considered significant.
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3.5. Results 
3.5.1. PON1 activity and gene expression in HepG2 cell 
Because the liver is the major source for circulating PON1, the best model to study 
the effect of anthocyanins on PON1 activity is to use human liver hepatocellular cells 
such as HepG2. Toward the goal of developing an assay to test the effect of 
anthocyanins and their metabolites on PON1 expression, activity and secretion, the 
ability of HepG2 to express and secrete PON1 was tested. 
3.5.1.1. Secreted PON1 activity. 
To investigate whether HepG2 secrete PON1 in to the media, HepG2 cells were 
treated with 10 µM PCA and DMSO (both prepared in FBS-free media) for 48 h before 
collecting the media and use it as a source of the enzyme. As shown in Fig 3.3, the 
absorbance obtained from treatment was similar to the absorbance from background 
which means that HepG2 did not secreted any PON1 and the colour was attributed to 
the autohydrolysis. The reason could be that the concentration of secreted PON1 is 
very low. Therefore, the cell number was increased (two times) and the volume of the 
media was also increased in the reaction mixture (9 times). In this experiment, 100 
µM 2-HQ was used to calculate PON-1-derived activity. As shown in Fig 3.4, the 
secreted arylesterase activity increased, although the activity was not derived from 
PON1 as the activity in the presence and the absence of PON1 inhibitor was identical 
which indicates that HepG2 did not secrete PON1. Probably, HepG2 synthesised the 
enzyme endogenously but could not secret it as FBS-free media was used in the 
treatment so there was not any sources of HDL for the enzyme to be structured on. 
To test the possibility of the endogenous production of PON1, cell-based PON1 
activity was measured.  
3.5.1.2. Cell-based PON1 
Cell-based PON1 is usually measured by removing the medium after treatment 
followed by incubation with substrate (reaction mixture) for a certain time prior to 
measuring change in absorbance.  
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Figure 3. 3: Secreted PON1 arylesterase activity using HepG2 cell. 
HepG2 cells (5x105) were seeded in 6-well plate and treated with treatments for 48 hr. 10 µl 
of media after treatment was used as a source of PON1. The arylesterase activity was 
measured using p-nitrophenyl acetate (1 mM) as a substrate and monitoring the change in the 
absorbance at 410 nm. PCA = protocatechuic acid (10 µM). Background was media collected 
from cell-free well.  
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Figure 3. 4: Secreted PON1 arylesterase activity using HepG2 cell. 
HepG2 cells (1x106) were seeded in 6-well plate and treated with DMAO for 48 hr. 90 µl of 
media after treatment was used as a source of PON1. The arylesterase activity was measured 
using p-nitrophenyl acetate (1 mM) as a substrate with the presence or the absence of 100 
µM of 2-HQ and monitoring the change in the absorbance at 410 nm. The measurement was 
corrected for background which was media collected from cell-free well.  
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To measure the cell-based PON1 activity, the cells were treated with DMSO and two 
concentration of aspirin (0.25 and 0.5 mM) which was previously reported to induce 
cell-associated PON1 by 3-fold [283]. The assay buffer that contain the substrate was 
added directly to the cell layer following the treatments and after removing the media 
and washing the cell layer. The assay was performed in presence and absence of 2-
HQ, the inhibitor of PON1, to measure the PON1-derived activity.  
As shown in Fig 3.5, it was obvious that the total endogenous cell-based arylesterase 
was higher than the secreted enzyme. The absorbance of cell based arylesterases 
was about 1.8 unit (Fig 3.5), while, the secreted arylesterases was less than 0.9 unit 
(Fig 3.4) confirming that the arylesterases were mostly stored in the cells without 
secretion. However, the data also showed that the cell-based arylesterases activity 
was not mediated by PON1 as the absorbance in presence and the absence of PON1 
inhibitor was similar. In addition, none of the aspirin treatments induced PON1 
production (Fig 3.5) suggesting that HepG2 cells model was not suitable for 
investigating the effects of treatments on PON1 enzyme activity. 
3.5.1.3. PON1 gene expression in HepG2  
Since, no secreted or cell-based PON1 activity was detected, the expression of PON1 
gene was quantified to explore whether PON1 was expressed in HepG2 cells or not. 
As shown in Fig 3.6, mRNA transcription level of PON1 was very low with Ct values 
higher than 30 indicating that PON1 gene is lowly expressed in HepG2. 
Overall, the HepG2 cells did not synthesize PON1 enzyme and the gene expression 
was very low suggesting that the used HepG2 cells were not suitable for testing the 
effects of anthocyanins and/or their metabolites on PON1 activities and gene 
expression. Instead, a stably transfected cell line with PON1 promoter was used as a 
model and the promoter activity was measured using the reporter gene assay.  
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Figure 3. 5: Cell-based PON1 arylesterase activity using HepG2 cell. 
HepG2 cells (5x105) were seeded in 6-well plate and treated with aspirin for 48 hr. The media 
was then removed, and the cell layer was washed prior to adding the reaction mixture. The 
cell layer was incubated for 20 min with 1 ml of reaction mixture that contain 1 mM p-
nitrophenyl acetate with the presence and the absence of PON1 inhibitor (100 µM of 2-HQ). 
The measurement was corrected for background which was the absorbance from cell-free 
well. Data are shown as means ± SD.  No significant differences were detected compared with 
control using one-way ANOVA coupled with Dunnett’s multiple comparison test. 
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Figure 3. 6: The amplification blot of PON1 gene expression in HepG2. 
HepG2 cells were treated with DMSO and 10 µM of PCA = protocatechuic acid for 48 hr and 
the gene expression was quantified using RT-qPCR method. NTC = no template control, 
RNA-free water was used as a template instead of RNA samples to monitor contamination. 
Ct = cycle threshold.  
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3.5.2. Effect of anthocyanins and their metabolites on PON1 promoter 
activity. 
3.5.2.1. Anthocyanins parent compounds 
To test whether the parent anthocyanins affect PON1 gene expression, PON1-Huh7 
cells which were stably transfected with PON1 promoter were incubated with C3G 
and D3G at two concentrations, 1 and 10 µM, for 24 hr at 37°C. 1 µM is physiologically 
achievable and 10 µM is supra-physiological concentration. PON1 promoter activity 
was then measured using reporter gene assay. As shown in Fig 3.7, C3G and D3G 
did not cause any significant change in PON1 promoter activity compared to control 
(DMSO), although the two concentrations of C3G caused a small increase in promoter 
activity but this was not significant (p ≥ 0.05).  
In the current model, curcumin was used as a positive control which significantly 
increased PON1 promoter activity by 5.3-fold (Fig 3.7, p ≤ 0.001)). This was consistent 
with data previously reported that curcumin induced PON1 promoter activity by 4.5-
fold. This demonstrates the current model is functioning properly and it is sensitive to 
treatments [282], [290].  
3.5.2.2. Anthocyanins metabolites and their conjugates 
To test the hypothesis that anthocyanin metabolites induce PON1 promoter activity, 
the anthocyanin metabolites used in the previous chapter were applied to PON1-Huh7 
cells for 24 hr at 1 and 10 µM. Fig 3.8 reports the effects of known metabolites of 
anthocyanins that were identified previously by using isotope-labelled anthocyanins, 
while, Fig 3.9 reports the effects of other predicted metabolites of anthocyanins. 
Similar to the parent compounds, none of these metabolites significantly changed 
PON1 promoter activity at either concentration (Fig 3.8 and 3.9). However, syringic, 
cyanidin, 5HFA and hippuric acid unexpectedly reduced the promoter activity by 10 
to 20%, although the changes were not significant (Fig 3.9).  
Moreover, PCA conjugates and gallic acid conjugates did not induce the promoter 
activity (Fig 3.10). Likewise, no significant changes were seen with a combination of 
C3G, PCA and its conjugates or with a combination of D3G, gallic acid and its 
conjugates (Fig 3.10). Although, there was a small decrease in PON1 promoter 
activity with the tested conjugates and mixtures except for a mixture of C3G, PCA and 
its conjugates (Fig 3.10), this was not significant (p ≥ 0.05). 
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 Curcumin (the positive control), on the other hand, significantly increased PON1 
promoter activity by 5.3-fold (Fig 3.8 - 3.10) which indicates that the model is working 
and confirms that the lack of effect of the tested metabolites of anthocyanins on PON1 
promoter activity and consequently PON1 gene expression were real. However, 
anthocyanins and their metabolites may target PON1 at different levels such as 
increasing the enzyme activity. Therefore, the effect of anthocyanins and their 
metabolites on PON1 enzyme activities were investigated.  
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Figure 3. 7: Effect of anthocyanins parent compounds on PON1 promoter 
activity.  
PON1-Huh7 cells were treated with treatments for 24 hr followed by protein extraction and 
measuring the promoter activity using the reporter gene assay. Control = DMSO, C3G = 
cyanidin-3-glucoside, D3G = delphinidin-3-glucoside and curcumin (20 µM) was the positive 
control. The luminescence of the reporter was normalized to the protein content. The fold 
change was calculated relative to control. Data are shown as means ± SD. *** p ≤ 0.001 as 
compared to control using one-way ANOVA coupled with Dunnett’s multiple comparison test. 
Treatments were conducted in quadruplicates and the experiments were repeated two times. 
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Figure 3. 8: Effect of known human anthocyanins metabolites on PON1 
promoter activity.  
PON1-Huh7 cells were treated for 24 hr followed by protein extraction and measurement of 
the promoter activity using the reporter gene assay. Control = DMSO, PGA = 
phloroglucinaldehyde, PCA = protocatechuic acid, 4HBA = 4-hydroxybenzaldehyde and 
curcumin (20 µM) was the positive control. The luminescence of the reporter was normalized 
to the protein content. The fold change was calculated relative to control. Data are shown as 
means ± SD. *** p ≤ 0.001 as compared to control using one-way ANOVA coupled with 
Dunnett’s multiple comparison test. Treatments were conducted in quadruplicates and the 
experiments were repeated two times. 
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Figure 3. 9: Effect of potential anthocyanins metabolites on PON1 promoter 
activity.  
PON1-Huh7 cells were treated for 24 hr followed by protein extraction and measurement of 
the promoter activity using the reporter gene assay. Control = DMSO, 5HFA = 5-hydroxyferulic 
acid and curcumin (20 µM) was the positive control. The luminescence of the reporter was 
normalized to the protein content. The fold change was calculated relative to control. Data are 
shown as means ± SD. *** p ≤ 0.001 as compared to control using one-way ANOVA coupled 
with Dunnett’s multiple comparison test. Treatments were conducted in quadruplicates and 
the experiments were repeated two times. 
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Figure 3. 10: Effect of phase-ii-conjugates of anthocyanin metabolites on PON1 
promoter activity.  
PON1-Huh7 cells were treated with treatments for 24 hr followed by protein extraction and 
measurement of the promoter activity using the reporter gene assay.  Control = DMSO, PCA-
GlcAs (1 µM of PCA-3-glucuronide and PCA-4-glucuronide), PCA-Sulphs (1 µM of PCA-3-
sulphate and PCA-4-sulphate), PCA-Mixture (1 µM of C3G, PCA and PCA conjugates), GA-
GlcAs (1 µM of gallic acid-3-glucuronide and gallic acid-4-glucuronide), MethGA (1 µM of 3-
O- Methylgallic acid and 4-O- Methylgallic acid), GA-Mixture (1 µM of D3G, gallic acid and 
gallic acid conjugates) and curcumin (20 µM) was the positive control. The luminescence of 
the reporter was normalized to the protein content. The fold change was calculated relative to 
control. Data are shown as means ± SD. *** p ≤ 0.001 as compared to control using one-way 
ANOVA coupled with Dunnett’s multiple comparison test. Treatments were conducted in 
quadruplicates and the experiments were repeated two times. 
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3.5.3. Effect of anthocyanins and their metabolites on PON1 arylesterase 
activity. 
3.5.3.1. Establishing a fit-for-purpose enzyme assay 
The enzyme assay is simply measured by monitoring the generation of the product of 
the enzyme reaction over time using a spectrophotometer. One advantage of 
measuring the absorbance over time rather than the endpoint is to avoid interference 
from other coloured compounds otherwise the product of the enzyme reaction. If the 
interfering compounds are inactive, their colour will remain unchanged over time and 
therefore, the rate will represent only the enzyme activity. If the enzyme activity was 
measured in an endpoint assay, the interfering compounds would be detected as a 
false positive if their absorbance started at a high value and no correction was done. 
To avoid inaccurate measurement, the rate should be measured within the linear 
stage of the enzyme reaction. Therefore, serial dilutions of PON-RR and PON-QQ 
enzymes in buffer were tested. The rate of hydrolysis of p-nitrophenyl acetate, the 
substrate, was measured using a colourimetric method.  
A concentration of 1% PON-RR (0.63 U/ml) and 0.7% PON-QQ (1.3 U/ml) enzymes 
resulted in a linear reaction which lasted for more than 15 min (Fig 3.11). The linear 
regression coefficient (R2) was 0.9997 which is very close to 1 meaning that the 
reaction is linear at these two concentrations of PON-RR and PON-QQ. As shown in 
Fig 3.11, the linearity lasted for 16 min or more which gave enough time to measure 
the plate after adding the substrate. Therefore, the rate was measured over 10 min 
using these two concentrations in all subsequent experiments.  
To validate that the commercial enzyme does not contain any other esterases rather 
than PON1 and to make sure that the model was working, 2-hydroxyquinoline (2-HQ), 
a potent inhibitor of PON1, was used at concentration of 100 µM. 2-HQ resulted in 
about 97.5% inhibition for PON-RR and PON-QQ which mean that the product 
contains only PON1 and the model is working properly (Fig 3.11).   
3.5.3.2. Effect of anthocyanins parent compounds on PON1 
arylesterase activity. 
In this study, the direct effect of anthocyanin parent compounds on PON1 arylesterase 
activity was examined using two different phenotypes, PON-RR and PON-QQ.  The 
two enzymes were incubated with C3G and D3G at concentrations of 1 and 10 µM 
for 10 min at 37°C. The substrate, p-nitrophenyl acetate, then was added, and the 
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reaction rate was colourimetrically measured over 10 min. The findings demonstrated 
that neither C3G or D3G affected the arylesterase activity at either concentration of 
either the PON-RR or PON-QQ enzyme (Fig 3.12 A&B). These data do not support 
the notion that anthocyanins interact directly with PON1 enzymes to change their 
enzyme activity. It is possible that the breakdown products and/or microbial 
metabolites affect PON1 activity, so this was investigated. 
 
 
 
 
 
Figure 3. 11: PON1 arylesterase reaction progress curve.  
The substrate was added to 1% PON-RR and 0.7% PON-QQ with and without 100 µM 2-
hydroxyquinoline. The enzymes were diluted in buffer. The absorbance was recorded over 16 
min. R2= linear regression coefficient. R2 was calculated using Excel software 2016.  
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Figure 3. 12: Effect of anthocyanin parent compounds on (A) PON-RR and (B) 
PON-QQ arylesterase activity.  
PON-RR and PON-QQ enzymes were incubated with treatments for 10 min at 37ºC. Control 
= DMSO (0.1%), C3G = cyanidin-3-glucoside and D3G = delphinidin-3-glucoside for 10 min at 
37ºC. The slope of the reaction was calculated using the instrument software. The % of change 
to the slope was calculated relative to the control. Data are shown as means ± SD. No 
significant differences were detected compared with control using one-way ANOVA coupled 
with Dunnett’s multiple comparison test.  Treatments were conducted in triplicates and the 
experiments were repeated two times.
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3.5.3.3. Effect of anthocyanins metabolites on PON1 arylesterase activity 
To measure the effect of anthocyanin metabolites on PON1 arylesterase, the same 
protocol was used.  Two types of metabolites were tested. Firstly, metabolites that are 
known to be or were predicted to be formed by either spontaneous or gut microbiota-
dependent breakdown/catabolism of the anthocyanins. In addition, phase-ii-
conjugates of the phenolic breakdown products formed as a result of human 
metabolism were also examined.  
The 10 µM gallic acid treatment significantly increased PON-QQ arylesterase but not 
PON-RR by 9% compared to the control (Fig 3.13 B, p ≤ 0.001). Similarly, 
phloroglucinol at both 1 and 10 µM increased PON-QQ but not PON-RR but by only 
4% (Fig 3.14 B, p ≤ 0.001). On the other hand, the high concentration of cyanidin (10 
µM) but not the low concentration slightly decreased PON-RR by 6% (Fig 3.14 A, p ≤ 
0.001). Otherwise, none of the other tested metabolites either the confirmed one or 
the potential caused any change in arylesterase activity with PON-RR or PON-QQ at 
any tested concentrations (Fig 3.13-3.14).  
Next, some phase-ii-conjugates of the metabolites were tested. None of the tested 
conjugates affected PON1 arylesterase activity (Fig 3.15). It was also shown that 
neither a mixture of C3G, PCA and its conjugates nor a mixture of D3G, gallic acid 
and its conjugates caused any significant changes in PON1 activity (Fig 3.15). 
Overall, none of the treatments had any substantial effects on PON1 activity. Although 
statistically significant effects were observed for gallic acid (increased PON-QQ by 
9% at 10 µM) and phloroglucinol (increase PON-QQ by 4% at 1 and 10 µM), the 
effects were small.  
PON1 is ‘promiscuous’ multi-activity enzyme. In addition to arylesterase activity, the 
enzyme possesses lactonase activity (see section 3.2.2). Indeed, lactonase is the 
enzyme function associated with it physiological function, especially in its action 
towards ox-LDL. Therefore, the effect of anthocyanins and their metabolites on 
lactonase activity have been investigated 
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Figure 3. 13: Effect of known human anthocyanin metabolites on (A) PON-RR 
and (B) PON-QQ arylesterase activity.  
PON-RR and PON-QQ enzymes were incubated with treatments for 10 min at 37ºC. Control 
= DMSO (0.1%), PGA = phloroglucinaldehyde, PCA = protocatechuic acid and 4HBA = 4-
hydroxybenzaldehyde. The slope of the reaction rate was calculated using the instrument 
software. The % of change to the slope was calculated relative to the control. Data are shown 
as means ± SD. *** p ≤ 0.001 as compared to control using one-way ANOVA coupled with 
Dunnett’s multiple comparison test. Treatments were conducted in triplicates and the 
experiments were repeated two times
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Figure 3. 14: Effect of anthocyanin potential metabolites on (A) PON-RR and (B) 
PON-QQ arylesterase activity.  
PON-RR and PON-QQ enzymes were incubated with treatments for 10 min at 37ºC. Control 
= DMSO (0.1%), 5HFA = 5-hydroxyferulic acid. The slope of the reaction rate was calculated 
using the instrument software. The % of change to the slope was calculated relative to the 
control. Data are shown as means ± SD. ** p ≤ 0.01 and *** p ≤ 0.001 as compared to control 
using one-way ANOVA coupled with Dunnett’s multiple comparison test. Treatments were 
conducted in triplicates and the experiments were repeated two times.
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Figure 3. 15: Effect of anthocyanin phase-ii-metabolite conjugates on (A) PON-
RR and (B) PON-QQ arylesterase activity.  
PON-RR and PON-QQ enzymes were incubated with treatments for 10 min at 37ºC. Control 
= DMSO, PCA-GlcAs = (1 µM of PCA-3-glucuronide and PCA-4-glucuronide), PCA-Sulphs = 
(1 µM of PCA-3-sulphate and PCA-4-sulphate), PCA-Mixture = (1 µM of C3G, PCA and PCA 
conjugates), GA-GlcAs = (1 µM of gallic acid-3-glucuronide and gallic acid-4-glucuronide), 
MethGA = (1 µM of 3-O- methylgallic acid and 4-O- methylgallic acid), GA-Mixture = (1 µM of 
D3G, gallic acid and gallic acid conjugates). The slope of the reaction rate was calculated 
using the instrument software. The % of change to the slope was calculated relative to the 
control. Data are shown as means ± SD.  No significant differences were detected compared 
with control using one-way ANOVA coupled with Dunnett’s multiple comparison test.  
Treatments were conducted in triplicates and the experiments were repeated two times.
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3.5.4. Effect of anthocyanins and their metabolites on PON1 lactonase activity. 
3.5.4.1. Setting up the assay 
Similar to the arylesterase activity, a serious of enzyme dilutions were performed to 
obtain a linear lactonase activity to allow accurate measurement. The rate of the 
cleavage of TBBL, the substrate of lactonase activity, was measured by monitoring 
the absorbance over time. Linearity was achieved with 0.2% PON-RR (0.13 U/ml) and 
with 0.125% PON-QQ (0.23 U/ml); and for both isoforms lasted for more than 15 min. 
The linear regression coefficient (R2) was about 0.996 for both phenotypes (Fig 3.16) 
meaning that the enzyme reaction rate was linear. Moreover, 2-HQ inhibited PON-RR 
and PON-QQ by 95 and 93%, respectively meaning that the observed changes in 
absorbance were due to PON1 lactonase activity and not an artefact, and the model 
is working well (Fig 3.16). 
 
 
 
Figure 3. 16: PON1 lactonase reaction progress curve.  
The substrate was added to 0.2% PON-RR and 0.125% PON-QQ with and without 100 µM 2-
hydroxyquinoline. The enzymes were diluted in buffer. The absorbance was recorded over 16 
min. R2= linear regression coefficient. R2 was calculated using Excel software 2016.
 121 
 
3.5.4.2. Effect of anthocyanins parent compounds on PON1 lactonase 
activity. 
C3G and D3G at concentrations of 1 and 10 µM were incubated with PON-RR and 
PON-QQ for 10 min at 37°C. After adding the substrate, TBBL, the lactonase activity 
was measured over 10 min and the reaction rate was measured to calculate the % 
change. As shown in Fig 3.17, C3G had a very small but significant effect on the 
enzyme activity of both PON-RR and PON-QQ. PON-QQ activity was affected more 
than PON-RR with increase of 11 and 9% at concentrations of 1 and 10 µM, 
respectively (p≤0.001). On the other hand, D3G did not cause any changes in PON-
RR, while the 1 µM concentration modestly increased PON-QQ (5%, p ≤ 0.001) (Fig 
3.17). 
3.5.4.3. Effect of anthocyanins metabolites on PON1 lactonase activity 
To investigate the effect of anthocyanin metabolites on PON1 lactonase activity, the 
same metabolites of anthocyanins that were tested in the arylesterase were tested for 
their effect on PON1 lactonase activity. A few of the tested metabolites caused very 
small changes in PON1 lactonase activity, although they were statistically significant 
(Fig 3.18 and 3.19). The only substantial effect was observed with cyanidin (Fig 3.19 
A). Unexpectedly, cyanidin at 10 µM significantly decreased PON-RR lactonase 
activity by 22% (p ≤ 0.001), while, the lower concentration of cyanidin did not cause 
any changes (Fig 3.19 A). This finding was confirmed by doing a dose-response curve 
for cyanidin with PON-RR enzyme. As shown in Fig 3.20, cyanidin decreased 
lactonase activity of PON-RR in a dose-dependent manner with about 30% reduction 
when incubated with 20 µM cyanidin. However, the lower more physiological 
concentrations of cyanidin (0.1 or 0.5 µM) did not affect PON-RR nor did 1 µM. On 
the other hand, PON-QQ behaved differently when treated with cyanidin. The low 
concentration of cyanidin (1 µM) but not the high one slightly increased PON-QQ by 
8% (Fig 3.19 B, p≤ 0.001).Regarding the effect of anthocyanin metabolite conjugates 
and the mixtures, no substantial effects were observed with either PON-RR or PON-
QQ (Fig 3.21 A &B). Only a very small decrease in PON-RR and PON-QQ was 
observed after treating with MethGA (p ≤ 0.001).  
In summary, the results showed that none of the tested biomarkers of the RCT 
pathway were affected by anthocyanins or their metabolites in vitro. However, other 
CVD-related pathways may be targeted. To investigate this further, RNA sequencing 
has been used as a non-targeted approach to define any other affected CVD-related 
pathways. 
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Figure 3. 17: Effect of anthocyanin parent compounds on (A) PON-RR and (B) 
PON-QQ lactonase activity.  
PON-RR and PON-QQ enzymes were incubated with treatments for 10 min at 37ºC. Control 
= DMSO (0.1%), C3G = cyanidin-3-glucoside and D3G = delphinidin-3-glucoside. The slope 
of the reaction rate was calculated using the instrument software. The % of change to the 
slope was calculated relative to the control. Data are shown as means ± SD. *** p ≤ 0.001 as 
compared to control using one-way ANOVA coupled with Dunnett’s multiple comparison test. 
Treatments were conducted in quadruplicates and the experiments were repeated at least two 
times.
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Figure 3. 18: Effect of known human anthocyanin metabolites on (A) PON-RR 
and (B) PON-QQ lactonase activity.  
PON-RR and PON-QQ enzymes were incubated with treatments for 10 min at 37ºC. Control 
= DMSO (0.1%), PGA = phloroglucinaldehyde, PCA = protocatechuic acid and 4HBA = 4-
hydroxybenzaldehyde. The slope of the reaction rate was calculated using the instrument 
software. The % of change to slope was calculated relative to the control. Data are shown as 
means ± SD. *** p ≤ 0.001 as compared to control using one-way ANOVA coupled with 
Dunnett’s multiple comparison test. Treatments were conducted in quadruplicates and the 
experiments were repeated at least two times.
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Figure 3. 19: Effect of putative anthocyanin metabolites on (A) PON-RR and (B) 
PON-QQ lactonase activity.  
PON-RR and PON-QQ enzymes were incubated with treatments for 10 min at 37ºC. Control 
= DMSO (0.1%), 5HFA = 5-hydroxyferulic acid. The slope of the reaction rate was calculated 
using the instrument software. The % of change to the slope was calculated relative to the 
control. Data are shown as means ± SD. ** p ≤ 0.01 and *** p ≤ 0.001 as compared to control 
using one-way ANOVA coupled with Dunnett’s multiple comparison test. Treatments were 
conducted in quadruplicates and the experiments were repeated at least two times.
 125 
 
 
 
PON-RR
Cyanidin (µM)
P
O
N
1
 l
a
c
to
n
a
s
e
 a
c
ti
v
it
y
(%
 o
f 
c
o
n
tr
o
l)
0 5 10 15 20
-30
-20
-10
0
 
 
Figure 3. 20: Effect of cyanidin on PON1 (RR) lactonase activity.  
PON-RR enzyme was incubated with different concentrations of cyanidin for 10 min at 37°C. 
TBBL then was added and the activity was measured. The slope of the reaction rate was 
calculated using the instrument software. The % of change was calculated relative to the 
control (0.1% DMSO). Treatments were conducted in quadruplicates and the experiments 
were repeated at least two times.
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Figure 3. 21: Effect of anthocyanin phase-ii-metabolite conjugates on (A) PON-
RR and (B) PON-QQ arylesterase activity.  
PON-RR and PON-QQ enzymes were incubated with treatments for 10 min at 37ºC. Control 
= DMSO, PCA-GlcAs = (1 µM of PCA-3-glucuronide and PCA-4-glucuronide), PCA-Sulphs = 
(1 µM of PCA-3-sulphate and PCA-4-sulphate), PCA-Mixture = (1µM of C3G, PCA and PCA 
conjugates), GA-GlcAs = (1 µM of gallic acid-3-glucuronide and gallic acid-4-glucuronide), 
MethGA = (1 µM of 3-O- methylgallic acid and 4-O- methylgallic acid), GA-Mixture = (1 µM of 
D3G, gallic acid and gallic acid conjugates). The slope of the reaction rate was calculated 
using the instrument software. The % of change to the slope was calculated relative to the 
control. Data are shown as means ± SD.  * p ≤ 0.05 and *** p ≤ 0.001 as compared to control 
using one-way ANOVA coupled with Dunnett’s multiple comparison test. Treatments were 
conducted in quadruplicates and the experiments were repeated at least two times.
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3.6. Discussion  
The aim of the research described in this chapter was to investigate whether 
anthocyanins and their metabolites are capable of increasing PON1 activities which 
would thereby be consistent with the reported observation of an inverse association 
with increased risks of cardiovascular diseases. Therefore, the experiments reported 
in this chapter were designed to investigate a number of hypothese: (1) Anthocyanins 
and their metabolites cause increases in PON1 gene expression and therefore its 
activities; (2) anthocyanins and their metabolites would act as activators for PON1 
itself and thereby increase its enzyme activities. In addition, it was planned to 
investigate the effect of anthocyanins and their metabolites on the process of PON1 
enzyme secretion using HepG2 as a cell model. But, since PON1 secretion could not 
be demonstrated in these cells, this could not be investigated. 
The data presented in this chapter show that: (1) none of the tested anthocyanins or 
their tested metabolites increased PON1 promoter activity; (2) none of these 
compounds significantly affected PON1 arylesterase activity or lactonase activity with 
either PON1 phenotypes, PON-RR or PON-QQ; except for some small effects that 
likely lack clinical importance; (3) cyanidin decreased the lactonase activity of PON-
RR in a dose-dependent manner. 
The novelty of this research is that it is the first study to investigate the effects of 
anthocyanins and their metabolites individually and in mixtures on activation of the 
PON1. Gallic acid, ellagic acid, punicalagin, naringenin, resveratrol, quercetin, 
catechin and isorhamnetin are the only pure phenolic compounds that have been 
investigated for their effects on PON1 gene expression or enzyme activity and 
reported so far. [254], [279]–[282], [291]–[293]. This study is the first to consider 
investigating the effect of anthocyanins and their metabolites directly on PON1 
lactonase activity which is the native activity of PON1. To the best of my knowledge, 
there was not any study investigated the effects of any other polyphenolic compounds 
on lactonase activity.  
It has been previously reported that anthocyanin consumption was able to increase 
PON1 arylesterase activity in humans and this was associated with improved 
antioxidant abilities of HDL [170].  This finding and others suggest that the increase 
of PON1 activity is a potential novel mechanism of anthocyanin to modulate 
cholesterol metabolism and therefore reduce CVD risk. However, the underlying 
molecular mechanisms by which anthocyanins induced PON1 activity have yet not 
been fully understood. Therefore, it was hypothesised here that anthocyanins and 
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their metabolites would increase PON1 by upregulating of gene expression, activating 
the enzyme itself, and/or enhancing the enzyme secretion process.  
3.6.1. Effect of anthocyanins and their metabolites on PON1 promoter activity. 
To investigate the effect of anthocyanins and their metabolites on PON1 gene 
expression, an PON-Huh7 cell line has been used as an in vitro model. PON1-Huh 7 
is a liver cell line that is stably transfected with a PON1 promoter. Since PON1 is 
secreted from liver, using a liver cell line is more relative to answer the question. The 
reason of not using normal non-transfected liver cell line is that the only available cell 
line was HepG2 which was tested and it was found that it did not produce any PON1 
and the gene expression was very low which make it hard to use it as model for PON1 
gene expression or secretion. On the other hand, PON1-Huh7 has been successfully 
used in several studies with phenolic compounds [275], [279], [281], [282], [291], 
[292]. Reporter gene assays have been extensively used for the same purpose [278].  
As shown in the results, none of the anthocyanins and their metabolites significantly 
changed PON1 promoter activity at any of tested concentrations. Apart from gallic 
acid, none of these tested compounds have been reported before. Gallic acid reported 
to increase PON1 promoter activity by 8.5-fold which is inconsistent with the present 
study[291]. This contradiction may be attributed to the difference in concentration of 
gallic acid. In the study that reported a positive effect of gallic acid [291], the 
concentration was 360 µM which was about 36 times higher than the highest 
concentration in the present study which may explain why gallic acid could not induce 
PON1 promoter activity in the current project. In addition, most of the other reported 
non-anthocyanins phenolic compounds such as catechin, quercetin, punicalagin, 
ellagic acid at concentrations similar to what was tested in the current study did not 
affect PON1 gene expression or PON1 promoter activity which support the current 
findings. [281], [291], [292]. On the other hand, curcumin, the positive control 
increased PON1 promoter activity which was consistent with previous reports [278], 
[282], [290]. This finding confirm that the model was working fine, and the non-
significant change was real.  
Regarding curcumin, it was chosen as a positive control for different reasons. First, 
because the previously reported effect on PON-Huh7, the model used in this 
experiment [278], [282], [290]. Secondly, because the chemical structure as curcumin 
is a phenolic compound and consists of two ferulic acid units, one of the main 
metabolites of C3G [290]. PON1 induction by curcumin seems to be mediated by an 
aryl hydrocarbon receptor-dependent signal transduction pathway [282]. Although, 
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the concentration of curcumin is higher than what detected in humans, curcumin was 
not cytotoxic to PON1-Huh7 cells at concentrations of up to 20 µmol/l [282].   
Since the treatments did not affect the gene expression, it was hypothesized that 
anthocyanins may act as an activator for PON1. Therefore, the effects of 
anthocyanins and their metabolites on enzyme activities was investigated.  
3.6.2. Effect of anthocyanin and their metabolites on PON1 enzyme activities 
Many small molecules can act as activators or inhibitors of PON1 [294]. Anthocyanin 
metabolites are small molecules and may have the potential to activate PON1. For 
this purpose, two phenotypes of purified PON1, PON-QQ and PON-RR, have been 
used as a model to test the effect of anthocyanins and their metabolites on PON1 
activity. The current study is the first study to look for the direct effect of anthocyanins 
and their metabolites on PON1 enzyme activity. In addition, this is the first study that 
considered the differences between PON1 genotype by using two different PON1 
phenotypes that isolated from individuals with Q192Q and R192R genotype. Naringin 
is the only pure flavonoids that has been tested for its direct effect on PON1 activities 
without considering the genetic background [254]. As shown in the results, except for 
the high concentration of cyanidin, none of the tested parent anthocyanins 
compounds and none of the tested metabolites has strong effect on PON1 activities, 
although some treatment had a very small significant effect. In addition, lactonase 
activity, the PON1 native activity, seemed to be more affected by anthocyanins 
treatments than arylesterase. For instance, C3G treatments significantly increased 
lactonase activity with PON-QQ and PON-RR, while, the same treatments have no 
effect on arylesterase. Lactonase activity is more important in terms of anti-
atherogenicity and apparently anthocyanins treatments affected it positively, although 
the effect was minor. The possible explanation of null/low positive effect could be 
using purified enzymes instead of serum. The purified enzyme lacks the native 
environment such as the presence of HDL and ApoA1 protein which may affect the 
enzyme structural conformation and its stability and therefore its activity [294]–[298]. 
The reason for not using serum as a source of the enzyme is that the serum may 
contain wide range of compounds such as lipoproteins that may bind with 
anthocyanins and conceal or inhibit its effect. In addition, the present study aimed to 
compare between two different PON1 phenotype which is difficult to obtain by using 
serum sample instead. 
On the other hand, cyanidin unexpectedly decreased PON1 lactonase activity in 
PON-RR but not PON-QQ in a dose-dependent manner. The low concentrations, 
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however, have no effect on the lactonase activity. The arylesterase remained 
unchanged after cyanidin treatment which confirm that lactonase was the main target 
of anthocyanins. In fact, cyanidin was not detected in serum in humans after 
consumption of 13C-labelled C3G. Only traces of cyanidin conjugates were detected 
in urine in the same study suggesting that the existence of cyanidin in serum in 
concentrations higher than 0.1 µM is not achievable which likely making the effect of 
cyanidin on PON1 physiologically unimportant [73]. Furthermore, cyanidin is 
extremely unstable  at high pH with about 50% instantaneous loss of the parent 
structure at pH 7.4 which was lower than the pH of the assay buffer (pH=8) suggesting 
that the reduction in PON1 activity was not mediated directly by cyanidin but may be 
through one or more of its intermediates [41]. In contrast, C3G, the glycoside form of 
cyanidin, slightly increased PON1 lactonase activity in both PON-RR and PON-QQ. 
Fortunately, C3G is found in serum in concentrations higher than cyanidin after 
anthocyanins consumption making the negative observed effect of cyanidin on 
lactonase insignificant.   
Although the effect of anthocyanins on lactonase activity, the physiological activity of 
PON1, was investigated in this chapter, the main role of anthocyanins in helping 
PON1 in prevention of LDL oxidation remained undiscovered. Anthocyanins may 
improve the ability of PON1 indirectly to prevent the oxidation of LDL. Studying the 
oxidation status of LDL before and after treatment with enzyme combined with 
anthocyanins may answer this question. Therefore, further investigation is still needed 
in this aspect. Additionally, the effect of anthocyanins and their metabolites on PON1 
secretion and protein level still yet to be investigated.  
Therefore, based on the results presented in this chapter, the tested anthocyanins 
and their tested metabolites have no strong significant effect on PON1 activities and 
gene expression. This result indicating that anthocyanins and their metabolites did 
not affect RCT pathway biomarker. However, anthocyanins may target different 
pathways related to atherosclerosis. To investigate this further, non-targeted 
approach such as RNA-sequencing can be used to detect which genes and pathways 
related to atherosclerosis and lipids metabolism were affected by anthocyanin 
treatments. Therefore, a transcriptomic analysis has been done and is presented in 
next chapter.   
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3.7. Conclusion  
The results presented in this chapter demonstrate that none of the anthocyanin 
compounds or their metabolites significantly changed PON1 promoter activity nor 
strongly changed the arylesterase or lactonase activities regardless PON1 
phenotypes. However, the effect of these compounds on PON1 protein level or 
secretion and on prevention of LDL from oxidation is not excluded. Future work still 
needed to investigate more untested metabolites, study the effects on LDL oxidation 
stats and on PON1 secretion. In addition, different atherosclerotic-related pathways 
need to be investigated. The next chapter therefore will use RNA transcriptomic 
analysis to discover pathways targeted by anthocyanins.  
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Chapter four: The atherosclerosis-
linked pathways and the possible direct 
molecular targets affected by the 
anthocyanin metabolites 
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4.1. Abstract 
Data presented in chapter two and three in this thesis showed no significant effects 
of anthocyanins and their metabolites on key genes of RCT and biomarkers of HDL 
function in relation to atherosclerosis. However, atherosclerosis is a multifactorial 
disease that involves various genetic and environmental factors. To enhance our 
understanding of underlying molecular mechanisms and to discover new biomarkers 
and pathways of atherosclerosis that might be affected by anthocyanins and their 
metabolites, an RNA sequencing (RNA-seq) study was conducted. Preloaded-THP-1 
macrophages were treated with 10 µM of phloroglucinaldehyde (PGA), syringic acid, 
vanillic acid and a mixture of them (3.3 µM each) in addition to DMSO as a vehicle 
control. RNA sequencing was performed using NovaSeq and 100 bp paired end 
reads. The differential expression analysis of sequencing data revealed no significant 
changes in gene expression to an adjusted p-value ≤0.05. However, PGA significantly 
changed the expression of 377 genes at adjusted p-value ≤ 0.3. Among those, 231 
genes were downregulated (average fold change 0.7-fold), and 146 genes were 
upregulated (average fold change 1.3-fold). Most of these were categorized as non-
atherosclerotic-linked genes. The functional enrichment analysis also showed that 
anthocyanin metabolites regulated pathways involved in DNA repair, cell cycles, 
inflammatory process, adipogenesis and cancerous-relevant pathways. In 
conclusion, the result from RNA seq showed no substantial effects of anthocyanin 
metabolites on the differentially expressed genes or pathways related to 
atherosclerosis. The lack of effect could be that the most beneficial metabolites have 
not been examined as only three metabolites were tested in this study or may due to 
using cell line that is not a target of anthocyanins and therefore future work is required 
to test more metabolites with several cell lines involved in atherosclerosis. 
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4.2. Introduction  
Atherosclerosis is a commonly described as multifactorial disease involves various 
genetic and environmental factors as well as conventional risk factors such as 
dyslipidemia, diabetes and hypertension [299], [300]. Several epidemiological studies 
revealed that the consumption of anthocyanins is strongly correlated with reduced risk 
factors of atherosclerosis [116], [119]. Additionally, human and animal intervention  
studies conducted with anthocyanin-rich fruit and extract showed a protective effects 
of anthocyanin against several risk factors of atherosclerosis [15], [164]. Although 
some of these studies provided evidences about the antiatherogenicity properties of 
anthocyanin such as improvement in lipid profile, modulation of vascular function and 
increase in the anti-inflammatory properties [15], [301], [302], the underlying 
mechanisms are not yet fully understood.  
There are several in vitro experiments were undertaken to explore the molecular 
mechanisms implicated in bioactivity of anthocyanins using targeted approaches 
which allow studying specific molecular mechanisms. In some of these studies, pure 
anthocyanin and its metabolites as well as anthocyanin-rich extracts showed that 
anthocyanins altered many genes and biomarkers related to atherosclerosis such as 
genes encoding the cholesterol transporters, scavenger receptors, cell adhesion 
molecules, vasoconstrictor ET-1 [45], [250], [303], [304]. However, the molecular 
targets of anthocyanins and their metabolites still largely unknown due to using pure 
compounds with concentrations higher than the physiologically relevant 
concentrations or using whole material extracts that contain other bioactives. In 
chapter two and three in this thesis, the effect of wide range of pure anthocyanin and 
their metabolites at physiologically relevant concentration on several biomarkers 
related to RCT and HDL function was investigated with no significant changes in any 
of these biomarkers. However, anthocyanin may target different genes and pathways 
suggesting using non-targeted approaches to identify them. The global genomic 
approaches such as microarray technology or next generation sequencing (NGS) 
technology allow studying the effects on the global gene expression which provide a 
better insight into the disease mechanisms and the possible interaction between 
different pathways especially in complex multifactorial diseases like atherosclerosis 
[249], [305], [306].  
The beneficial effects of anthocyanins were also supported by several reports that 
studied the global gene expression using microarray. In a very recent study, the 
impact of consuming 11 g wild blueberry powder (containing 150 mg of anthocyanins) 
 137 
 
for 28 days on the expression of miRNAs in human was analysed using Human 
miRNA Microarray [307]. The data has shown that 608 genes were significantly 
differentially expressed. In addition, there was 35 significant gene networks identified 
following the functional annotation using gene ontology. Among them, 11 are known 
to be involved in the regulation of chemotaxis and inflammation/immune response, 9 
in cell adhesion and cytoskeleton organization, and few networks regulating signal 
transduction, apoptosis, or development [307].  
In mice, there are several studies investigated the effect of anthocyanin on differential 
expression. Mauray et al. (2010) reported that the consumption of bilberry extract for 
two weeks altered the expression of 2,289 genes involved in various molecular 
pathways such as cholesterol metabolism, inflammatory processes and cell adhesion 
in liver tissue of apo E-/- mice [308]. In another study, bilberry extract changed 1261 
genes in aorta tissue of apo E-/- mice. The modulated genes were involved in 
inflammatory response, cell proliferation through vascular endothelial growth factor 
(VEGF), cell adhesion and lipid metabolism [45]. Moreover, the effects of bilberry 
extract (75 µg/ml) on genes expression profile were also investigated in mouse 
macrophages. In this study, the bilberry extract downregulated about 2000 genes by 
2-fold. Among of them, protein coding genes for liposaccharide synthesis (LPS), 
tumour necrosis factor (TNF), prostaglandin-endoperoxide synthase (PTGS), 
Tenascin  (TNC) , Interleukin -1β and -6 (IL-1β and IL-6), and cyclooxygenase2 (COX-
2) which attenuate the atherosclerosis [309]. Furthermore, in a study where 
adipocytes were isolated from human and rat that were treated with 100 µM of C3G 
and cyanidin, a reduction in the expression of pathways related to inflammatory 
process, cell adhesion and lipid metabolism were reported using microarray genes 
profiling [310], [311].  
Although the global gene expression analysis in these studies supported the notion 
that anthocyanin demonstrates protective effects against risk factors of CVD and 
provided insight into some possible targeted pathways, the underlying mechanisms 
are still inconclusive as whole materials that contain other bioactives were used. 
Additionally, these studies did not investigate the effect of anthocyanin metabolites or 
examined the effects at high concentrations. Therefore, more transcriptomic studies 
are needed to investigate this further.   
High-throughput sequencing technologies such as RNA sequencing (RNA seq) have 
become more popular alternative to microarrays technologies [312]. Unlike 
microarray, RNA seq does not require specific probes allowing detection of novel 
transcripts, alternative splicing junctions, new single nucleotide variants, allele-
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specific expression and other changes that arrays cannot identify [313]–[315]. 
Compared to microarrays, the high specificity and sensitivity of RNA seq allow 
detecting the expressed genes in the whole genome and detecting low expressed 
genes in more accuracy than microarray that require hybridization [312]. With all the 
previous advantageous and many others, RNA seq provide a powerful tool for 
discovering and profiling the transcriptome with deep information that allow exploring 
and predicting biomarkers and help understanding the underlying molecular 
mechanisms of interaction between diet and diseases, especially the complicated one 
such as atherosclerosis. Therefore, RNA seq transcriptomic study was conducted as 
explore the molecular mechanisms and the possible targeted by which anthocyanin 
deliver its action.  
4.3. Objectives 
The main aim of the research presented in this chapter was to perform RNA seq 
transcriptomic study to investigate the influence of C3G and D3G main metabolites 
on (1) the transcriptome profiling, (2) the differentially expressed genes and (3) the 
functional pathways using human macrophages cell line to gain better insight into the 
molecular mechanisms by which anthocyanins and their metabolites deliver their 
effects. 
 
4.4. Materials and methods 
4.4.1. Cell culture 
THP-1 human monocyte cells were routinely maintained and cultured in bicarbonate 
RPMI-1640 media as described previously in section 2.4.1. THP-1 monocyte cells 
were seeded at 5 x 105 cell/ml in 12-well plates and differentiated by 100 ng/ml PMA 
for 48h followed by preloading step with ac-LDL (25 µg/ml) for additional 24 h and 
prior to the treatments. 
4.4.2. Treatments 
Preloaded THP-1 macrophages were treated with control (DMSO 0.1%), 10 µM of 
PGA, vanillic acid, syringic acid individually and a mixture of them with 3.3 µM each 
for 24 hr. The stock solutions as well as the treatments were prepared as described 
in section 2.4.2. After treatment, the cells were subjected to RNA extraction. 
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4.4.3. RNA extraction  
RNA extracted from treated cells as previously mentioned in section 2.4.3. Briefly, the 
cell layer was washed twice with cold PBS and subjected to RLT extraction buffer. 
RNA extract then was collected and homogenised using QIAshredder prior to 
purification with RNeasy® Mini kit. RNA quantity and purity were measured using the 
nanodrop. Three readings for RNA quantification were obtained per sample and the 
average of RNA concentration was then calculated. RNA samples were aliquoted and 
stored at -80°C until using.  
4.4.4. RNA integrity assessment 
An aliquot of RNA sample was used to assess the quality of RNA using an Agilent 
RNA 6000 Nano LapChip kit (Cat # 5067-1511) and an Agilent 2100 Bioanalyzer 
according to the manufacturing protocol. RNA integrity using this method is simply 
measured using chip system that allow quick electrophoresis separation. There are 
microchannels within the chip that should be filled with a mixture of fluorescence dye 
and a sieving polymer that allow a separation of RNA fragments based on their size. 
The fluorescence dye binds with RNA fragment producing fluorescent signal that can 
be measured and plotted graphically. To measure the size and the concentration of 
RNA fragments, RNA 6000 ladder standard was run alongside RNA samples on every 
chip. The software automatically compares the size and the concentration of the 
unknown RNA samples with the reference ladder and to identify the ribosomal RNA 
(rRNA). RNA integrity (quality) was then calculated for each sample based on the ratio 
of the 28S and 18S rRNA fragments. High RNA quality samples can be characterized 
by two distinguished peaks corresponding to 28S and 18S rRNA and flat baseline 
especially between 28S and 18S bands. 28S peak should be larger than 18S. The 
software automatically assesses RNA quality based on the electrophoretic RNA 
measurement using a number called RNA Integrity Number (RIN) which range from 
1 to 10 where 1 is completely degraded RNA, while 10 being the most intact RNA. Fig 
4.11 shows an example of high integrity RNA sample.   
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Figure 4. 1: An electropherogram of high-quality RNA sample analysed 
by Agilent 2100 Bioanalyzer. 
RIN = 9.4, 18S rRNA area is 23.3 % of total area, 28S rRNA is 46.5 % of total area.  
 
 
4.4.5. RNA sequencing 
After RNA quality assessment, 20 samples (5 treatments x 4 replicates) with RIN 
higher than 8 were sent for sequencing by Macrogen Human Genomics Ltd 
(https://dna.macrogen.com/eng/index.jsp) in Rep of Korea using Illumina sequencing. 
The company was responsible for quality control, libraries preparation and 
sequencing.    
The libraries were first constructed using TruSeq RNA (Poly-A) library preparation kit 
according to the manufacturing protocols. This kit is stranded mRNA sample 
preparation kit that generate mRNA-focused sequencing libraries from total RNA. The 
basic of this kit is simply purifying the poly-A containing mRNA molecules using poly-
T oligo attached magnetic beads. The mRNA was then fragmented and copied into 
cDNA library using reverse transcriptase and random primers which then ligated into 
adaptors to create the final cDNA library.  The libraries were then sequenced using 
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the Illumina NovaSeq and 100 bp paired end reads were generated with average of 
40 million reads per samples.   
4.4.6. Data processing 
The sequences raw data was provided in FASTQ file format. The data processing and 
analysis was performed by a bioinformatician in house according to the protocol 
described elsewhere [316]. Briefly, the analysis of RNA seq data started with the pre-
processing of the raw sequencing reads to remove ribosomal reads using SortMeRNA 
v 2.1b [317]. The next step was to remove adaptor sequences, which was done with 
a stringency of a minimum of 5 bases overlap. Then, for quality control, low quality 
reads (< 30) were removed as well as short reads (< 60 bp). To remove adaptor 
sequences and for quality control, TrimGalore v 0.4.2 software was 
used(https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). The high-
quality filtered reads were then aligned to the human reference genome (ensemble 
release 84, GRCh38, ftp://ftp.ensembl.org/pub/release-
84/fasta/homo_sapiens/dna/Home_sapiens.GRCh38.dna.primary_assembly.fa) 
using the splice-aware aligner HISAT2 v 2.0.5 [318].  These alignments were then 
assembled into full-length transcripts and quantified in each sample using String Tie 
v 1.3.3 [319]. String Tie estimates the expression levels of all genes and transcripts. 
Finally, the read alignments and merged transcripts were used to re-estimate 
abundances when necessary to create transcript and gene counts for further analysis 
differential expression. 
4.4.7. Differential expression analysis 
The raw counts of genes were transformed to counts per million (CPM) and log CPM 
which then filtered to remove the low expressed genes prior to normalization and 
unsupervised clustering. The transformation, normalization and differential 
expression analysis was performed using Limma (v 3.38.3), edgeR (v 3.24.3) in 
RStudio [320]–[322]. The ranked genes subjected to gene set enrichment analysis 
(GSEA) using The Molecular Signatures Database (MsigDB) hallmark database to 
identify the enriched pathways [323].     
The differential expression analysis was performed using adjusted p-value and 
Benjamini-Hochberg multiple testing correction. adjusted p-values were used to 
identify differentially expressed genes. A p-value ≤ 0.05 was considered significant. 
Four biological replicates of each treatment were conducted with total 20 samples 
were sequences and analysed
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4.5. Results 
4.5.1. Quality control for RNA sequence data 
In order to understand the possible target of anthocyanin metabolites, a transcriptomic 
analysis of THP-1 was carried out. Preloaded THP-1 macrophages were treated 
with10 µM of PGA, syringic, vanillic acid; or a mixture of these three (3.3 µM each) 
and the result was compared to vehicle control (DMSO). First, high-quality RNA 
samples should be used for sequencing and therefore, RNA integrity was assessed 
using the bioanalyzer. The quality of all twenty RNA samples was very high and the 
RIN number varied from 9 to 10 which was enough to access library preparation and 
sequencing process using Illumina NovaSeq to generate paired-end (100 bp) 
platform. In total, an average of 48,172,840 ± 7,230,344 non-paired-end reads were 
obtained. The average total paired-end reads were 24,086,420 ± 3,615,172 (Table 
4.1) The smallest library was 20,009,537 (40,019,074 non-paired-end) reads and the 
largest library was 29,607,296 (59,214,592 non-paired-end) reads. First, rRNA reads 
were removed. Since the libraries was constructed using TruSeq RNA (Poly-A) 
technology, the non-rRNA reads (mRNA) represented 99.1 ± 0.2 % of total reads 
(average of 23,963,981 ± 3,597,631 paired-end reads). After adapters sequences 
trimming and discarding low quality reads (reads shorter than 60 bp), an average of 
23,920,067 ± 3,593,971 high quality clean paired-end reads were obtained which 
represent about 99.8 % of total non-rRNA reads (Table 4.1).  
High quality reads where then mapped to the reference genome using HISAT 2 
software. A large number of clean reads which represent an average of 97.3 ± 0.3 of 
total reads were successfully aligned (Table 4.1) which was consistent with what was 
reported previously with high-quality datasets  [324], [325].  
4.5.2. Differentially expressed genes  
After calculating the gene counts using StringTie software, the output file is a matrix 
with raw counts. In gene expression raw counts cannot be used for the analysis. 
Instead the raw counts are transformed onto a scale that accounts for the library size 
differences [322], [326]. For RNA-seq data in this study, the data was transformed 
into counts per millions (CPM) and log-CPM which then used for differential 
expression analysis.  
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Table 4. 1: Summary of quality characteristics of RNA sequencing reads before and after processing  
Treatment 
Raw data Filtering rRNA and quality control Mapping 
Total read 
(Paired-end) 1 
Non-rRNA reads 
(Paired-end) 
Reads after adapter 
trimming and QC 2 
Clean 
reads 
(%)2 
Uniquely 
aligned reads 
Multi-mapped 
reads 
Overall 
alignment 
control 28,164,254 28,048,609 27,991,331 99.8 22,640,305 3,823,649 97.0 
control 29,607,296 29,496,260 29,443,480 99.8 23,853,415 4,033,492 97.1 
control 20,463,816 20,360,355 20,301,988 99.7 16,462,979 2,735,237 97.3 
control 23,446,159 23,334,686 23,290,828 99.8 18,937,973 3,200,771 97.5 
Vanillic acid 28,554,853 28,368,366 28,311,277 99.8 22,838,966 3,843,615 96.8 
Vanillic acid 20,465,809 20,332,956 20,291,633 99.8 16,558,090 2,711,796 97.3 
Vanillic acid 20,152,652 20,014,782 19,957,143 99.7 16,244,479 2,697,930 97.2 
Vanillic acid 29,400,022 29,246,167 29,198,440 99.8 23,679,905 3,984,232 96.9 
Syringic acid 22,941,377 22,806,237 22,747,048 99.7 18,492,026 3,098,335 97.3 
Syringic acid 27,907,865 27,715,962 27,669,083 99.8 22,495,511 3,715,977 97.0 
Syringic acid 21,418,009 21,238,580 21,170,387 99.7 17,185,728 2,909,678 97.3 
Syringic acid 22,493,356 22,373,270 22,334,872 99.8 18,231,297 3,062,658 97.7 
 
- (1) Paired-end = sequence both ends of a DNA fragment, total read = paired-end reads x 2 both reverse and forward sequence;  
- (2) QC = quality control, % of clean read is reads after adapter trimming and QC divided by non-rRNA paired-end reads. 
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Table 4.1: continued  
Treatment 
Raw data Filtering rRNA and quality control Mapping 
Total read 
(Paired-end) 1 
Non-rRNA reads 
(Paired-end) 
Reads after adapter 
trimming and QC 2 
Clean 
reads 
(%)2 
Uniquely 
aligned reads 
Multi-mapped 
reads 
Overall 
alignment 
PGA3 26,736,887 26,539,520 26,493,195 99.8 21,450,870 3,606,728 96.9 
PGA 20,015,254 19,941,386 19,916,164 99.9 16,267,642 2,679,859 97.5 
PGA 28,034,259 27,939,984 27,906,229 99.9 2,275,746 3,874,849 97.0 
PGA 21,539,828 21,448,060 21,420,582 99.9 17,453,835 2,956,037 97.6 
mixture 20,009,537 19,948,650 19,927,256 99.9 16,334,782 2,694,368 97.7 
mixture 27,006,383 26,903,599 26,870,744 99.9 21,950,897 3,648,409 97.4 
mixture 20,466,052 20,386,827 20,362,707 99.9 16,712,065 2,724,257 97.7 
mixture 22,904,740 22,835,371 22,809,038 99.9 18,700,808 3,106,361 97.8 
 
- (1) paired-end = sequence both ends of a DNA fragment, total read = paired-end reads x 2 both reverse and forward sequence;  
- (2) QC = quality control, % of clean read is reads after adapter trimming and QC divided by non-rRNA paired-end reads. 
- (3) PGA = phloroglucinaldehyde, control = DMSO. 
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Based on CPM, 56662 features (genes) were identified which include a mix of 
expressed and lowly expressed genes. The genes that are lowly expressed or 
unexpressed throughout all samples interfere with some of the statistical 
approximations that are used in the pipeline and therefore, it is recommended to filter 
them [326]. Using edgeR package and CPM threshold 0.4 which means that the gene 
is considered expressed if at least 12 counts in the smallest libraries and 18 counts 
in the largest libraries in at least 4 samples were identified. Based on that, the number 
of expressed genes after filtering were 17,233 genes. Fig 4.2, demonstrates the 
difference between pre-filtered and post-filtered.  
These genes were normalized using trimmed mean of M-value to identify the 
differentially expressed genes. Using cutoffs of adjusted p-value less than 0.05, only 
one gene and two genes were differentially expressed after syringic acid and PGA 
treatment, respectively. Therefore, the analysis was repeated using higher adjusted 
p-value (≤ 0.3).  
As shown in Fig 4.3, PGA was the only treatment that showed an effect on the 
differential gene expression with total of 377 genes were differentially expressed; 231 
genes were downregulated, and 146 genes were upregulated at adjusted p-value ≤ 
0.3.  Syringic acid, on the other hand, changed the expression of six genes compared 
to the control; four genes were downregulated, and two genes were upregulated at 
the same adjusted p-value. Whereas, there was no significant differentially expressed 
gene after vanillic acid or mixture in comparison with control treatment. The genes 
that were differentially expressed after PGA treatment were ranked according to their 
fold change. The fold change ranged from 1.07 to 4.79-fold compared to control for 
upregulated genes, while, the fold change ranged from 0.03 to 0.95-fold for 
downregulated genes compared to control group. Table 4.2 and 4.3 show the top 
twenty and the lowest twenty expressed genes.  
Most of changed genes were not relevant to lipid metabolism or CVD risk factors. 
CD36 and Plin2 genes were the only genes that were identified as CVD relevant 
genes. CD36 is a gene encode for CD36 scavenger receptor protein synthesis, while, 
Plin2 is a gene encode for lipid droplet protein which is involve in lipid droplet 
formation. The fold change for both genes were 1.2 and 1.13 for CD36 and Plin2, 
respectively. 
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Figure 4. 2: The distribution of Log-CPM for (A) raw data and (B) of filtered data. 
Raw data represent all features identified, while filtered data represents the filtered data after 
removing genes with CPM ≥ 0.4. The dotted vertical lines mark the Log-CPM threshold (Log 
0.4 = -0.4). The features that had log-CPM ≤ -0.4 were removed.  
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q<0.05 q<0.1 q<0.2 q<0.3 
Down Up Down Up Down Up Down Up 
Vanillic vs control 0 0 0 0 0 0 1 0 
Syringic vs control 1 0 2 2 3 2 4 2 
PGA vs control 2 0 4 0 21 11 231 146 
Mixture vs control 0 0 0 0 1 0 1 0 
 
Figure 4. 3: Interactive mean-difference plot of expression and a table of number 
of differentially expressed genes at different adjusted p-value. 
Average log-expression = average log-CPM, q = adjusted p-value (≤ 0.3), red spots = 
downregulated genes; green spots = upregulated genes; black spots= genes with no 
significant difference at q ≤ 0.3. PGA = phloroglucinaldehyde, Control = DMSO. mixture = 
mixture of syringic acid, vanillic acid, PGA (3.3 µM or each).
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Table 4. 2: The top twenty differentially upregulated genes based on fold-
change in PGA treatment.  
Gene name Log FC1 
Adjusted 
p-value 
FC 1 Gene encode 4 
LRRC4 2.26 0.25 4.79 Excitatory synapses 
NA2 1.30 0.30 2.47 - 
ASXL2 1.25 0.22 2.37 ASXL transcriptional regulator 2 
LINC00942 1.21 0.30 2.31 
Intergenic Non-Protein Coding 
RNA 942 
MAGEA4 1.02 0.30 2.03 Melanoma-associated antigen 4 
ZNF35 0.99 0.30 1.98 Zinc finger protein 35 
NA 0.93 0.30 1.91 - 
AC009303.4 0.90 0.26 1.87 
Nuclear factor (erythroid-derived 
2)-like 2  
AC116347.1 0.87 0.30 1.83 Proteasome activator subunit 2 
HHLA3 0.76 0.25 1.70 
HERV-H LTR-associating protein 
3 
CDKL1 0.75 0.30 1.69 Cyclin dependent kinase Like 1 
NACA2 0.72 0.26 1.65 
Nascent polypeptide associated 
complex subunit alpha 2 
NA 0.64 0.22 1.56 - 
DMC1 0.63 0.30 1.55 
meiotic recombination protein 
DMC1/LIM15 homolog 
WDR31 0.57 0.30 1.49 WD repeat Domain 31 
NA 0.54 0.14 1.45 - 
CCNG2 0.52 0.25 1.44 NF3 
GPT2 0.52 0.26 1.44 NF 
AL590764.1 0.52 0.30 1.43 NF 
NA 0.52 0.26 1.43 - 
 
(1) FC = fold change, (2) NA = the gene name was not identified, (3) NF = the gene function 
was not found, (4) the function of genes were identified using genecards database 
(https://www.genecards.org/)  
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Table 4. 3: The twenty most downregulated genes based on fold-change in PGA 
treatment.  
Gene name Log FC1 
Adjusted 
P-value 
FC Gene encode4 
NA -6.97 0.14 0.01 - 
C7 -5.18 0.16 0.03 Complement C7 
NA2 -3.88 0.24 0.07 - 
PHLDB2 -3.84 0.23 0.07 
Pleckstrin homology like domain 
family b member 2 
UMOD -3.76 0.25 0.07 Tamm-horsfall urinary glycoprotein 
AQP2 -3.46 0.30 0.09 Aquaporin 2 
YTHDF2P1 -3.13 0.25 0.11 
Yth domain family member 2 
pseudogene 1 
ALDOB -3.10 0.26 0.12 Aldolase, fructose-bisphosphate b 
ABHD17AP4 -3.09 0.26 0.12 
Ab-hydrolase domain containing 
17a pseudogene p4 
LIMCH1 -2.94 0.26 0.13 
Lim and calponin homology 
domains 1 
7SK -2.88 0.15 0.14 
RNA component of 7sk nuclear 
ribonucleoprotein 
AC048382.5 -2.74 0.29 0.15 
Novel transcript, antisense to 
ZSCAN2 
RN7SKP203 -2.71 0.20 0.15 Rn7sk pseudogene 203 
PCK1 -2.53 0.30 0.17 
Phosphoenolpyruvate 
carboxykinase 1  
PTPRM -2.43 0.28 0.19 
Protein tyrosine phosphatase 
receptor type m 
NA -2.33 0.28 0.20 - 
AC021016.3 -2.24 0.30 0.21 
Novel transcript, antisense to 
CTDSP1 
RN7SL4P -2.16 0.13 0.22 
RNA, 7sl, cytoplasmic 4, 
pseudogene 
RN7SL5P -2.11 0.05 0.23 
RNA, 7sl, cytoplasmic 5, 
pseudogene 
AC007952.4 -2.06 0.28 0.24 Novel transcript 
(1) FC = fold change, (2) NA = the gene name was not identified, (3) NF = the gene function 
was not found, (4) the function of genes were identified using genecards database 
(https://www.genecards.org/)  
 150 
 
4.5.3.    Functional enrichment analysis.  
In order to interpret and identify the relevant biological pathways of the sequenced 
genes, gene set enrichment analysis (GSEA) was performed using The Molecular 
Signatures Database (MsigDB) hallmark gene sets.  
The hallmark analysis revealed that PGA significantly affected 13 pathways in 
comparison to control group at adjusted p-value ≤ 0.05. All of them were upregulated 
(Fig 4.4-A). Apart from adipogenesis pathways [327], none of the changed pathways 
were atherosclerotic-relevant. For instance, MYC Targets V1 which got the highest 
normalized enrichment is cancerous-relevant pathway [328], while, G2M Checkpoint 
pathway prevents cells from entering mitosis when DNA is damaged [329].  
When the adjusted p-value increased to ≤ 0.08, two additional upregulated pathways 
and two downregulated pathways were identified (Fig 4.4-B). One of the additional 
upregulated pathways is fatty acid metabolism that is particularly  relevant to CVD  
[330], while, epithelial-mesenchymal transition (EMT) was one of the downregulated 
pathways which is involved indirectly in atherosclerosis. EMT pathway is mainly 
involved in embryonic development, wound healing, regeneration, heart development 
and cancer. However, EMT can be described as specialized form of endothelial- 
mesenchymal transition which involves in pathophysiology of atherosclerosis [331], 
[332]. 
On the other hand, vanillic acid barely affected the pathways with Interferon Alpha 
Response being the only significantly changed pathway in comparison to control 
group at adjusted p-value ≤ 0.05 (Fig 4.5). Interferon Alpha Response pathway is 
involved in antiviral response of the host and it is not atherosclerotic-related pathway 
[333].  
In contrast, syringic acid upregulated 13 gene sets with adjusted p-value ≤ 0.05 (Fig 
4.6). Although, none of the upregulated pathways are involved in lipid/lipoprotein 
metabolism or RCT, two of the upregulated pathways are involved in inflammation 
process; tumour necrosis factor alpha (TNFα) via NF/HB and inflammatory response 
pathways (Fig 4.6-A). Additionally, syringic acid upregulated EMT pathway. These 
three pathways may be involved indirectly in atherosclerosis.  
Furthermore, a mixture of PGA, vanillic acid, syringic acid (3.3 µM of each) 
upregulated only two pathways, MYC Targets V1 and G2M Checkpoint pathways at 
adjusted p-value ≤ 0.05 (Fig 4.7-A). These two pathways were also upregulated by 
PGA and they are not atherosclerotic-related pathways. On the other hand, using 
adjusted p-value ≤ 0.1 revealed an additional 9 pathways that were upregulated by 
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the mixture treatment (Fig 4.7 A&B). However, none of them were atherosclerotic- 
linked pathways. Moreover, none of the dysregulated pathways were downregulated.  
The enrichment analysis was also conducted using Reactom and Gene Ontology 
databases (Appendix 1) without a big difference in changed pathways with Hallmark 
database. 
 
 
 
 
 
Figure 4. 4: Hallmark pathway analysis of genes expressed by PGA treatment, 
(A) upregulated and (B) downregulated pathways. 
Blue bars represent the significantly changed pathways by PGA in comparison with control 
group at adjusted p-value ≤ 0.05; red bars represent the significantly changed pathways at 
adjusted p-value ≤ 0.08.  
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Figure 4. 5: Hallmark pathway analysis of genes expressed by vanillic acid 
treatment, (A) upregulated and (B) downregulated pathways. 
Blue bars represent the significantly changed pathways by vanillic acid in comparison with 
control group at adjusted p-value ≤ 0.05; red bars represent the significantly changed 
pathways at adjusted p-value ≤ 0.7.  
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Figure 4. 6: Hallmark pathway analysis of genes expressed by syringic acid 
treatment, (A) upregulated and (B) downregulated pathways. 
Blue bars represent the significantly changed pathways by syringic acid in comparison with 
control group at adjusted p-value ≤ 0.05.  
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Figure 4. 7: Hallmark pathway analysis of genes expressed by mixture 
treatment. 
Mixture treatment is a mixture of PGA, syringic acid and vanillic acid (3.3 µM each). Blue bars 
represent the significantly changed pathways by mixture treatment in comparison with control 
group at adjusted p-value ≤ 0.05; red bars represent the significantly changed pathways at 
adjusted p-value ≤ 0.1. 
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4.6. Discussion  
The data presented in this chapter described the RNA transcriptomic study that was 
conducted as a non-targeted approach to find out which genes involved in 
atherosclerosis processes are responsive to the major anthocyanin metabolites and 
to identify any genes and pathways affected by the anthocyanin metabolites (i.e. not 
usually associated with atherosclerosis) in THP-1 macrophages. The main findings 
were that (1) no significant changes were observed in the differentially expressed 
gene expression at adjusted p-value ≤ 0.05 to 0.2, (2) the only observation was 
achieved at adjusted p-value ≤ 0.3 and PGA was the only treatment that caused a 
significant change, (3) most of the 377 affected genes and the enriched pathways 
after PGA treatment were not atherosclerotic-linked.  
The result in the previous two chapters clearly demonstrated that anthocyanins and 
their metabolites did not affect the expression of the key genes involved in RCT and 
did not change the biomarkers of HDL function. However, atherosclerosis is a 
multifactorial disease that can involve many genetic factors and pathways which might 
have been targeted by anthocyanins. Therefore, the main aim of this chapter was to 
conduct a transcriptomic study as a non-targeted approach to identify the possible 
atherosclerotic-related genes and pathways that may be affected by anthocyanins 
and their metabolites. 
mRNA expression profiling using the high-throughput next generation sequencing 
platforms such RNA sequencing is a new powerful and revolutionary tool for 
understanding the molecular mechanisms of treatments and discovering new 
predictive biomarkers, especially in complex disease such as atherosclerosis [334]–
[337] .To the best of my knowledge, this study was the first that used RNA sequencing 
to explore the underlying mechanisms by which anthocyanin reduce the risk factors 
of CVD. The majority of studies that used non-targeted transcriptomic approaches 
were conducted using microarray and investigated the effects of anthocyanin-rich fruit 
or extract [45], [308], [309], [338] without investigating the effects of pure anthocyanin 
or their metabolites which make the data in this chapter novel.  
In this chapter,  RNA-seq study was suggested as an additional route to investigate 
more broadly the effect of anthocyanin metabolites on other atherosclerosis-linked 
genes and pathways that were not investigated in the previous two chapters and 
involved in atherosclerosis such as liver X receptor (LXR), retinoic X receptor (RXR), 
peroxisome proliferator-activated receptors (PPARs), junction adhesion molecules 
and other members of scavenger receptors family. To test this hypothesis, preloaded 
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THP-1 macrophages were treated with three different type of anthocyanin 
metabolites; PGA, vanillic acid, syringic acid and a mixture of them at physiologically 
relevant concentrations. These metabolites were selected to represent the main 
metabolites of the predominant type of anthocyanins (C3G and D3G). Syringic acid 
was the main delphinidin-type metabolites and represents the metabolites of tri-
hydroxylated B-ring anthocyanin, while, vanillic acid was the main metabolites of C3G 
and represent the metabolites of di-hydroxylated-B ring anthocyanins [91], [73]. PGA, 
on the other hand, represent the metabolites of A-ring structure of C3G and D3G [73], 
[91]. The reason of choosing these metabolites was to represent the major 
metabolites of the major three different chemical structure of anthocyanins found in 
nature, although, there are many others that might be more beneficial and should be 
investigated in future work.           
The result in this chapter support the null hypothesis as there were not any changes 
in the differentially expressed genes after any of the anthocyanin metabolites 
treatment. When the adjusted p-value cut-off was increased to 0.3, PGA was the only 
treatment that caused substantial changes in the gene expression. However, the 
change was not big as the average fold change of upregulated genes was 1.3 ± 0.2, 
while, the average fold change of downregulated genes was 0.7 ± 0.22 which 
indicates that anthocyanin metabolites have no substantial effect on atherosclerotic-
related genes in THP-1 macrophages. Among those changed genes, CD36 and Plin2 
were atherosclerotic-linked genes. CD36 is a member of scavenger receptor B family 
responsible for binding modified LDL. Previously, it has been reported that 
downregulation of CD36 caused a reduction in foam cell formation [225]. In contrast 
to what was expected, PGA upregulated CD36. But the effect was very low and at 
high adjusted p-value which means the upregulation was likely physiologically 
unimportant. In addition, the RT-qPCR data presented in chapter two support that the 
effect of PGA in upregulation CD36 was not real as no significant changes were 
observed in CD36 gene expression with PGA or the other tested metabolites 
treatments (see section 2.5.3). Similar to CD36, Plin2 gene is involved in lipid droplet 
formation and foam cell formation. The overexpression of Plin2 increases the lipid 
accumulation in THP-1 macrophages and hinders cholesterol efflux from 
macrophages [339]. Although, Plin2 gene expression increased after PGA treatment, 
the increase was very small which likely lack clinical importance. 
In addition to the changes at level of single genes, anthocyanin metabolites showed 
no substantial effect on the atherosclerotic-linked pathways. Initially, GSEA was 
conducted using Hallmark database which is one of the most widely used and 
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comprehensive database [339]. The majority of the changed pathways were not 
atherosclerotic-linked pathways. Most of them, contrarily, were related to DNA repair 
and replication such as G2M checkpoint [329], E2 targets [340], androgen response 
[341], mitotic spindle [342], and hedgehog-signaling [343]. Others were involved in 
protein secretion and cell prefiltration such as mTORC1 signaling [343], notch-
signaling [344]. On the other hand, few dysregulated pathways such as TNFα 
signaling via NFKB, epithelial-mesenchymal transition, oxidative phosphorylation, 
interferon gamma response and inflammatory response were linked with inflammation 
which a key step in atherosclerosis [345]. These pathways could be a target for 
researcher to further investigate the mechanisms behind the beneficial effects of 
anthocyanins.  
Several studies that used microarray reported that anthocyanin affected genes and 
pathways that are involved directly in atherosclerosis. Muauray et al. (2010) and 
Mauray et al. (2012) found that bilberry anthocyanin-rich extract (0.02 % w/w of 
standard diet) for two weeks altered the gene expression related to atherosclerosis 
development in liver and aorta of apo E-/- mice [45], [308]. Moreover, Chen et al. 
(2008) found similar results in mice macrophages with bilberry extract [309]. 
Additionally, Lefevre et al. (2008) reported that grape anthocyanins affected several 
atherosclerotic-related genes in liver and skeletal muscle of C57Bl/6 mice [338] which 
was inconsistent with the current data.   Probably, the contradiction between this study 
and the other is due to the difference in the tested material. In the current study, 
purified anthocyanin metabolites were used, while, anthocyanin-rich fruit or extract 
were used in the previous reports. The extracts contain many types of anthocyanins 
that may synergistically affect the genes expression which was not the case in the 
present study. Another explanation of the lack of effect could be that the most 
beneficial metabolites haven not been tested as only three metabolites were 
examined and many other still need to be investigated individually and as mixtures. 
Additionally, in RNA seq, the number of biological replicates has a large impact on 
the power of differential expression analysis. The more biological replicates are 
analysed, the more transcriptional noise can be eliminated and the more clear image 
and clear differences can be obtained [346]–[348]. Schofield et al. (2016), suggested 
that six replicates should be used in differential expression analysis [349]. In the 
present study, due to the cost and the number of treatments, four biological replicates 
were analysed for each treatment which may explain why significant differentially 
expressed genes was obtained at high adjusted p-value and therefore, future work is 
required with more biological replicates. Furthermore, anthocyanin and their 
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metabolites may target different cells that are involved in atherosclerosis 
pathogenesis such as endothelial cells rather than cholesterol-laden macrophages. 
Krga et al. (2018) found that the anthocyanins and their gut metabolites 
downregulated the monocyte adhesion and trans-endothelial migration pathways in 
HUVECs cell line using miRNA microarray [249]. Since the project focused on the role 
of anthocyanin in modulating the lipid metabolism as a mechanism by which 
anthocyanin attenuate the progression of atherosclerosis, preloaded-THP-1 
macrophages was chosen as a model in this experiment to mimic in vivo situation and 
to be in agreement with last two result chapters that focused on RCT and lipoprotein 
function. However, the suitability of other cell models is not excluded (see section 
2.6). Therefore, additional transcriptomic studies using different cell lines such as 
endothelial cell lines or liver cell lines are still required to explore the underlying 
mechanisms of protective effects of anthocyanins.  
Overall, there were not any substantial changes observed in the differential gene 
expression or in the enriched functional pathways after treatments. PGA, on the other 
hand, was the only treatment that caused relatively big effects, although, the adjusted 
p-value was high, and the changed genes and pathways were not atherosclerotic-
relevant. These findings were consistent with the in vitro data that presented in last 
two chapters in which no significant changes were observed after anthocyanins and 
their metabolites treatments. 
Although, the in vitro models are useful for the mechanistic studies, they only allow 
studying the direct effect in cell levels and do not allow studying the secondary effects 
or the effects in the organs level and thereby, studying the effects of anthocyanins 
using an in vivo model is necessarily. Since only in vitro models were used in the 
investigation in the last three chapters, using an in vivo model was suggested to 
further investigate the effects of anthocyanin on markers of CVD. Therefore, a 
randomized controlled trial was conducted to investigate the effects of anthocyanin 
consumption on lipid/lipoprotein profiles and biomarkers of HDL function.  
 159 
 
4.7. Conclusion  
In conclusion, the data presented in this chapter showed that the three tested 
metabolites of anthocyanins did not cause substantial changes in expression of genes 
and pathways related to atherosclerosis in cultured human macrophages. However, 
other untested metabolites might be more biologically active or target different cell 
line rather than cholesterol-laden macrophages. Therefore, future works are still 
required to investigate the effects of more untested metabolites on transcriptomes in 
several cell lines. Due to the limitation in the in vitro models, an in vivo model is 
required to investigate the secondary effects of anthocyanins and the effects on the 
body as whole. Therefore, the next chapter will explore the effects of anthocyanins in 
randomized controlled trial.   
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Chapter five: The effects of 
consumption of cyanidin-type 
anthocyanins and delphinidin-type 
anthocyanins on lipid/lipoprotein 
profiles and markers of HDL function in 
humans 
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5.1. Abstract 
Elevated levels of cholesterol and LDL are one of the major risk factors for CVD. On 
the other hand, HDL is known to protect against atherosclerosis. Not only HDL levels 
are important, its function and quality are also important. Several human interventions 
have shown that the consumption of anthocyanin-rich foods and extracts have a 
beneficial effect on lipid profile and other markers of CVD. However, the beneficial 
effect of anthocyanins on lipid profile remains inconclusive due to the limitations 
applied in these studies. Moreover, little is known about the interactions between 
anthocyanins and biomarkers of HDL function including PON1 genotype. Therefore, 
the aim of the BERI randomized controlled trial was to compare the effects of cyanidin- 
and delphinidin-type anthocyanins (two major dietary forms) on lipid/lipoprotein 
profiles and markers of HDL function. In a double-blind, placebo-controlled, crossover 
trial, fifty-two hypercholesteraemic males and females (aged ≥ 45 years) with 
cholesterol higher than 5 mmol/L consumed capsules containing either bilberry 
extract (delphinidin-type anthocyanins) or black rice extract (cyanidin-type 
anthocyanins) that provided 320 mg anthocyanins/day for 28 day followed by a 
minimum 4-week washout period. Lipid/lipoprotein profiles, biomarkers of glycemic 
control and markers of HDL function were assessed in serum at the start and end of 
each treatment. All participants were genotyped for Q192R and L55M PON1 
polymorphisms. No significant changes were observed in total, LDL- and HDL-
cholesterol, triglycerides, cholesterol-HDL ratio, glucose, fructosamine, Apo A1, Apo 
B, ApoA1-ApoB ratio, HDL-ApoA1 ratio, HDL3 subfraction, HDL2 subfraction, PON1 
arylesterase and PON1 lactonase activities. In addition, there was no significant 
interaction between the participants PON1 genotype, anthocyanin treatments and any 
of the tested biomarkers of HDL function. These data do not support the notion that 
consumption of anthocyanins favorably affects circulating lipoprotein profiles, nor do 
they provide any evidence of interactions with HDL components or HDL function. The 
lack of effects may be due to the short duration of the intervention. 
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5.2. Introduction 
In the general introduction to this thesis (chapter 1), it was noted that epidemiological 
studies and meta-analysis of randomized control trial consistently reported a strong 
association between increased consumption of anthocyanins and reduced CVD risk. 
It was also noted that several reports of randomized controlled trials suggested that 
consumption of anthocyanins has protective effects on biomarkers related to CVD, 
with favourable improvements in lipid profiles being common across many of these 
studies. In their systematic review, Wallace et al. (2016) suggested that anthocyanins 
have the potential to improve lipid profiles in general, and decrease LDL levels in 
particular [164]. In another systematic review and meta-analysis of 17 randomized 
clinical trials that published recently, it was reported that crude and purified 
anthocyanins consumption positively influenced the lipid profile and inflammatory 
markers related to CVD [127]. For more details see sections 1.5.2, 1.5.3 and 1.5.4.  
Additionally, there were another ten recently published papers that reported effects of 
anthocyanin interventions and improvements in lipid profiles were observed in three 
of them [132], [140], [144]. However, there were inconsistencies and limitations in 
most of the randomized controlled trials which make it difficult to reach conclusions 
with respect the beneficial effects of anthocyanins.  
One of the most critical limitations in most of these studies was the lack of an 
appropriate control [42], [174]–[181]. A Control group should be as identical as 
possible to the investigational group, so the treatment is the only difference between 
them. In many previous clinical trials, the placebo control group was absent and the 
comparison was conducted between the baseline and the endpoint values, or the 
comparison was conducted between an unhealthy investigational group with a healthy 
control group which is completely different physiologically to the treatment group 
[178]. Such limitations make it impossible to conclude whether the effect was from the 
treatment or a result of confounding factors. Therefore, more rigorous clinical trials 
with proper controls are still required. 
Another important limitation was using whole fruit and vegetables or extracts that 
contain many bioactives such as vitamins, minerals and other phenolic compounds in 
addition to anthocyanins. It is difficult to conclude whether the effect is mediated by 
anthocyanins alone or is due to interactions between several or all of these bioactives. 
However, sometimes these limitations are ignored when reports of studies with 
anthocyanins are published. For example, the paper of Kianbakht et al. (2014) in 
which they reported a 27% reduction in cholesterol in humans following 2 months 
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consumption of whortleberry powder, the authors concluded that this was an effect 
caused by the whortleberry anthocyanins. However, the anthocyanin concentration in 
whortleberry is less than 1% (w/w). In fact, the anthocyanin dose in this trial was less 
than 7.5 mg/day which makes the conclusion that anthocyanins caused the response 
in cholesterol reduction highly uncertain [162]. Therefore, conducting more trials with 
purified anthocyanins is fundamental to fill this gap in knowledge. Several studies 
have used Medox™ which is a mixture of purified anthocyanins from bilberries and 
blackcurrants [136], [165], [167], [170]–[173][136], [165], [167], [170]. However, 
Medox™ contains 17 different types of anthocyanin which doesn’t allow a comparison 
between the effects of certain type of anthocyanin. Should a comparison between the 
effects of different type of anthocyanin help to identify the most beneficial anthocyanin 
type and define a specific dietary recommendation for health promotion. Therefore, 
conducting a trial using purified anthocyanin extracts that contain one type or a single 
group of anthocyanins is necessary to provide information about the biological 
activity/clinical benefits of specific anthocyanins that can be obtained from specific 
foods.  
Additionally, in chapter two, three and four in this thesis, anthocyanins and their 
metabolites showed no significant effects on several biomarkers related to RCT and 
HDL function. However, in vitro models were used in this investigation. Although, in 
vitro models are very useful to identify specific molecular mechanisms and provide a 
means to understand the influence of anthocyanin treatments, in vitro models can 
only show the response in one specific cell type and do not allow studying the 
secondary effects or investigating the response of the body as a whole. In vivo 
studies, on the other hand, allow investigations that include any secondary effects 
and to study the responses in organs and tissues level especially in complex disease 
such as atherosclerosis that involve different organs and tissues. Therefore, 
conducting a randomized control trial is essential to translate the in vitro findings into 
the in vivo situation.
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5.3. Objectives 
In this chapter, the design, implementation and results from a human dietary 
intervention study to investigate the effects of anthocyanins on lipid/lipoprotein profiles 
and HDL quality are reported. The aims of the human randomized controlled study 
were to (1) compare between cyanidin-type and delphinidin-type anthocyanins in their 
ability to improve lipid/lipoprotein profiles and markers of glycaemic control and HDL 
function in humans; (2) investigate the effect of anthocyanin consumption on PON1 
arylesterase and lactonase activities; (3) study the association between PON1 
genotype, PON1 activities and biomarkers of CVD risk and (4) explore interactions 
between PON1 genotype, anthocyanin treatments and PON1 activities.  
 
5.4. Materials and methods 
5.4.1. Quantification of anthocyanins and other phenolic compounds in 
bilberry and black rice extracts. 
Bilberry extract (MyrtiPRO®) and black rice extract powders were supplied by the 
Beijing Gingko Group (BGG), China. According to the manufacturer details, the 
anthocyanins in bilberry fruit and black rice were extracted with ethanol/water and 
then purified using a specific column. The purified eluants were then dried to get 
anthocyanin-rich extract powders. The BGG product specification sheets for both 
types of extract are provided (Appendix 6). Bilberry extract and black rice extract were 
analysed for anthocyanin (aglycons and glycosides) and non-anthocyanins phenolics 
content and composition using an HPLC/MS based method (see section 5.4.1.1 – 
5.4.1.3). 
5.4.1.1. Extraction 
Extraction of anthocyanins were carried out using acidified aqueous methanol (water: 
methanol: formic acid 70: 28: 2) as described elsewhere [350], [351]. The samples (in 
triplicates) were rigorously vortexed with solvent for 1 min for homogenization before 
centrifugation at 13000 rpm for 5 min. The pellet was reextracted three times with the 
same procedure. All supernatants were pooled and centrifuged before injection on to 
the HPLC column [350]. 
For non-anthocyanin phenolics, the extraction was performed using 70% methanol 
(60°C) and heating for 30 min at 60°C as described previously [352]. The extract was 
then centrifuged for 5 min at 13000 rpm. The pellet was reextracted three times using 
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the same procedure and the supernatants were pooled together and centrifuged 
before injection to HPLC.  
5.4.1.2. HPLC/MS analysis 
Anthocyanins (aglycons and glycosides) in bilberry and black rice extracts were 
analysed by reverse phase HPLC/MS using protocol developed in house. 20 µl of 
sample was injected to Kinetex XB-C18 column (100× 4.6 mm; particle size 2.6 μm) 
at 40°C. The separation method was carried out using Agilent 1100 series system 
(HP1100 Agilent Technologies, Waldbronn, Germany) equipped with G1956B single 
quadrupole mass spectrometer. The mobile phase consisted of 5% aqueous formic 
acid (eluent A) and 5% formic acid in acetonitrile (eluent B). Samples were eluted with 
a gradient consisted of 5% B at 0 min, 7% B at 10 min, 10% B at 15 min, 13% B at 
16:50 min, 20% B at 18 min, 5% B at 20 min to 25 min and flow rate was 1 ml per 
min. The anthocyanins were detected by diode array detection (DAD) and the 
detection was established at 520 nm [59], [353]. 
Phenolics and flavonoids were analysed similarly with differences in column and 
conditions as previously described [354], [355]. The samples injected to a Luna C18 
column (250 x 4.5 mm 2, 5 μM particle size) (Phenomenex, Macclesfield, UK) and 
eluted with a mobile phase consisting of 0.1% aqueous formic acid (eluent A) and 
0.1% formic acid in acetonitrile (eluent B).   The HPLC column temperature was set 
at 40 °C. The flow rate was 1 ml/min and a gradient consisting of gradient 0% at 0 
min, 17% B at 15 min, 25% B at 22 min, 35% B at 30 min, 50% B at 35 min, 100% B 
at 40 min, 0% B at 55 to 65 min. DAD was used for phenolics and flavonoids detection 
at 270, 325 and 370 nm.  
Procyanidin was analysed as described previously[355], [356]. Briefly, 2 µl of extract 
was injected to Phenomenex Luna Hilic (150 x 2.0 mm; particle size 3 μm) at 35°C 
using 2% acetic acid in acetonitrile (eluent A) and 2% acetic acid, 95% methanol and 
3% water as eluent B. The flow rate was 0.350 µl/min with an increasing gradient of 
7% B at 0 min, 30% B at 15 min, 49% B at 40 min, 7% B at 40:10 to 45 min. 
Fluorescence detection was achieved using wavelengths 321 nm for emission and 
230 nm for excitation.   
5.4.1.3. Quantification and qualification 
The identification and peak assignment of anthocyanins and non-anthocyanin 
phenolics in bilberry extract and black rice extract powders were established by 
running standards for each compound of interest and comparing the retention times 
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and mass spectral data of each compound with reference standards and previously 
published data [39], [45], [56], [58]–[60], [233], [357]–[359]. C3G, D3G and malvidin-
3-glucoside (Mal3G) (Extrasynthese) were used as standards for anthocyanins 
quantification and qualification, while, gallic acid, caffeic acid, chlorogenic acid, 
catechin, epicatechin, phloridzin, myricetin, quercetin, quercetin-3-glucoside and 
quercetin-3-rhamnoside (Sigma Aldrich, Alfa Aesar, Extrasynthese) were used for 
quantification and qualification of other non-anthocyanins phenolics. Procyanidin 
content was calculated using epicatechin as reference standard and the relative 
response factor that was obtained from apple procyanidns standards [356].  
5.4.2. Human intervention (BERI study) 
5.4.2.1. Ethics  
The protocol was approved by both the Human Research Governance Committee of 
the Quadram Institute Bioscience and the East of England Cambridge and 
Hertfordshire Research Ethics Committee (17/WM/0154). The trial was conducted in 
the Human Nutrition Unit at the Quadram Institute Bioscience, Norwich, UK from 
September 2017 to August 2018 in compliance with the guidelines laid down in the 
Declaration of Helsinki. The trial is registered on a publicly-accessible database 
(NCT03213288). All participants gave written informed consent before participating in 
the study. The study protocol was written by Wendy Hollands and Paul Kroon at QIB 
and the recruitment process was managed by Wendy Hollands. My role was mainly 
helping in sample processing, dealing with participants and conducting the assays.  
5.4.2.2. Study population 
A total of fifty-two males and females aged ≥ 45 years with a total cholesterol 
concentration ≥ 5.0 mmol/L at eligibility screening were recruited in and around 
Norwich, UK from (i) the volunteer database held at the Human Nutrition Unit (HNU) 
at Quadram Institute Bioscience; (ii) GP surgeries with the help of the co-ordinators 
from the Primary Research Network (PCRN) – East of England and (iii) from poster 
and e-mail advertisements placed on the Norwich Research Park and other suitable 
places. A letter of invitation (Appendix 5) along with a participant information sheet 
(Appendix 4) were sent to volunteers in the data bases and to those responded to the 
advertisements. The potential subjects were then screened for eligibility by the HNU 
research nurse following a 10 hour overnight fast and a blood sample was collected. 
The subjects were then included/excluded based on the inclusion/exclusion criteria, 
eligibility questionnaire and the results of clinical laboratory tests. The exclusion 
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criteria were as follows: total cholesterol level lower than 5 mmol/L; men and women 
≤ 45 years of age; smoker; medical condition that judged to affect the outcome such 
as diabetes; prescribed and non-prescribed medication that affect the study outcome 
such as statin; depressed or elevated blood pressure measurements (<90/50 or 95/55 
if symptomatic or ≥160/100 mmHg); BMI (Kg/m2) <19.5 or > 40; unwillingness to 
discontinue dietary supplements 4 weeks prior and for the during the trial; using food 
for lowering cholesterol such as Benecol or Flora Active;  gastrointestinal problem or 
recent use of colonic irrigation or other bowel cleansing techniques; intend to change 
their normal use of pre or probiotics during the study; has given blood  or intends to 
donate blood within 16 weeks prior to or during the intervention and clinical results 
deemed by the HNU Medical Advisor  to affect the trial outcome or be indicative of a 
health problem.   
5.4.2.3. Study design 
The study was conducted as a randomised, double-blind, placebo-controlled three-
arm cross-over trial studying the effects of 28 days consumption of two types of 
anthocyanin-rich extract on biomarkers for CVD. The three treatments were as follows 
(i) bilberry extract providing 320mg/day anthocyanins mainly trihydroxylated-B ring 
type; (ii) black rice extract delivering 320 mg/day anthocyanins mainly dihydroxylated-
B ring type and (iii) a placebo control (microcrystalline cellulose). The capsules were 
opaque, cellulose-based, suitable for oral consumption, had an identical appearance 
and release their contents within 15 min of reaching the stomach (K-caps vegetarian 
capsules; GoCap). Each treatment was allocated a letter (A, B or C) by a member of 
staff not involved with the trial. The randomization sequences list for treatment order 
were generated using computer-generated block randomization (randomization.com). 
Each time a participant is successfully recruited onto the study, the order of 
intervention will be assigned by allocating the participant to the next sequence of 
letters from the list generated previously. Both researchers, HNU research nurses and 
the participants will be blinded to the treatments.  
The subjects were asked to restrict their intake of berry fruits to a combined maximum 
of 3 portions per week for 2 weeks before the start of each treatment period and for 
the 28-d treatment period, including the washout period (4 weeks). In addition, they 
were asked to exclude completely berry fruits from their diet for the 24 hr preceding 
test days at the start and end of each treatment period. A list of restricted fruits was 
provided to each participant (Appendix 3). The participants were asked to fast 
overnight for a minimum 10 hours with drinking water before undergoing the baseline 
and post intervention assessment. At the day 1, the baseline assessment was 
 170 
 
conducted, and a 35 ml of blood was collected from fasted participants. Participants 
then consumed 4 capsules (equivalent to the daily dose) with plenty of water once 
daily in the morning for 28 days with a minimum 4 weeks washout period. To assist 
with compliance to treatment, participants were provided with a capsule checklist and 
asked to record the consumption of the capsules on each day and return the unused 
capsules and the record sheet at the end of the treatment period. Participants were 
also contacted 2-weeks into each of the treatment periods to assess progress. The 
compliance was assessed using the record sheet and by counting the unused 
capsules returned at the end of 28 days of treatment. Participants who ingest less 
than 80% of the capsules over the entire treatment period may be withdrawn from the 
study. The compliance with dietary restriction was assessed measuring the 
anthocyanins and their metabolites in urine at the baseline. On day 29, a further 35 
ml of blood was obtained from fasted participants. A minimum of 4 weeks washout 
period was performed before starting the next phase. Fig 5.1 illustrates the study 
design. The primary outcome measure for this trial was change (0 to 28 days) in LDL-
cholesterol, while the secondary outcome measures were the changes in total and 
HDL-cholesterol, triglycerides, apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), 
HDL3, HDL2, PON1 activities, glucose and fructosamine.  
5.4.2.4. Blood processing  
The blood was collected from fasted participants at day1 and day 29 and processed 
as previously described [141]. Briefly, whole blood was collected into serum 
separating tubes (Becton Dickenson) and allowed to clot for 30 min at room 
temperature before centrifugation at 2000 x g for 10 mins.  Sera were then aliquoted 
and stored at –80°C. For PON1 genotyping, a sub-sample of whole blood was 
collected in EDTA tubes and stored at -80°C until used.  
5.4.2.5. Biochemical markers for CVD analysis 
Total, HDL- and LDL-cholesterol, triglycerides, apolipoprotein A1 (ApoA1), 
apolipoprotein B (ApoB), HDL3, HDL2, glucose and fructosamine were analysed 
using an automated bench top clinical chemistry analyser (Randox Daytona plus) 
according to the manufacturer’s instructions. The Randox Daytona instrument uses 
an enzymatic reagent system coupled to a photometric detector system based on a 
specific analytical method for each compound of interest. LDL, HDL, HDL3 were 
analysed by a clearance method, total cholesterol and fructosamine were analysed 
by an enzymatic method, triglycerides and glucose were analysed by a GPO-POD 
method, while, ApoA1 and ApoB were analysed by an immunoturbidimetric method. 
HDL2 levels were estimated by subtracting HDL3 from total HDL.  
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Figure 5. 1: (A) Flow diagram of participants through the trial and (B) 
Study protocol detailing the involvement of participants through the 
study.  
3-OH-B ring ANCs = trihydroxylated-B ring anthocyanins, 2-OH-B ring ANCs = dihydroxylated-
B ring anthocyanins 
Assessed for eligibility  
(n= 92)   
Randomly assigned to intervention 
(n= 55) 
Bilberry extract 
(3-OH-B ring ANCs) 
Completed (n= 52) 
Lost to follow-up (n= 3) 
Black rice extract 
(2-OH-B ring ANCs) 
Completed (n= 52) 
Lost to follow-up (n= 3) 
Placebo 
Completed (n= 52) 
Lost to follow-up (n= 3) 
Lost to follow-up 
(n= 3)  
Self-withdrawal part way through first study phase 
Analysed 
(n= 52) 
Excluded (n=37) 
Did not meet criteria (n= 34) 
Declined to participate (n= 3) 
B 
A 
Recruitment / eligibility 
assessment / randomization  
Day 0 
Day 29 
Baseline assessment: 
Health status check. 
Blood sample collection 
Post intervention assessment: 
Health status check. 
Blood sample collection 
Day 1 
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5.4.2.6. PON1 activities  
PON1 arylesterase and lactonase activities were measured as described earlier in 
sections 3.4.2.1 and 3.4.2.2 with some modifications. Briefly, arylesterase was 
measured by adding 20 µl of diluted serum (50-fold in assay buffer) to 80 µl assay 
buffer in 96-well plate. After incubation for 10 min at 37°C,100 µl of p-nitrophenyl 
acetate (2 mM) was add to the previous mixture. Therefore, the final volume was 200 
µl and the concentration of substrate was 1 mM, while the final concentration of serum 
was 0.2%. The increase in absorbance was measured immediately at 410 nm and 
over 10 min using a FLUROstar Optima plate-reader (BMG labtech, UK).  Similarly, 
lactonase activity was measured by adding 20 µl diluted serum (90-fold dilution in the 
assay buffer) to 80 µl assay buffer and 50 µl of DTNB (4 mM) in a 96-well plate prior 
to incubation at 37°C for 10 min. After that, 50 µl of TBBL (2 mM) was added and the 
absorbance was measured immediately at 412 nm. The final volume was therefore 
200 µl and the concentration of reactants were 0.1% serum,1 mM DTNB and 0.5 mM 
TBBL. 
In order to quantify the activities that catalaysed only by PON1 (and not other serum 
arylesterases/lactonases), PON1 lactonases/arylesterase was measured with 100 
µM of 2-hydroxyquinoline (2-HQ) alongside the assay without inhibitor. 2-HQ is a 
selective competitive inhibitor of PON1[235], [254], [294], [360], [361]. PON1-
mediated arylesterase/lactonase activity was then calculated by subtracting the 
activities in the presence of 2-HQ from the total arylesterase/lactonase in the absence 
of 2-HQ (Fig 5.2). Each 96-well plate included blank control samples (no serum) to 
correct for any spontaneous non-enzymatic hydrolysis of substrates. The assays were 
performed in duplicate for each sample and the average measurement was 
calculated. A standard curve of p-nitrophenol (arylesterase product) was performed 
under the same conditions to quantify the enzyme units of arylesterase, while the 
extinction coefficient of TBBL (Ɛ 412 nm = 7000 OD.M-1.cm-1) value was used to 
calculate the enzyme units for lactonase. One unit of arylesterase activity is equal to 
1 µmol of phenyl acetate hydrolysed per ml per minute, while, enzyme unit of 
lactonase activity is equal to 1 µmol of TBBL hydrolysed per ml per minute. 
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Figure 5. 2: An illustration of the measurement of PON1-mediated activities. 
Arylesterase/lactonase activity was measured with and without a PON1 inhibitor. PON1-
dependant arylesterase/lactonase activity was measured by the subtraction of the activities in 
the presence of 2-HQ from the total arylesterase/lactonase in the absence of 2-HQ.  
 
 
 
 
 
5.4.2.7. PON1 genotypes  
All participants were genotyped for their Q192R and L55/M polymorphisms using PCR 
amplification as previously described [362]–[366]. Genotyping by this method is 
simply conducted using PCR reactions with primers designed to amplify the exon that 
contains the SNP. The PCR product is then purified and sequenced using standard 
sequencing techniques. The sequence was then aligned to the reference genome to 
identify the genotype.    
DNA was extracted and purified from whole blood using a DNeasy Blood & Tissue Kit 
(Qiagen, Cat# 69504) according to the manufacturer’s protocol. DNA quantity and 
quality were measured using the NanoDrop ND-1000 spectrophotometer. The 
samples were aliquoted and stored at -20°C until using.  
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To sequence exon 3 (contains L55M SNP) and exon 6 (contains Q192R SNP), 
specific primers designed for each exon were used in the PCR reactions. The forward 
and reverse primers were designed using NCBI Reference Sequences and Primer-
BLAST. (https://ncbiinsights.ncbi.nlm.nih.gov/). To allow sequencing of the entire 
exon, the primers were designed to cover small additional sequences from adjacent 
introns. PCR amplification of exon 3 (L55M polymorphism) was performed using the 
following primers: Forward 5`-CCCAGTTTCAAGTGAGGTGT-3` and reverse 
5`TGGGCATGGGTATACAGAAAGC-3` (PCR product size 240-bp). The primers for 
amplification of exon 6 (Q192R polymorphism) were: Forward 5`- 
AGACAGTGAGGAATGCCAGTTA-3` and reverse 
5`TCTCCTGAGAATCTGAGTAAATCCA-3` (PCR product size 333-bp).   
PCR reactions were performed using a Veriti® 96-Well Thermal Cycler (Applied 
Biosystems) as described previously in section 2.4.6 with some modifications. The 
reaction mixture (20 µl) comprised of DNA template (20ng), 1 X ImmoMix PCR 
MasterMix (Bioline, Cat. # BIO-25022), magnesium chloride (0.5 mM), BSA 
(50 µg/ml) and 10 nM forward and reverse primers. The following PCR cycling 
conditions were used; one cycle at 95°C/10 min for initial denaturation, followed by 
35 cycles of amplification (95 °C/15 sec, 60 °C/1 min and 72°C/30sec) then a final 
extension of 7 min at 72°C. To check the product size, samples of amplified 
products were separated alongside DNA standard ladder in 1.5% agarose gel at 50 
V for 1 hour. The bands were visualised using ethidium bromide solution (0.5µg/ml) 
and the gel then was exposed to UV light and the picture was taken with gel imaging 
system. PCR products were purified using a QIAquick PCR purification kit (Qiagen, 
Cat# 28104) according to the manufacturer’s protocol. The purified products were 
aliquoted and stored at -20°C or sent for sequencing (Eurofins, UK). To determine 
the genotypes, the sequences were aligned to the human reference genome and 
SNPs were identified using Ugene software for windows version 1.29.0.  
5.4.2.8. Statistical analysis and power calculation 
The primary outcome measure in this trial was LDL-cholesterol. The study was 
powered to detect a change of 0.14 mmol/L in LDL- cholesterol (relative to placebo) 
at a significance level of 0.05 with 90% power. Assuming a standard deviation 
similar to that observed in the data from Zhu et al. 2013 (approximately 0.5 mmol/L) 
[167], the power calculation indicated that 50 participants were required to 
complete the trial. The power calculation has performed according to the primary 
outcome and not for the secondary outcome.  
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The analysis was performed using the changes in parameters which was calculated 
by subtracting the measurements at the end of the intervention from the 
measurements at day 1 (baseline). No baseline correction has been done. 
All data and statistics were analysed by using GraphPad Prism (version 5.04 for 
Windows, GraphPad Software, La Jolla California USA, www.graphpad.com). All 
values are given as means ± SD. Any statistical difference between the study arms 
was determined with one-way ANOVA coupled with Dunnett’s Multiple Comparison 
Test comparing all study arms with placebo arm. Newman-Keuls’ Multiple 
Comparison Test was used to conduct all possible pairwise comparisons in the case 
of studying the association of PON1 genotypes and haplotypes; activities. Values of 
p ≤ 0.05 were considered significant. 
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5.5. Results 
5.5.1. Identification and quantification of anthocyanins and other 
(poly)phenolics in bilberry and black rice extracts 
Anthocyanins quantity and identity were determined for the two anthocyanin-rich 
extracts used in the BERI study, bilberry (MyrtiPRO®) and black rice extracts powder, 
using reverse-phase HPLC analysis with DAD detection at 520 nm. Identification was 
performed using the mass obtained from a single quadrupole mass spectrometer and 
matching the mass and retention time with authentic standards and with data reported 
previously for bilberry and black rice. C3G was used as a reference standard to 
quantify dihydroxylated-B ring anthocyanins, D3G was used as a reference standard 
to quantify trihydroxylated-B ring anthocyanins, while, Mal3G was used as a reference 
standard to quantify malvidin-types of anthocyanins (methylated-B ring 
anthocyanins).    
A total of 14 anthocyanins were identified and quantified in the bilberry extract powder 
as shown in Fig 5.3. The total anthocyanin content was 436.8 ± 4.6 mg (g powder) -1 
(Table 5.1). The major anthocyanin types that were identified and quantified in the 
bilberry extract were delphinidin-3-galactoside (15.1%), delphindin-3-glucoside 
(15.0%), delphinidin-3-arabinoside (13.9%), whereas, peonidin-3-arabionoside was 
found to be the least concentrated anthocyanin in this extract. Cyanidin-3-glucoside 
and cyanidin-3-galactoside were the main dihydroxylated-B ring anthocyanins with 
content of 9.5 and 9.2% of total anthocyanins in bilberry extract powder, respectively. 
As shown in Fig 5.3 and Table 5.1, trihydroxylated-B ring anthocyanins (delphinidin, 
petunidin and malvidin types) were the predominant type of anthocyanins in the 
bilberry extract powder and they represented approximately 76% of total 
anthocyanins that were quantified in the bilberry extract. Since malvidin and petunidin 
are methylated forms of delphinidin, bilberry extract powder can be considered as a 
good representative of delphinidin type of anthocyanins. 
In contrast, only 5 anthocyanin types were identified in black rice extract and all of 
them were dihydroxylated-B ring anthocyanins (Fig 5.4). The total anthocyanin 
content was 312.2 ± 1.6 mg (g powder)-1 expressed as cyanidin-3-glucoside. About 
90% of the total anthocyanins was cyanidin-3-glucoside, while peonidin-3-glucoside 
content was about 7% and traces of the other dihydroxylated-B ring types (Table 5.2).   
The content of non-anthocyanins was also analysed for bilberry and black rice powder 
extracts using reverse-phase HPLC. The total polyphenol content included the 
following analysed compounds: Gallic acid, caffeic acid, chlorogenic acid, catechin, 
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epicatechin, phloridzin, myricetin, quercetin, quercetin-3-glucoside and quercetin-3-
rhamanoside using authentic standards for these compounds. In bilberry extract 
powder, non-anthocyanin phenolic content was very low with about 35.1 mg (g 
powder)-1 (3.5% of powder) mainly due to chlorogenic acid. In black rice extract, only 
traces of non-anthocyanin phenolics were detected but were not quantified as the 
signals were very low, even though a large quantity of powder was extracted. 
Procyanidins were analysed in extracts using normal-phase HPLC combined with a 
fluorescence detector at wavelengths 230 nm for excitation and 321 nm for emission. 
Procyanidins were then quantified using the relative response factor that had 
previously been established for apple procyanidins in our lab and which were 
published recently [354]. In bilberry extract powder, procyanidins with degree of 
polymerization (DP) from 2 to 6 were separated and detected. However, the signals 
were very weak. The total monomeric and oligomeric procyanidins accounted for 27.6 
mg (g powder)-1 of bilberry extract. Only traces of monomeric procyanidins were 
detected in black rice extract powder, while oligomeric procyanidins were not 
detected, even though a high concentration of extract had been used in the analysis. 
Based on these results, non-anthocyanins (poly)phenolics were minor components of 
the bilberry extract and present only in trace quantities in black rice extract. 
Anthocyanins were the predominant (poly)phenolics found in both extracts. Therefore, 
any effect of treatments will almost certainly be due to anthocyanins. The composition 
data confirmed that the bilberry extract and black rice extract were very rich sources 
and good representative of tri-hydroxylated-B ring (delphinidin type) and 
dihydroxylated-B ring (cyanidin type) of anthocyanins, respectively.  
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Figure 5. 3: HPLC anthocyanins chromatogram (at 520 nm) of bilberry extract (100 µg/ml).  
The extraction was performed in (water: methanol: formic acid 70: 28: 2). The mobile phases were 5% aqueous formic acid (eluent A) and 5% formic acid in 
acetonitrile (eluent B). The peak number corresponding to anthocyanin name is shown in Table 5.1 
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Table 5. 1: Anthocyanins profile and content in bilberry extract powder1 
Peak 
number 
Anthocyanin type 
Content  
mg (g powder)-1 
% from total 
anthocyanins2 
Peak 1 Delphindin-3-galactoside 65.84 ± 0.07 15.07 
Peak 2 Delphindin-3-glucoside 65.31 ± 0.10 14.95 
Peak 3 Cyanidin-3-galactoside 40.23 ± 0.07 9.21 
Peak 4 Delphindin-3-arabinoside  60.66 ± 0.09 13.89 
Peak 5 Cyanidin-3-glucoside 41.79 ± 0.05 9.57 
Peak 6 Petunidin-3-galactoside 55.27 ± 0.14 12.65 
Peak 7 Petunidin-3-glucoside 37.85 ± 0.06 8.66 
Peak 8 Peonidin-3-galactoside 3.57 ± 0.02 0.82 
Peak 9 Petunidin-3-arabinoside 11.77 ± 0.04 2.69 
Peak 10 Peonidin-3-glucoside 13.92 ± 0.05 3.19 
Peak 11 Malvidin-3-galactoside 7.77 ± 0.03 1.78 
Peak 12 Peonidin-3-arabinoside 2.32 ± 0.03 0.53 
Peak 13 Malvidin-3-glucoside 23.18 ± 0.07 5.31 
Peak 14 Malvidin-3-arabinoside 7.35 ± 0.13 1.68 
Total 436.8 ± 0.82 0.82 
 
1 Values are mean ± SD. 
2 The percentage was calculated using the average of content of each analyte. Three separate 
samples of extract and three replicates per mass of extract were analysed.  
 180 
 
 
Figure 5. 4: HPLC anthocyanins chromatogram (at 520 nm) of black rice extract (100 µg/ml). 
The extraction was performed in (water: methanol: formic acid 70: 28: 2). The mobile phases were 5% aqueous formic acid (eluent A) and 5% formic acid in 
acetonitrile (eluent B). The peak number corresponding to anthocyanin name is shown in Table 5.2 
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Table 5. 2: Anthocyanins profile and content in black rice extract powder1 
 
Peak 
number 
Anthocyanin type 
Content 
mg (g powder)-1 
% from total 
anthocyanins2 
1 Cyanidin-3,5-diglucoside 3.77 ± 0.01 1.21 
2 Cyanidin-3-glucoside 278.61 ± 0.6 89.25 
3 
Cyanidin-3-O-(6"-O-p-
coumaryl) glucoside 
4.41 ± 0.01 1.41 
4 Peonidin-3-glucoside 22.4 ± 0.11 7.17 
5 
Peonidin-3-O-(6"-O-p-
coumaryl) glucoside 
5.94 ± 0.11 1.9 
Total 312.15 ± 0.75 100 
 
1 Values are mean ± SD. 
2 The percentage was calculated using the average of content of each analyte. Three separate 
samples of extract and three replicates per mass of extract were analysed. 
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5.5.2. Study population and baseline characterization.  
Of the fifty-five subjects randomly assigned to treatments, fifty-two participants 
completed the study (twenty-four men and twenty-eight women). Three participants 
self-withdrew part way through the first phase, mentioning difficulties with study time 
commitments as the reason for withdrawal. Overall compliance to treatments was 
high. When assessed as a proportion of the intended total, > 99% of capsules were 
ingested across all three treatments. As an indication of excellent compliance, the 
total anthocyanin was quantified in urine. In the baseline 24-h urine collections, small 
quantities of anthocyanins were detected and was similar across all three treatment 
arms (28 ± 36, 23 ± 25 and 30 ± 62 nmols; placebo, bilberry extract and black rice 
extract, respectively). After 28 days treatment, the quantities of anthocyanins detected 
in the 24-h urine collections was substantially higher (631 ± 539 and 299 ± 204 nmols; 
bilberry extract and black rice extract, respectively), while, the amount of 
anthocyanins in urine after placebo remained unchanged (22 ± 21) indicating 
excellent compliance with the capsule ingestion regime and that the anthocyanins in 
treatment were available and can demonstrate a biological effect (the quantification 
of anthocyanins was performed by Jasmin Perceval, unpublished data).      
Fig 5.1 (in material and method section) describes the flow of participants through the 
study and Table 5.3 shows the baseline demographics and values for biomarkers of 
CVD at the beginning of the study. The baseline characteristics at eligibility 
assessment were summarized in Table 5.3. There were no serious adverse events 
were reported during the study.  
5.5.3. Effect of the intervention on lipid profiles 
Total cholesterol, LDL-cholesterol, HDL-cholesterol and triglyceride were quantified 
in serum before and after 28 days consumption of 320 mg/day of either bilberry extract 
(delphinidin type of anthocyanins) or black rice extract (cyanidin type of anthocyanins) 
in 52 hypercholesterolemic individuals using Randox. The change (0 to 28 days) was 
calculated by subtracting the measurements at the end of the intervention from the 
measurements at day 1. Firstly, no effects of the treatments was observed for LDL-
cholesterol, the primary outcome of the intervention compared to the placebo control 
group (Fig 5.5). In addition, total cholesterol, HDL-cholesterol and triglyceride 
remained unchanged (Fig 5.6 to 5.8). Moreover, the treatments had no effect on the 
cholesterol/HDL ratio (Fig 5.9).  
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The treatment-placebo average difference in all these lipoprotein biomarkers was 
close to zero. HDL, triglyceride and cholesterol/HDL ratio values were within the 
reported physiological ranges. However, cholesterol and LDL-cholesterol were higher 
than the normal physiological ranges which was expected as we recruited 
hypercholesterolemic individuals.  
 
 
 
 
Table 5. 3: Baseline demographics and biomarkers of CVD of the subjects at 
start of trial1 
Measurement variable Mean SD 
Age (year) 62.6 7.8 
Gender 24 males and 28 females 
BMI (kg/m2) 25.9 3.4 
Cholesterol (mmol/L) 6.2 0.9 
HDL-C (mmol/L) 1.7 0.5 
LDL-C (mmol/L) 3.9 0.8 
Triglycerides (mmol/L) 1.3 0.8 
Cholesterol/HDL ratio 3.8 1.3 
ApoA1 (mg/dL) 229.1 62.6 
ApoB (mg/dL) 128.0 25.7 
Glucose (mmol/L) 5.5 0.4 
Fructoseamine µmol/L 268.8 22.3 
HbA1c (mmol/mol) 35.3 3.7 
Haemoglobin (g/L) 144 12 
Systolic blood pressure (mmHg) 134 15.3 
Diastolic blood pressure (mmHg)  79 10.8 
 
1 Values are mean ± S.D., n=52. BMI= body mass index. 
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Figure 5. 5: Change in LDL-cholesterol in serum of humans after 28 days dietary 
intervention.  
LDL-cholesterol in serum of all 52 hypercholesterolemic individuals was quantified at the start 
and end of the intervention with bilberry or black rice extract capsules that provided 320 
mg/day anthocyanins. Data are shown as means ± SD. No significant differences were 
detected compared with control using one-way ANOVA coupled with Dunnett’s multiple 
comparison test (p ≥ 0.05). One measurement was conducted for each participant. 
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Figure 5. 6: Change in total cholesterol in serum of humans after 28 days dietary 
intervention.  
Total cholesterol in serum of all 52 hypercholesterolemic individuals was quantified at the start 
and end of the intervention with bilberry or black rice extract capsules that provided 320 
mg/day anthocyanins. Data are shown as means ± SD. No significant differences were 
detected compared with control using one-way ANOVA coupled with Dunnett’s multiple 
comparison test (p ≥ 0.05). One measurement was conducted for each participant.
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Figure 5. 7: Change in HDL-cholesterol in serum of humans after 28 days dietary 
intervention.  
HDL-cholesterol in serum of all 52 hypercholesterolemic individuals was quantified at the start 
and end of the intervention with bilberry or black rice extract capsules that provided 320 
mg/day anthocyanins. Data are shown as means ± SD. No significant differences were 
detected compared with control using one-way ANOVA coupled with Dunnett’s multiple 
comparison test (p ≥ 0.05). One measurement was conducted for each participant. 
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Figure 5. 8: Change in triglycerides in serum of humans after 28 days dietary 
intervention.  
Triglycerides in serum of all 52 hypercholesterolemic individuals was quantified at the start 
and end of the intervention with bilberry or black rice extract capsules that provided 320 
mg/day anthocyanins. Data are shown as means ± SD. No significant differences were 
detected compared with control using one-way ANOVA coupled with Dunnett’s multiple 
comparison test (p ≥ 0.05). One measurement was conducted for each participant.
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Figure 5. 9: Change in total cholesterol / HDL ratio in humans after 28 days 
dietary intervention.  
Total cholesterol / HDL ratio of all 52 hypercholesterolemic individuals was quantified by 
dividing the total cholesterol level of each individual by their HDL at the start and end of the 
intervention with bilberry or black rice extract capsules that provided 320 mg/day 
anthocyanins. Data are shown as means ± SD. No significant differences were detected 
compared with control using one-way ANOVA coupled with Dunnett’s multiple comparison test 
(p ≥ 0.05).  
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5.5.4. Effect the treatments on Apo A1, Apo B and HDL subfractions 
The circulating levels of Apo A1 (the major protein component of HDL) and Apo B (the 
major protein component of LDL) were quantified in serum of all 52 
hypercholesterolemic individuals at the start and end of the intervention with bilberry 
and black rice extract using the turbidity method by of the Randox autoanalyser. As 
shown in Fig 5.10 A and B, the intervention with bilberry extract did not statistically 
change either Apo A1 or Apo B proteins levels compared to the placebo group, nor 
did the intervention with black rice extract. The average change values of Apo A1 and 
Apo B were close to zero (mg/dL) after intervention. Similarly, the HDL-Apo A1 ratio 
and ApoA1-Apo B ratio did not statistically change after treatments and the average 
change values were close to zero (Fig 5.11 A and B).  
Another common marker in humans for lipid metabolism and HDL function is the 
profile of HDL subfractions. Therefore, the effect of the treatments on HDL3 and HDL 
2 was investigated (Fig 5.12 A and B). In the serum samples of all 52 participants, 
HDL subfraction (HDL3) was measured using clearance method by Randox at the 
start and end of the intervention. HDL2 was quantified by calculating the difference 
between total HDL and HDL3.  As observed in the analysis of total HDL, there was 
no significant differences between study arms in either HDL3 or HDL2 subfractions 
and the average of changes was close to zero (mmol/L). 
5.5.5. Effect of the treatments on biomarkers of glycaemic control 
Additional to the quantification of lipid and lipoproteins profile in serum of human 
subjects, the effect of anthocyanins consumption on glycaemic control was measured. 
The long-term effect of consumption of anthocyanins on glycaemic control was 
measured by quantifying glucose and fructosamine levels in serum as alternative 
biomarkers of glycaemic index at the start and end of the the intervention using 
Randox. After 28 days consumption of either bilberry or black rice extract, no 
significant differences between treatments and control group were observed in either 
glucose or fructosamine (Fig 5.13 A and B). The change in glucose and fructosamine 
was close to zero (mmol/L and µmol/L, respectively) in placebo, black rice and bilberry 
groups. All values were within the normal reported physiological ranges (3.9 - 7.1 
mmol/L for glucose and 258 - 317 μmol/L for fructosamine).
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Figure 5. 10: Change in (A) Apo A1 protein levels and (B) Apo B protein level in 
serum of humans after 28 days dietary intervention.  
Apo A1 and Apo B levels in serum of all 52 hypercholesterolemic individuals were quantified 
at the start and end of the intervention with bilberry or black rice extract capsules that provided 
320 mg/day anthocyanins. Data are shown as means ± SD. No significant differences were 
detected compared with control using one-way ANOVA coupled with Dunnett’s multiple 
comparison test (p ≥ 0.05). One measurement was conducted for each participant.
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Figure 5. 11: Change in (A) HDL-ApoA1 ratio and (B) ApoA1-ApoB ratio in serum 
of humans after 28 days dietary intervention.  
Data are shown as means ± SD (n=52). No significant differences were detected compared 
with control using one-way ANOVA coupled with Dunnett’s multiple comparison test (p ≥ 0.05). 
One measurement was conducted for each participant. 
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Figure 5. 12: Change in (A) HDL3 subfraction level and (B) HDL2 subfraction 
level in serum of humans after 28 days dietary intervention. 
HDL3 and HDL2 subfractions levels in serum of all 52 hypercholesterolemic individuals were 
quantified at the start and end of the intervention with bilberry or black rice extract capsules 
that provided 320 mg/day anthocyanins. Data are shown as means ± SD. No significant 
differences were detected compared with control using one-way ANOVA coupled with 
Dunnett’s multiple comparison test (p ≥ 0.05). One measurement was conducted for each 
participant.
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Figure 5. 13: Change in (A) glucose concentration and (B) fructosamine 
concentration in serum of humans after 28 days dietary intervention.  
Glucose and fructosamine levels in serum of all 52 hypercholesterolemic individuals were 
quantified at the start and end of the intervention with bilberry or black rice extract capsules 
that provide 320 mg/day anthocyanins. Data are shown as means ± SD. No significant 
differences were detected compared with control using one-way ANOVA coupled with 
Dunnett’s multiple comparison test (p ≥ 0.05). One measurement was conducted for each 
participant.
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5.5.6. Effect of the treatments on PON1 arylesterase and lactonase 
activities. 
To investigate if the consumption of delphinidin-type or cyanidin-type of anthocyanins 
can affect PON1 activities; arylesterase and lactonase activities were quantified in 
serum of all 52 participants at the start and end of the intervention. The enzyme 
kinetics was measured using colourimetric assays and the enzyme units were 
calculated using the slop of the linear part of the enzyme reaction curve for the exact 
reasons that mentioned earlier in section 3.5.2.1. The linearity of the enzyme reaction 
was obtained at 50-fold dilution of serum for arylesterase (final concentration of serum 
0.2%) and 90-fold dilution of serum for lactonase (final concentration of serum 0.1%) 
and lasted for at least 15 min. As shown in Fig 5.14 A and B, there was no significant 
effect of any of the study treatments on arylesterase or lactonase activities.  
In general, lactonase activity was higher than arylesterase activity by about 2-fold. 
The average enzyme units of arylesterase was 3.7 (rang 0.83 to 9.36 µmol min-1 (ml 
serum)-1, while, the average enzyme units of lactonase was 6.5 (range 2 to 11.4 µmol 
min-1 (ml serum)-1. However, both activities remained unchanged after intervention. 
The very high variance between individuals is probably due to the differences in 
genotypes. Therefore, the effect of treatments on PON1 activities in association with 
genotype was investigated.  
5.5.7. The interaction between anthocyanins consumption, PON1 
genotype and PON1 activities. 
5.5.7.1. Q192R and L55M genotype 
All 52 participants were genotyped for Q192R (rs662) and for L55M (rs854560) using 
Sanger sequencing after amplification of the exons that contain the polymorphism. 
The sequence then was aligned with reference genome using Ugen software to 
identify the genotype of each participants.  
First, Genomic DNA was extracted from whole blood samples of all participants with 
a mean 260:280 ratio of 1.8 (range 1.7 to 2.1) indicating that DNA samples were pure 
and in high quality. The efficiency of PCR reactions were checked to make sure that 
only the targeted exons were amplified and the primers were well-designed. 
Therefore, after PCR amplification reaction, samples of PCR products were separated 
by agarose gel electrophoresis against DNA standard ladder to check the size of PCR 
products. 
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Figure 5. 14: Change in (A) arylesterase and (B) lactonase activity in serum of 
humans after 28 days dietary intervention.  
The activities were measured in serum of all 52 hypercholesterolemic individuals at the start 
and end of the intervention with bilberry or black rice extract capsules that provided 320 
mg/day anthocyanins using a colourimetric assay. Data are shown as means ± SD. No 
significant differences were detected compared with control using one-way ANOVA coupled 
with Dunnett’s multiple comparison test (p ≥ 0.05). Measurements were conducted in duplicate 
for each participant  
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As shown in Fig 5.15, bands for exon 3 products (containing L55M polymorphic site) 
were located between 200 and 300 bp, while bands for exon 6 products (containing 
Q192R polymorphic site) were observed between 300 and 400 bp, indicating that the 
PCR products were of the correct size (240 bp for exon 3 and 333 bp for exon 6) and 
the PCR reaction was specific.  
After the amplification of exon 3 and exon 6 for all participants, PCR products were 
sent for sequencing and then the genotype was determined using Ugen software. 
Examples of sequence of PON1 polymorphism chromatograms were shown in Fig 
5.16.  
Q192R and L55M genotypes and alleles distribution of subjects are reported in Table 
5.4. The Q192R genotype frequencies were 42.3% QQ, 46.2% QR, and 11.5% RR, 
while the frequencies for L55M genotype were 42.3% LL, 48.1% LM and 9.6% MM. 
The frequencies of all mutations were in line with previously reported data for 
European population studies [367]–[373].  
 
 
 
 
Table 5. 4: Genotype and allele frequency of Q192R and L55M PON1 
polymorphisms in study population1 
Polymorphism 
Genotype 
N=52 
Frequency 
Number % 
Q192R QQ 22 42.3 
 QR 24 46.2 
 RR 6 11.5 
    
L55M LL 22 42.3 
 LM 25 48.1 
 MM 5 9.6 
 
1 The study population was British and predominantly from the county of Norfolk. Q/R and L/M 
denote exchange of the amino acid at positions 192 and 55, respectively.  
.
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Figure 5. 15: Post electrophoresis gel image of PCR amplification 
products of PON1 gene.  
The separation was performed in 1.5% agarose gel at 50 V for 1 hr. The gel was 
added to ethidium bromide solution (0.5µg/ml) and then the gel was exposed to UV 
light and the picture was taken with a gel imaging system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. 16: Sequence chromatograms for (A) L55M SNP and (B) Q192R SNP 
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5.5.7.2. Association between PON1 genotypes and arylesterase and 
lactonase activity 
PON1 arylesterase and lactonase activities were shown to be linked with the Q192R 
and L55M PON1 genotype (Table 5.5). Arylesterase was significantly higher among 
RR homozygotes participants followed by QR heterozygotes and QQ homozygotes 
(p ≤ 0.001). People with RR genotype had arylesterase activity higher than QQ 
genotype by 3-fold. The average enzyme units were 6.85, 4.12 and 2.42 µmol 
substrate hydrolysed (min)-1 (ml serum)-1 for participants with RR, QR and QQ 
phenotype, respectively. Similarly, lactonase activity in participants with RR alleles 
was clearly higher than lactonase in participants with QQ by 1.6-fold (p ≤ 0.001), while, 
the differences between QQ and QR was not significant, although lactonase activity 
of QR was higher than QQ.  
Regarding the association between the L55M genotype and PON1 activities, 
arylesterase was significantly different between the three genotypes. The highest 
arylesterase activity was observed for participants with the LL genotype, while MM 
genotype was the lowest. Arylesterase in people with the LL genotype was higher 
than MM genotype by 2.3-fold, while the LL genotype was higher than LM by only 1.3-
fold. Likewise, lactonase activity in people with LL genotype was significantly higher 
than people with MM. However, there was not a significant difference between people 
with LL or LM genotype. In addition, people with heterozygous LM genotype were 
significantly higher than people with the homozygous MM genotype by only 1.4-fold. 
The average enzyme units of lactonase were 7.2, 6.5 and 4.8 µmol substrate 
hydrolysed (min)-1 (ml serum)-1 for participants with LL, LM and MM genotype, 
respectively. 
Furthermore, the association between PON1 haplotypes and PON1 activities was 
analysed and data are shown in Table 5.6. Of the nine possible combinations of 
haplotypes, eight were detected, of which two haplotype combinations (QR-MM and 
RR-LM) were rare with only one participant of each type. The RR-MM haplotype was 
not detected within the study population. The predominant haplotypes were QQ-LM, 
QR-LM and QR-LL which together accounted for 67% of the study population.   
Table 5.6 shows the activities of PON1 as a function of PON1 haplotypes. The highest 
arylesterase activities was observed with the RR-LM haplotype with arylesterase 
activity of 9.4 µmol substrate hydrolysed (min)-1 (ml serum)-1  and lactonase activity of 
11.45 µmol substrate hydrolysed (min)-1 (ml serum)-1. On the other hand, the lowest 
activities were observed with QQ-MM haplotype with activity of 1.4 µmol substrate 
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hydrolysed (min)-1 (ml serum)-1 for arylesterase and 4.01 µmol substrate hydrolysed 
(min)-1 (ml serum)-1 for lactonase. In addition, the analysis showed that the presence 
of the R allele was associated with higher arylesterase and lactonase activities; as 
the haplotypes of RR-LM, RR-LL, QR-LM, QR-LL and QR-MM had the highest 
arylesterase and lactonase activities, while, the haplotypes QQ-MM and QQ-LM had 
the lowest arylesterase and lactonase activity. These data indicate that the effect of 
the presence of L allele on enzyme activity was not as strong as allele R.  
 
 
 
 
Table 5. 5: Association of PON1 Q192R and L55M polymorphism with 
arylesterase and lactonase activities  
Polymorphism Genotype 
Arylesterase 
U1/ml 
Lactonase 
U1/ml 
Q192R QQ 2.42 ± 0.76a 5.99 ± 1.51ab 
 
QR 4.12 ± 0.73b 6.68 ± 1.16b 
 
RR 6.85 ± 1.74c 9.00 ± 2.01c 
      
L55M L 4.42 ± 1.39d 7.23 ± 1.48de 
 
LM 3.46 ± 1.58e 6.52 ± 1.41e 
 
M 1.92 ± 1.06f 4.80 ± 1.94f 
 
1U is one enzyme unit= 1 µmol substrate hydrolysed (min)-1 (ml serum)-1. Values are mean ± 
SD.  Data were statistically analysed using one-way ANOVA coupled with Newman-Keuls’ 
multiple comparison test for arylesterase and lactonase separately. Activities with different 
superscript letters are significantly different (Values of p ≤ 0.05 were considered to be 
significant).  
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Table 5. 6: Association of PON1 haplotype with arylesterase and lactonase 
activities  
Haplotype 
Frequency 
Arylesterase 
U1/ml 
Lactonase 
U1/ml 
Number % 
QQ-LL 6 11.5% 3.2 ± 0.3a 7.3 ± 1.3adf 
QQ-LM 12 23.1 2.3 ± 0.5b 5.9 ± 0.7abce 
QQ-MM 4 7.7 1.4 ± 0.5c 4.0 ± 1.5j 
QR-LL 11 21.2 4.2 ± 0.8d 6.6 ± 1.2cde 
QR-LM 12 23.1 4.1 ± 0.7f 6.7 ± 1.2b 
QR-MM 1 1.9 3.92j 7.96h 
RR-LL 5 9.6 6.3 ± 1.4f 8.5 ± 1.8f 
RR-LM 1 1.9 9.36h 11.45i 
RR-MM 0 0     
 
1U is one enzyme unit= 1 µmol substrate hydrolysed (min)-1 (ml serum)-1. Values are mean ± 
SD.  Data was statistically analysed using one-way ANOVA coupled with Newman-Keuls’ 
multiple comparison test for arylesterase and lactonase separately. Activities with different 
superscript letters are significantly different (Values of p ≤ 0.05 were considered to be 
significant).  
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5.5.7.3. Interaction between treatments and PON1 activities according 
to PON1 genotypes.  
All participants were categorized into groups according to their Q192R and L55M 
genotypes. The average changes in PON1 activities after treatments were quantified 
for each genotypic group and analysed to investigate the interaction between 
treatments and PON1 activities in relation to the genotype. As shown in Table 5.7, no 
significant effects were observed in either arylesterase or lactonase activities after 
treatments whatever the genotype.  
Likewise, the interaction between treatments and activities in association with Q192R 
and L55M haplotypes were investigated after classifying the participants into different 
groups according to their haplotype and quantifying the average of change in activities 
after treatment for each haplotype group. Table 5.8 showed that there is no interaction 
between treatments, PON1 activities and PON1 haplotypes. 
5.5.7.4. Association between PON1 genotype and markers of CVD. 
The association between PON1 genotype and biomarkers related to CVD are shown 
in Table 5.9. The analysis was conducted with values at baseline for each biomarker. 
The results show there were no associations between Q192R and L55M 
polymorphisms and lipid/lipoprotein profiles, HDL subfractions or glycaemic control 
indexes.   
5.5.7.5. Interaction between treatments, PON1 genotype and HDL 
function biomarkers 
After categorizing all participants according to their Q192R and L55M genotype; the 
interaction between treatments, genotype and biomarkers of HDL function was 
investigated. The average change in total HDL, HDL3, HDL2 and Apo A1 protein was 
quantified in each genotype group after consumption of bilberry extract and black rice 
extract powders and the effect was compared to placebo treatment. As shown in table 
5.10, no significant changes were observed in total HDL, HDL3, HDL2 and Apo A1 
levels within PON1 genotype after either bilberry extract or black rice extract 
intervention.  
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Table 5. 7: Effect of anthocyanins consumption on PON1 activities with association with PON1 genotype1 
1 The activities were measured in serum of all 52 hypercholesterolemic individuals at the start and end of the intervention. Bilberry and black rice extract capsules 
provide 320 mg/day anthocyanins. The participants were grouped according to their genotype. The change was calculated within each genotype group. Data 
are shown as means ± SD. No significant differences were detected compared with placebo using one-way ANOVA coupled with Dunnett’s multiple comparison 
test (p ≥ 0.05). Baseline enzyme units of PON1 were arylesterase (0.83 to 9.36 µmol substrate hydrolysed (min)-1 (ml serum)-1) and lactonase (2 to 11.4 µmol 
substrate hydrolysed (min)-1 (ml serum)-1)   
2 U is one enzyme unit= 1 µmol substrate hydrolysed (min)-1 (ml serum)-1 
Polymorphism Genotype 
Change in arylesterase 
U2/ml 
Change in lactonase 
U2/ml 
Placebo 
Black rice 
extract 
Bilberry 
 extract 
Placebo 
Black rice 
extract 
Bilberry 
 extract 
Q192R QQ 0.11 ± 0.25 0.00 ± 0.26 0.07 ± 0.22 -0.06 ± 0.57 0.13 ± 0.52 0.03 ± 0.32 
 QR 0.15 ± 0.43 -0.05 ± 0.28 0.11 ± 0.34 0.00 ± 0.38 -0.06 ± 0.23 0.13 ± 0.50 
 RR -0.09 ± 0.29 0.08 ± 0.40 0.07 ± 0.68 -0.25 ± 0.22 -0.01 ± 0.32 0.03 ± 0.59 
             
L55M L 0.13 ± 0.33 0.04 ± 0.30 0.02 ± 0.41 0.03 ± 0.48 0.09 ± 0.35 -0.03 ± 0.56 
 LM 0.07 ± 0.38 -0.04 ± 0.27 0.15 ± 0.28 -0.09 ± 0.41 -0.01 ± 0.43 0.16 ± 0.30 
 M 0.13 ± 0.18 -0.15 ± 0.15 0.05 ± 0.09 -0.25 ± 0.46 -0.09 ± 0.24 0.10 ± 0.17 
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Table 5. 8: Effect of anthocyanins consumption on PON1 activities with association with PON1 haplotypes1 
Haplotype3 
Change in arylesterase 
U2/ml 
Change in lactonase 
U2/ml 
Placebo Black rice extract Bilberry extract Placebo Black rice extract Bilberry extract 
QQ-LL 0.19 ± 0.27 0.09 ± 0.27 -0.07 ± 0.34 0.18 ± 0.83 0.43 ± 0.32 -0.13 ± 0.50 
QQ-LM 0.07 ± 0.26 -0.02 ± 0.31 0.14 ± 0.16 -0.15 ± 0.41 0.07 ± 0.63 0.10 ± 0.23 
QQ-MM 0.06 ± 0.15 -0.09 ± 0.14 0.08 ± 0.08 -0.23 ± 0.59 -0.08 ± 0.30 0.08 ± 0.21 
QR-LL 0.18 ± 0.38 -0.05 ± 0.33 0.03 ± 0.30 0.07 ± 0.29 -0.08 ± 0.29 0.02 ± 0.62 
QR-LM 0.09 ± 0.50 -0.02 ± 0.24 0.19 ± 0.38 -0.04 ± 0.46 -0.03 ± 0.18 0.22 ± 0.38 
RR-LL -0.05 ± 0.30 0.20 ± 0.30 0.12 ± 0.74 -0.24 ± 0.25 0.05 ± 0.31 -0.01 ± 0.66 
1 The activities were measured in serum of all 52 hypercholesterolemic individuals at the start and end of the intervention. Bilberry and black rice extract capsules 
provide 320 mg/day anthocyanins. The participants were grouped according to their haplotype. The change was calculated within each group. Data are shown 
as means ± SD. No significant differences detected compared with placebo using one-way ANOVA coupled with Dunnett’s multiple comparison test (p ≥ 0.05). 
Baseline enzyme units of PON1 were arylesterase (0.83 to 9.36 µmol substrate hydrolysed (min)-1 (ml serum)-1) and lactonase (2 to 11.4 µmol substrate 
hydrolysed (min)-1 (ml serum)-1)   
2 U is one enzyme unit= 1 µmol substrate hydrolysed (min)-1 (ml serum)-1 
3 Haplotypes QR-MM, RR-LM and RR-MM were excluded from table because the number of particpiants within each haplotype was one or zero. 
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Table 5. 9: Association of PON1 Q192R genotype with markers of CVD1 
 QQ QR RR LL LM MM 
HD (mmol/L) 1.83 ± 0.49 1.75 ± 0.38 2.16 ± 0.56 1.85 ± 0.56 1.79 ± 0.31 1.89 ± 0.72 
LDL (mmol/L) 3.58 ± 0.65 4.24 ± 0.92 3.66 ± 0.72 3.81 ± 0.63 3.99 ± 0.95 3.77 ± 1.21 
Cholesterol (mmol/L) 5.59 ± 0.73 6.26 ± 1.00 6.09 ± 0.64 5.89 ± 0.64 6.04 ± 1.05 5.89 ± 1.28 
Triglyceride (mmol/L) 1.10 ± 0.42 1.43 ± 0.70 0.92 ± 0.32 1.19 ± 0.40 1.29 ± 0.71 1.08 ± 0.63 
ApoA1 (md/dL) 223.4 ± 52.3 221.4 ± 57.4 274.4 ± 94.8 246.9 ± 84.5 210.7 ± 12.3 235.4 ± 76.7 
Apo B (md/dL) 117.0 ± 14.6 139.44 ± 28.9 124.2 ± 14.9 126.0 ± 16.8 130.5 ± 27.4 126.4 ± 40.2 
HDL3 (mmol/L) 0.70 ± 0.11 0.73 ± 0.10 0.74 ± 0.07 0.71 ± 0.10 0.73 ± 0.09 0.67 ± 0.12 
HDL2 (mmol/L) 1.13 ± 0.42 1.02 ± 0.30 1.42 ± 0.50 1.15 ± 0.48 1.06 ± 0.24 1.22 ± 0.60 
Glucose (mmol/L) 5.38 ± 0.38 5.61 ± 0.39 5.26 ± 0.32 5.43 ± 0.44 5.50 ± 0.37 5.56 ± 0.30 
Fructosamine (µmol/L) 272.5 ± 30.2 260.2 ± 22.6 268.39 ± 14.5 261.8 ± 23.2 267.8 ± 23.9 279.0 ± 42.3 
1 The participants were grouped according to their genotype. Values are shown as means ± SD of the baseline measurement of participants within each 
group. No significant differences detected between genotypes using one-way ANOVA coupled with Newman-Keuls’ multiple comparison test (p ≥ 0.0
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Table 5. 10: The interaction between anthocyanins consumption, PON1 genotype and HDL function1. 
 
1 HDL function biomarkers were measured in serum of all 52 hypercholesterolemic individuals at the start and end of the intervention. Bilberry and black rice 
extract capsules provide 320 mg/day anthocyanins. The participants were grouped according to their genotype. The change was calculated within each genotype 
group. Data are shown as means ± SD. No significant differences detected compared with placebo using one-way ANOVA coupled with Dunnett’s multiple 
comparison test (p ≥ 0.05). Base line values were as follows: Total HDL (1.05 to 3.05 mmol/L), HDL3 (0.46 to 0.95 mmol/L), HDL2 (0.59 to 2.17 mmol/L) and 
Apo A1 (137 to 441 mg/dL).
Polymorphism Genotype 
Change in total HDL 
(mmol/L) 
Change in HDL3 
(mmol/L) 
Placebo 
Black rice 
extract 
Bilberry 
extract 
Placebo 
Black rice 
extract 
Bilberry 
extract 
Q192R QQ 0.03 ± 0.19 0.04 ± 0.24 -0.02 ± 0.11 0.00 ± 0.21 -0.01 ± 0.22 -0.08 ± 0.23 
 QR 0.00 ± 0.17 0.03 ± 0.14 0.02 ± 0.15 -0.06 ± 0.27 -0.01 ± 0.23 0.03 ± 0.24 
 RR 0.07 ± 0.29 0.05 ± 0.24 0.03 ± 0.32 -0.16 ± 0.24 0.11 ± 0.37 -0.08 ± 0.41 
        
L55M LL 0.07 ± 0.21 0.06 ± 0.16 -0.01 ± 0.20 -0.03 ± 0.22 0.11 ± 0.25 -0.05 ± 0.32 
 LM -0.01 ± 0.17 0.03 ± 0.23 0.00 ± 0.13 -0.04 ± 0.27 -0.10 ± 0.20 -0.02 ± 0.21 
 MM -0.05 ± 0.17 -0.06 ± 0.12 0.03 ± 0.09 -0.13 ± 0.20 0.06 ± 0.18 0.03 ± 0.15 
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Table 5.10 Continued1 
1 HDL function biomarkers were measured in serum of all 52 hypercholesterolemic individuals at the start and end of the intervention. Bilberry and black rice 
extract capsules provide 320 mg/day anthocyanins. The participants were grouped according to their genotype. The change was calculated within each genotype 
group. Data are shown as means ± SD. No significant differences detected compared with placebo using one-way ANOVA coupled with Dunnett’s multiple 
comparison test (p ≥ 0.05). Base line values were as follows: Total HDL (1.05 to 3.05 mmol/L), HDL3 (0.46 to 0.95 mmol/L), HDL2 (0.59 to 2.17 mmol/L) and 
Apo A1 (137 to 441 mg/dL). 
Polymorphism Genotype 
Change in HDL2 
(mmol/L) 
Change in Apo A1 
(mg/dL) 
Placebo 
Black rice 
extract 
Bilberry 
extract 
Placebo 
Black rice 
extract 
Bilberry 
extract 
Q192R QQ -0.80 ± 7.33 3.08 ± 8.67 1.54 ± 7.41 0.02 ± 0.16 0.04 ± 0.21 -0.02 ± 0.09 
 QR 0.12 ± 7.23 -0.50 ± 6.07 3.13 ± 9.55 0.01 ± 0.12 0.02 ± 0.12 0.00 ± 0.08 
 RR -0.02 ± 6.85 2.16 ± 8.94 -1.72 ± 11.76 0.07 ± 0.25 0.06 ± 0.20 0.02 ± 0.29 
        
L55M LL 0.06 ± 0.16 0.05 ± 0.14 -0.01 ± 0.15 0.77 ± 8.13 2.20 ± 6.65 1.75 ± 11.39 
 LM 0.01 ± 0.14 0.03 ± 0.20 -0.01 ± 0.10 -0.51 ± 5.72 0.84 ± 8.88 1.24 ± 6.53 
 MM -0.06 ± 0.16 -0.05 ± 0.12 0.02 ± 0.09 -4.55 ± 9.12 -0.15 ± 5.53 5.83 ± 7.46 
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5.6. Discussion  
This chapter describes the effect of dietary supplementation (BERI study) with bilberry 
fruit- and black rice- derived anthocyanins on lipid/lipoproteins profile and PON1 
activities as biomarkers of HDL function in humans with hypercholesterolemia. The 
main aim of this randomized, placebo controlled, cross-over study was to compare 
the differences in LDL cholesterol and other lipid/lipoproteins and markers of HDL 
function, after ingestion of two different major types of anthocyanins found in the diet; 
cyanidin-type which is found in black rice extract and delphinidin-type which is found 
in bilberry extract. The intention was also to determine the relationship between diet 
mediated changes in PON1 activity and PON1 genotype. For this purpose and 
according to the power calculation, 52 of hypercholesterolemic patients were recruited 
to consume capsules containing (i) a bilberry extract providing 320 mg anthocyanins 
(delphinidin-type), (ii) a black rice extract providing 320 mg anthocyanins (cyanidin-
type) and (iii) a placebo control, once daily for 28 days. 
The main findings in the BERI study were that (1) the intervention did not affect LDL 
cholesterol or other biomarkers related to vascular function (e.g. total cholesterol, 
HDL cholesterol, triglycerides and Apo B) and glycaemic control (glucose, 
fructosamine); (2) the intervention did not affect biomarkers of HDL function such as 
Apo A1, HDL subfractions and PON1 arylesterase and lactonase activity; (3) there 
was no interaction between consumption of anthocyanin, PON1 genotype, PON1 
activities and markers of HDL function; (4) there was no association between PON1 
genotype and biomarkers for CVD. These findings did not support the notion that 
anthocyanin consumption had a favourable effect on lipid/lipoproteins profiles and 
biomarkers of HDL function. 
The primary outcome for this intervention was to investigate the effect of treatments 
on reduction of LDL-cholesterol which did not significantly change. These findings 
were inconsistent with several human intervention studies that were reported a 
reduction in LDL-cholesterol following a consumption of anthocyanins-rich extracts. 
Many of them used a whole fruit or extracts that contain several bioactives in addition 
to anthocyanins, while others used a proprietary product that contains isolated 
anthocyanins, Medox™.  Zhu et al. (2013) and Qin et al. (2009) found that 
consumption of 320 mg/day purified anthocyanins (Medox™) for 12 to 24 weeks 
caused a 10% reduction in LDL cholesterol in hyperlipidaemic participants [165], 
[167]. They also reported a significant increase in HDL-cholesterol which contradict 
the findings in the BERI study [165], [167]. One possible reason for this contradiction 
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could be because the duration of the intervention in those two studies was 12 and 24 
weeks which is 3 to 6 times longer than the current study. In a recent systematic 
review and meta-analysis conducted by Daneshzad et al. (2018), the duration of 
intervention was be one of the key points that create contradiction between reports in 
terms of the effect of anthocyanins on lipid profile [130]. In this systematic review, 
consumption of anthocyanins showed a significant effect on lipid profile only with trials 
that were conducted for longer than 12 weeks, which was not the case in our current 
study (BERI study). Moreover, the study design could be another possible reason that 
created differences in results between the previous two reports and the present study. 
The BERI study was a cross-over design, which is one of the main strengths in this 
study that minimises the effect of confounding variables and allows for assessing the 
actual effects of treatments, while, Qin et al. (2009) and Zhu et al. (2013) used parallel 
design. 
On the other hand, other human intervention studies support the findings in the current 
study. Several human interventions reported a null effect of anthocyanins on lipid 
profiles when purified anthocyanins or anthocyanin-rich extracts were investigated. 
Thompson et al. (2017) reported non-significant effect on lipid profiles when 320 
mg/day purified anthocyanins (Medox™) was consumed for 4 weeks [172]. In 
addition, Istas et al. (2019) found that (poly)phenol-rich aronia extract (116 mg/day) 
for 12 week has no effect on lipid profile [94]. Likewise, the same findings were 
reported when whole fruit materials were used. For Instance, Rodriguez-Mateos et al. 
(2019) found no effect of blueberry powder consumption for 4 weeks on blood lipids 
[307]. Moreover, Hollands et al. (2018) and Azzini et al. (2017) found that red orange 
juice that contained anthocyanins did not affect blood lipids compared to blond orange 
juice which did not contain anthocyanins after an intervention for four weeks [132], 
[141]. In addition, chokeberry juice providing 113 mg/day anthocyanins for 4 weeks 
did not affect the lipid profile [142]. In contrast, some other reports have shown that 
anthocyanins intervention increased lipid profile. For instance, Bergland et al. 2019 
found that 320 mg/day anthocyanins (Medox™) for 16 weeks increased cholesterol 
and triglyceride in patients with mild dementia [173]. Probably, because the population 
was unhealthy and there was not a record whether the participants in control group 
are taking statin or other lipid lowering medication.     
The BERI study was one of the most comprehensive human intervention that 
investigated the effect of anthocyanins on several biomarkers related to CVD and 
HDL function such as Apo A1, Apo B, HDL subfractions, ApoA1-AboB ratio, HDL-
ApoA1 ratio and markers of glycaemic control in addition to the lipid profile.The 
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increase in ApoA1 and the decrease in ApoB was reported to be inversely associated 
with atherosclerosis [374], [375]. Additionally, the apoB/ apoA-I ratio was reported to 
better reflect the lipoprotein atherogenic balance in blood than any of the cholesterol 
ratios [60]. HDL subfractions were also measured. HDL comprises of several 
subfraction according to the density [209], [256]. HDL3 is smaller and denser and can 
carry more cholesterol than HDL2 subfraction [376], [377]. An increased HDL3 
fraction is inversely correlated with increased CVD risk [238]. In addition, 
epidemiological evidence also supports an association between glycaemic control and 
CVD risk [378].  Similar to the lipid profile, the treatments in the current study did not 
affect any of these biomarkers. Likewise, Medox™ consumption and anthocyanin-
containing blood orange did not affect glucose or fructosamine levels [141], [173].  
Contrary, Curtis et al. (2019) found that the consumption of blueberry fruit (26 g/day 
freeze-dried for 6 months) increased Apo A1 and HDL particle density. Probably, 
because the duration of study was longer and they used a whole fruit that contained 
other bioactives which may synergistically increase the effect of anthocyanins [139].    
In the current study, participants with cholesterol higher than normal were recruited. 
The reason was because the recent systematic review by Wallace et al. (2016) in 
which anthocyanins significantly affected LDL-cholesterol only among dyslipidaemic 
individuals [164]. In this systematic review, the impact of purified anthocyanins and 
anthocyanin-rich extracts on biomarkers of CVD risk was assessed in twelve 
randomized trials. Nine Of twelve intervention included LDL-cholesterol as an 
outcome. Of these nine trials, only four reported improvements in LDL cholesterol. 
These four studies were conducted in hyperlipidaemic population with a total 
cholesterol and LDL-cholesterol at baseline was ≥ 5.17 mmol/L and 3.8 µol/L, 
respectively. The other five trials which conducted in healthy individuals did not show 
significant effect on cholesterol or LDL-cholesterol. The authors concluded that 
anthocyanins significantly improved LDL-cholesterol among individuals with elevated 
cholesterol.  
Regarding the extracts used in this intervention, the analysis of bilberry extract 
(MyrtiPRO®) and black rice extract revealed that these two anthocyanin-rich extracts 
were suitable for the purpose of the trial. Black rice contains only dihydroxylated-B 
ring anthocyanins (cyanidin-type) and bilberry extract contains mainly tri-
hydroxylated-B ring anthocyanins (delphinidin-type). In fact, the analysis showed that 
bilberry extract contains 44% delphinidin (trihydroxylated-B ring anthocyanin), while 
contains 24% petunidin and 8.8% malvidin. Petunidin and malvidin are methylated 
anthocyanins derived from delphinidin which mean that the bilberry extract represents 
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mainly the delphinidin types of anthocyanins (76.8%). The analysis also showed that 
the extracts were pure and contain mainly anthocyanins. Thereby, the effects were 
directly linked to anthocyanin. Additionally, the dose of 320 mg/day anthocyanins was 
chosen because it has previously been reported to be safe, well tolerated and have 
biological effects [136], [165], [167], [170], [379]. Doses up to 640 mg/day showed no 
adverse events [164]. However, the findings did not support the notion that 
anthocyanin consumption improve the lipid profiles. 
In the current study, it was suggested that separating the study phases with at least 
4 weeks washout is long enough to eliminate any carryover effects. This suggestion 
based on several human interventions that reported significant effects on cholesterol 
and LDL-cholesterol in crossover studies with two weeks washout period which is 
shorter than the washout phase used in the current study [380], [381]. Other studies 
reported significant effect in crossover studies with washout period of 4 weeks 
supporting the notion that 4 weeks is long enough for cholesterol and LDL-cholesterol 
to back to normal after treatments [382]. In addition, it is unlikely that the carryover 
effects confounded the effect of treatments as the levels of LDL-cholesterol and all 
measured parameters remained unchanged after all the study treatments.  
Human variation (e.g. differences in microbiota or absorption and metabolism of 
bioactives) may be one of the factors modifying response to constituents of food [383].  
Therefore, the inter-individual differences in response to treatments among the 
participants were checked to figure out whether there is heterogeneity across the 
study population in responding to treatments and whether this could help to 
understand the null result obtained in this study.  First 88 % of study population 
responded similarly to treatments, supporting the notion that there is no inter-
individual variation toward the treatments. Secondly, in the participants who 
responded differently, there was not a specific trend to explain this variation. For 
example, one participant reported reduced LDL (~ - 28%) with one treatment and 
increased LDL (~18%) with another treatment, reported a decrease in HDL from ~-2 
% to ~ 17% and responded equally in the other biomarkers, indicating that the odd 
response is not attribute to treatment.  
5.6.1. Interaction between treatments, PON1 activities and PON1 
genotype. 
In the current study, the effect of purified anthocyanins on two PON1 activities, 
arylesterase and lactonase activity was investigated. No significant effect of either 
black rice extract or bilberry extract was observed in either arylesterase or lactonase 
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activity. Few reports have investigated the effect of polyphenols on PON1 activity in 
humans. Only one report used purified anthocyanins and another used pomegranate 
juice to study their effects on arylesterase and no one investigated the effects on 
lactonase, the native activity of PON1. The BERI study is the first trial to report the 
effect of consumption of anthocyanins on PON1 lactonase activity. Zhu et al. (2014) 
reported that 320 mg/day purified anthocyanins (Medox™) for 24 weeks increased 
arylesterase by 17% in 122 hypercholesteraemic subjects which contradict the current 
findings [170]. Two reasons could explain this contradiction. First, the duration of 
study was 6 times longer than the BERI study. Secondly, I measured the PON1-
mediated activity by using a potent inhibitor and excluded all other interfering 
arylesterases which was not the case in the previous report. Zhu et al. measured the 
total arylesterases without eliminating the activities of other interfering enzymes, thus, 
it is hard to tell whether treatment affected PON1 or other arylesterases.  
It is well established that PON1 polymorphism affect the enzyme activities, stability, 
antiatherogenicity and sometimes the substrate’s specificity [269], [270], [365], [366], 
[372] [260], [268], [285], [384]. Among all of PON1 SNPs, Q192R and L55M 
polymorphism are the most studied polymorphisms and they have previously been 
found to be associated with CVD, diabetes and obesity [362], [363], [373], [385], [386]. 
Thereby, these two polymorphisms were the main focus in my project. People with R 
allele has higher arylesterase activity than Q allele; and people with L allele has 
activity higher than M allele [387], [388]. However, some reports indicated that people 
with QQ possess a greater protection against LDL oxidation [266]. Thereby the 
genetic background related to PON1 should be considered while investigating PON1 
which was the case in the BERI study. To the best of my knowledge, the BERI study 
is the first study to investigate the interaction between the consumption of 
anthocyanins, PON1 activities and PON1 genotype. In line with previous studies, 
there were differences between genotypes in activities in the BERI study population. 
It was found that RR has high arylesterase and lactonase activity than QQ.; and LL 
has high arylesterase and lactonase. Moreover, there was a significant association 
between PON1 haplotype and PON1 activities confirming the importance of 
categorizing the participants into different groups according to their genotype.  
In addition to the polymorphisms, PON1 activities can be affected by life style and 
food components [389]. Therefore, the interaction between diet, PON1 activities and 
PON1 genotype should be further investigated. Rizzi et al. (2016) studied the 
interaction between polyphenol and PON1 variants on markers of CVD such as lipid 
profile using a nutrigenetic approach. They found an association with anthocyanins 
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intake and HDL level in interaction with some PON1 polymorphisms [273]. However, 
no significant interaction between treatments, PON1 activities and genotypes was 
observed in the current study. Probably, because studying the interaction between 
diet and genotype require big population size and population size might be small to 
detect the interaction. The power calculation was done according to LDL-cholesterol, 
the primary outcome, not for PON1. Therefore, not all PON1 genotypes were 
adequately represented in the study population and they might show a significant 
interaction in bigger populations. Should human interventions be undertaken in future 
to investigate this aspect further, the power calculation should be done according to 
PON1 to recruit representative study population. However, the non-significant 
interaction trend seen in this study doesn’t support this notion as the change in 
activities were close to zero even in the well-represented genotypes groups such as 
QQ-LM, QR-LL and QR-LM.     
Since PON1 binds with HDL via Apo A1, it is possible that treatments interact with 
HDL, HDL subfractions and Apo A1 in relation to PON1 genotype and enhance HDL 
function. However, there was not any significant effect of treatments on HDL function 
biomarkers in any of PON1 genotype groups. Possibly, other PON1 polymorphisms 
may interact with anthocyanins consumption and deliver preferable effects. For 
instance, T (-107) C polymorphism was associated with PON1 activity and HDL-
cholesterol level. Therefore, more investigation still needs to be done to study the 
interaction of anthocyanins, more PON1 polymorphisms and markers of HDL function 
in big population. 
5.6.2. The strengths and weaknesses of the BERI study. 
There are several points of strength for this trial. This was reflected by the 
comprehensive analysis of biomarkers of CVD including the lipid/lipoproteins profiles 
and HDL function. The trial measured for the first time the effect of anthocyanin 
consumption on HDL subfractions and PON1 lactonase activity; and described for the 
first time the interaction between PON1 genotype and anthocyanin consumption in 
relation to biomarkers of CVD. Moreover, the trial examined the effect of purified 
anthocyanins so any observed effects can be directly linked to the anthocyanin. In 
addition, the trial included a placebo control treatment that was identical in 
composition and appearance to the anthocyanin treatment except for the independent 
variables. Control group is essential to eliminate the effects of the external factors 
other than the effect of treatment and provide direct comparison between 
anthocyanin-rich and -null food [390]. Additionally, the study was double-blinded 
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crossover designed. Unlike the parallel design, the crossover design allows each 
participants to act as his/her own control and remove between-subject variability and 
any other confounding factors which gives more precise estimate of treatment 
compared with parallel design [391]–[394]. Furthermore, the study recruited good 
number of participants with hypercholesterolaemia and the compared composition of 
the materials used in trial was identified 
On the other hand, the trial was limited by the short duration due to its crossover 
design and therefore, further long-term studies are recommended. Another limitation 
was not measuring ox-LDL the main factor that initiate atherosclerosis and the 
ultimate target of PON1. The reason of not measuring ox-LDL was discussed in 
section 6.4 in this thesis. 
5.7. Conclusion 
In conclusion, in the undertaken human intervention trial, the consumption of 320 
mg/day of bilberry extract or black rice extract derived anthocyanins for 28 days did 
not significantly changed the lipid/lipoprotein profile, biomarkers of HDL function, 
glycaemic control index or PON1 arylesterase and lactonase activities. The analysis 
also showed that there was no interaction between treatments, PON1 activities and 
PON1 genotype. The lack of effects may be due to the short duration of the 
intervention. Therefore, conducting interventions longer than 12 weeks should be 
considered in future research. 
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6.1. Summary of main findings 
The overall aims of this thesis were  to (1) assess the ability of anthocyanins and their 
metabolites to modulate the reverse cholesterol transport (RCT) pathway and alter 
HDL function as mechanisms by which anthocyanins would improve lipid/lipoprotein 
profiles, (2) identify possible underlying mechanisms for the atheroprotective effects 
of anthocyanins and (3) investigate the ability of purified anthocyanins to improve 
lipid/lipoprotein profiles and markers of HDL function in human in a well-controlled 
dietary intervention study. The main findings described in this are summarized as 
follows: 
• None of C3G, D3G or their major metabolites/mixtures at physiologically 
relevant concentrations significantly changed the expression of the 
cholesterol transporter genes or the expression of scavenger receptor genes 
(markers of RCT) either in cultured human macrophages or in tissues isolated 
from ApoE-/- mice fed with anthocyanin-and flavonol-expressing tomatoes. 
• Neither anthocyanin parent compounds, their tested metabolites or mixtures 
of metabolites affected the expression of the PON1 gene (a marker of HDL 
function), nor did they affect PON1 arylesterase and lactonase activities, 
regardless of PON1 phenotype.  
• Cyanidin, the aglycone form of C3G, significantly decreased the lactonase 
activity of PON1 but only for the RR phenotype and only at super-
physiological concentrations. 
• Further, the evidence that the major anthocyanin metabolites were not 
effective at causing significant changes in the expression of genes was 
extended to the entire transcriptome of human macrophages using RNA-Seq.  
• Daily consumption of cyanidin- or delphinidin-type anthocyanins for 4 weeks 
caused no significant changes in lipid/lipoprotein profiles, markers of HDL 
function and PON1 activities, nor were interactions with the Q192R and L55M 
PON1 genotype observed.  
6.2. Novelty of the presented work 
The rationale for the notion that the biological activities of anthocyanins were most 
likely mediated by their metabolites [91] [73], [395] was presented  in the general 
introduction (Chapter one). However, there are only a few reports describing studies 
of the biological effects of these metabolites [301], [302], [395]. Only two reports could 
be found in the scientific literature that included evidence of the effects of PCA, vanillic 
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acid, ferulic acid or gallic acid on markers of RCT [227], [228] and no studies 
concerned with the effects on PON1 gene expression and enzyme activities. In this 
thesis, it was investigated for the first time the possible effects of other known and 
potential metabolites of C3G and D3G on markers of RCT. In addition, the effect of 
the pure synthetic phase-2- conjugates of the major anthocyanin degradation 
products on markers of RCT were investigated for the first time. Moreover, this is the 
first in vitro study that has examined the effect of anthocyanins and their metabolites 
on PON1 gene expression and enzyme activities. Additionally, most of the previous 
studies examined the effects of metabolites individually and did not consider that 
anthocyanin metabolites are present in mixtures in vivo and they most likely interact 
together if they cause effects. This study is the first to look for the potential synergistic 
effects of anthocyanin metabolites on markers of RCT and PON1. 
In the human intervention study presented in this thesis, a direct comparison between 
the effects of two predominant types of anthocyanin (cyanidin- and delphinidin-types) 
on markers of CVD was conducted for the first time. Additionally, this intervention is 
one of the most comprehensive trials to study the effects of consuming anthocyanins 
on lipid/lipoprotein profiles and to include several markers of HDL function such as 
HDL sub-fractions.  
PON1 lactonase is the physiologically relevant activity that associated with PON1 
biological functions [260]–[262]. However, paraoxonase and arylesterase were the 
only activities that measured in all the previous studies that investigated the effect of 
polyphenols on PON1. The human intervention study and the in vitro work presented 
in this thesis are the first that examined the effect of anthocyanins on PON1 lactonase 
activity, providing unique data concerned with another aspect of how anthocyanins 
might modulate HDL function. 
Furthermore, it was shown in chapter three that PON1 has many polymorphisms 
associated with CVD risk and they often affect its enzyme activities. Therefore, it is 
recommended to compare between values of PON1 levels within each different 
genotype instead of a general comparison of the whole study population. However, 
the genetic background of participants has not been taken into account in any of the 
previous reports that investigated the effects of anthocyanins and other polyphenols 
on PON1 activities. This study stands out from others as it is the only one that has 
considered the interaction of anthocyanins with CVD risk factors in the context of 
PON1 polymorphisms. Thus, data from the intervention study described in this thesis 
is the only observational clinical trial that has investigated the interaction and the 
association between consumption of anthocyanins, PON1 genotype, PON1 activities 
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and markers of CVD. In the pre-existing literature, the only study that studied the 
association between consumption of anthocyanins with PON1 genotype and markers 
of CVD was a nutrigenomic study and not clinical trial [273].  
6.3. Does the consumption of anthocyanin improve lipid/lipoprotein 
metabolism and what are the underlying mechanisms? 
As detailed in Chapter 1, higher levels of consumption of dietary anthocyanins is 
associated with decreased risk of cardiovascular and other cardiometabolic diseases, 
and dietary interventions with anthocyanin-rich extracts and anthocyanin-rich foods 
has been reported to cause significant improvements in circulating lipoprotein profiles 
in human participants. However, it should be noted that there were significant 
limitations in most of these studies; typical examples include the lack of a proper 
control group and the use of whole fruits or whole fruit extracts which contained many 
other bioactives alongside the anthocyanins. Wallace et al. (2016) in a systematic 
review of intervention studies, concluded that anthocyanins may have the potential to 
affect markers of CVD [164]. However, the authors also recommended that more 
carefully controlled trials were needed to draw more concrete conclusions [164]. To 
investigate whether the consumption of anthocyanins does cause beneficial changes 
in lipid profiles and to explore the mechanisms of action, a randomised, placebo-
controlled crossover trial which is one of the most rigorous, robust and comprehensive 
studies was conducted and accompanied with a series of in vitro experiments to 
examine the effects of anthocyanins and their metabolites on various biomarkers 
related to lipid/lipoprotein metabolism. In light of the previous literature and the 
apparent consensus view that consumption of anthocyanins favourably affects 
lipoprotein profiles and reduces CVD risk, it was somewhat unexpected to find no 
evidence in the studies reported here to support the notion that anthocyanins improve 
lipid/lipoprotein profiles.  One possibility is that the previously reported effects were 
attributed to the interaction between anthocyanins and other bioactives in complex 
foods and crude extracts (as reported previously [42], [162], [166], [175]) and such 
effects are not observed when isolated anthocyanins are consumed (as reported here 
[131], [171], [173]). After reviewing the literature during the preparation of this thesis 
(summer 2019), 7 articles describing the outcomes from 5 different dietary 
intervention studies that examined the effect of isolated anthocyanins on lipid profiles 
were found, all of them describing studies that used Medox™. In only two of the 
studies (reported in  4 separate articles) reported significant effects on lipid profiles 
[136], [167], [169], [170]. Whereas, no significant effects on lipid profiles were reported 
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for the other three studies [131], [171], [173]. The differences between the studies for 
which significant effects were reported compared to those where significant effects 
were not observed were the duration of studies and the health status of the 
participants. In the two studies that reported significant effects, the duration was 12-
24 weeks and the participants were hypercholesterolemic. In contrast, the duration of 
two of the studies not showing significant effects the durations were 3-4 weeks (in 
healthy participants) and for the third the duration longer (16 weeks) but the 
participants were cognitively impaired. The current human intervention study was 
conducted in hypercholesterolemic individuals, similar to the reports with significant 
findings. However, the duration was shorter which may explain the contradiction in 
findings.  
In addition to the human intervention, the in vitro studies aimed to investigate the 
underlying mechanisms of action of anthocyanins. In chapters  2 and 3, the RCT 
pathway was investigated as a possible target for anthocyanins to deliver their action 
since it is the main way for regulating the accumulation of cholesterol in foam cells 
and therefore the development of atherosclerosis [214], [220], [396], [397]. In those 
two chapters, the influence of pure anthocyanins and their pure metabolites on the 
key players in RCT were investigated. To the best of my knowledge, there are only 
two reports that examine the effects of pure anthocyanin metabolites on the RCT 
pathway; these covered PCA, vanillic acid, ferulic acid and gallic acid [227], [228]. 
The effect of treatments on the expression of cholesterol transporter genes was 
measured in one study in which PCA and C3G were the only compounds tested, and 
PCA was reported to upregulate the expression of cholesterol transporter genes, 
suggesting that it is indeed the anthocyanin metabolites that interact with cells/tissues 
to promote RCT [228]. However, the data in this thesis does not support this notion, 
even though a wide range of known and predicted human metabolites of anthocyanins 
were studied, including the most abundant ones found in human peripheral blood after 
consumption of anthocyanins. As reported here in chapter two, the in vitro model was 
shown to be fit-for-purpose, responding strongly to the RCT-associated genes 
stimulator such as c-AMP and kaempferol (the positive control). These observations 
were consistent with gene expression data obtained from both aortic and liver tissues 
from mice that were fed diets supplemented with anthocyanin- and flavonol-
expressing versus anthocyanin-free tomatoes, i.e. no significant effects were 
observed. Bearing in mind the broad range of approaches reported in this thesis, and 
that none of these generated any data to support the notion that anthocyanins (or their 
metabolites) cause favourable changes in lipid/lipoprotein profiles or biomarkers of 
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HDL function, it raises some doubts with regard the conclusions of the previously 
reported studies referred to above. Further, not only were no effects observed in a 
well-controlled human dietary intervention study (chapter 5), a well-controlled animal 
dietary intervention study (chapter 2), and a fairly comprehensive survey of the effects 
of anthocyanins and their human metabolites on the expression of key genes involved 
in the RCT pathway (chapter 2) and on PON1 expression and activity (chapter 3), no 
significant effects of the major human anthocyanin metabolites on the expression of 
any genes was observed for cultured human macrophages. Taken together, the data 
presented in this thesis support the notion that isolated anthocyanins and their human 
metabolites cannot themselves (in isolation) cause beneficial changes in lipoprotein 
profiles, and therefore that previously reported effects of anthocyanin-rich foods and 
extracts on lipoproteins are due to other components in the treatments, or combination 
effects with anthocyanins.  
In summary, the unique data presented in this thesis provide useful, high quality data 
that contributes to our knowledge of the role of anthocyanins in modulating 
lipid/lipoprotein profiles and indeed raises several questions regarding the current 
ideas of their importance presented in the scientific literature 
6.4. Limitations of the research 
There are some limitations in the presented work in this thesis. Although the data in 
chapter two gave a good picture about the effect of wide range of anthocyanin 
metabolites at different physiologically relevant concentrations on key molecular 
players in the RCT process, the findings showed only the effects on gene expression 
with no further investigation on other regulatory elements or at the protein level. If time 
and the availability of commercial kits had permitted, it would have been useful to 
conduct cholesterol efflux capacity (CEC) assays to quantify the rate of cholesterol 
efflux from LDL-pre-loaded cultured macrophages [396], [398]–[400]. The CEC assay 
would reflect the overall effects of anthocyanins on the process including the effects 
on all regulatory elements and proteins involved in this pathway. However, there was 
a quality issue with the batch of the kit that was obtained (Sigma Cat# MAK192-1KT), 
and eventually the company withdrew the batch completely and a new working 
product did not become available in time for these assays to be completed. 
There were some minor limitations in the research presented in chapter three. The 
working hypothesis was that anthocyanin metabolites would increase PON1 via 
upregulating gene expression, stimulating the enzyme activities and/or increasing 
enzyme secretion. Since the treatments did not show any effect on gene expression 
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or enzyme activities, the next step should have been studying of possible effects on 
the secretion of the enzyme from liver cells. However, the lack of a suitable cell model 
did not allow such studies to be completed. HepG2 cells did not secret detectable 
quantities of the enzyme, precluding its use as a model for this process. The Huh7 
liver cell line which was previously reported to secret the enzyme [279], [401], [402] 
was not available in house and it was not feasible due to the lack of time and 
resources to test and optimize Huh7 cell as a model.  
One of the main aims of the human intervention study that presented in chapter five 
was to measure the effects of anthocyanins on PON1 activities as a marker of HDL 
function to protect LDL from oxidation [377], [403], [404]. An increase in PON1 
activities as a result of treatment would lead to a reduction in ox-LDL levels, the 
element that initiate the atherosclerosis [405]–[407]. However, ox-LDL level has not 
been measured. Although, the treatments did not show any effects on PON1 
lactonase activity, the substrate that was used in the assay was synthetic and may 
not give a true reflection of the activity towards the physiologically relevant substrate; 
it was shown in chapter three that PON1 activity very much depends on the type of 
substrate. It is possible (although quite unlikely) that there were changes in PON1 
lactonase activity towards physiological substrates (i.e. lipid peroxides) induced by 
the dietary intervention in humans or exposure of the enzyme to 
anthocyanins/metabolites, but these changes were not reflected in the enzyme 
activity toward TBBL. Nevertheless, future studies should include measures of ox-
LDL, the true physiological substrate for PON1 in relation to HDL function. The reason 
that ox-LDL was not measured was that the commercially available kit (OxiSelect™ 
Human Oxidized LDL, Cambridge Bioscience, Cat # STA-369) has a limitation to only 
use newly frozen samples and not with samples that have been stored for more than 
6 months. Additionally, the supplier doesn’t have any data on the stability of ox-LDL 
and whether the differences in sample age would create variance in measurement. 
Since, the human intervention was a crossover design and took approximately one 
year to complete, it was not possible to conduct the oxLDL assays retrospectively with 
confidence, and so the measurement of ox-LDL was not undertaken.   
6.5. Recommendations for future work 
The human intervention trial in this thesis showed that the fairly substantial doses of 
isolated anthocyanins did not cause any significant effects on lipid profiles. This 
finding was actually in agreement with the outcomes reported for several human 
studies that used the proprietary isolated anthocyanin product Medox™ for the same 
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duration as the human intervention reported in this thesis [131], [171], [173]. On the 
other hand, other reports of human dietary intervention studies with Medox™ showed 
a beneficial change in lipid profiles either after consumption of Medox™ for a longer 
period (12-24 weeks) or with crude fruit extract. This raised important questions as to 
whether the isolated anthocyanins improve lipid profiles only after long-term 
consumption, or the anthocyanins in isolation do not cause the reported effects and 
instead the beneficial effects are due to other components in the crude extract 
treatments or as a result of interaction between anthocyanins and other components. 
Therefore, it would be useful to conduct additional human intervention studies to 
answer these questions. One is needed to compare the effect of isolated 
anthocyanins (such as those used here or the Medox™ product) over both shorter 
and longer durations, e.g. 4 weeks vs 16 weeks; This could be done via repeated 
sampling of participants over 16 weeks in a placebo-controlled trial (parallel or 
preferably crossover design). In a separate trial, it would be useful to directly compare 
isolated anthocyanins such as the bilberry extract used here (MyrtiPRO®) with a 
crude bilberry fruit extract (i.e. containing various polyphenols and possibly other 
bioactive components in addition to the anthocyanins). Preferably this would be 
placebo controlled and of crossover design, and the duration of the intervention would 
be informed by the first trial investigating the effect of intervention period. This should 
verify if a combination of anthocyanins and the other fruit bioactives is effective 
whereas isolated anthocyanins are not.   
The data presented in chapter two showed that treatment of LDL-loaded 
macrophages with C3G and D3G and with a wide range of their metabolites had no 
effect on the expression of key RCT genes. However, the selection of D3G 
metabolites was based on predictions that were based on the reported metabolites 
from a human study conducted with bilberry extract which contains many types of 
anthocyanins and it is not known for certain whether the metabolites identified in this 
study were derived from D3G [91]. The best way to identify D3G metabolites would 
be to use a stable isotope-labelled compound (normally 13C-labelled) and a human 
study using such an approach would advance our knowledge in this area. It would 
then be useful to investigate the putative biological effects of any newly discovered 
metabolites from this human study. 
With regard newly discovered metabolites, recent work in the Kroon group at QIB has 
shown that high concentrations of homoprotocatechuic acid (3,4 dihydroxyphenyl 
acetic acid) are produced and accumulate when C3G is incubated with a human 
faecal slurry in a colon model (Emad Shehata, Priscilla Day and Paul Kroon, 
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unpublished data) and future work to investigate the possible biological effects of this 
compound is recommended. 
As discussed in chapter three, PON1 has many SNPs that associated with different 
chronic diseases. However, the human intervention study in chapter five only focused 
on Q192R and L55M SNPs, as they were associated with CVD. It is possible that 
other PON1 SNPs interact with consumption of anthocyanin and decrease the risk of 
CVD. For instance, the rs 3735590 polymorphism at the 3′ UTR of the PON1 gene 
which is within a miRNA binding site has been reported to be associated with 
ischaemic stroke and thinner carotid artery intima-media thickness (IMT) [269]. 
Therefore, it would be interesting to undertake a human intervention study with 
anthocyanins in a large study population to investigate the potential interactions 
between anthocyanin consumption and different PON1 SNPs after sequencing the 
whole gene and determining the genotype of each participant.  
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Table S1. 1: Summary of GSEA using Gene Ontology database for PGA 
treatment  
 
- GSEA = gene set enrichment analysis, ES = enrichment score, NES = 
normalized enrichment score, FDR = false discovery rate (adjusted p-value) 
- Cells highlighted with yellow are significantly changed at FDR ≤ 0.05, while 
blue cells are significant at FDR ≤ 0.2. 
- Positive NES values = upregulated pathways, negative NES values = 
downregulated pathways 
 
NAME ES NES FDR 
GO_SISTER_CHROMATID_SEGREGATION 0.5498 2.2603 0.0012 
GO_MITOTIC_SISTER_CHROMATID_SEGR
EGATION 
0.5959 2.2349 0.0006 
GO_NUCLEAR_CHROMOSOME_SEGREG
ATION 
0.5195 2.2084 0.0004 
GO_REGULATION_OF_CENTROSOME_CY
CLE 
0.6585 2.1473 0.0020 
GO_CHROMOSOME_SEGREGATION 0.4922 2.1286 0.0023 
GO_TRANSLATIONAL_INITIATION 0.5158 2.0956 0.0039 
GO_MITOTIC_NUCLEAR_DIVISION 0.4661 2.0952 0.0034 
GO_MITOCHONDRIAL_TRANSLATION 0.5299 2.0949 0.0029 
GO_SISTER_CHROMATID_COHESION 0.5360 2.0794 0.0034 
GO_POSITIVE_REGULATION_OF_COAGU
LATION 
0.7697 2.0792 0.0031 
GO_ESTABLISHMENT_OF_PROTEIN_LOC
ALIZATION_TO_ENDOPLASMIC_RETICUL
UM 
0.5371 2.0586 0.0041 
GO_RIBOSOMAL_SMALL_SUBUNIT_BIOG
ENESIS 
0.5882 2.0316 0.0060 
GO_RIBOSOME_BIOGENESIS 0.4555 2.0290 0.0058 
GO_CELL_CYCLE_PHASE_TRANSITION 0.4641 2.0196 0.0062 
GO_TRNA_TRANSPORT 0.6545 2.0128 0.0071 
GO_NEGATIVE_REGULATION_OF_AXON_
EXTENSION 
-0.6732 -1.9822 0.1115 
GO_POSITIVE_REGULATION_OF_EXCITA
TORY_POSTSYNAPTIC_POTENTIAL 
-0.7530 -1.9208 0.1608 
GO_MODULATION_OF_EXCITATORY_POS
TSYNAPTIC_POTENTIAL 
-0.6675 -1.8618 0.1934 
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Table S1. 2: Summary of GSEA using Reactome database for PGA 
treatment  
 
NAME ES NES FDR 
INFLUENZA_LIFE_CYCLE 0.553 2.256 0 
G1_S_TRANSITION 0.575 2.252 0 
CELL_CYCLE_MITOTIC 0.494 2.223 0.001 
S_PHASE 0.554 2.155 0.001 
MITOTIC_G1_G1_S_PHASES 0.539 2.141 0.001 
HOST_INTERACTIONS_OF_HIV_FACTOR
S 
0.537 2.137 0.001 
CELL_CYCLE_CHECKPOINTS 0.543 2.137 0.000 
DNA_REPLICATION 0.512 2.134 0.000 
INFLUENZA_VIRAL_RNA_TRANSCRIPTIO
N_AND_REPLICATION 
0.541 2.119 0.001 
ORC1_REMOVAL_FROM_CHROMATIN 0.585 2.108 0.001 
MITOTIC_M_M_G1_PHASES 0.512 2.100 0.001 
METABOLISM_OF_RNA 0.474 2.098 0.000 
HIV_INFECTION 0.499 2.081 0.000 
CYCLIN_E_ASSOCIATED_EVENTS_DURI
NG_G1_S_TRANSITION_ 
0.582 2.076 0.000 
REGULATION_OF_MITOTIC_CELL_CYCL
E 
0.565 2.074 0.000 
SMOOTH_MUSCLE_CONTRACTION -0.584 -1.606 0.299 
 
- GSEA = gene set enrichment analysis, ES = enrichment score, NES = 
normalized enrichment score, FDR = false discovery rate (adjusted p-value). 
- Cells highlighted with yellow are significantly changed at FDR ≤ 0.05, while 
blue cells are significant at FDR ≤ 0.3. 
- Positive NES values = upregulated pathways, negative NES values = 
downregulated pathways 
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Table S1. 3: Summary of GSEA using Gene Ontology database for 
mixture treatment  
 
NAME ES NES FDR 
 RIBOSOMAL_SMALL_SUBUNIT_BIOGENESIS 0.584 2.081 0.046 
 DNA_DEALKYLATION 0.780 2.040 0.047 
 MATURATION_OF_SSU_RRNA 0.603 1.961 0.127 
 MEMBRANE_DISASSEMBLY 0.587 1.950 0.109 
 REGULATION_OF_CELL_AGING 0.638 1.917 0.141 
MATURATION_OF_SSU_RRNA_FROM_TRICI
STRONIC_RRNA_TRANSCRIPT_SSU_RRNA_
5_8S_RRNA_LSU_RRNA_ 
0.610 1.908 0.132 
 
ANDROGEN_RECEPTOR_SIGNALING_PATH
WAY 
0.597 1.901 0.122 
 
REGULATION_OF_CELLULAR_SENESCENCE 
0.663 1.873 0.154 
 
REGULATION_OF_CELLULAR_RESPONSE_T
O_HEAT 
0.521 1.850 0.185 
INTRACELLULAR_STEROID_HORMONE_REC
EPTOR_SIGNALING_PATHWAY 
0.522 1.838 0.186 
REGULATION_OF_TRANSCRIPTION_REGUL
ATORY_REGION_DNA_BINDING 
0.607 1.827 0.193 
 SPLICEOSOMAL_SNRNP_ASSEMBLY 0.577 1.818 0.201 
 
REGULATION_OF_SYNAPTIC_VESICLE_TRA
NSPORT 
0.621 1.787 0.271 
 LONG_TERM_MEMORY 0.642 1.786 0.254 
 
REGULATION_OF_HORMONE_METABOLIC_
PROCESS 
0.651 1.782 0.250 
HUMORAL_IMMUNE_RESPONSE_MEDIATED
_BY_CIRCULATING_IMMUNOGLOBULIN 
-0.662 -1.927 0.202 
 ACTIN_MYOSIN_FILAMENT_SLIDING -0.709 -1.870 0.237 
 
- Mixture treatment is a mixture of PGA, syringic acid and vanillic acid (3.3 µM 
each). 
- GSEA = gene set enrichment analysis, ES = enrichment score, NES = 
normalized enrichment score, FDR = false discovery rate (adjusted p-value). 
- Cells highlighted with yellow are significantly changed at FDR ≤ 0.05, while 
blue cells are significant at FDR ≤ 0.3. 
- Positive NES values = upregulated pathways, negative NES values = 
downregulated pathways 
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Table S1. 4: Summary of GSEA using Reactome database for mixture 
treatment. 
  
NAME ES NES FDR 
METABOLISM_OF_NON_CODING_RNA 0.592 1.952 0.087 
CYTOSOLIC_TRNA_AMINOACYLATION 0.685 1.932 0.060 
AMINO_ACID_TRANSPORT_ACROSS_T
HE_PLASMA_MEMBRANE 
0.657 1.810 0.183 
GLUCOSE_TRANSPORT 0.581 1.761 0.240 
DNA_REPAIR 0.456 1.756 0.201 
REGULATION_OF_GLUCOKINASE_BY_
GLUCOKINASE_REGULATORY_PROTEI
N 
0.588 1.729 0.222 
TRANSPORT_OF_RIBONUCLEOPROTEI
NS_INTO_THE_HOST_NUCLEUS 
0.582 1.722 0.202 
FANCONI_ANEMIA_PATHWAY 0.636 1.718 0.185 
TRNA_AMINOACYLATION 0.541 1.703 0.185 
RORA_ACTIVATES_CIRCADIAN_EXPRE
SSION 
0.579 1.685 0.195 
NEP_NS2_INTERACTS_WITH_THE_CEL
LULAR_EXPORT_MACHINERY 
0.573 1.677 0.189 
NOTCH1_INTRACELLULAR_DOMAIN_R
EGULATES_TRANSCRIPTION 
0.492 1.651 0.225 
CA_DEPENDENT_EVENTS 0.589 1.647 0.215 
INTERACTIONS_OF_VPR_WITH_HOST_
CELLULAR_PROTEINS 
0.532 1.640 0.211 
INFLUENZA_LIFE_CYCLE 0.402 1.639 0.199 
INTERFERON_ALPHA_BETA_SIGNALIN
G 
-0.530 -1.743 0.288 
COMPLEMENT_CASCADE -0.652 -1.667 0.219 
MUSCLE_CONTRACTION -0.537 -1.622 0.250 
 
- Mixture treatment is a mixture of PGA, syringic acid and vanillic acid (3.3 µM 
each). 
- GSEA = gene set enrichment analysis, ES = enrichment score, NES = 
normalized enrichment score, FDR = false discovery rate (adjusted p-value). 
- Cells highlighted with yellow are significantly changed at FDR ≤ 0.05, while 
blue cells are significant at FDR ≤ 0.3. 
- Positive NES values = upregulated pathways, negative NES values = 
downregulated pathways 
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Table S1. 5: Summary of GSEA using Gene Ontology database for vanillic 
acid treatment 
NAME ES NES FDR 
POSITIVE_REGULATION_OF_VIRAL_GENOME_
REPLICATION 
0.667 2.031 0.051 
CYCLIC_NUCLEOTIDE_CATABOLIC_PROCESS 0.785 2.030 0.026 
REGULATION_OF_NUCLEOSIDE_METABOLIC_
PROCESS 
0.605 1.899 0.161 
 
- GSEA = gene set enrichment analysis, ES = enrichment score, NES = 
normalized enrichment score, FDR = false discovery rate (adjusted p-value). 
- Cells highlighted with yellow are significantly changed at FDR ≤ 0.05, while 
blue cells are significant at FDR ≤ 0.3. 
- Positive NES values = upregulated pathways, negative NES values = 
downregulated pathways 
 
 
 
 
Table S1. 6: Summary of GSEA using Reactome database for vanillic acid 
treatment. 
NAME ES NES FDR 
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED
_GENES 
0.506 1.756 0.385 
TGF_BETA_RECEPTOR_SIGNALING_ACTIVATE
S_SMADS 
-0.672 -1.959 0.043 
BASIGIN_INTERACTIONS -0.637 -1.772 0.325 
DOWNREGULATION_OF_TGF_BETA_RECEPTO
R_SIGNALING 
-0.636 -1.762 0.248 
SIGNALING_BY_TGF_BETA_RECEPTOR_COMP
LEX 
-0.489 -1.715 0.301 
SPHINGOLIPID_DE_NOVO_BIOSYNTHESIS -0.572 -1.662 0.393 
 
- GSEA = gene set enrichment analysis, ES = enrichment score, NES = 
normalized enrichment score, FDR = false discovery rate (adjusted p-value). 
- Cells highlighted with yellow are significantly changed at FDR ≤ 0.05, while 
blue cells are significant at FDR ≤ 0.4. 
- Positive NES values = upregulated pathways, negative NES values = 
downregulated pathways. 
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Table S1. 7: Summary of GSEA using Gene Ontology database for 
syringic acid treatment 
NAME ES NES FDR 
CAMP_METABOLIC_PROCESS 0.737 2.070 0.034 
AORTA_DEVELOPMENT 0.664 2.066 0.018 
CORONARY_VASCULATURE_DEVELOPME
NT 
0.673 2.046 0.016 
POSITIVE_REGULATION_OF_TRANSCRIPTI
ON_FROM_RNA_POLYMERASE_II_PROMO
TER_INVOLVED_IN_CELLULAR_RESPONSE
_TO_CHEMICAL_STIMULUS 
0.726 1.993 0.032 
EMBRYONIC_CAMERA_TYPE_EYE_DEVEL
OPMENT 
0.706 1.976 0.034 
CYCLIC_NUCLEOTIDE_METABOLIC_PROC
ESS 
0.625 1.959 0.038 
CYCLIC_NUCLEOTIDE_CATABOLIC_PROCE
SS 
0.766 1.953 0.036 
RESPONSE_TO_ACTIVITY 0.602 1.936 0.042 
EMBRYONIC_EYE_MORPHOGENESIS 0.695 1.922 0.047 
ARTERY_DEVELOPMENT 0.553 1.894 0.066 
AORTA_MORPHOGENESIS 0.682 1.856 0.106 
POSITIVE_REGULATION_OF_FAT_CELL_DI
FFERENTIATION 
0.604 1.855 0.099 
REGULATION_OF_PROTEIN_IMPORT_INTO
_NUCLEUS_TRANSLOCATION 
0.692 1.835 0.116 
REGULATION_OF_SYNAPTIC_TRANSMISSI
ON_GABAERGIC 
0.683 1.816 0.140 
EYE_MORPHOGENESIS 0.500 1.807 0.146 
DNA_STRAND_ELONGATION_INVOLVED_IN
_DNA_REPLICATION 
-0.674 -1.952 0.203 
DNA_STRAND_ELONGATION -0.672 -1.936 0.130 
NUCLEOTIDE_EXCISION_REPAIR_DNA_GA
P_FILLING 
-0.634 -1.824 0.285 
 
- GSEA = gene set enrichment analysis, ES = enrichment score, NES = 
normalized enrichment score, FDR = false discovery rate (adjusted p-value). 
- Cells highlighted with yellow are significantly changed at FDR ≤ 0.05, while 
blue cells are significant at FDR ≤ 0.3. 
- Positive NES values = upregulated pathways, negative NES values = 
downregulated pathways. 
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Table S1. 8: Summary of GSEA using Reactom database for syringic acid 
treatment 
NAME ES NES FDR 
RORA_ACTIVATES_CIRCADIAN_EXPRESSION 0.669 1.886 0.110 
CIRCADIAN_REPRESSION_OF_EXPRESSION_
BY_REV_ERBA 
0.675 1.875 0.068 
GLOBAL_GENOMIC_NER_GG_NER -0.629 -1.992 0.029 
S_PHASE -0.502 -1.976 0.019 
SYNTHESIS_OF_DNA -0.498 -1.874 0.046 
DNA_STRAND_ELONGATION -0.613 -1.874 0.035 
LAGGING_STRAND_SYNTHESIS -0.702 -1.852 0.038 
M_G1_TRANSITION -0.493 -1.810 0.051 
G1_S_TRANSITION -0.458 -1.778 0.064 
ACTIVATION_OF_ATR_IN_RESPONSE_TO_RE
PLICATION_STRESS 
-0.559 -1.765 0.063 
ACTIVATION_OF_THE_PRE_REPLICATIVE_CO
MPLEX 
-0.564 -1.759 0.059 
EXTENSION_OF_TELOMERES -0.585 -1.705 0.094 
DNA_REPLICATION -0.408 -1.695 0.095 
TELOMERE_MAINTENANCE -0.493 -1.692 0.089 
FORMATION_OF_INCISION_COMPLEX_IN_GG
_NER 
-0.582 -1.638 0.131 
CYCLIN_E_ASSOCIATED_EVENTS_DURING_G
1_S_TRANSITION_ 
-0.458 -1.628 0.133 
MITOTIC_M_M_G1_PHASES -0.392 -1.624 0.129 
 
- GSEA = gene set enrichment analysis, ES = enrichment score, NES = 
normalized enrichment score, FDR = false discovery rate (adjusted p-value). 
- Cells highlighted with yellow are significantly changed at FDR ≤ 0.05, while 
blue cells are significant at FDR ≤ 0.25. 
- Positive NES values = upregulated pathways, negative NES values = 
downregulated pathways. 
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Table S1. 9: list of upregulated genes by phloroglucinaldehyde (10 µM) 
in THP-1 macrophages at adjusted p-value ≤ 0.3 using RNA sequencing 
 
Gene name Ensembl ID 
Log fold 
change 
p-value 
Adjusted 
p-value 
Fold 
change 
RPGRIP1L ENSG00000103494 0.51 0.00 0.11 1.4 
CD36 ENSG00000135218 0.27 0.00 0.13 1.2 
NA NA 0.54 0.00 0.14 1.4 
FABP4 ENSG00000170323 0.40 0.00 0.14 1.3 
HACL1 ENSG00000131373 0.28 0.00 0.14 1.2 
MAT2B ENSG00000038274 0.23 0.00 0.14 1.2 
FABP5 ENSG00000164687 0.19 0.00 0.14 1.1 
RBL1 ENSG00000080839 0.21 0.00 0.14 1.2 
PLIN2 ENSG00000147872 0.18 0.00 0.16 1.1 
SSB ENSG00000138385 0.21 0.00 0.17 1.2 
MFAP1 ENSG00000140259 0.23 0.00 0.19 1.2 
WDR48 ENSG00000114742 0.22 0.00 0.20 1.2 
DHX9 ENSG00000135829 0.19 0.00 0.21 1.1 
REPS1 ENSG00000135597 0.20 0.00 0.21 1.1 
ASXL2 ENSG00000143970 1.25 0.00 0.22 2.4 
NA NA 0.64 0.00 0.22 1.6 
PSAT1 ENSG00000135069 0.24 0.00 0.24 1.2 
OPN3 ENSG00000054277 0.21 0.00 0.24 1.2 
SEC24B ENSG00000138802 0.21 0.00 0.24 1.2 
HHLA3 ENSG00000197568 0.76 0.00 0.25 1.7 
CCNG2 ENSG00000138764 0.52 0.00 0.25 1.4 
WTH3DI ENSG00000233087 0.52 0.00 0.25 1.4 
NA NA 0.51 0.00 0.25 1.4 
C5orf42 ENSG00000197603 0.35 0.00 0.25 1.3 
NA NA 0.29 0.00 0.25 1.2 
GBP3 ENSG00000117226 0.29 0.00 0.25 1.2 
PLA2G12A ENSG00000123739 0.27 0.00 0.25 1.2 
LRRC4 ENSG00000128594 2.26 0.00 0.25 4.8 
AC006111.2 ENSG00000263235 0.17 0.00 0.25 1.1 
NA NA 0.52 0.00 0.26 1.4 
AC009303.4 ENSG00000279227 0.90 0.00 0.26 1.9 
NACA2 ENSG00000253506 0.72 0.00 0.26 1.7 
GPT2 ENSG00000166123 0.52 0.00 0.26 1.4 
ASIC1 ENSG00000110881 0.50 0.00 0.26 1.4 
PLEKHG1 ENSG00000120278 0.46 0.00 0.26 1.4 
SKA3 ENSG00000165480 0.42 0.00 0.26 1.3 
NFYA ENSG00000001167 0.41 0.00 0.26 1.3 
NPAT ENSG00000149308 0.35 0.00 0.26 1.3 
CAAP1 ENSG00000120159 0.30 0.00 0.26 1.2 
C4orf3 ENSG00000164096 0.29 0.00 0.26 1.2 
 256 
 
Table S1.9 continued 
 
Gene name Ensembl ID 
Log fold 
change 
p-value 
Adjusted 
p-value 
Fold 
change 
CFAP36 ENSG00000163001 0.28 0.00 0.26 1.2 
LINC00909 ENSG00000264247 0.28 0.00 0.26 1.2 
C5orf34 ENSG00000172244 0.26 0.00 0.26 1.2 
PIBF1 ENSG00000083535 0.25 0.00 0.26 1.2 
SPG20 ENSG00000133104 0.24 0.00 0.26 1.2 
TMEM55A ENSG00000155099 0.22 0.00 0.26 1.2 
DYNC1I2 ENSG00000077380 0.22 0.00 0.26 1.2 
RPS3AP6 ENSG00000234797 0.21 0.00 0.26 1.2 
MRPS30 ENSG00000112996 0.20 0.00 0.26 1.2 
ERMP1 ENSG00000099219 0.20 0.00 0.26 1.1 
ADCY1 ENSG00000164742 0.19 0.00 0.26 1.1 
SCOC ENSG00000153130 0.19 0.00 0.26 1.1 
TLR4 ENSG00000136869 0.19 0.00 0.26 1.1 
HIF1A ENSG00000100644 0.15 0.00 0.26 1.1 
SLC30A5 ENSG00000145740 0.15 0.00 0.26 1.1 
RCN2 ENSG00000117906 0.15 0.00 0.26 1.1 
PPIH ENSG00000171960 0.13 0.00 0.26 1.1 
HMGB1P6 ENSG00000259781 0.13 0.00 0.26 1.1 
MIR5703 ENSG00000284092 0.13 0.00 0.26 1.1 
FEM1B ENSG00000169018 0.12 0.00 0.26 1.1 
PEBP1 ENSG00000089220 0.11 0.00 0.26 1.1 
PLPBP ENSG00000147471 0.11 0.00 0.26 1.1 
RPL29P11 ENSG00000224858 0.34 0.00 0.26 1.3 
HSPE1 ENSG00000115541 0.49 0.00 0.28 1.4 
HAT1 ENSG00000128708 0.15 0.00 0.28 1.1 
RPSAP12 ENSG00000240087 0.32 0.00 0.28 1.2 
MRPL46 ENSG00000259494 0.28 0.00 0.28 1.2 
ENPP4 ENSG00000001561 0.20 0.00 0.28 1.2 
NCEH1 ENSG00000144959 0.19 0.00 0.28 1.1 
SMARCA5 ENSG00000153147 0.16 0.00 0.28 1.1 
CYCS ENSG00000172115 0.14 0.00 0.28 1.1 
DCLK3 ENSG00000163673 0.42 0.00 0.28 1.3 
NEK1 ENSG00000137601 0.29 0.00 0.28 1.2 
DDX10 ENSG00000178105 0.26 0.00 0.28 1.2 
AC009487.2 ENSG00000226121 0.19 0.00 0.28 1.1 
RALGAPB ENSG00000170471 0.18 0.00 0.28 1.1 
CCT4 ENSG00000115484 0.20 0.00 0.28 1.1 
MTMR9 ENSG00000104643 0.15 0.00 0.28 1.1 
GFM1 ENSG00000168827 0.14 0.00 0.28 1.1 
SCD ENSG00000099194 0.17 0.00 0.28 1.1 
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Table S1.9 continued 
 
Gene name Ensembl ID 
Log fold 
change 
p-value 
Adjusted 
p-value 
Fold 
change 
SACS ENSG00000151835 0.29 0.00 0.29 1.2 
GBE1 ENSG00000114480 0.17 0.00 0.29 1.1 
PCM1 ENSG00000078674 0.11 0.00 0.29 1.1 
USP28 ENSG00000048028 0.26 0.00 0.29 1.2 
ERCC8 ENSG00000049167 0.25 0.00 0.29 1.2 
PM20D2 ENSG00000146281 0.23 0.00 0.29 1.2 
SNRPD1 ENSG00000167088 0.19 0.00 0.29 1.1 
ABL2 ENSG00000143322 0.23 0.00 0.29 1.2 
TMSB10 ENSG00000034510 0.10 0.00 0.29 1.1 
ERCC6L ENSG00000186871 0.29 0.00 0.29 1.2 
PABPC1 ENSG00000070756 0.21 0.00 0.29 1.2 
NA NA 1.30 0.01 0.30 2.5 
LINC00942 ENSG00000249628 1.21 0.01 0.30 2.3 
MAGEA4 ENSG00000147381 1.02 0.01 0.30 2.0 
ZNF35 ENSG00000169981 0.99 0.01 0.30 2.0 
NA NA 0.93 0.01 0.30 1.9 
AC116347.1 ENSG00000238000 0.87 0.01 0.30 1.8 
CDKL1 ENSG00000100490 0.75 0.01 0.30 1.7 
DMC1 ENSG00000100206 0.63 0.01 0.30 1.6 
WDR31 ENSG00000148225 0.57 0.00 0.30 1.5 
AL590764.1 ENSG00000228427 0.52 0.01 0.30 1.4 
AC004080.2 ENSG00000253508 0.46 0.01 0.30 1.4 
BCYRN1 ENSG00000236824 0.42 0.00 0.30 1.3 
PLOD2 ENSG00000152952 0.41 0.01 0.30 1.3 
ZNF830 ENSG00000198783 0.36 0.00 0.30 1.3 
FKBP7 ENSG00000079150 0.35 0.01 0.30 1.3 
TTC21B ENSG00000123607 0.31 0.01 0.30 1.2 
SPIN4 ENSG00000186767 0.30 0.00 0.30 1.2 
EXTL2 ENSG00000162694 0.29 0.00 0.30 1.2 
CALN1 ENSG00000183166 0.28 0.00 0.30 1.2 
TOGARAM1 ENSG00000198718 0.28 0.01 0.30 1.2 
NA NA 0.27 0.01 0.30 1.2 
TPM3P9 ENSG00000241015 0.26 0.01 0.30 1.2 
CARNMT1 ENSG00000156017 0.25 0.01 0.30 1.2 
AKAP11 ENSG00000023516 0.23 0.01 0.30 1.2 
RPL36 ENSG00000130255 0.22 0.00 0.30 1.2 
UBE2C ENSG00000175063 0.22 0.01 0.30 1.2 
AC091959.3 ENSG00000275740 0.22 0.01 0.30 1.2 
TXNL4B ENSG00000140830 0.21 0.01 0.30 1.2 
MRPL39 ENSG00000154719 0.21 0.01 0.30 1.2 
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Table S1.9 continued  
 
Gene name Ensembl ID 
Log fold 
change 
p-value 
Adjusted 
p-value 
Fold 
change 
STAG1 ENSG00000118007 0.20 0.01 0.30 1.2 
ZKSCAN7 ENSG00000196345 0.20 0.01 0.30 1.1 
MRPL1 ENSG00000169288 0.19 0.01 0.30 1.1 
SECISBP2L ENSG00000138593 0.19 0.01 0.30 1.1 
SUZ12 ENSG00000178691 0.18 0.00 0.30 1.1 
ARRDC3 ENSG00000113369 0.18 0.01 0.30 1.1 
UBA6 ENSG00000033178 0.17 0.00 0.30 1.1 
LANCL1 ENSG00000115365 0.17 0.01 0.30 1.1 
ACAP2 ENSG00000114331 0.16 0.01 0.30 1.1 
RFC1 ENSG00000035928 0.15 0.01 0.30 1.1 
SESN3 ENSG00000149212 0.15 0.01 0.30 1.1 
AGPS ENSG00000018510 0.15 0.01 0.30 1.1 
TMSB4XP8 ENSG00000187653 0.15 0.00 0.30 1.1 
SRPK1 ENSG00000096063 0.15 0.01 0.30 1.1 
CDK1 ENSG00000170312 0.14 0.01 0.30 1.1 
PDS5A ENSG00000121892 0.14 0.01 0.30 1.1 
RCAN1 ENSG00000159200 0.14 0.00 0.30 1.1 
RUNDC1 ENSG00000198863 0.14 0.01 0.30 1.1 
TMA7 ENSG00000232112 0.13 0.01 0.30 1.1 
IRF2 ENSG00000168310 0.13 0.00 0.30 1.1 
PJA2 ENSG00000198961 0.11 0.01 0.30 1.1 
EIF1AX ENSG00000173674 0.11 0.01 0.30 1.1 
ZMPSTE24 ENSG00000084073 0.10 0.01 0.30 1.1 
TOP1 ENSG00000198900 0.10 0.01 0.30 1.1 
PLEK ENSG00000115956 0.10 0.01 0.30 1.1 
HNRNPA1P7 ENSG00000215492 0.12 0.01 0.30 1.1 
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Table S1. 10: list of downregulated genes by phloroglucinaldehyde (10 
µM) in THP-1 macrophages at adjusted p-value ≤ 0.3 using RNA 
sequencing 
 
Gene name EnsemblID 
Log fold 
change 
p-Value 
Adjusted p-
value 
Fold 
change 
ZBTB14 ENSG00000198081 -0.87 0.00 0.00 0.55 
RN7SL5P ENSG00000265735 -2.11 0.00 0.05 0.23 
AC133065.2 ENSG00000262222 -1.26 0.00 0.09 0.42 
MED31 ENSG00000108590 -0.47 0.00 0.09 0.72 
HSPA7 ENSG00000225217 -1.42 0.00 0.11 0.37 
SEMA6A ENSG00000092421 -0.69 0.00 0.11 0.62 
UNC93B1 ENSG00000110057 -0.23 0.00 0.11 0.85 
RN7SL4P ENSG00000263740 -2.16 0.00 0.13 0.22 
RN7SL2 ENSG00000274012 -1.92 0.00 0.13 0.26 
NA NA -6.97 0.00 0.14 0.01 
AC092384.2 ENSG00000259881 -1.50 0.00 0.14 0.35 
SNHG17 ENSG00000196756 -0.42 0.00 0.14 0.75 
IDUA ENSG00000127415 -0.41 0.00 0.14 0.75 
CCDC88B ENSG00000168071 -0.32 0.00 0.14 0.80 
7SK ENSG00000202198 -2.88 0.00 0.15 0.14 
C7 ENSG00000112936 -5.18 0.00 0.16 0.03 
SP140L ENSG00000185404 -0.57 0.00 0.17 0.67 
PIDD1 ENSG00000177595 -0.38 0.00 0.17 0.77 
MIB2 ENSG00000197530 -0.32 0.00 0.17 0.80 
OPLAH ENSG00000178814 -0.26 0.00 0.19 0.83 
CD37 ENSG00000104894 -0.26 0.00 0.19 0.84 
ERP27 ENSG00000139055 -0.52 0.00 0.20 0.70 
RN7SKP203 ENSG00000200488 -2.71 0.00 0.20 0.15 
IRF5 ENSG00000128604 -0.41 0.00 0.21 0.75 
AL139099.5 ENSG00000283029 -1.43 0.00 0.21 0.37 
NLGN2 ENSG00000169992 -0.81 0.00 0.21 0.57 
SYTL1 ENSG00000142765 -0.54 0.00 0.21 0.69 
ARL2 ENSG00000213465 -0.41 0.00 0.21 0.75 
ADGRL1 ENSG00000072071 -0.37 0.00 0.21 0.77 
RELT ENSG00000054967 -0.17 0.00 0.22 0.89 
PHLDB2 ENSG00000144824 -3.84 0.00 0.23 0.07 
PDXDC2P-
NPIPB14P 
ENSG00000196696 -0.50 0.00 0.23 0.70 
KCNQ1OT1 ENSG00000269821 -0.45 0.00 0.24 0.73 
NA NA -3.88 0.00 0.24 0.07 
CHKA ENSG00000110721 -0.29 0.00 0.24 0.82 
UMOD ENSG00000169344 -3.76 0.00 0.25 0.07 
YTHDF2P1 ENSG00000270503 -3.13 0.00 0.25 0.11 
UBE2Q2P1 ENSG00000189136 -0.97 0.00 0.25 0.51 
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Table S1.10 continued 
 
Gene name EnsemblID 
Log fold 
change 
p-Value 
Adjusted p-
value 
Fold 
change 
MZF1 ENSG00000099326 -0.53 0.00 0.25 0.69 
NA NA -0.47 0.00 0.25 0.72 
ANKS3 ENSG00000168096 -0.45 0.00 0.25 0.73 
RHBDF1 ENSG00000007384 -0.37 0.00 0.25 0.77 
IRF7 ENSG00000185507 -0.36 0.00 0.25 0.78 
PARVG ENSG00000138964 -0.26 0.00 0.25 0.84 
PKN3 ENSG00000160447 -0.23 0.00 0.25 0.85 
PNPLA2 ENSG00000177666 -0.22 0.00 0.25 0.86 
ARHGEF1 ENSG00000076928 -0.22 0.00 0.25 0.86 
NAPRT ENSG00000147813 -0.15 0.00 0.25 0.90 
PNKD ENSG00000127838 -0.14 0.00 0.25 0.91 
AC233280.2 ENSG00000271662 -1.41 0.00 0.25 0.38 
MST1L ENSG00000186715 -0.73 0.00 0.25 0.60 
NOS2 ENSG00000007171 -0.40 0.00 0.25 0.76 
ALOX5 ENSG00000012779 -0.26 0.00 0.25 0.83 
RN7SL3 ENSG00000278771 -1.34 0.00 0.25 0.39 
NA NA -1.04 0.00 0.25 0.49 
IKBKGP1 ENSG00000275882 -0.19 0.00 0.26 0.88 
ALDOB ENSG00000136872 -3.10 0.00 0.26 0.12 
ABHD17AP4 ENSG00000229107 -3.09 0.00 0.26 0.12 
LIMCH1 ENSG00000064042 -2.94 0.00 0.26 0.13 
RMRP ENSG00000269900 -1.89 0.00 0.26 0.27 
ADAMTS12 ENSG00000151388 -1.80 0.00 0.26 0.29 
TSACC ENSG00000163467 -1.41 0.00 0.26 0.38 
CUBN ENSG00000107611 -1.37 0.00 0.26 0.39 
C11orf94 ENSG00000234776 -1.30 0.00 0.26 0.41 
SNORD3A ENSG00000263934 -1.19 0.00 0.26 0.44 
AL589935.1 ENSG00000232295 -1.09 0.00 0.26 0.47 
AC006277.1 ENSG00000279452 -0.94 0.00 0.26 0.52 
NA NA -0.91 0.00 0.26 0.53 
MEPE ENSG00000152595 -0.90 0.00 0.26 0.54 
TAS1R3 ENSG00000169962 -0.86 0.00 0.26 0.55 
LRRC24 ENSG00000254402 -0.81 0.00 0.26 0.57 
MIR503HG ENSG00000223749 -0.78 0.00 0.26 0.58 
LBX2 ENSG00000179528 -0.64 0.00 0.26 0.64 
ANO9 ENSG00000185101 -0.63 0.00 0.26 0.65 
CACTIN-AS1 ENSG00000226800 -0.57 0.00 0.26 0.67 
LIMS2 ENSG00000072163 -0.53 0.00 0.26 0.69 
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Table S1.10 continued 
 
Gene name EnsemblID 
Log fold 
change 
p-Value 
Adjusted p-
value 
Fold 
change 
AC080038.1 ENSG00000274565 -0.53 0.00 0.26 0.69 
OSMR ENSG00000145623 -0.46 0.00 0.26 0.73 
AC087499.1 ENSG00000188013 -0.42 0.00 0.26 0.75 
CENPT ENSG00000102901 -0.41 0.00 0.26 0.75 
TRPT1 ENSG00000149743 -0.40 0.00 0.26 0.76 
SLC22A31 ENSG00000259803 -0.39 0.00 0.26 0.77 
SLC22A18 ENSG00000110628 -0.36 0.00 0.26 0.78 
WDR24 ENSG00000127580 -0.35 0.00 0.26 0.78 
NEK8 ENSG00000160602 -0.34 0.00 0.26 0.79 
IFFO1 ENSG00000010295 -0.33 0.00 0.26 0.80 
KIAA1614 ENSG00000135835 -0.33 0.00 0.26 0.80 
ADCK5 ENSG00000173137 -0.31 0.00 0.26 0.81 
SUSD3 ENSG00000157303 -0.31 0.00 0.26 0.81 
DENND6B ENSG00000205593 -0.31 0.00 0.26 0.81 
ABCA7 ENSG00000064687 -0.30 0.00 0.26 0.81 
LPAR2 ENSG00000064547 -0.30 0.00 0.26 0.81 
FCHO1 ENSG00000130475 -0.26 0.00 0.26 0.83 
CECR6 ENSG00000183307 -0.26 0.00 0.26 0.84 
POLR2J4 ENSG00000214783 -0.26 0.00 0.26 0.84 
ARRDC2 ENSG00000105643 -0.23 0.00 0.26 0.85 
WDR55 ENSG00000120314 -0.21 0.00 0.26 0.86 
UBA7 ENSG00000182179 -0.21 0.00 0.26 0.87 
FASTK ENSG00000164896 -0.20 0.00 0.26 0.87 
DGAT1 ENSG00000185000 -0.20 0.00 0.26 0.87 
PPP1R16A ENSG00000160972 -0.19 0.00 0.26 0.88 
ARRDC1 ENSG00000197070 -0.18 0.00 0.26 0.88 
TMEM55B ENSG00000165782 -0.18 0.00 0.26 0.88 
TMEM259 ENSG00000182087 -0.18 0.00 0.26 0.88 
JAG2 ENSG00000184916 -0.17 0.00 0.26 0.89 
CHI3L1 ENSG00000133048 -0.15 0.00 0.26 0.90 
NDUFS7 ENSG00000115286 -0.15 0.00 0.26 0.90 
PPP1R12C ENSG00000125503 -0.14 0.00 0.26 0.90 
ARSA ENSG00000100299 -0.14 0.00 0.26 0.91 
P3H1 ENSG00000117385 -0.13 0.00 0.26 0.92 
SCRIB ENSG00000180900 -0.11 0.00 0.26 0.92 
SLC12A9 ENSG00000146828 -0.23 0.00 0.27 0.85 
NA NA -1.82 0.00 0.28 0.28 
AC051649.2 ENSG00000283787 -0.83 0.00 0.28 0.56 
GPC2 ENSG00000213420 -0.71 0.00 0.28 0.61 
 
 262 
 
Table S1.10 continued 
 
Gene name EnsemblID 
Log fold 
change 
p-Value 
Adjusted p-
value 
Fold 
change 
AC024270.1 ENSG00000166503 -0.47 0.00 0.28 0.72 
IRF3 ENSG00000126456 -0.39 0.00 0.28 0.76 
OFD1 ENSG00000046651 -0.17 0.00 0.28 0.89 
NA NA -2.33 0.00 0.28 0.20 
SYNE2 ENSG00000054654 -1.76 0.00 0.28 0.30 
AP001059.2 ENSG00000275799 -0.94 0.00 0.28 0.52 
AL365277.1 ENSG00000182109 -0.45 0.00 0.28 0.73 
PTPRM ENSG00000173482 -2.43 0.00 0.28 0.19 
AC138356.1 ENSG00000183154 -0.54 0.00 0.28 0.69 
IFNAR2 ENSG00000159110 -0.53 0.00 0.28 0.69 
SSPO ENSG00000197558 -0.48 0.00 0.28 0.72 
MST1P2 ENSG00000186301 -0.39 0.00 0.28 0.76 
DOK3 ENSG00000146094 -0.20 0.00 0.28 0.87 
GSDMD ENSG00000104518 -0.19 0.00 0.28 0.88 
TGFB1 ENSG00000105329 -0.15 0.00 0.28 0.90 
AC007952.4 ENSG00000262202 -2.06 0.00 0.28 0.24 
AC096733.2 ENSG00000273472 -0.70 0.00 0.28 0.62 
CCDC130 ENSG00000104957 -0.43 0.00 0.28 0.74 
ZNF785 ENSG00000197162 -0.41 0.00 0.28 0.76 
NA NA -0.40 0.00 0.28 0.76 
GRAMD4 ENSG00000075240 -0.13 0.00 0.28 0.92 
BAIAP2L2 ENSG00000128298 -1.80 0.00 0.28 0.29 
GDPD5 ENSG00000158555 -0.19 0.00 0.29 0.88 
AC127521.1 ENSG00000262823 -1.11 0.00 0.29 0.46 
PDLIM7 ENSG00000196923 -0.21 0.00 0.29 0.86 
SAMD10 ENSG00000130590 -1.21 0.00 0.29 0.43 
MADCAM1 ENSG00000099866 -1.17 0.00 0.29 0.45 
SLC11A1 ENSG00000018280 -0.31 0.00 0.29 0.81 
NADK ENSG00000008130 -0.20 0.00 0.29 0.87 
RBBP4 ENSG00000162521 -0.44 0.00 0.29 0.74 
PGA4 ENSG00000229183 -0.40 0.00 0.29 0.76 
PNPLA7 ENSG00000130653 -0.35 0.00 0.29 0.79 
ASB16-AS1 ENSG00000267080 -0.31 0.00 0.29 0.81 
AL031846.2 ENSG00000279833 -0.85 0.00 0.29 0.55 
TCAF2 ENSG00000170379 -0.71 0.00 0.29 0.61 
MBD6 ENSG00000166987 -0.35 0.00 0.29 0.78 
RAB44 ENSG00000255587 -0.29 0.00 0.29 0.82 
AC090114.2 ENSG00000273270 -0.26 0.00 0.29 0.84 
DHTKD1 ENSG00000181192 -0.20 0.00 0.29 0.87 
AP5Z1 ENSG00000242802 -0.18 0.00 0.29 0.88 
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Gene name EnsemblID 
Log fold 
change 
p-Value 
Adjusted 
p-value 
Fold 
change 
OGFR ENSG00000060491 -0.13 0.00 0.29 0.91 
CYBA ENSG00000051523 -0.11 0.00 0.29 0.92 
AC048382.5 ENSG00000275120 -2.74 0.00 0.29 0.15 
SDCBP2 ENSG00000125775 -0.77 0.00 0.29 0.59 
COL9A2 ENSG00000049089 -0.35 0.00 0.29 0.78 
ARHGAP27P1-
BPTFP1-KPNA2P3 
ENSG00000215769 -0.33 0.00 0.29 0.80 
MAN2C1 ENSG00000140400 -0.30 0.00 0.29 0.81 
ZMIZ2 ENSG00000122515 -0.21 0.00 0.29 0.86 
STK25 ENSG00000115694 -0.18 0.00 0.29 0.89 
ELAC1 ENSG00000141642 -0.17 0.00 0.29 0.89 
NBDY ENSG00000204272 -0.72 0.00 0.29 0.61 
AQP2 ENSG00000167580 -3.46 0.01 0.30 0.09 
PCK1 ENSG00000124253 -2.53 0.01 0.30 0.17 
AC021016.3 ENSG00000273361 -2.24 0.00 0.30 0.21 
PLP1 ENSG00000123560 -1.95 0.01 0.30 0.26 
AL020996.1 ENSG00000228172 -1.07 0.00 0.30 0.48 
TMEM79 ENSG00000163472 -1.01 0.01 0.30 0.50 
AC138028.6 ENSG00000278341 -0.94 0.01 0.30 0.52 
EPS8L2 ENSG00000177106 -0.87 0.01 0.30 0.55 
OLFM3 ENSG00000118733 -0.78 0.01 0.30 0.58 
DNM1P35 ENSG00000246877 -0.71 0.00 0.30 0.61 
PROC ENSG00000115718 -0.69 0.01 0.30 0.62 
AL355075.5 ENSG00000259162 -0.67 0.01 0.30 0.63 
AC073957.3 ENSG00000273151 -0.66 0.01 0.30 0.63 
AC005253.1 ENSG00000268030 -0.66 0.00 0.30 0.63 
AC012615.6 ENSG00000267244 -0.65 0.01 0.30 0.64 
NA NA -0.61 0.00 0.30 0.66 
MLLT11 ENSG00000213190 -0.59 0.01 0.30 0.66 
AL390066.1 ENSG00000224950 -0.59 0.00 0.30 0.67 
RPARP-AS1 ENSG00000269609 -0.54 0.01 0.30 0.69 
ZNF789 ENSG00000198556 -0.52 0.01 0.30 0.70 
MROH6 ENSG00000204839 -0.50 0.01 0.30 0.71 
ZFP41 ENSG00000181638 -0.49 0.00 0.30 0.71 
CEACAM4 ENSG00000105352 -0.46 0.01 0.30 0.73 
ATG16L2 ENSG00000168010 -0.44 0.01 0.30 0.73 
AMT ENSG00000145020 -0.44 0.00 0.30 0.74 
CAPRIN2 ENSG00000110888 -0.42 0.01 0.30 0.75 
AKT2 ENSG00000105221 -0.41 0.01 0.30 0.76 
ADAMTS13 ENSG00000160323 -0.40 0.01 0.30 0.76 
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Gene name EnsemblID 
Log fold 
change 
p-Value 
Adjusted p-
value 
Fold 
change 
MTMR9LP ENSG00000220785 -0.40 0.00 0.30 0.76 
NPIPB12 ENSG00000169203 -0.39 0.01 0.30 0.76 
AC244502.1 ENSG00000251002 -0.39 0.01 0.30 0.76 
STOM ENSG00000148175 -0.37 0.00 0.30 0.77 
ZNF783 ENSG00000204946 -0.34 0.01 0.30 0.79 
IL3RA ENSG00000185291 -0.33 0.00 0.30 0.80 
SUGP2 ENSG00000064607 -0.33 0.01 0.30 0.80 
STAG3L5P ENSG00000242294 -0.33 0.01 0.30 0.80 
DCAF8 ENSG00000132716 -0.30 0.01 0.30 0.81 
SUZ12P1 ENSG00000264538 -0.29 0.01 0.30 0.82 
ADCY4 ENSG00000129467 -0.29 0.01 0.30 0.82 
ZNF586 ENSG00000083828 -0.28 0.00 0.30 0.82 
DYNLL2 ENSG00000264364 -0.27 0.01 0.30 0.83 
TMEM80 ENSG00000177042 -0.27 0.01 0.30 0.83 
MMP17 ENSG00000198598 -0.26 0.01 0.30 0.83 
ZNF511 ENSG00000198546 -0.26 0.01 0.30 0.83 
PRR14 ENSG00000156858 -0.25 0.01 0.30 0.84 
IL21R ENSG00000103522 -0.25 0.01 0.30 0.84 
MYO1G ENSG00000136286 -0.24 0.01 0.30 0.85 
CBS ENSG00000160200 -0.24 0.00 0.30 0.85 
MICAL1 ENSG00000135596 -0.22 0.01 0.30 0.86 
GBA2 ENSG00000070610 -0.21 0.01 0.30 0.87 
MRI1 ENSG00000037757 -0.17 0.00 0.30 0.89 
PRKAB1 ENSG00000111725 -0.16 0.01 0.30 0.89 
PITPNM1 ENSG00000110697 -0.16 0.01 0.30 0.90 
L1CAM ENSG00000198910 -0.15 0.00 0.30 0.90 
REXO1 ENSG00000079313 -0.14 0.00 0.30 0.91 
ABCD1 ENSG00000101986 -0.13 0.01 0.30 0.91 
NCF4 ENSG00000100365 -0.12 0.01 0.30 0.92 
NECTIN2 ENSG00000130202 -0.12 0.00 0.30 0.92 
ICAM5 ENSG00000105376 -0.44 0.01 0.30 0.74 
FSCN1 ENSG00000075618 -0.08 0.01 0.30 0.95 
TPM2 ENSG00000198467 -0.46 0.01 0.30 0.73 
STX1A ENSG00000106089 -0.42 0.01 0.30 0.75 
KIFC2 ENSG00000167702 -0.52 0.01 0.30 0.70 
DNPEP ENSG00000123992 -0.16 0.01 0.30 0.89 
NA NA -0.59 0.01 0.30 0.67 
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1. Summary 
Human intervention trials with anthocyanin-rich berry fruits/extracts such as 
whole strawberries, elderberry juice and whortleberry extracts, and purified 
anthocyanins from a mixture of blackcurrant and bilberry have been shown to 
beneficially alter biological markers for CVD risk, with beneficial effects on lipid 
profiles common across these studies. The primary aim of the current study is 
to directly compare the two major types of anthocyanins found in the diet; 
cyanidin-type and delphinidin-type.  In a double-blind, randomized, 3-arm 
crossover trial we aim to recruit 50 participants to consume capsules 
containing (i) a bilberry extract providing 320 mg anthocyanins (delphinidin-
type), (ii) a black rice extract providing 320 mg anthocyanins (cyanidin-type) 
and (iii) a placebo control. Capsules for each treatment arm will be consumed 
for a period of 28 days with a washout period of at least 4 weeks in-between. 
Samples will be collected at the start (day 1) and end (day 29) of each 
treatment period. Changes in circulating LDL-Cholesterol will be evaluated as 
a primary outcome measure in this study. In addition, total/HDL_cholesterol & 
triglycerides, other markers for cardio-metabolic risk (blood glucose, 
fructosamine and insulin), markers for lipid metabolism (cholesterol efflux 
capacity & PON-1 activity) and circulating bile acids and bile acid derivatives will 
be evaluated. In a subset of participants (n= 24) we will also investigate the 
relationship between bilberry and black rice anthocyanin ingestion on RNA 
expression profiles that are known to be involved in atherosclerosis, non-
alcoholic fatty liver disease and reverse cholesterol transport as well as faecal 
excretion of bile acids and lipids.  Should more resources become available we 
will also determine the effects of the interventions on cardio-metabolic disease 
related microRNA’s and gut microbiota profiles in this subset of participants. 
Dr Paul Kroon (a Quadram Institute Bioscience Research Leader) is Chief 
Investigator for this study. The study will be conducted and managed at the 
Quadram Institute Bioscience (QIB) by Wendy Hollands (research 
scientist/study manager). Other members of the research group (Dr Priscilla 
Day, Dr Natalia Perez, Mark Philo, Jasmine Percival, Emad Shehata, Dr 
Supriya Yadav and Hassan Aboufarrag) will be required to assist. This study 
is funded through the Food and Health Institute Strategic Programme grant to 
QIB.  
 
2. Scientific Background 
  
Dietary anthocyanins 
 Flavonoids are phenolic compounds present in plant based foods and 
beverages. Anthocyanins are a sub-class of flavonoid that exist in a variety of 
berry fruits such as blueberry, bilberry, raspberry, strawberry and other foods 
such as aubergine skins and black rice. Anthocyanins are what confer the red, 
black, purple and blue colours of anthocyanin rich foods. The daily 
consumption of anthocyanins is reported to range from 29 – 153 mg/d in 
European countries [1]. More than 90% of our intake of anthocyanins is derived 
from soft fruit and is therefore readily incorporated into the habitual diet. There 
are three main types of anthocyanins based on the number of hydroxyl groups 
on the B-ring; pelargonidin-type (monohydroxy), cyanidin-type (dihydroxy) and 
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delphinidin-type (trihydroxy) (see Figure 1). Although there are numerous 
substitutions (e.g. glycosylation, methylation, acylation) that give rise to a 
much larger number of structures, all anthocyanins are derived from these 
three structures, and the important B-ring metabolites will also be derived from 
these three structures. The major anthocyanins in human diets are the 
cyanidin-type and delphinidin-type.  
 Epidemiological evidence indicates that those consuming the highest 
quantities of anthocyanins are at a lower risk of developing cardiovascular 
disease (CVD) [2-4]. These observations are substantiated by several 
published reports from randomized controlled trials (RCT’s) providing evidence 
that consumption of anthocyanin rich foods/extracts such as whole 
strawberries [5, 6], elderberry juice [7] and whortleberry extracts [8] have 
beneficial effects on biomarkers of CVD with beneficial effects on lipid profiles 
common across these studies.  
 
 
 
Dyslipidaemia and atherosclerosis 
 Atherosclerosis is an underlying pathophysiological cause of CVD and is 
characterized, in part at least, by dyslipidaemia; an elevation in LDL 
cholesterol and triglycerides and a reduced conc. HDL cholesterol, either 
singly or in combination. Cholesterol is predominantly produced in the liver. 
LDL particles transport cholesterol away from the liver and deliver it into the 
peripheral tissues. Once inside the vessel wall, LDL cholesterol is susceptible 
to oxidation by free radicals that are produced by endothelial cells, and 
oxidized LDL drives the atherosclerotic process. HDL on the other hand is 
known to protect against the development of atherosclerosis by mediating a 
process called reverse cholesterol transport; a process by which cholesterol is 
transported from the peripheral tissues back to the liver for conversion to bile 
acids and excretion via the bile, thus inhibiting atherosclerosis. A critical part 
in the reverse cholesterol transport process is the transfer of cholesterol from 
cells to circulating HDL’s and this function can be measured as the cholesterol 
efflux capacity (CEC) of serum.  It is not only the levels of HDL that are 
important, its quality is also important. For example, paroxinase-1 (PON-1) is 
a protein which, in serum, is almost exclusively located on HDL. PON-1 has 
been the focus of research activities because of its capacity to stimulate 
Figure 1. Chemical structures of the two major dietary anthocyanin types, cyanidin
and delphinidin. In plant foods, anthocyanins are always present as O-linked conjugates
with sugars. For example, the major anthocyanin in black rice is cyanidin-3-O-glucoside.
The B-ring is also important because it is the main source of gut microbiota-derived
metabolites that have been shown to be accumulate in peripheral blood.
A A
B
C
B
C
Cyanidin (dihydroxy B-ring) Delphinidin (trihydroxy B-ring)
3’3’ 4’
5’
4’
3 3
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cholesterol efflux and protect HDL and LDL from oxidative modifications, thus 
inhibiting atherosclerotic development. In fact, there is a suggestion that PON-
1 might be a better marker for risk of atherosclerotic CVD compared with HDL 
cholesterol [9]. PON1 genotype is also crucial, since it has been shown that 
the single nucleotide polymorphisms that alter amino acids located at position 
55 (leucine/L or methionine/M) and 192 (arginine/Q or glutamine/R) of PON1 
have a profound effect on the lipid peroxide hydrolytic activity of PON1 that is 
important in protecting LDL from oxidation, and that people with 55-M/M and 
192-Q/Q genotypes gain greater protection against CVD [10]. MicroRNA’s are 
small non-coding RNA molecules that have been shown to regulate gene 
expression and have been implicated in atherosclerosis and CVD risk. Several 
microRNA’s are known to correlate with disease states such as atherosclerosis 
(mirs 33 and 758) and non-alcoholic fatty liver disease (mirs122, 192, 19a and 
19b) [11, 12]. Other microRNA’s (mirs 223, 24, 342p, 17 and 624) have been 
directly associated with familial hypercholesterolemia [13, 14]. 
 
Effects of anthocyanin consumption on lipids/lipoproteins and CVD risk 
 Berry fruit extract and anthocyanin supplementation has been shown to 
increase HDL cholesterol concentrations [8, 15], enhance HDL-associated 
PON-1 activity [16] and promote cholesterol efflux capacity [16] in subjects with 
hypercholesterolemia. Similarly, in a recent systematic review of RCT’s [17] 
assessing the impact of anthocyanins on biomarkers of CVD risk, nine studies 
included LDL cholesterol as an outcome evaluated for statistical significance in 
the intervention group compared with a control group. Of these nine studies, 
four reported improvements in LDL cholesterol. Of note, is that these four 
studies were conducted in a population of individuals already hyperlipidaemic 
with a total cholesterol conc. ≥ 5.17mmol/L upon enrolment to the study.  For 
example, in the trial conducted by Zhu et al [18], upon which the power 
calculations for the proposed study has been based, the mean total and LDL 
cholesterol conc. was 6.5 and 3.5 mmol/L respectively, derived from a study 
population recruited with a total cholesterol conc. ranging between 5.17 – 8 
mmol/L at eligibility assessment.  
Bile acids are synthesised from cholesterol in the liver and later transported 
to the small intestine for re-absorption or subsequent excretion in the faeces. 
The conversion of cholesterol into bile acids and subsequent faecal excretion is 
the final step in the reverse cholesterol transport process described above. The 
initial products of the bile acid synthetic pathway are referred to as primary bile 
acids. The action of intestinal bacterial flora on primary bile acids results in the 
formation of secondary bile acids. As such, the quantity and composition of bile 
acids is determined by the intestinal microbiota which in turn has been shown to 
correlate with the risk of atherosclerotic development [19, 20].Thus it is 
considered important to determine how intestinal microbiota relates to 
atherosclerotic disease markers such as bile acids, LDL/HDL cholesterol and 
whether their profile can be modulated by anthocyanins.   
 
 
Glycaemic control and CVD risk 
 271 
 
Epidemiological evidence also supports an association between glycaemic 
control and CVD risk [21]. Fructosamine is a glycosylated protein that reflects 
cumulative glycaemic control in humans over the short term. There is evidence 
that glycated proteins are increased in non-diabetic subjects [22, 23] and that 
the increase is associated with insulin resistance [22]. As insulin resistance 
progresses, increased blood glucose levels ensue.  Insulin resistance is 
associated with abnormal lipid profiles [24]. It is well documented that ingestion 
of berry anthocyanins has an acute beneficial effect on blood glucose status 
by delaying carbohydrate digestion and inhibiting the rate of glucose 
absorption across the intestine [25].  However, the literature evidence for the 
long term effects of ingestion of berry anthocyanins on glucose and insulin 
status is not entirely clear.  
 
Anthocyanins from bilberry and black rice 
 Bilberry fruit (Vaccinium myrtillus L) and black rice (Oryza sativa L.) are 
particularly rich sources of anthocyanins.  Bilberry fruit is related to (albeit distinct 
from) the blueberry. Bilberries are reported to contain ~ 285 mg 
anthocyanins/100g fresh fruit and the majority of the anthocyanins are of the 
delphinidin-type [26]. Black rice is a special cultivar of rice and is reported to 
contain ~ 300 mg anthocyanins/100g [27]. Black rice contains exclusively 
cyanidin-type anthocyanins, mainly cyanidin (92 %) with a small amount of 
peonidin (8 %) which is 3-O-methyl-peonidin [28]. Thus, the anthocyanins in 
black rice are largely di-hydroxy B-ring anthocyanins whilst those in bilberry fruit 
are largely tri-hydroxy anthocyanins (see Figure 1). The relationship between 
anthocyanin structure and biological activity is not well understood but there is 
evidence to indicate that it may influence both absorption [29] and subsequent 
bioactivity [30]. 
 
Purpose of the proposed intervention trial 
 In the proposed study we aim to investigate the ability of each of the two major 
dietary types of anthocyanins to improve biomarkers of cardiovascular health in 
hyperlipidaemic individuals by assessing the effects on circulating 
cholesterol/lipids (total/HDL/LDL cholesterol & triglycerides) and markers of 
cardio-metabolic risk (blood glucose, fructosamine and insulin). We also aim to 
determine the effects of supplementing diets with these two anthocyanin types 
on bile acids and markers for lipid metabolism (CEC & PON-1 activity) and 
determine the relationship between diet-mediated changes in PON-1 activity 
and PON-1 genotype. In a subset of participants (n=24) we will also investigate 
the effects of dietary supplementation with bilberry (trihydroxy) and black rice 
(dihydroxy) anthocyanins  on the expression of microRNAs that are known to 
be involved in atherosclerosis, non-alcoholic fatty liver disease and reverse 
cholesterol transport processes, and on faecal excretion of bile acids and lipids.  
Should more resources become available during the course of the trial, we will 
also determine the effects of the interventions on cardio-metabolic disease 
related microRNA’s as well as gut microbiota profiles in this subset of 
participants. 
3. Study hypotheses 
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● Daily consumption for 28 days of a bilberry extract delivering a 320 mg 
dose of anthocyanins will significantly reduce LDL cholesterol compared 
with a placebo control in individuals with higher than optimal plasma 
cholesterol concentrations. 
 
● Daily consumption for 28 days of a black rice extract delivering a 320 mg 
dose of anthocyanins will significantly reduce LDL cholesterol compared 
with a placebo control in individuals with higher than optimal plasma 
cholesterol concentrations. 
 
4. Study Objectives  
 
Primary objective 
 
To determine the effects of 28 days dietary supplementation with bilberry 
fruit and black rice-derived anthocyanins on circulating levels of LDL 
cholesterol.   
 
Secondary objectives 
 
To determine the effects of 28 days dietary supplementation with bilberry 
fruit and black rice derived anthocyanins on other biomarkers related to 
vascular function (e.g. total cholesterol, HDL cholesterol and triglycerides), 
and glycaemic control (glucose, insulin, fructosamine). 
 
To investigate the effects of bilberry fruit and black rice derived 
anthocyanin ingestion on circulating bile acids and bile acid derivatives, 
PON-1 activity and cholesterol efflux capacity, and determine the 
relationship between diet mediated changes in Pon-1 activity and PON-1 
genotype affecting PON-1 protein at positions 55 and 192.  
 
To investigate in the sub-set of participants the relationship between 
bilberry fruit and black rice derived anthocyanin ingestion on (i) expression 
of microRNAs that have been implicated in atherosclerosis, non-alcoholic 
fatty liver disease and reverse cholesterol transport and (ii) faecal 
excretion of bile acids and lipids.  
 
Should more resources become available during the course of the trial we 
will also determine the effects of the interventions on gut microbiota 
profiles and cardio-metabolic disease related microRNA’s in this subset of 
participants.  
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5. Study Design 
A randomized, double blind, placebo-controlled, three-arm crossover trial 
(see fig 2 for overview) will be undertaken to assess the effects of (i) a bilberry 
extract providing 320 mg/d anthocyanins, (ii) a black rice extract providing 320 
mg/d anthocyanins and, (iii) a placebo control. The test materials will be 
encapsulated. Each test arm will comprise a 28-day treatment period which 
will be identical in nature (except for the test compound consumed) and 
separated by a washout period of at least 4 weeks. For 2 weeks prior to 
commencing the first study arm and then for the duration of the entire study 
participants will be required to restrict berry fruit consumption to a combined 
maximum of 3 portions per week. However, berry fruits will be completely 
excluded from the diet for the 24-h period immediately preceding the pre and 
post intervention assessment days.   
 
 
 
5.1 Basic inclusion criteria 
● Men and women ≥ 45 years of age 
● Total cholesterol ≥ 5.0 mmol/L 
 
5.2 Basic exclusion criteria 
● Smokers (or stopped smoking for less than 3 months) 
● Medical conditions that are judged to affect the primary outcome measure 
   for this study or which may compromise the well-being of the participant e.g. 
   diabetes. This will be assessed on a case by case basis.  
● Prescribed and non-prescribed medications that may affect the primary 
    outcome measure for this study e.g. lipid lowering therapy (this will be 
assessed on a case by case basis).  
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● Dietary supplements judged to affect the study data unless the participant is 
willing to discontinue them for 4 weeks preceding the start of the study and 
for the duration of the study. (This will be assessed on a case by case basis) 
● Use foods for lowering cholesterol e.g. benecol, flora proactive (this will be 
assessed on a case by case basis). 
● Regular/recent use of colonic irrigation or other bowel cleansing techniques. 
● Intend to change the normal use of pre or probiotics during the study e.g. if 
participants do not take these products then we do not want them start but 
equally if they do take them regularly we do not want them to stop during 
the study. (only applies to those collecting faecal samples) 
● Bowel movements ≤ 3 times per week (only applies to those collecting faecal 
samples) 
● Gastro-intestinal diseases (excluding hiatus hernia unless symptomatic or 
   study intervention/procedure is contra-indicated). 
● Parallel participation in another research project which involves dietary 
    intervention 
● Participation in another research project which has involved blood sampling 
   within the last four months unless the total amount of combined blood from 
   both studies does not exceed 470 ml.  
● Has donated or intends to donate blood within 16 weeks prior to or during 
   the study period. 
● Any person related to or living with any member of the study team 
● Lack of capacity to provide written informed consent 
● Are pregnant or have been pregnant within the last 12 months 
 
5.3 Clinical screening exclusion criteria 
● Clinical screening results deemed by the HNU Medical Advisor to be 
indicative of a health problem, which may compromise the well-being of the 
participant, or which could affect the study data.  
● Depressed or elevated blood pressure measurements (<90/50 or 95/55 if  
    symptomatic or ≥160/100 mmHg)  
● BMI (Kg/m2) <19.5 or > 40 
 
6. Recruitment strategy 
A total of 50 participants aged ≥ 45 years with a total cholesterol 
concentration ≥ 5.0 mmol/L at clinical screening are required to complete this 
trial. Based on screening data obtained from two previous trials we expect ~ 
70% of otherwise eligible participants aged 45+ years to have a total cholesterol 
conc. ≥ 5.0 mmol/L.  However, recruitment for this study will only cease once 
we are confident that the required number of participants will complete the 
study. 
Potential participants meeting the basic criteria for this study will be 
identified using the Quadram Institute Bioscience Human Nutrition Unit (HNU) 
volunteer database. The HNU database contains names and contact details of 
people who have registered an interest in volunteering for human studies. 
Identification of participants from the database is carried out by the HNU senior 
research nurse. Those identified from the database will be sent a participant 
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information sheet (Annex 1) supported by a letter of invitation (Annex 2). A 
response slip and pre-paid envelope will be included.  
We also aim to recruit potential participants via GP surgeries. We intend 
to seek the adoption of this study onto the National Institute of Health Research 
(NIHR) portfolio which will enable us to recruit via GP surgeries with the help 
of the co-ordinators from the Primary Research Network (PCRN) – East of 
England. Identification of potential participants from GP surgeries will be 
carried out by the surgery administrative staff and/or research nurses. The list 
containing the names of eligible patients identified on the database search will 
be checked by the GPs in that practice before mailing the participant an 
invitation letter (Annex 3), participant information sheet (Annex 1) and a pre-
paid response envelope.  A pack containing information about the study and 
copies of the study approval letters will be sent to all GP surgeries who indicate 
an interest in assisting with recruitment. If permitted, we will place an electronic 
copy of the study advertisement (Annex 4) on the website of participating GP 
surgeries.     
In addition, poster and E-mail advertisements (Annex 4) will be placed 
across the Norwich Research Park (University of East Anglia (UEA), John 
Innes Centre (JIC), The Earlham institute, QI and other suitable locations such 
as social clubs, supermarkets, fitness centres etc. within the vicinity of QI 
(approx. 40 mile radius), inviting anyone who is interested in receiving 
information about the study to contact named researchers or the HNU senior 
research nurse. The local media (e.g. radio, newspapers/magazines etc.) may 
also be approached to advertise the study. We will also take advantage of 
social networking sites such as Facebook and twitter which will display either 
the ethically approved advert or be used to direct potential participants to a 
website where the approved advert is already displayed.   Those responding 
to advertisements will be sent a letter of invitation (Annex 5) along with a 
participant information sheet (Annex 1). A response slip and pre-paid envelope 
will also be included.  
Those participants responding positively after reading the information 
sheet will be invited to the HNU for an informal meeting with a member of the 
research team who will explain the study fully, focusing on the participant’s 
involvement. Participants will be encouraged to ask questions at this stage 
prior to making any commitment. At the end of the meeting, participants will be 
given a minimum of 24 hours to consider whether they wish to take part in the 
study. During the consideration period, participants will not be contacted. If, 
following the consideration period they wish to participate in the study, they will 
be asked to contact the study scientist or HNU senior research nurse to 
arrange an appointment at the HNU for the pre-study clinical screening. For 
those individuals who are very keen to participate in the study and request to 
book a date for their clinical screening whilst at this meeting, this may be 
arranged. However, the screening appointment will be arranged for some time 
after the 24-hour consideration period and there will be no contact during this 
time. 
 
6.1 Clinical screening 
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Prior to the clinical screening, participants will be reminded to bring details 
of any prescribed medication, herbal remedies or dietary supplements. 
Participants will attend the HNU following a 10 hour overnight fast but will be 
advised that they should drink water during the fasting period. All potential 
participants will be assessed for eligibility on the basis of the 
inclusion/exclusion criteria, eligibility questionnaire and the results of clinical 
laboratory tests.  
On arrival at the HNU the study scientist will go through the consent form 
(Annex 6) with the participant and answer any questions that may arise at this 
stage. He/she will then be asked to sign a consent form agreeing to participate 
in the study. Participants will also be asked to sign a medication declaration 
form (Annex 7) agreeing to inform the study scientist of any medication 
(prescribed or not) that they ingest once they have started the trial. A copy of 
these forms will be given to the participant to keep. An HNU research nurse 
will then complete a basic eligibility questionnaire (Annex 8) measure and 
record blood pressure, pulse, height and weight and calculate body mass 
index. A 12 mL blood sample (equivalent to ~ 2 teaspoons) will be obtained 
and sent to Spire hospital for FBC, lipid profile (Total cholesterol, HDL & LDL 
cholesterol & triglycerides) and HbA1c analysis. Upon completion of the 
clinical screening, participants will be offered a standard HNU breakfast.  
Results of the screening blood test that fall outside the standard reference 
ranges will be assessed by the HNU Medical Advisor (or in her absence a 
doctor from the UEA medical centre) who will advise whether inclusion, re-
screen or exclusion is appropriate. It is possible that some minor deviations 
from the normal reference range will neither affect the study data nor have 
health implications for the participant. In this case, the medical advisor may 
deem inclusion the appropriate course of action and write ‘satisfactory’ on the 
blood result form. These participants will be included in the study without being 
informed that the results of the blood test fell outside the standard reference 
range. If however, a re-screen is deemed the appropriate course of action then 
the participant will be contacted and offered an appointment for a further blood 
test. This will be after an appropriate period of time as advised by the medical 
advisor.  Those participants who display screening parameters outside the 
standard reference ranges on both occasions may be excluded from the study 
depending upon the results flagged. Participants who do not wish to be re-
screened will be excluded from the study. Participants who are excluded from 
the study will be informed of ‘flagged’ results by telephone and a letter advising 
them to contact their GP (Annex 9). Study scientists will not inform the 
participant which results are flagged or advise on any course of action. If the 
blood test results indicate a medical problem requiring immediate attention 
(e.g. anaemia, raised blood glucose) the HNU medical advisor may advise the 
HNU senior research nurse to contact the participant directly to inform them of 
the results and enable them to make an appointment with their GP. The test 
results will be sent to the GP within 24 hours of comment by the medical 
advisor.  Participants who meet the study criteria and whose clinical screening 
results are deemed satisfactory will be advised that they may continue with the 
study. All clinical screening results will be forwarded to the respective GP 
(Annex 10) supported by an appropriate letter (Annex 11; flagged results and 
Annex 12; normal results). Additionally, the respective GP of those participants 
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successfully recruited onto the study will be informed by letter of their patient’s 
participation (annex 13). 
 
7. Study procedure 
Once successfully recruited onto the study, participants will commence the 
trial no later than 12 weeks from the screening date.  
 
7.1 Participant Randomization 
Participants in this study will act as their own controls in a 3-arm 
randomised cross-over study involving the daily ingestion of capsules 
containing (i) a bilberry extract providing 320 mg anthocyanins, (ii) a black rice 
extract providing 320 mg anthocyanins and (iii) a placebo control over a 28 day 
period.  Each treatment will be assigned a letter (A-C) by a staff member not 
involved with the trial. For emergency purposes only, a member of QI staff will 
receive a sealed envelope containing the above letters and corresponding 
treatment. In the absence of an emergency the envelope will only be opened 
upon completion of the data analysis by the study statistician.  Randomization 
to treatment order will be assigned as follows: There are 6 possible sequences 
of the letters A-C. Each sequence of letters will be listed 1-6. Each time a 
participant is successfully recruited onto the study, the order of intervention will 
be assigned by allocating the participant to the next sequence of letters from 
the list. Once all 6 sequences have been used the process will be repeated. 
The randomization sequences will be generated by the computer programme, 
randomization.com. The study scientist will be responsible for the 
randomization process and subsequent allocation of participant code to 
treatment sequence.  However, both the study scientists, HNU research 
nurses and the participants will be blinded to the treatments.  
 
7.2 Capsule preparation 
Bilberry fruit and black rice extract powders will be supplied by the Beijing 
Gingko Group (BGG). The BGG product specification sheets for both types of 
extract have been supplied with this submission (Annexes 14 & 15). The 
bilberry and black rice extracts will be analysed at the QI to confirm the 
anthocyanin content of the material. This information will be used to determine 
the correct mass of ‘active’ material required to deliver the daily dose of 
treatments (i) and (ii). Once established, the extracts will be encapsulated in 
the food grade kitchen in the HNU by appropriately trained members of the 
study team holding certificates in Level 2 Food Safety and Catering. Members 
of the research team have experience in encapsulating test materials for 
human consumption acquired as part of the EU BACCHUS project (REC ref 
No: 13/EE/0393).  Product specification sheets for the capsules to be used 
have been included with this submission (Annexes 16 & 17). Each capsule will 
contain a total mass not exceeding 500 mg of material which will comprise the 
active ingredient (bilberry or black rice extract) and pharmaceutical grade 
microcrystalline cellulose (Vivapur 112); a biologically inactive and commonly 
used filler in tablets and capsules (product specification sheet attached; Annex 
18). The placebo capsules will contain microcrystalline cellulose only. Filled 
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capsules for each treatment arm will be counted into moisture resistant HDPE 
bottles with an integrated desiccant cap and labelled accordingly.  A subset of 
sealed bottles containing filled capsules for each treatment and placebo arm 
will be sent to an accredited laboratory for microbial safety analysis prior to 
human consumption. All capsules will look the same. Preliminary analysis at 
QI of a small sample of the two extracts indicates that participants will be 
required to ingest four capsules per day for each of the three treatment phases. 
The capsules will be stored according to the manufacturer’s instructions.  
 
NOTE: As stated previously bilberries contain ~ 285 mg anthocyanins per 100 
g fresh weight (USDA).  Therefore, to achieve the 320mg daily dose of 
anthocyanins proposed in this trial, an equivalent 112 g fresh bilberry would be 
required. Based on an average portion size of 80 g (FSA) this is equivalent to 
ingesting ~ 1.5 portions of bilberries per day.  
 
7.3 Intervention procedure 
Participants will be required to restrict their intake of berry fruits to a 
combined maximum of 3 portions per week. The restrictions will commence 2 
weeks before starting the first study phase and then continue until he/she has 
completed the study in its entirety (inclusive of wash-out phases). In addition, 
for the 24-h preceding test days at the start and end of each treatment period, 
berry fruits will be completely excluded from the diet. Participants will be 
provided with a list of restricted fruits.  
Each of the three study phases will comprise a 28-day treatment period 
which will be identical in nature (except for the treatment consumed) and 
separated by a washout period of at least 4 weeks. Each treatment period is 
described below. 
 
Day 0 – As mentioned above participants will already be restricted in terms of 
berry fruit consumption. For this 24-h period preceding day 1 they will be 
required to collect all urine passed and to completely exclude berry fruits from 
the diet. They will also be asked to fast overnight (minimum 10 hours) but will 
be advised to drink as much water as they need during the fasting period.  
 
Day 1 – Fasted participants will arrive at the HNU on the morning of day 1 to 
undergo a baseline assessment. The sub-set of participants (n= 24) will be 
required to arrive with a faecal sample. Instructions on how to do this (Annex 
19) will have been given. Prior to starting any procedures, participants will be 
asked some basic questions to establish whether or not any changes in 
medical conditions/medications etc. have occurred since their last visit and 
whether they have experienced any adverse events not already disclosed by 
telephone, E-mail or letter (Annexe 20). Next, the participant will be weighed, 
after which a 35 mL blood sample will be obtained. Participants will then 
consume 4 capsules (equivalent to the daily dose) containing the allocated 
treatment. The capsules will be ingested with 150 mL water. Participants will 
be required to remain in the nutrition unit for at least 20 minutes after ingestion 
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of the capsules. A standard HNU breakfast consisting of toast with spread 
and/or cereals, tea/coffee will then be served.  
Prior to leaving the HNU participants will be instructed on the correct 
administration/storage of the capsules and supplied with the required number 
of capsules to be consumed over the ensuing 28 day period. Participants will 
also be reminded to continue restricting berry fruit consumption to a maximum 
of 3 portions per week. Participants will be contacted 2-weeks into the 
treatment period to check on progress. Regardless, they will be advised to 
contact a member of the study team should they become unwell or experience 
any problems with taking the capsules.  
 
Day 28 – As per day 0, participants will be required to exclude all berry fruits 
from the diet and collect all urine passed for the 24-h period preceding day 29. 
They will also be asked to fast overnight (minimum 10 hours) but will be 
advised to drink as much water as they need during the fasting period. 
 
Day 29 – Fasted participants will arrive at the HNU on the morning of day 29 
to undergo post intervention assessment as described for D1. The sub-set of 
participants (n= 24) will be required to arrive with a faecal sample. A further 35 
mL blood sample will be obtained. On completion of the post intervention 
assessment, participants will be given a standard HNU breakfast. 
 
In the unlikely event that a participant is unable to attend the pre-scheduled 
d29 assessment day, a lee-way of ± 3 days is considered an acceptable time 
period for the purposes of re-scheduling the appointment. In the event that the 
original appointment is delayed, the participant will remain on the treatment 
until the day preceding the final assessment day. If the participant is unable to 
re-schedule within ± 3 days or due to unforeseen circumstances is required to 
interrupt the treatment period (e.g. minor illness) they will be given the 
opportunity to repeat the treatment at a later date.   
The blood volume obtained from a participant during a single test phase is 
70 ml. The total blood volume taken over the entire study is 222 ml (incl. 
screening sample). This will rise to 234 mL if a participant requires a repeat 
screening blood test. The container to be used for each of the 24-hour urine 
collections will contain ~ 1 g ascorbic acid (vitamin C) as an antioxidant.  
Donation of faecal samples by the sub-group of participants on this trial 
will be done so on a voluntary basis. It will be made clear to participants that if 
he/she is willing to donate the sample then it is a requirement to do so at the 
start and end of all three treatment phases. Participants will be given the option 
of providing a faecal sample within 3 days preceding the start of the treatment 
period (D1) or ± 3 days of finishing the treatment period (D29). If they have 
been unable to produce a faecal sample within the time period preceding or 
on D29, the assessment day will continue as scheduled but the participant will 
be asked to continue consuming capsules until the faecal sample has been 
produced. Any faecal samples provided outside the d1 and d29 assessment 
days will be delivered to QI within 6 hours of production. Since we will be 
excluding participants from this aspect of the study if their habitual daily bowel 
movements are ≤ 3 days per week, we do not anticipate faecal sample 
collection to be a problem. 
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The number of participants required to provide faecal samples is twenty 
four. To ensure that we finish the trial with the required number of faecal 
samples we will review the situation part way through. Should there be doubt 
that we will reach the target number, we will take the decision to only enrol 
those participants willing to donate faecal samples. This is reflected in the 
participant information sheet. We adopted a similar approach to recruitment in 
a previous study (REC ref: 13/EE/03930).  
 
7.4 Treatment compliance 
Participants will consume four capsules once daily for 28-days. They will 
be instructed to consume the capsules in the morning time. However, in the 
event that they forget, the capsules may be consumed later in the day.  To 
assist participants with compliance to treatment they will be provided with a 
capsule checklist (Annex 21). Each time the capsules are consumed, 
participants will record this on the checklist. Participants will be contacted 2-
weeks into each of the treatment periods to assess progress. Compliance to 
treatment will be assessed from the record sheet and the number of unused 
capsules returned at the end of the treatment period. Participants who ingest 
less than 80% of the capsules over the entire treatment period may be 
withdrawn from the study.  This will be assessed on a case-by-case basis. 
 
7.5 Participant expenses/payments 
An inconvenience payment of £125 will be given to each participant who 
completes the study or pro rata for non-completion; this will increase to £155 
for those participants collecting faecal samples. Participants will also be 
reimbursed travel expenses to and from the QI (at the current QI mileage rate) 
or bus/train fares on production of a receipt. Participants will be notified that 
such payments are liable to tax. QI staff will be taxed at source.  
 
7.6 Participant travel during treatment periods 
Participants will not be able to travel during a 28-day treatment period. 
However, they may travel in-between treatment periods (e.g. during the 
washout phases of the study). The length of time between returning from 
abroad and commencing the next treatment will be determined on a case-by-
case basis depending upon where travelled and whether or not they developed 
any gastro-intestinal symptoms.   
 
 
 
 
8. Analytical methods 
 
8.1 Processing and analysis of blood samples 
Whole blood will be collected into EDTA, and serum separating tubes. 
EDTA samples will be immediately centrifuged at 2500 x g for 10 mins to obtain 
plasma. Samples collected into serum separating tubes will be allowed to clot 
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for 30 min before centrifugation at 2000 x g for 10 mins. Sub-samples of 
plasma and serum will aliquoted into appropriate storage tubes, frozen on dry 
ice and then subsequently stored at – 80 0C until analysis.  
    
8.1.1. Analysis of lipids, glucose, fructosamine and insulin  
Total/HDL/LDL cholesterol, triglycerides glucose and fructosamine will be 
analysed using an automated bench top clinical chemistry analyser (RX 
Daytona plus) according to the manufacturer’s instructions. Plasma levels 
of apolipoprotein A1 (ApoA1) will be quantified using an ELISA kit 
(Cusabio Biotech Co., Wuhan, P.R. China). We will separate and quantify 
HDL sub-fractions using a commercial product that is based on 
polyacrylamide gel electrophoresis separation of the sub-fractions, such 
as the Lipoprint® HDL Subfractions product from Quantimetrix 
(http://quantimetrix.com/lipoprint-2/product-information-2/lipoprint-hdl-
subfractions-100-tests/). Insulin concentrations will be determined by 
enzyme-linked immunosorbent assay (Elisa) according to the 
manufacturer’s instructions. 
 
8.1.2 Analysis of PON-1 and cholesterol efflux capacity 
PON-1 activity will be measured using spectrophotometric assays to 
determine the rate of cleavage of a general PON1 substrate such as para-
nitrophenol-acetate. In addition, the activity will be measured using a 
physiologically relevant lipid peroxide substrate as described by Aviram et 
al [31]. PON1 protein will be quantified using ELISA or western blotting 
using commercially available ELISA kits or anti-PON1 antibodies. The 
PON1 genotypes for the major single nucleotide polymorphisms at 
positions 192 (glutamine/Q versus arginine/R) and 55 (leucine/L versus 
methionine/M) and other known SNPs in PON1 will be determined using 
PCR reactions with specific primers with DNA obtained from whole blood 
as described by Browne et al. [32] and Mackness et al [10] and sequencing 
of the PCR products using standard sequencing techniques.  
 
The effects of the diets on the cholesterol efflux capacity (CEC) of blood 
will be quantified by measuring the rate of efflux of labelled cholesterol 
from pre-loaded human macrophages (phorbol myristate-treated THP-1 
cells) to serum samples obtained before and after the 4-week dietary 
intervention. Assays will be conducted using a cholesterol efflux assay 
available from Abcam (Product: ab196985). By quantifying the CEC of 
minimally processed plasma and also plasma that has been pre-
processed to remove ApoB1, we will also be able to determine if the 
anthocyanin-mediated changes in CEC are due to changes in ApoB1, 
HDL-cholesterol or both. Ethylene glycol precipitation (MW=8,000; Sigma) 
will be used to strip serum of apoB lipoprotein according to a protocol 
published by Asztalos et al. [33] CEC values will also be correlated with 
HDL concentrations (determined in 8.1.1).   
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8.1.3 Analysis of bile acids (and derivatives) 
Bile acids and bile acid derivatives will be analysed using an established 
in-house LC-MS technique. In brief, aliquots of plasma will be mixed with 
methanol prior to centrifugation at 17,000 x g for 10 min. The resultant 
supernatant will be rotary evaporated, almost to dryness, before the 
addition of 1 mL aqueous methanol. Samples will be passed through an 
SPE cartridge before applying to LC-MS.    
 
8.1.4 Analysis of anthocyanins  
Plasma anthocyanins and anthocyanin metabolites will be analysed using 
an established in-house extraction procedure and LC-MS technique. In 
brief, trifluoroacetic acid will be added to aliquots of plasma to precipitate 
the proteins. Post centrifugation (16,000 x g; 4°C; 15 minutes) samples of 
plasma will be transferred into auto-sampler vials for HPLC analysis.  
 
8.1.5 microRNA analysis 
MicroRNA’s will be extracted using a miRNAeasy serum/plasma kit 
(Qiagen, UK) according to the manufacturer’s instructions. cDNA for 
individual microRNA will be synthesised using a Taqman MicroRNA 
reverse transcription kit (Life technologies) and quantitative PCR will be 
carried out using Taqman MicroRNA assays for individual microRNAs (Life 
technologies).   
 
8.1.6 Plasma metabolite profiling 
Plasma metabolite profiles will be determined using a protocol/platform 
such as the Absolute/DQ® p180 kit marketed by Biocrates Life Sciences 
(Innsbruck, Austria) or similar. In addition, other metabolites of interest 
such as those in the L-carnitine / trimethylamine (TMA) / trimethylamine-
N-oxide (TMAO) pathway that are prognostic of cardiovascular and 
metabolic diseases will be measured using targeted LC-MS or other 
methods as appropriate. 
  
8.2 Processing and analysis of faecal and urine samples 
Participants will be provided with a faecal collection kit consisting of an 
insulated container, a plastic pot, bag and clip, and ice cube bags. A 
description of the collection procedure is given in Annex 19. Urine will be 
collected in containers with ascorbic acid as previously described. Aliquots of 
fresh faecal matter and urine will be placed into appropriate vials and stored at 
– 80 0C until analysis. Portions of faecal matter will also be used to prepare 
faecal slurry glycerol stocks and these will be stored at -80 0C until used.  
 
8.2.1 Analysis of bile acids and bile acid derivatives in faeces 
Bile acids and bile acid derivatives from faecal samples will be analysed 
using established in-house LC-MS protocols.  
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8.2.2 Analysis of cholesterol in faeces 
Faecal cholesterol will be measured using a colorimetric assay (Cell 
Biolabs Inc) according to the manufacturer’s instructions. 
 
8.2.3 Microbiota profiling (resources permitting) 
DNA will be extracted from the faecal samples using FastDNATM spin kits 
according to the manufacturer’s instructions. Gut microbiota composition 
will be done under contract at the Earlham Institute (Norwich Research 
Park, UK) using Illumina MiSeq technology to undertake 16S-based rRNA 
gene profiling metagenomics. In addition, we will use faecal slurries to 
seed simple anaerobic batch colon models which will be used to (a) 
measure the anthocyanin metabolic capacity of the individual faecal 
microbiota samples which can be compared with the appearance of 
anthocyanin metabolites in plasma and urine samples, and (b) identify 
polyphenol metabolites that alter the gut microbiota profile and metabolic 
capacity.  
 
8.2.4 Analysis of anthocyanins in urine 
Urinary anthocyanins and anthocyanin metabolites will be analysed using 
an established in-house extraction procedure and LC-MS technique. In 
brief, an internal standard will be added to aliquots of urine before 
centrifugation (16,000 x g; 4°C; 15 minutes). Samples of urine will be 
transferred into auto-sampler vials for HPLC analysis. 
 
8.2.5 Analysis of microbial metabolites in faeces and urine 
Metabolites in faeces and urine will be determined using NMR and / or LC-
MS methods. In addition, other metabolites of interest such as those in the 
L-carnitine / trimethylamine (TMA) / trimethylamine-N-oxide (TMAO) 
pathway that are prognostic of cardiovascular and metabolic diseases will 
be measured using targeted LC-MS or other methods as appropriate.  
 
8.3. Analysis of anthocyanins in berry fruit and black rice extracts 
Berry fruit and black rice powder (5 mg), will be dissolved in 1 mL acidified 
aqueous methanol and centrifuged at 17,000 x g for 5 mins. The supernatant 
will be applied to LC-MS. Chromatographic anthocyanin peak identification will 
be achieved by comparison of retention times with analytical standards and 
mass spectral data. Anthocyanins will be quantified against reference 
standards over the range 0-50 µg/mL.  
 
9. Ethical considerations 
 
9.1 Confidentiality 
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Participants will be assigned a unique code which will be used on all 
samples/data arising from this study. Only the study scientist named in the 
approved documentation will be able to link the code with the participant. 
However, the confidential code may be broken in the event of a medical 
emergency as deemed appropriate and necessary by the HNU senior research 
nurse or medical advisor. Coded information will be kept in locked cabinets at 
the QI.  
All personal information will be kept confidential and known only to the 
Chief Investigator or project scientist, HNU nurses and medical advisor and 
the participants GP. Personal information will be kept separately to coded 
information in locked cabinets at the QI. 
 
9.2  Informed consent 
To ensure participants can make an informed decision as to whether or 
not they wish to take part on the trial they will be provided with a PIS and invited 
to an informal discussion about the study. Consent will be obtained by a 
member of staff who is GCP trained and experienced in conducting human 
intervention trials. 
 
9.3 Risks and burdens  
This study involves blood sampling and as such there is a risk of minor 
discomfort and/or bruising at the site of venepuncture. The research nurses at 
QI are experienced in this procedure thus minimizing this risk. The total volume 
of blood collected over the entire duration of the study is 222 mL, which is less 
than that donated at a single session with the blood transfusion service. 
Regardless, iron status will be measured as part of the eligibility assessment 
to exclude anaemia prior to participation.  
This trial also involves overnight fasting. Participants will be advised to 
drink water during the fasting. All study sessions will be scheduled for the 
morning time to reduce the length of fast and participants will be offered 
breakfast prior to leaving the nutrition unit. At the eligibility assessment, we will 
also undertake an HbA1c test to exclude undiagnosed diabetic participants  
As part of the eligibility assessment exercise it is possible that some blood 
test results are abnormal. The procedure for this eventuality is described in 
section 6.1. All blood results (normal or otherwise) will be forwarded to the 
respective GP.  
On this trial we will be recruiting participants with a higher than optimal 
total cholesterol. Participants who are subsequently treated with lipid lowering 
therapies will be excluded/removed from the trial. This information is provided 
in the PIS. 
 
10. Power calculations & statistical analysis 
LDL Cholesterol: The primary outcome measure for this study is LDL-
cholesterol. Sample size was determined based on data from a study reported 
by Zhu et al [18]. We have chosen to use a conservative effect size of 0.14 
mmol/L for the change in LDL cholesterol. In order to detect a change (relative 
to placebo) in LDL cholesterol of 0.14 mmol/L at the 0.05 level of significance 
and with 90% power in at least one of the treatment groups, 50 participants 
would be needed to complete a cross-over trial. This assumes that the 
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standard deviations in the treatment and placebo groups are similar to that 
observed in the data from Zhu et al (approximately 0.5mmol/L). 
MicroRNA: Sample size for the sub-set of participants was based on a 
study conducted by Kim et al [34]. In order to detect a change (relative to the 
athero-risk group) in Mir33a of 2.24 units at the 0.05 level of significance and 
with 90% power in the treatment group, 24 participants would be needed to 
complete a crossover trial. This assumes the standard deviations in the 
treatment and athero-risk groups are similar to that observed by Kim et al 
(approximately 3.24 units).   
Data will be checked for normality and transformed if necessary to allow 
parametric statistical techniques (e.g. paired t-test, repeated measures 
ANOVA) to be used for analysis. Tests will be reported as significant if P<0.05. 
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LIST OF FRUITS TO RESTRICT 
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                              Fruits to exclude/restrict 
 
 
No more than 3 portions per week (total) of the fruits listed below. 
 
 
 
Strawberries 
Blackberries 
Blueberry 
Raspberries 
Bilberry 
Blackcurrants 
Red currants 
Whortleberry 
Cherry 
Chokeberry 
Cranberry 
Elderberry 
Goji Berry 
Black/red grapes 
Black plums 
 
Please remember to completely exclude these for 24 hours before your study 
day assessments. 
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     Quadram Institute Bioscience
  
                                                 Norwich Research 
Park 
      Colney 
                 Norwich 
      NR4 7UA       
 
 
PARTICIPANT INFORMATION SHEET 
 
 
 
The effects of bilberry fruit and black rice derived 
anthocyanins on lipid status in adults  
 
Short title: BERI Study 
  
     
You are being invited to take part in a research study at the Quadram Institute 
Bioscience (formerly Institute of Food Research). Before you decide to take 
part it is important for you to understand why the research is being done and 
what it will involve for you. Please take time to read the following information 
carefully and discuss it with others if you wish. 
 
Part 1 of this information sheet tells you the purpose of the study and what will 
happen if you decide to take part. 
 
Part 2 gives you more detailed information about the conduct of the study. 
 
Please ask if there is anything contained in the information sheet that is not 
clear, or if you would like more information. Take time to decide whether or not 
you would like to take part. This information is yours to keep. Thank you for 
reading this. 
 
Study contact details: 
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Wendy Hollands (study manager)          Aliceon Blair (HNU senior research 
(01603) 255051                                      nurse) (01603) 255305 
Wendy.hollands@quadram.ac.uk           aliceon.blair@quadram.ac.uk 
 
Dr Paul Kroon (Chief Investigator) 
(01603) 255236 
Paul.kroon@quadram.ac.uk 
 
………………………………………………………………………………………… 
 
 
 
 
 
 
 
 
 
Part 1 
 
What is the purpose of the study? 
Regular consumption of fruit and vegetables has been shown to reduce the risk 
of cardiovascular disease (CVD). The protective effect may be because of 
compounds contained within these foods, called flavonoids. Anthocyanins are 
a particular group of flavonoids and are found in berry fruits (e.g. blueberry, 
bilberry, raspberry, and strawberry) and other foods such as aubergine skins 
and black rice. Anthocyanins are what give the red, black, purple and blue 
colours to such foods and different foods may contain different types of 
anthocyanins. For example, bilberry fruit contains a different type of 
anthocyanin to that of black rice.  
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There are several ‘risk’ factors for CVD which can be easily measured. One of 
the measurements that most people know about is blood cholesterol; that is 
good cholesterol (otherwise called HDL cholesterol), bad cholesterol (otherwise 
called LDL cholesterol) and triglycerides. A small number of studies have found 
improvements in blood cholesterol after consumption of foods rich in 
anthocyanins. In this study we want to compare the effects of two different types 
of anthocyanins (one from bilberry fruit and the other from black rice) on 
cholesterol status in people with higher than optimal blood cholesterol levels. 
We also want to investigate the effects of the different anthocyanin types on 
how the body processes cholesterol (called transport and metabolism) and 
relate this information to a specific gene involved in the cholesterol metabolism 
process. How we achieve all this is describe throughout this information sheet. 
This study will involve the consumption of capsules that contain anthocyanins 
that have been removed from bilberry fruit and black rice and not the whole 
food. It will also involve the collection of blood and urine samples and for a small 
sub-group of people, the collection of faecal samples. 
 
Why have I been invited? 
You have received this information because you have responded to an 
advertisement about the study OR you have been identified as a potentially 
suitable candidate either from the volunteer database held at the QI (formerly 
Institute of Food Research) human nutrition unit (HNU) or via your GP 
surgery.  
 
We are aiming to recruit a total of 50 volunteers (male and female), who are 
aged 45 years or more with a cholesterol level at or greater than 5 mmol/L.  
 
You will not be able to volunteer if you:      
 
● Are a smoker (or stopped smoking for less than 3 months) 
● are diabetic  
● are taking medication for high 
   cholesterol (e.g. statins) 
● have a medical condition or are taking 
   other medications (prescribed or 
   otherwise) which may affect the study  
   outcome (we will advise you 
   accordingly) 
● have gastro-intestinal disease (except 
   hiatus hernia) 
● take supplements judged to affect 
   the study data (we will advise you 
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   accordingly). 
● Use foods for lowering cholesterol e.g. benecol, flora proactive (this will be 
assessed on an individual basis). 
● Intend to change your normal use of pre or probiotics during the study e.g. if 
you don’t take these products we don’t want you to start taking them but 
equally if you take them regularly we don’t want you to stop taking them 
during the study.  
● Regular/recent use of colonic irrigation or other bowel cleansing techniques. 
● are pregnant or have been pregnant 
    within the last 12 months 
● are related to someone in the study 
    team (e.g. spouse, partner, immediate family member) 
● have donated or intend to donate blood within 16 weeks of the first and last 
study samples.  
● have participated in another study 
   which has involved blood sampling 
   within the last four months unless the 
   total amount of combined blood from 
   both studies does not exceed 470 mL 
● are currently involved in a study which involves dietary intervention. 
● the results of our screening test indicate that you are not suitable to take part 
in this study 
● Are unable to provide written informed 
   Consent 
● Have a BMI less than 19.5 or more than 40 kg/m2 
 
Do I have to take part? 
It is up to you to decide. We will describe the study in this information sheet. If, 
after reading it you are interested in taking part in the study, you should contact 
one of the researchers named on the first page of this information sheet 
 
OR 
 
You can complete the attached response form and return it using the pre-paid 
envelope enclosed. Please feel free to say no by not responding to this 
information. Do not worry, nobody will contact you to try and persuade you to 
join the study. 
 
After you have replied to tell us you are interested in participating, a member 
of the study team will contact you, and you will be invited to the HNU at the QI 
for a talk with the study scientist/manager. An expression of interest does not 
commit you to taking part.  
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If you are on the QI HNU volunteer database, a decision to withdraw or not to 
take part will not affect your participation in future studies. Similarly, if you have 
been recruited via your GP surgery, a decision to withdraw or not to take part 
will not affect your care.   
 
 
What will happen to me if I do take part?  
If you decide to take part, your involvement in the study will last about 6 months 
depending upon your availability for the study visits. You will be required to 
visit the HNU on 8 separate occasions (2 visits before the study starts and 6 
visits during the study). Each of these visits is described below. Where possible 
appointments will be made at your convenience but will take place on a 
weekday (Mon-Fri).  
 
Pre-study talk (Visit 1) 
 
This meeting will last for about one hour. The study scientist will go through 
this information sheet with you and answer any questions you may have. At 
the end of the meeting you will be given as much time as you need to decide 
whether or not to take part, but this will be at least 24 hours. You will not be 
contacted during this time. After the 24 hours if you decide to take part you will 
need to contact the study scientist to arrange an appointment for the next visit. 
 
Elibility assessment /informed consent (Visit 2). 
 
This visit will last up to one and three quarter hours. You will be asked to come 
to the HNU between 07.30 and 10.30 hours. You will be asked to arrive having 
fasted for at least 10 hours. Fasting means you must not eat anything or drink 
anything other than plain water. During the fasting period you may drink as 
much water as you need.  
 
Before we complete the eligibility assessment you will be asked to sign a 
consent form agreeing to take part in the study. You will also be asked to sign 
a medical declaration form. These forms will also be signed by the 
scientist/nurse and you will be given a copy of the forms to keep. After signing 
the consent form you are still free to withdraw from the study at any time 
without giving a reason. 
 
An HNU research nurse will then complete a brief eligibility questionnaire with 
you and also measure and record your blood pressure, pulse rate, weight, 
height and body mass index (BMI). Your height and weight measurements will 
be used to work out your BMI. BMI is an expression of body weight which takes 
into account your height. A simple formula is used to calculate your BMI. If your 
BMI falls outside the range for this study you will be excluded from taking part.  
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The HNU research nurse will then take a 12ml blood sample (equivalent to 2 
teaspoons) from a vein in one of your arms. The blood sample will be used to 
test Full Blood Count (FBC), cholesterol (total, HDL, LDL and triglycerides) and 
HbA1c (blood sugar). These tests will check for anything outside of the 
standard reference ranges, which may affect your wellbeing or the study data 
if you participate. However, we are looking to recruit people with a higher than 
optimal total cholesterol level (at or greater than 5 mmol/L). After this you will 
be encouraged to have breakfast (cereal, toast, tea, coffee) before you leave 
the HNU. 
 
If any of your clinical results are outside the standard reference ranges, we 
may recommend that you speak to your GP about the results. All results 
outside the reference ranges are checked by the HNU medical advisor. The 
medical advisor will decide whether we may include you in the study, offer you 
the opportunity of a second screening (re-screen) or exclude you from taking 
part in the study. If your results fall outside the standard reference ranges on 
the second occasion you may be excluded from the study depending on the 
results flagged. We cannot tell you what your results may mean as we are not 
medically qualified to do so. You should not worry if your results are flagged 
as it may be a one off result or it may be perfectly normal for you and your GP 
will be able to explain them to you. Please remember these tests are performed 
to determine if you are suitable for the study not to find out if you are healthy.  
 
You will be excluded from the study if the results of the test are judged by the 
medical advisor to be unsuitable for your participation or your cholesterol level 
is less than 5 mmol/L. 
 
The HNU research nurses are experienced in carrying out clinical procedures, 
and if you have any questions about any of the tests, please ask one of the 
nurses. 
 
You will be invited to take part in this study if the blood test from the eligibility 
assessment is satisfactory and you meet all the listed criteria for participation.  
 
The study  
 
There are three phases to this study each of which will last for a period of 29 
days. The only difference between each of the three test phases is the content 
of the capsules consumed. These are described here.  
 
a) 4 capsules/ day containing 320 mg bilberry anthocyanins  
b) 4 capsules/day containing 320 mg black rice anthocyanins  
c) 4 capsules/day containing no anthocyanins (placebo) 
 
The dose of anthocyanins is equivalent to eating about one and a half standard 
portions of bilberries per day. 
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The order in which you consume the capsules containing 
each of the three test products will be ‘randomly’ assigned 
by a computer programme. When we say “randomly 
assigned” this means that the order is assigned by a 
method similar to being picked out of a hat.  You will not 
be able to choose your order.   Neither the scientist in 
charge of the project or you will know in which order you 
are consuming them. The capsules will all look the same. 
 
Two weeks before starting the first phase of the study you will be required to 
restrict your intake of berry fruits to a combined maximum of 3 portions per 
week. A list of fruits to restrict is provided at the end of this information sheet. 
The restrictions will continue until you have completed the study in its entirety. 
A test phase is described below: 
 
Day 0 – You will be asked to collect all urine passed (in containers which we 
will provide) for 24 hours before the visit on day 1. Please note that this urine 
bottle will contain a white powder called ascorbic acid (vitamin C) which is 
needed to preserve the urine. The urine container should be kept away from 
children and animals. You will also be asked to completely avoid eating berry 
fruits.   
 
Day 1 - (Visit 3) 
This visit will last for approximately 1 hour. You will be asked to come to the 
HNU between 07.30 and 10.30 hours. You will be asked to arrive having fasted 
for at least 10 hours. During the fasting period, you may drink as much water 
as you need.  
 
After arrival and before consumption of the test capsules a nurse will weigh 
you and take a 35mL blood sample (equivalent to about 3 tablespoons).  You 
will then be given 4 capsules containing one of the test products to consume. 
The capsules will be taken with 150 mL water (equivalent to about ½ a glass). 
You will be required to remain in the nutrition unit for at least 20 minutes after 
consuming the capsules. Breakfast (toast, cereal and tea/coffee) will then be 
offered.  
 
For the next 28 days you will be asked to continue taking 4 capsules once 
daily. Capsules should be taken some time during the morning. However, if 
you forget, they can be taken in the afternoon. Capsules may be taken with 
water but not at the same time as food (please allow 15 minutes either side of 
food). If you become unwell or experience any problems with taking the 
capsules, then please contact a member of the study team. You will be 
provided with a capsule checklist and asked to tick the checklist each day the 
capsules are taken. Remember, you will also be restricting your berry fruit 
intake.   
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Day 28 - You will again be required to collect all urine passed for this 24-h 
period immediately preceding the day 29 visit. You will also be asked to 
completely avoid eating all berry fruits.   
 
Day 29 (Visit 4) 
This visit will last about 1 hour. You will be asked to come to the HNU between 
07.30 and 10.30 hours. You will be asked to arrive having fasted for at least 
10 hours. On this visit another 35mL blood sample will also be obtained. 
Afterwards, breakfast (tea/coffee, toast and/or cereal) will be provided. This 
completes phase 1 of the study.  
 
The remaining 2 test phases will each be separated by a minimum of 4 weeks 
and there are 2 visits per test phase (Visits 5-8). You will be asked to restrict 
your berry fruit intake to 3 portions per week during these wash-out phases 
and completely avoid berry fruits for 24-hours before each of the visits to the 
nutrition unit.  
 
Please note: If you intend to holiday/ travel whilst taking part on the 
study, we will require you to remain in the UK during each of the three 
28-day test phases. However, you may holiday/travel outside the UK in-
between test phases. 
 
A flowchart giving a brief outline of the study can be found on page 
10. 
 
A small sub-group of participants (24 people) will be required to provide a 
faecal sample at the start and end of each of the three test phases. You will 
be given a choice as to whether or not you donate faecal samples but you will 
not be able to donate if your normal bowel movements are equal to or less 
than 3 times per week. If, part way through the trial there is doubt that we will 
reach the required number of participant donations, we will take the decision 
to only enrol onto the study those willing to donate faecal samples. If you do 
volunteer to collect faecal samples you will be provided with a collection kit and 
instructions on how to do this.  
 
The total amount of blood we take in a single test phase (day 1 and day 29 
inclusive) is 70 ml (about 6 tablespoons). The total amount of blood we take 
over the whole study, including the screening sample is 222 ml. If you need to 
have a repeat screening blood test this will rise to 234 mL). This is about half 
of that which you would give during a single blood donor session. 
 
What we do with the blood and faecal samples is described in part 2 of 
this information sheet. 
 
Should you become unwell whilst on a test phase we may ask you to stop 
taking the capsules and repeat that test phase once you are better. This will 
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depend upon the nature of the illness and whether or not it will affect the study 
outcome.  
 
Access to personal information 
Once recruited onto the study you will be given a code number. This number 
will be unique to you and is used to protect your information and make your 
samples anonymous. Access to your personal information is restricted to the 
research team, HNU research nurses, HNU medical advisor and your GP. 
Further details about this are given in part 2 of this information sheet. 
 
Expenses and payments 
Participation in these studies is done on a voluntary basis. However, we do 
recognize that being involved in the study can cause you some inconvenience 
and there are costs associated with visiting the HNU. You will receive an 
inconvenience payment of £125 for participation. This will be increased to £155 
if you collect faecal samples. If you are excluded from the study or you 
withdraw from the study the inconvenience payment you receive will be 
adjusted according to how much of the study you completed before 
exclusion/withdrawal. You will also be reimbursed travelling expenses to and 
from HNU on production of a receipt for buses and trains or at the current QI 
mileage rate for private cars.  
 
Please note that payments are liable to tax and you are personally liable for 
your own tax assessment. If you are claiming state benefit, your entitlement 
may be affected by payments made for participating in the study. QI employees 
will be taxed via the payroll. 
 
What are the risks and side effects from taking part in this study? 
There can be a small amount of discomfort associated with taking blood. This 
may affect some people more than others, but the discomfort occurs generally 
only on insertion of the needle.  
 
You may develop a small bruise at the site of the blood sample, but this will 
fade as with any bruise.  
 
The HNU research nurses will be happy to answer any questions you may 
have about any procedures involved. 
 
What are the potential benefits of taking part? 
There are no direct benefits for you taking part in this study. However, the 
information we find out from this study will contribute to our understanding of 
the effects of anthocyanins on risk for CVD.  
 
Will my taking part be kept confidential? 
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Yes. We follow Ethics and Research Governance requirements. All information 
about you will be handled in confidence. More details about this are included 
in part 2 of this information sheet. 
 
This concludes part 1 of the information sheet. 
 
If the information in part 1 has interested you and you are considering taking 
part, then it is important that you read the additional information in part 2 before 
making any decision. 
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Part 2 
 
What if relevant new information becomes available or changes to the 
study are made? 
If this happens we will let you know. If changes to the study are made and they 
impact on your participation, you will be given the new amended participant 
information sheet to read before being asked to sign another consent form. 
 
What will happen if I don’t want to carry on with the study? 
You are free to withdraw from the study at any time without giving a reason. 
However, the study scientist will need to be informed of your decision to 
withdraw. You will receive payment pro rata for samples given up to the point 
of withdrawal. Samples collected will be kept until the study has finished and 
any data collected until the point of withdrawal will still be used. 
 
What if there is a problem?  
If you have a concern about any aspect of the study you should ask to speak 
to a member of the study team who will do their best to answer your queries. 
You can telephone Wendy Hollands on (01603) 255051 or the HNU senior 
research nurse on (01603) 255305. 
 
If you require independent advice about the study or you are unhappy about 
any aspect of the study and/or wish to complain formally, you can do this 
through the chairperson of the QI Human Research Governance Committee 
(Dr Linda Harvey) on (01603) 255000.  
 
The QI accepts responsibility for carrying out trials, and as such will give 
consideration to claims from participants for any harm suffered by them as a 
result of participating in the trial, with the exception of those claims arising out 
of negligence by the participant. The QI has liability insurance in respect of 
research work involving human volunteers. 
 
Please note that the Institute will not fund any legal costs arising from any such 
action unless awarded by a court. 
 
Will my taking part on this study be confidential?  
Only personal information which is needed for the study will be collected and 
this will be held in the strictest confidence. Access to your personal records is 
restricted to the study team, the HNU nurses, HNU medical advisor and your 
GP. All personal information is kept in locked cupboards at the QI. 
 
Once recruited onto the study you will be issued with a volunteer code number. 
This number will be used on all your personal information and samples so that 
nobody else will know or be able to work out that they are yours. Coded 
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information is also kept in a locked filing cabinet at the QI but separately to 
your personal information.  
 
The data generated from study samples will be stored in a secure archive for 
up to fifteen years after the end of the study. It will then be destroyed.  
 
All research is subject to inspection and audit and although your records may 
be accessed for this purpose any personal information remains confidential.  
 
Please note that the QI has CCTV cameras in use for security purposes. 
However, provision has been made so that volunteers attending HNU will not 
be identified. 
 
Will my GP be informed?  
Yes. It is routine practice to inform your GP that you are taking part in a study 
at QI. We will also send your GP details of all your clinical screening results 
(blood tests, blood pressure weight and BMI measurements). Your permission 
will be sought and this is one of the things you are agreeing to when you sign 
the consent form.  If any of these blood results fall outside the standard 
reference ranges we may recommend you speak to your GP about it. We are 
unable to discuss your blood results with you. 
 
What will happen to the samples I provide? 
For all participants: The 12mL blood sample you provide at visit 2 (eligibility 
assessment) will be sent to Spire hospital for Full Blood Count, HbA1c (blood 
sugar) and lipid profile (total cholesterol, HDL and LDL cholesterol and 
triglycerides). The purpose of this is to check for anything outside the reference 
ranges which may affect your well-being if you took part but also to make sure 
you fit the criteria for the study.  
 
The blood samples you provide during the course of the study will be used to 
investigate the differences in effects between the two anthocyanin types in the 
capsules you consumed on (i) components associated with CVD ‘risk’. These 
include blood sugar status (glucose and fructosamine), levels of insulin and 
also lipids (total cholesterol, HDL and LDL cholesterol and triglycerides); (ii) 
components of blood associated with how we metabolize and transport lipids 
within the body and the specific gene (called PON-1) associated with the 
cholesterol metabolism process; and (iii) bile acids (these are breakdown 
products of cholesterol found in blood). Blood and urine samples you provide 
will also be analysed for anthocyanins and the breakdown products of 
anthocyanins to check how much has been absorbed by the body after 
consumption. 
 
The PON-1 gene is important because it is involved in preventing 
atherosclerosis (a cause of CVD). We want to determine if there is a 
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relationship between the effects of consuming anthocyanins with PON-1 activity 
and PON-1 genotype. There are differences between people in their PON-1 
gene (called genotype). We can find out which PON-1 genotype you are, and 
then we will determine if there is a relationship between different PON-1 
genotypes and how they responded to the anthocyanins (e.g. changes in good 
cholesterol). The result of this gene test has no significance for you or your 
family, and you will not be told your genotype. 
 
For the sub-group (24 people): In the faecal samples you provide, we will 
measure the amount of bile acids and lipids that are excreted. We will also 
make additional measurements of something called RNA (Ribonucleic acid) in 
the blood samples you have already provided. In short, when your body 
naturally produces new proteins your DNA (Deoxyribonucleic acid) is the code 
used to make RNA which in turn is the code for making the new protein. By 
looking at the RNA we can get an idea of the proteins that were especially 
made as a result of the anthocyanins you consumed from the study. The RNA’s 
we measure will be some of those specifically related to atherosclerosis (a 
cause of CVD) and cholesterol metabolism.  
NOTE: Should more resources become available during the trial, we will 
determine the effect of the two anthocyanin types on other RNA’s related to 
CVD. By using the faecal samples you provided we may also investigate the 
relationship between the natural gut bacteria and faecal bile acids and lipids to 
determine if they can be modulated by anthocyanins. 
 
What will happen to the results of the research study? 
As a volunteer you are valuable to us but we are unable to tell you any of your 
individual results. The general findings of the study however, will be fed back 
to you in the form of a talk or in the form of a letter.  
 
Results may be published in scientific journals or presented at meetings. It is 
also possible that data arising from this study will be shared with other 
researchers to support future research.  
 
Please note that data is presented as a whole and is anonymous. Your name 
will not appear anywhere in any of the results presented, shared or published. 
 
Who is funding the study? 
This study is being funded through the Food and Health Strategic Programme 
grant to QI. 
 
Who has reviewed this study? 
Human studies research carried out at QI is reviewed by the Human Research 
Governance Committee (HRGC) and a group of independent people called a 
Research Ethics Committee to protect your safety, rights, wellbeing and 
dignity.   
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This study has been reviewed and approved by HRGC and a Research Ethics 
Committee.         
 
What you need to tell us?  
We do need you to tell us some things for your safety and for the success of 
the study. Some medication may affect the information we are collecting so 
you need to tell us if you take any medication. You will also need to tell us if 
you become pregnant whilst on the study. Should you become unwell during 
the study or after a visit to the HNU then you need to tell us. 
 
Taking part in this study is entirely voluntary. You are free to withdraw at any 
time and without giving a reason.  
 
For further information or to arrange a study appointment, please contact: 
 
Wendy Hollands (01603) 255051 E-mail: 
wendy.hollands@quadram.ac.uk   
 
OR 
 
Aliceon Blair HNU senior research nurse (01603) 255305 
 
Alternatively you can complete the attached response slip and return this to us 
in the prepaid envelope provided.    
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Outline of study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pre-study talk 
(Visit 1) 
Pre-study 
eligibility 
assessment 
(Visit 2) 
Restrict berry 
fruits  
Test phase 1 
Test phase 2 (visits 5 & 
6) (Identical to test phase 1 above) 
Test phase 3 (visits 7 & 
8) 
(Identical to test phase 1 above) 
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                               Fruits to exclude/restrict 
 
 
No more than 3 portions per week (total) of the fruits listed below. 
 
 
 
Strawberries 
Blackberries 
Blueberry 
Raspberries 
Bilberry 
Blackcurrants 
Red currants 
Whortleberry 
Cherry 
Chokeberry 
Cranberry 
Elderberry 
Goji Berry 
Black/red grapes 
Black plums 
 
Please remember to completely exclude these for 24 hours before your study 
day assessments. 
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The effects of bilberry fruit and black rice derived anthocyanins on lipid 
status in adults 
 
Short title: BERI Study 
 
I am interested in taking part and/ or finding out more information about this 
study (please complete the personal details below). 
 
Name: ……………………………………………………… 
Address: ……………………………………………………… 
……………………………………………………… 
……………………………………………………… 
 
Daytime telephone no: ………………………………………….. 
 
Evening telephone no: ………………………………………….. 
 
I am happy for a message to be left via my daytime/evening* no: YES/NO 
*please delete as applicable 
 
Email address:……………………………………………………. 
 
Please return this form in the FREEPOST envelope provided to: 
 
Wendy Hollands 
Quadram Institute Bioscience 
FREEPOST NC 252 
Norwich Research Park 
Colney 
NORWICH 
NR4 7BR 
 
Expressing an interest does not commit you to taking part in the study 
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Letter of invitation for QIB database participants  
 
 
                                                      
 
  Quadram Institute Bioscience 
                Colney Lane 
                 Norwich 
      NR4 7LU 
         
 
Dear 
 
Thank you for your interest in studies at the Quadram Institute Bioscience 
(formerly Institute of Food Research). Please find enclosed information on a 
study in progress at present entitled: The effects of bilberry fruit and black rice 
derived anthocyanins on lipid status in adults (short title: BERI study)  
 
Details held on the QIB Human Nutrition Unit (HNU) volunteer database 
suggest that you may fit the criteria for this study. If, after reading the 
information, you are interested in participating in this study, please complete 
the reply slip and return in the freepost envelope provided. Alternatively, you 
can contact the scientist concerned Wendy Hollands (01603) 255051.  
 
Should your details have changed or you would prefer to no longer remain on 
the database please could you inform the Human Nutrition Unit on (01603) 
255305. 
 
Expressing an interest does not commit you to taking part. 
 
Thank you very much for your time. 
 
Yours sincerely, 
 
 
Aliceon Blair 
Senior Research Nurse 
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Letter of invitation for GP registered participants  
 
GP Practice Headed Paper 
Date 
Dear (name and address), 
Research study: The effects of bilberry fruit and black rice derived 
anthocyanins on lipid status in adults  
 
Recently, doctors at the practice have been approached to ask if any of our 
patients would be interested in taking part in a research study at the Quadram 
Institute Bioscience in Norwich (formerly Institute of Food Research).   
The aim of the study is to determine whether a compound in berry fruits and 
black rice, called anthocyanins, can have an effect on some ‘risk’ factors for 
cardiovascular disease.  One main example being investigated is whether 
anthocyanins can lower blood cholesterol.  
Our records show that you might be suitable for this research.  The Participant 
Information Sheet (PIS), included with this letter, will tell you all about what 
taking part in the study would mean. If, after reading the PIS you would like to 
find out more about the study please return the reply slip (at the back of the 
PIS) to the study team at the Quadram Institute in the freepost envelope 
supplied. A member of the study team will contact you once they have received 
the reply slip. You can also contact a member of the study team if you wish to 
ask any questions about the study before you return the reply slip. The contact 
details for the study team are on the front of the PIS. 
The study will take place in the Human Nutrition Unit at the Quadram 
Institute Bioscience (near the Norfolk and Norwich University Hospital).  
Please do not send any reply slips to your GP surgery 
Yours sincerely 
 
Dr……………………………………  
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Letter of invitation for non-registered participants  
 
 
   
     Quadram Institute Bioscience 
     Norwich Research Park 
     Colney Lane 
     Norwich 
     NR4 7UA 
 
 
Dear  
  
Thank you for your response to the advertisement regarding a study at the 
Quadram Institute Bioscience (formerly Institute of Food Research). Please 
find enclosed the details of the study. 
If, after reading the information, you are still interested in participating please 
complete the reply slip and return in the freepost envelope provided. 
Alternatively, you can contact the scientist/study manager Wendy Hollands 
(01603) 255051 or the HNU Senior Research Nurse Aliceon Blair (01603) 
255305 as stated on the study information sheet.   
 
Expressing an interest does not commit you to taking part. 
 
Thank you very much for your time 
 
Yours sincerely, 
 
 
 
Wendy Hollands 
Study Manager 
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APPENDIX 6 
 
 
PRODUCT SPECIFICATIONS FOR BERI 
STUDY 
 
 
 
 
 
 
 
 
A/1 
Beijing Gingko Group 
Your natural partner 
Room 1706, Tower  A, Building 1, Tianzuo International Center,  No. 
12 Zhongguancun South Avenue, Haidian District, Beijing, China, 100081 
Phone: +86 (0) 10 5970 5209 Fax: +86 (0) 10 5970 5660 
www.bggworld.com 
 
 
 
PRODUCT SPECIFICATION SHEET FOR BLACK RICE 
EXTRACT 
PRODUCT: Black Rice Extract Powder PRODUCT NO.: BR-30 
ISSUE DATE: Jan. 16, 2017 
SPECIFICATION NO.: 000 
STARTING HERBAL MATERIAL: 
BOTANICAL NAME: Oryza sativa L. PART OF PLANT USED: Seed 
CULTIVATED/WILD: Cultivated 
PRODUCTION: 
SOLVENT USED: Ethanol COUNTRY OF PROCESSING: China 
DRUG-TO-EXTRACT RATIO: 150-250:1 EXCIPIENTS/OTHER COMPONENTS: None 
ANTIOXIDANTS/PRESERVATIVES: None 
 
PHYSICAL/CHEMICAL SPECIFICATIONS 
 
ITEMS SPECIFICATIONS METHOD 
CHARACTERISTICS: Purple black powder Visual inspection 
※HEAVY METALS: 20ppm Max. According to Eur. Ph. 2.4.8 
※CADMIUM: 1ppm Max. According to Eur. Ph. 2.4.27 
※LEAD: 3ppm Max. According to Eur. Ph. 2.4.27 
※MERCURY: 0.1ppm Max. According to Eur. Ph. 2.4.27 
LOSS ON DRYING: 5.0% Max. According to Eur. Ph. 2.8.17 
ASH: 3.0% Max. According to Eur. Ph. 2.4.16 
 
※PESTICIDES: 
In accordance to EC 
Regulation No. 396/2005 
and modifications 
 
ANTHOCYANINS: 
Content of Anthocyanins by 
HPLC (on dry basis, expressed as 
Cyanidin 
3-O-glucoside) 
 
 
30.0% Min. 
 
 
In-house method 
   
 
   
A/0 
 
314 
 
 
 
Not from Japan (Regulation (EC) No 297/2011) Not irradiated 
 
※Periodic test (not carried out batch by batch) for which BGG tests batches 
randomly every year. Complies: BGG can provide a Certificate of Compliance 
for this test with historical data from tested batches. 
 
STORAGE: 
Preserve in tight containers, protected from light. Avoid excessive heat. 
 
SHELF LIFE: 
Three (3) years when properly stored. 
 
 
 
 
CYANIDIN 3-O-GLUCOSIDE: 
Content of Cyanidin 3-O-
glucoside by HPLC (on dry basis) 
 
20.0% Min. 
 
In-house method 
MICROBIOLOGY 
 According to Eur. Ph. 2.6.12 and 
2.6.13 
TOTAL PLATE COUNT: < 5,000cfu/g 
 
YEAST & MOLD: < 500cfu/g 
 
BILE-TOLERANT 
GRAM-NEGATIVE BACTERIA: 
 
< 100cfu/g 
 
ESCHERICHIA COLI: Absence/g  
SALMONELLA: Absence/10g 
 
※AFLATOXINS: 
 
According to Eur. Ph. 2.8.18 
SUM OF AFLATOXIN B1, B2, 
G1 AND G2: 
 
< 4ppb 
 
AFLATOXIN B1: < 2ppb  
※BENZO(a)PYRENE: < 10ppb In-house method 
※SUM OF BENZO(a)PYRENE, 
BENZO(a)ANTHRACENE, 
BENZO(a)FLUORANTHENE, 
CHRYSENE: 
 
 
< 50ppb 
 
 
In-house method 
   
 
   
A/0 
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PRODUCT SPECIFICATION SHEET FOR BILBERRY 
EXTRACT POWDER 
 
PRODUCT: Bilberry Extract Powder (MyrtiPRO)  
PRODUCT NO.: GC-021J  
ISSUE DATE: Jul. 6, 2016  
SPECIFICATION NO.: 000 
 
STARTING HERBAL MATERIAL:  
BOTANICAL NAME: Vaccinium myrtillus L.  
PART OF PLANT USED: Fresh Frozen Fruit  
CULTIVATED/WILD: Wild 
 
PRODUCTION:  
SOLVENT USED: Ethanol/Water  
COUNTRY OF PROCESSING: China  
DRUG-TO-EXTRACT RATIO: 80-100:1  
EXCIPIENTS/OTHER COMPONENTS: None  
ANTIOXIDANTS/PRESERVATIVES: None 
 
PHYSICAL/CHEMICAL SPECIFICATIONS 
 
ITEMS SPECIFICATIONS METHOD 
CHARACTERISTICS: Purple black powder Visual inspection 
IDENTIFICATION: HPLC complies According to Eur. Ph. monograph 2394 
※HEAVY METALS: 20ppm Max. According to Eur. Ph. 2.4.8 
※CADMIUM: 1ppm Max. According to Eur. Ph. 2.4.27 
※LEAD: 3ppm Max. According to Eur. Ph. 2.4.27 
※MERCURY: 0.1ppm Max. According to Eur. Ph. 2.4.27 
PH: 3.0-4.5 According to Eur. Ph. 2.2.3 
LOSS ON DRYING: 5.0% Max. According to Eur. Ph. 2.8.17 
ASH: 3.0% Max. According to Eur. Ph. 2.4.16 
※PESTICIDES: 
In accordance to EC 
Regulation No. 
396/2005 
and modifications 
 
 
 
FREE ANTHOCYANIDINS: 
Free Anthocyanidins by HPLC 
1.0% Max. According to Eur. Ph. monograph 2394 
 
   
 
   
A/0 
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ANTHOCYANIDINS:  
Content of Anthocyanidins by UV (on 
dry basis) 
25.0% Min. In-house method 
 
ANTHOCYANINS: 
 
Content of Anthocyanins by HPLC (on 
dry basis, expressed as Cyanidin 3-O-
glucoside chloride) 
36.0% Min. 
According to Eur. Ph. 
monograph 2394 
         
MICROBIOLOGY According to Eur. Ph. 2.6.12 and 2.6.13 
TOTAL PLATE COUNT: < 5,000cfu/g 
YEAST & MOLD: < 500cfu/g 
BILE-TOLERANT 
< 100cfu/g 
GRAM-NEGATIVE BACTERIA: 
 
ESCHERICHIA COLI: Absence/g 
SALMONELLA: Absence/10g 
※AFLATOXINS: According to Eur. Ph. 2.8.18 
SUM OF AFLATOXIN B1, B2, G1 
< 4ppb 
AND G2: 
 
AFLATOXIN B1: < 2ppb 
 
 
GMO: This is IP Non-GMO product (Regulation (EC) No 1830/2003)  
Not from Japan (Regulation (EC) No 297/2011)  
Free from food allergens (Dir. 2000/13/EC and subsequent amendments)  
Not irradiated 
 
※Periodic test (not carried out batch by batch) for which BGG tests batches randomly 
every year. Complies: BGG can provide a Certificate of Compliance for this test with 
historical data from tested batches. 
 
STORAGE: 
Preserve in tight containers, protected from light. Avoid excessive heat. 
 
SHELF LIFE: 
Three (3) years when properly stored. 
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Article 
The Effects of Anthocyanins and Their Microbial 
Metabolites on the Expression and Enzyme 
Activities of Paraoxonase 1, an Important Marker 
of HDL unction 
Hassan T Aboufarrag 1,2, Paul W Needs 1, Gerald Rimbach 3 and Paul A Kroon 1,* 
1 Food Innovation & Health, Quadram Institute Bioscience, Norwich Research Park, Norwich, 
Norfolk, NR4 7UA, UK; hassan.aboufarrag@quadram.ac.uk (H.T.A.); paul.needs@quadram.ac.uk 
2 Food Science and Technology Department, Faculty of Agriculture, Alexandria University, 
Alexandria, 23511, Egypt 
3 Institute of Human Nutrition and Food Science, Christian-Albrechts-University of Kiel, 24118 Kiel, 
Germany; rimbach@foodsci.uni-kiel.de  
* Correspondence: paul.kroon@quadram.ac.uk 
Received: 7 November 2019; Accepted: 21 November 2019; Published: date 
Abstract: High circulating HDL concentrations and measures of various HDL functions are 
inversely associated with cardiovascular disease (CVD) risk. Paraoxonase 1 (PON1) 
contributes to many of the athero-protective functions of HDL, such as promoting the reverse 
cholesterol transport process and reducing the levels of oxidized LDL. PON1 activities are 
influenced by several factors, the most important being diet and genetic polymorphisms. 
Reported data from randomized controlled trials have shown that anthocyanin consumption 
increased PON1 activity. However, the underlying molecular mechanisms by which 
anthocyanins increase PON1 activity are not understood. Therefore, the aim of this research 
was to investigate the ability of anthocyanins and their metabolites to increase PON1 gene 
expression and/or enzyme activities as potential mechanisms. The effect of the two 
predominant dietary anthocyanins and 18 of their recently identified microbial metabolites 
including their phase-II conjugates on PON1 gene expression was studied using a PON1-
Huh7 stably-transfected cell line and reporter gene assay. The effects of these compounds on 
PON1 arylesterase and lactonase activities were investigated using two isoforms of the 
PON1 enzyme that are the phenotypes of the 192Q/R polymorphism. None of the 
compounds caused even modest changes in PON1 promoter activity (p ≥ 0.05). Further, none 
of the compounds at physiological concentrations caused any significant changes in the 
arylesterase or lactonase activity of either of the iso-enzymes. Cyanidin reduced the lactonase 
activity of the PON1-R192R enzyme at high concentrations (−22%, p < 0.001), but not at 
physiologically achievable concentrations. In conclusion, none of the data reported here 
support the notion that anthocyanins or their metabolites affect PON1 transactivation or 
enzyme activities. 
Keywords: polyphenols; flavonoids; phase-II metabolism; anthocyanin metabolites; human 
metabolism; lactonase activity; arylesterase activity; promoter activity; single nucleotide 
polymorphism; protocatechuic acid; phloroglucinaldehyde 
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1. Introduction 
Many epidemiological and clinical studies suggest that the consumption of anthocyanin-
rich fruit and vegetables is associated with favorable improvements in lipid profiles, 
specifically with reductions in LDL cholesterol and increases in HDL cholesterol [1–4]. High 
levels of circulating HDL cholesterol are inversely correlated with the incidence of 
cardiovascular disease (CVD), mainly coronary heart disease (CHD) [5–7]. However, more 
recent studies have suggested that the relationship between HDL and CVD markers extends 
beyond the concentration of HDL alone and that the function of HDL may be more important 
than HDL concentration in protecting against CVD [8–11]. HDL possesses a number of 
atheroprotective functions such as mediation of cholesterol efflux from cholesterol-loaded 
cells, protection against oxidation and inflammation, and promotion of nitric oxide synthesis 
[12]. This protective effect is largely attributed to enzymes associated with HDL, including 
paraoxonase 1 (PON1) [13]. 
PON1 is an HDL-associated enzyme secreted by the liver and found to have significant 
anti-oxidative and anti-inflammatory properties though its lactonase, peroxidase, and esterase 
activities [14]. The anti-atherogenicity of PON1 is thought to be related to its ability to 
hydrolyze oxidized cholesteryl esters and oxidized phospholipids and degrade hydrogen 
peroxide, thus protecting lipoprotein particles from any further oxidative modification [15]. 
Polymorphisms in the PON1 gene can affect enzyme activities, stability, and the anti-
atherogenicity of the PON1 enzyme [16–20]. Among the numerous PON1 polymorphisms in 
humans, the Q192R and L55M polymorphisms are the ones most associated with lipoprotein 
oxidation and CHD risk, and there is evidence that these polymorphisms explain a significant 
proportion of the differences in PON1 activity between individuals [21]. People with the 192-
Q/Q genotype gain greater protection against CVD compared to those with 192-R/R PON1. 
The 192-Q/Q PON1 enzyme is more potent in decreasing the levels of oxidized lipids in human 
atherosclerotic lesions than the 192-R/R PON1 enzyme [22,23]. The PON1 L55M 
polymorphism has also been associated with variation in serum PON1 activity but has a 
weaker effect [24]. PON1 polymorphisms also affect the enzyme’s substrate specificity [25]. 
For instance, the 192-R/R PON1 enzyme hydrolyses paraoxon approximately nine times faster 
than the 192-Q/Q, PON1 enzyme, while the opposite occurs with diazoxon and sarin 
substrates [25]. Therefore, ignoring the genetic variant could lead to a false interpretation, 
especially, when substrates that are strongly influenced by polymorphisms such as paraoxon 
are being used [26]. Therefore, it is recommended to compare PON1 levels within each 
different genotype/phenotype group. 
Anthocyanins have been reported to increase PON1 activity. A 17.4% mean increase in 
PON1 arylesterase was reported in response to a 24-week intervention with a mixture of 
purified anthocyanins extracted from bilberry and blackcurrant (Medox™) in human 
participants with hypercholesterolemia compared to placebo [27]. A similar effect on serum 
PON1 was reported for participants who had consumed pomegranate juice for two weeks 
compared to a control beverage [28]. In addition, treatment of PON1-Huh7 cells with 
polyphenol-rich and anthocyanin-rich purple sweet potato fractions was reported to cause 
significant induction of PON1 promoter transactivation [29]. Other polyphenols such as 
quercetin, resveratrol, and catechin have also been reported to modulate PON1 activity and 
gene expression in vivo and in vitro [30–35]. 
There is growing evidence that anthocyanins are subjected to extensive metabolism, 
especially by the gut microbiota, producing a wide range of metabolites [36]. After 
consumption of penta-13C-labelled cyanidin-3-glucoside (C3G), most of the given dose was 
recovered as breakdown products (A- and B-ring-derived phenolics), while only minor 
quantities of intact C3G were recovered [37,38]. Of the 35 metabolites identified in human 
plasma, urine, and feces in this study, hippuric acid, vanillic acid, ferulic acid, 4-
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hydroxybenzaldehyde, and vanillic acid sulphate were the predominant metabolites [38]. The 
much higher concentrations in blood and the relative stability of anthocyanin metabolites 
suggest that the high bioactivity of anthocyanins is more likely to be mediated by their 
metabolites rather than the parent compounds. However, the biological activity of the 
majority of these metabolites has not been investigated. 
Therefore, the aim of this study was to investigate the effects of two predominant dietary 
anthocyanins (C3G and delphindin-3-glucoside (D3G)), and their degradation products 
including their phase-II conjugates on PON1 gene expression and PON1 arylesterase and 
lactonase activities. The potential for anthocyanins or their metabolites to induce PON1 
expression was determined using a reporter gene assay and the effects on enzyme activities 
assessed using isolated PON1 isoenzymes corresponding to the major functional SNPs in 
humans. 
2. Materials and Methods 
2.1. Reporter Gene Assay 
2.1.1. Cell Culture 
The effect of anthocyanins and their metabolites on PON1 gene expression was evaluated 
using a reporter gene assay (Bioluminescence firefly luciferase assay) in cultured hepatocytes. 
PON1-Huh7 was a Huh7 liver hepatoma cell line that had been stably transfected with a 
reporter plasmid containing 1009 bp [–1013, –4] of the PON1 gene promoter cloned into the 
firefly luciferase reporter vector pGL3 basic [30,39]. 
PON1-Huh7 cells were kindly provided by Dr. X. Coumoul and Dr. Robert Barouki, 
French National Institute of Health and Medical Research (INSERM), France. PON1-Huh7 
cells were maintained following the protocol as previously described [39]. Briefly, PON-Huh7 
cells were cultivated in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 
fetal bovine serum (FBS) 10% (v/v), penicillin (100 U/mL) and streptomycin (100 µg/mL), 
glutamine (2 mM), and G418 disulphate (100 µg/mL) (Sigma-Aldrich) at 37 °C in 5% CO2 until 
reaching 80%–90% confluency, with the media changed every two days. The cells were then 
detached by adding trypsin-EDTA for 2–3 min at 37 °C. A complete DMEM that contained 
10% FBS was then added to inhibit the trypsin. The trypsinized cell suspension was collected 
and the cells were either split or seeded for treatments. In 24-well plates, cells were seeded at 
an initial density of 0.15 × 106 cells/well and left to attach for 24 h. 
2.1.2. Treatments 
Following seeding the cells, the media was removed and new pre-warmed media 
containing anthocyanins treatment was added to the appropriate wells and incubated at 37 
°C, 5% CO2 for 48 h. The treatments were C3G, D3G, and their major known human 
metabolites (reported elsewhere [38]) together with their potential/predicted metabolites at 1 
and 10 µM. The cells were also treated with phase-II conjugates of protocatechuic acid (PCA) 
and gallic acid, namely PCA-glucuronides (PCA-GlcAs, including PCA-3-glucuronid (PCA-
3-GlcA) and PCA-4-glucuronide (PCA-4-GlcA), each at 1 µM), PCA-sulphates (PCA-sulphs, 
including PCA-3-sulphate (PCA-3-Sulph) and PCA-4-sulphate (PCA-4-Sulph), each at 1 µM), 
gallic acid glucuronides (GA-GlcAs, including gallic acid-3-glucuronide (GA-3-GlcA) and 
gallic acid-4-glucuronide (GA-4-GlcA), each at 1 µM), and methylgallates (MethGA, including 
3-O-methylgallic acid (3MethGA) and 4-O-methylgallic acid (4MethGA), each at 1 µM). Figure 
1 depicts the chemical structure of these metabolites. In order to investigate the interaction 
between anthocyanin metabolites, the cells were treated with two different mixtures of 
anthocyanin metabolites, PCA-Mix and GA-Mix. PCA-Mix contains C3G, PCA, PCA-4-GlcA, 
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PCA-3-GlcA, PCA-3-Sulph, and PCA-4-Sulph, at 1 µM each. GA-Mix contains D3G, gallic 
acid, GA-3-GlcA, GA-4-GlcA, 3MethGA, and 4MethGA, at 1 µM each. The vehicle control was 
DMSO with final concentration of 0.1%. Curcumin (20 µM) (Fisher Scientific) served as a 
positive control alongside the anthocyanins and their metabolite treatments. Treatments were 
conducted in quadruplicate and the experiments were repeated at least two times. The tested 
compounds were purchased from Sigma Aldrich, syringic acid was purchased from Alfa 
Aesar, and phloroglucinol was purchased from Across Organics. PCA conjugates and gallic 
acid conjugates were synthesized in-house [40]. After treatment, the luciferase activity was 
measured as a marker of PON1 promoter activity. 
2.1.3. Luciferase Assay 
Luciferase activity was measured using the Luciferase Assay System (Promega, 
Hampshire, UK, Cat# E1500) according to the manufacturer’s instructions. Briefly, after 48 h 
treatment, the media was removed, and the cell layer was washed twice with cold calcium- 
and magnesium-free PBS. The lysis buffer was then added to the cell layer and the cells were 
scraped. Immediately, the lysate was collected and centrifuged for 2 min at 12,000 XG at 4 °C. 
After that, in 96-well white plates, 100 µL of luciferase assay reagent were added to 20 µL cell 
lysate. The luminescence was immediately measured over 20 s using a plate reader, 
FLUROstar Optima (BMG labtech, UK). 
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Figure 1. The chemical structures of cyanidin-3-O-glucoside, delphinidin-3-O-glucoside, and 
their known and potential metabolites: phloroglucinaldehyde (PGA), protocatechuic acid 
(PCA), 4-hydroxybenzaldehyde (4HBA), PCA-3-sulphate (PCA-3-sulph), PCA-4-sulphate 
(PCA-4-Sulph), PCA-3-glucuronide (PCA-4-GlcA), PCA-4-glucuronide (PCA-4-GlcA), 3-O-
methylgallic acid (3MethGA), 4-O-methylgallic acid (4MethGA), gallic-3-glucuronide (GA-4-
GlcA), and gallic acid-4-glucuronide (GA-4-GlcA). AccelrysDraw (version 4.2 for windows) 
was used to draw the chemical structures. 
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The plate reader is capable of injecting the reagent automatically and can perform multi-
well readings. The luminescence was expressed as total light intensity which was collected 
over 20 s. Results were normalized to the total cell protein content. The total protein in each 
sample was determined using the bicinchoninic acid (BCA)-Reducing Agent Compatible 
assay as per the manufacturer’s protocol (Thermofisher, Paisley, UK, Cat# 23252). 
2.1.4. PON1 Promoter Activity Calculation 
First, the light intensity which reflects the promoter activity was normalized to the total 
protein content in the cell lysate. 
Promoter activity = Total light intensity/total protein content (µg/mL). 
Then, the fold change of PON1 promoter activity was calculated relative to the control 
(DMSO). 
2.1.5. PON1 Enzyme Activities 
The direct effect of anthocyanins on PON1 activities was measured using a commercially 
available purified PON1 that phenotyped into two phenotypes based on Q192R 
polymorphism. PON1 phenotype QQ (PON-QQ) and phenotype RR (PON-RR) were 
purchased from ZeptoMetrix (Buffalo NY, USA, Cat# 0801384). The treatments were prepared 
as described earlier and were diluted in the assay buffer. Arylesterase and lactonase PON1 
activities were measured using colourimetric assays as described below. 
2.1.6. PON1 Arylesterase 
PON1 arylesterase activity was quantified by measuring the hydrolysis rate of p-
nitrophenyl acetate (a colorless substrate) into p-nitrophenol (that has a yellow color) and 
measuring the increase in absorbance using a spectrophotometer [41]. PON1 arylesterase 
activity was measured as described elsewhere [13,42,43]. First, PON-RR and PON-QQ were 
diluted in assay buffer consisting of 20 mM Tris-HCl buffer, pH = 8 and 1 mM CaCl2, just prior 
to conducting the assay. The dilution factors for PON-RR and PON-QQ were 10- and 15-fold, 
respectively. The assay was developed with a final volume of 200 µL in 96-well polystyrene 
plate. Here, 20 µL of diluted enzyme and 20 µL of treatment were mixed together with 140 µL 
pre-warmed assay buffer. The plate was then sealed to prevent evaporation and incubated at 
37 °C for 10 min. Quickly, 20 µL of diluted substrate was added to the previous reaction 
mixture and the increase in absorbance was measured immediately at 410 nm for 10 min using 
FLUROstar Optima (BMG labtech, UK). The final concentrations of reactants were 1% PON-
RR (0.63 U/mL)/0.7% PON-QQ (1.3 U/mL), 1 mM p-nitrophenyl acetate, and 1 or 10 µM 
anthocyanin treatments. The final concentration of DMSO was 0.1% in all treatments. The 
control treatment was enzyme treated with DMSO at final concentration of 0.1%. The slope of 
the reaction rate was calculated using the instrument software. Blanks without enzymes or 
treatments were used to correct for the spontaneous nonenzymatic hydrolysis of p-
nitrophenyl acetate by subtracting blanks from the hydrolysis rate of treatments. The % of 
change was calculated relative to the control as following: 
% 𝑜𝑓 𝐶ℎ𝑎𝑛𝑔𝑒 =  
ℎ𝑦𝑑𝑟𝑜𝑙𝑦𝑠𝑖𝑠 𝑟𝑎𝑡𝑒 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 − ℎ𝑦𝑑𝑟𝑜𝑙𝑦𝑠𝑖𝑠 𝑟𝑎𝑡𝑒 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
ℎ𝑦𝑑𝑟𝑜𝑙𝑦𝑠𝑖𝑠 𝑟𝑎𝑡𝑒 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
 𝑥 100 
Treatments were conducted in triplicates and the experiments were repeated at least two 
times. The purity of the enzymes was determined by measuring the activity of enzymes with 
100 µM of 2-hydroxyquinoline (2-HQ), the PON1-potent inhibitor (Sigma-Aldrich, Dorset, 
UK, Cat# 270873). 
2.1.7. PON1 Lactonase 
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PON1 lactonase activity was measured spectrophotometrically by monitoring the 
hydrolysis of the synthetic lipolactone substrate, 5-thiobutyl butyrolactone (TBBL) [44,45]. 
Lactonase activity was measured as described previously [46,47]. Briefly, PON-RR and PON-
QQ were diluted to 50- and 80-fold, respectively, in the assay buffer that consisted of 50 mM 
Tris-HCl, 1 mM CaCl2, 50 mM NaCl, and pH = 8. Using 96-well polystyrene plates, 20 µL of 
enzyme and 20 µL of treatment were mixed together with 60 µL pre-warmed assay buffer, 
and then 50 µL of 5,5′-dithiobis (2-nitrobenzoic acid) (DTNB, 4 mM) were mixed with the 
reaction mixture. The plate was sealed to prevent evaporation and incubated for 10 min at 37 
°C. A solution of TBBL (2 mM) was prepared in pre-warmed assay buffer contain 2% 
acetonitrile just before use. After that, 50 µL of TBBL (2 mM) was added to the reaction mixture 
and the absorbance was measured immediately at 412 nm using a FLUROstar Optima plate 
reader (BMG labtech, UK). The final volume was 200 µL and the concentrations of reactants 
were 0.2% PON-RR (0.13 U/mL)/0.125% PON-QQ (0.23 U/mL), 1 mM DTNB, 0.5 mM TBBL, 
and 1 or 10 µM treatments. The lactonase activity was calculated as previously described for 
arylesterase. Treatments were conducted in quadruplicate and the experiments were repeated 
at least two times. The purity of the enzymes was determined by measuring the activity of 
enzymes with 100 µM of 2-hydroxyquinoline (2-HQ). 
2.1.8. Statistical Analysis 
All data and statistics were analyzed using GraphPad Prism (version 5.04 for Windows, 
GraphPad Software, La Jolla California USA, (https://www.graphpad.com/).  All values are 
given as means ± SD. Any statistical difference between the groups was determined with one-
way ANOVA coupled with Dunnett’s multiple comparison test comparing all sample groups 
to control (DMSO 0.1%). Values of p ≤ 0.05 were considered significant. 
3. Results 
3.1. Effects of Anthocyanins and Their Metabolites on PON1 Promoter Activity 
The effect of anthocyanins and their metabolites on PON1 gene expression was 
investigated by measuring activation of the PON1 promoter in PON1-Huh7 stably transfected 
cells. As shown in Figure 2A, C3G and D3G did not cause any significant change in PON1 
promoter activity compared to the control (DMSO) at either 1 or 10 µM; C3G treatment 
resulted in a small increase but this was not significant (p ≥ 0.05). Similarly, a large number of 
anthocyanin metabolites were tested, including known metabolites of anthocyanins that were 
reported previously from the study that used penta-13C-labelled C3G [38] (Figure 2B) and a 
series of predicted anthocyanin metabolites. None of these metabolites (Figure 2C) or the 
phase-II-conjugates (Figure 2D) that were tested had any significant effect on PON1 promoter 
activity. In contrast to what we had predicted, syringic acid, cyanidin, 5-HFA, and hippuric 
acid reduced promoter activity by between 10% and 20%, although the changes were not 
significant (Figure 2C). In contrast, curcumin (the positive control) significantly increased 
PON1 promoter activity by 5.3-fold (Figure 2A–D, p ≤ 0.001) which was consistent with 
previous reports [29,39,48]. This demonstrates that the model is functioning properly and 
sensitive to treatments. Although these data showed that anthocyanins and their metabolites 
did not significantly alter the promoter activity of PON1, it is possible that they may interact 
with PON1 in a different way, for example by activating the enzyme and increasing its 
activities. Therefore, the effect of anthocyanins and their metabolites on PON1 enzyme 
activities were investigated. 
3.2. Effect of Anthocyanins and Their Metabolites on PON1 Activities 
3.2.1. Establishing a Fit-for-Purpose Enzyme Assay 
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To avoid inaccurate enzyme activity measurements, the reaction rate should be measured 
within the linear stage of the enzyme reaction. To establish a linear enzyme reaction, serial 
dilutions of PON-RR and PON-QQ enzymes were tested with p-nitrophenyl acetate (the 
substrate for arylesterase) and TBBL (the substrate for lactonase). A concentration of 1% PON-
RR (0.63 U/mL) and 0.7% PON-QQ (1.3 U/mL) enzymes resulted in a linear reaction of 
arylesterase (Figure 3A), while the linearity of the lactonase enzyme reaction was achieved 
with 0.2% PON-RR (0.13 U/mL) and with 0.125% PON-QQ (0.23 U/mL) (Figure 3B). The linear 
regression coefficient (R2) was about 0.99, which is very close to 1 for both arylesterase and 
lactonase, meaning that the reaction is linear at these concentrations of PON-RR and PON-
QQ. In addition, the reaction remained linear for at least 16 min for both reactions (Figure 3A 
and B). To make sure that the model was working and to validate that the commercial enzyme 
does not contain any other esterases rather than PON1, the arylesterase and lactonase 
activities were measured in the presence and absence of 2-hydroxyquinoline (2-HQ), a potent 
inhibitor of PON1. It was found that 2-HQ resulted in about 97.5% inhibition for PON-RR and 
PON-QQ for both activities, confirming the suitability of the model for this purpose of study 
(Figure 3A and B). 
  
Figure 2. Effect of anthocyanin parent compounds (A), their known human metabolites (B), 
their potential/predicted metabolites (C), and phase-II conjugates (D) on paraoxonase 1 
(PON1) promoter activity. A reporter gene assay was used to measure the promoter activity 
in PON1-Huh7 cells. The fold change was calculated relative to control (DMSO). Data are 
shown as means ± SD. *** p ≤ 0.001 as compared to control using one-way ANOVA coupled 
with Dunnett’s multiple comparison test. Treatments were as follows: cyanidin-3-glucoside 
(C3G), delphinidin-3-glucoside (D3G), phloroglucinaldehyde (PGA), protocatechuic acid 
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(PCA), 4-hydroxybenzaldehyde (4HBA), 5-hydroxyferulic acid (5HFA), PCA-glucuronides 
(PCA-GlcAs), PCA-sulphates (PCA-Sulphs) PCA-Mix (C3G, PCA, and PCA conjugates), 
gallic acid glucuronides (GA-GlcAs), methylgallates (MethGA), GA-Mix (D3G, gallic acid and 
gallic acid conjugates), and curcumin (20 µM) which served as a positive control. Treatments 
were conducted in quadruplicate and the experiments were repeated at least two times. 
3.2.2. Effect of Anthocyanins and Their Metabolites on PON1 Arylesterase Activity 
In this study, the direct effect of anthocyanin parent compounds and their metabolites on 
PON1 arylesterase activity was examined using two different phenotypes, PON-RR and PON-
QQ (Figure 4A–D). The findings demonstrated that neither C3G or D3G affected the 
arylesterase activity at either concentration of the PON-RR or PON-QQ enzymes (Figure 4A). 
Likewise, none of the tested metabolites either the known, the potential or the phase-II 
conjugates affected the arylesterase activity, except for gallic acid, phloroglucinol, and 
cyanidin (Figure 4B–D). 
Gallic acid at the higher concentration (10 µM) significantly increased PON-QQ 
arylesterase (but not PON-RR) by 9% compared to the control (Figure 4B, p ≤ 0.001). Similarly, 
phloroglucinol at both 1 and 10 µM increased PON-QQ (but not PON-RR) but by only 4% 
(Figure 4C, p ≤ 0.001). On the other hand, the high concentration of cyanidin (10 µM) but not 
the low concentration slightly decreased PON-RR by 6% (Figure 4C, p ≤ 0.001). Although 
statistically significant effects were observed for gallic acid, phloroglucinol and cyanidin, the 
effects were very modest. 
 
Figure 3. PON1 enzyme reaction progress curve for arylesterase (A) and lactonase (B). For 
arylesterase, the substrate was added to the 1% PON1 R192R phenotype (PON-RR) and to the 
0.7% PON1 Q192Q phenotype (PON-QQ) with and without PON1 inhibitor (100 µM 2-
hydroxyquinoline (2-HQ)). For lactonase, the substrate was added to 0.2% PON-RR and 
0.125% PON-QQ with and without 100 µM 2-HQ. The enzymes were diluted in assay buffer. 
The absorbance was recorded over 16 min. R2 = linear regression coefficient. R2 was calculated 
using Excel software 2016.  
3.2.3. Effect of Anthocyanins and Their Metabolites on PON1 Lactonase Activity. 
As shown in Figure 5A–D, a few of the tested anthocyanins and their metabolites caused 
significant changes in PON1 lactonase activity, although the changes were not substantial. 
C3G had a very small but significant effect on the enzyme activity of both PON-RR and PON-
QQ phenotypes. However, PON-QQ phenotype lactonase activity was affected more with 
increases of 11% and 9% at concentrations of 1 and 10 µM, respectively (p ≤ 0.001), while the 
lactonase activity of PON-RR increased by 6% and 8% at concentrations of 1 and 10 µM of 
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C3G, respectively (p ≤ 0.001, Figure 5A). On the other hand, only a modest increase (5%) in 
PON-RR lactonase activity was observed with D3G (1 µM) (Figure 5A, p ≤ 0.001). Moreover, 
most of the tested anthocyanin metabolites did not cause significant changes, except for small 
changes in response to treatment with gallic acid, vanillic acid, and ferulic acid (Figure 5B, p ≤ 
0.001). 
The only substantial effect was observed with cyanidin (Figure 6A and B). Unexpectedly, 
cyanidin at 10 µM significantly decreased PON-RR lactonase activity but not PON-QQ by 22% 
(p ≤ 0.001), while the lower concentration of cyanidin did not cause a change (Figure 6A). This 
finding was confirmed by doing a dose-response curve for cyanidin with PON-RR enzyme. 
As shown in Figure 6B, cyanidin decreased lactonase activity of PON-RR in a dose-dependent 
manner with about 30% reduction observed at the highest concentration (20 µM cyanidin). 
However, the lower more physiological concentrations of cyanidin (0.1, 0.5 µM, 1 µM) did not 
affect PON-RR activity. On the other hand, PON-QQ appeared to respond differently when 
treated with cyanidin: The low concentration of cyanidin (1 µM) but not the high one slightly 
increased PON-QQ by 8% (Figure 6A, p ≤ 0.001). However, it should be taken into account 
that the magnitude of effects where statistically significant effects were detected were modest 
(typically 4%−11%). 
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Figure 4. Effect of anthocyanins parent compounds (A), their known human metabolites (B), 
their potential/predicted metabolites (C), and phase-II-conjugates (D) on arylesterase activity 
of PON1 R192R (PON-RR) and Q192Q (PON-QQ) phenotypes. The % of change in activity 
was calculated relative to the control (DMSO). Data are shown as means ± SD. ** p ≤ 0.01 and 
*** p ≤ 0.001 as compared to control using one-way ANOVA coupled with Dunnett’s multiple 
comparison test. Treatments were: cyanidin-3-glucoside (C3G), delphinidin-3-glucoside 
(D3G), phloroglucinaldehyde (PGA), protocatechuic acid (PCA), 4-hydroxybenzaldehyde 
(4HBA), 5-hydroxyferulic acid (5HFA), PCA-glucuronides (PCA-GlcAs), PCA-sulphates 
(PCA-Sulphs) PCA-Mix (C3G, PCA, and PCA conjugates), gallic acid glucuronides (GA-
GlcAs), methylgallates (MethGA), and GA-Mix (D3G, gallic acid, and gallic acid conjugates). 
Treatments were conducted in triplicates and the experiments were repeated two times. 
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Figure 5. Effect of anthocyanins parent compounds (A), their known human metabolites (B), 
their potential/predicted metabolites (C), and phase-II conjugates (D) on lactonase activity of 
PON1 R192R (PON-RR) and Q192Q (PON-QQ) phenotypes. The % of change in activity 
calculated relative to the control (DMSO). Data are shown as means ± SD. * p ≤ 0.05 and *** p 
≤ 0.001 as compared to control using one-way ANOVA coupled with Dunnett’s multiple 
comparison test. Treatments were: cyanidin-3-glucoside (C3G), delphinidin-3-glucoside 
(D3G), phloroglucinaldehyde (PGA), protocatechuic acid (PCA), 4-hydroxybenzaldehyde 
(4HBA), 5-hydroxyferulic acid (5HFA), PCA-glucuronides (PCA-GlcAs), PCA-sulphates 
(PCA-Sulphs) PCA-Mix (C3G, PCA and PCA conjugates), gallic acid glucuronides (GA-
GlcAs), methylgallates (MethGA), and GA-Mix (D3G, gallic acid and gallic acid conjugates). 
Treatments were conducted in triplicates and the experiments were repeated two times. 
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Figure 6. Effect of cyanidin on lactonase activity of PON1 R192R (PON-RR) and Q192Q (PON-
QQ) phenotypes (A) and the dose response of PON-RR lactonase activity in the presence of 
cyanidin (B). The % of change in activity calculated relative to the control (DMSO). Data are 
shown as means ± SD. *** p ≤ 0.001 as compared to control using one-way ANOVA coupled 
with Dunnett’s multiple comparison test. % reduction in activity calculated relative to the 
control treatment. Treatments were conducted in triplicates and the experiments were 
repeated two times. 
In summary, the data presented in this study do not support the notion that anthocyanins 
and/or their metabolites significantly affect PON1 gene promoter activity or change the 
activity of PON1 enzymes. Even though some statistically significant changes were detected, 
the changes were very modest and probably lack clinical importance. 
4. Discussion 
The overall findings of the work reported here are that neither intact anthocyanins and 
anthocyanidins, nor their many phenolic degradation products, nor the tested phase-II-
conjugates that are the forms found in human blood caused any substantive activation of the 
PON1 promoter or in the arylesterase or lactonase activities of the major isoforms of PON1. 
Previously reported data from epidemiological studies and from dietary interventions 
with human participants and animal models suggests that anthocyanins have the potential to 
decrease the risk of CVD [49–51]. In addition, there are numerous reports describing putative 
biological activities of anthocyanins based on treating, for example, cultured human cells with 
anthocyanins, typically at supraphysiological concentrations. The vast majority of these 
reported in vitro studies have examined only the activity of the intact form of anthocyanins 
and ignored the fact that anthocyanins undergo extensive metabolism [52,53]. The 
unequivocal identity of the metabolites of C3G was recently established from an elegant 
human feeding study that used penta-13C-labelled C3G that allowed the source of the 
metabolites (A- or B-ring of the anthocyanidin) to be established [37,38]. In addition, a number 
of metabolites of D3G and other trihydroxylated- and methylated-B ring anthocyanins have 
been reported, although anthocyanin-rich dietary sources were used instead of pure or 
isotope-labelled compounds [54]. The quantity of the parent (un-metabolized) 13C-C3G was 
very low (about 0.147 µm of 13C-labelled C3G), while the concentration of phenolic metabolites 
ranged from 0.1 to 2 µM with the cumulative concentration of metabolites reaching 10 µM 
[38,55] suggesting that the high bioactivity of anthocyanins is more likely to be mediated by 
the metabolites. However, the activities of most of these metabolites are unexplored or have 
only been reported at non- physiological doses, even up to 2.2 mM [56]. The present study, 
P
O
N
1
 l
a
c
to
n
a
s
e
 a
c
ti
v
it
y
(%
 o
f 
c
o
n
tr
o
l)
C
on
tr
ol
P
O
N
-R
R
P
O
N
-Q
Q
0
40
80
120
1 M
10 M
***
***
PON-RR
Cyanidin (µM)
%
 R
e
d
u
n
c
ti
o
n
 i
n
 P
O
N
1
la
c
to
n
a
s
e
 a
c
ti
v
it
y
0 5 10 15 20
-30
-20
-10
0
A B 
 332 
 
therefore, investigated for the first time the possible effects of known and potential metabolites 
of C3G and D3G including their phase-II-conjugates relative to their parent compounds at 
physiologically relevant concentrations, individually and in mixtures, on PON1 gene 
expression and enzyme activities. In addition, the research presented in this paper is the first 
to the best of our knowledge to consider the potential interaction between PON1 genotype 
and the dietary anthocyanins using two different phenotypes corresponding to Q192Q and 
R192R genotype. 
As the consumption of anthocyanins or anthocyanin-rich beverages has been reported to 
increase serum PON1 activity in some human studies [27,28], the underlying hypothesis of 
this research was that the increase in PON1 activity observed in these human studies was 
caused by the anthocyanins or their gut microbiota metabolites interacting with PON1 gene 
expression or enzyme activity and increasing the enzyme concentration and/or the enzyme 
activity. Here, we screened the effects not just of the anthocyanins but also of most of the major 
metabolites of these compounds that are products of gut microbiota metabolism. We aimed to 
connect the compounds to the effect and identify which compounds caused the increase in 
activity and/or gene expression and at which concentrations. However, the data showed that 
none of these compounds at physiologically relevant concentrations (1–10 µM) caused 
significant changes in either PON1 promoter activity or arylesterase and lactonase activities, 
regardless of the phenotype, except for some small effects that likely lack clinical importance. 
The data presented here does not support the notion that there is a direct interaction between 
anthocyanins and/or their metabolites with the PON1 protein or the expression of the PON1 
gene. It is possible that the increase in PON1 activity in human interventions reported 
previously [27,28] was due to a secondary effect(s) of consuming anthocyanins. For example, 
the anthocyanins/metabolites might cause changes in the gut microbiome or interact with 
other organs such as the liver, but it is the anthocyanin-induced changes in the function of 
these organs that somehow caused the levels of PON1 activity to increase. 
With regard effects on expression of the PON1 gene, we have only reported effects on the 
PON1 promotor activation using a reporter assay. We attempted to assess the effects of the 
treatments on the abundance of PON1 transcripts in the classic human hepatic cell line HepG2 
using qRT-PCR. However, we were not able to detect significant expression of the PON1 gene 
in HepG2 cells in our laboratory. In keeping with this observation, we were also not able to 
detect PON1 activity in culture supernatants (secreted PON1, Figure S1) or cell homogenates 
(intracellular PON1, Figure S2). Details of the experiments with HepG2 cells are provided in 
the supplementary information (Supplementary information 1). Others have reported the use 
of a PON1-Huh7 transfected cell line and reported changes in PON1 promoter activity in 
response to treatment with several phenolic compounds such as curcumin, resveratrol, 
quercetin and isorhamnetin [30,33]. Gallic acid increased PON1 promoter activity by 8.5-fold, 
however this was in response to a very high and non-physiological concentration of gallic acid 
(360 µM) [57]. Here we report the effects of a physiological concentration (1 µM) and a slightly 
higher concentration (10 µM), but we observed no significant effects. 
Very little is currently known of the effects of direct interaction between anthocyanins or 
their metabolites with the PON1 enzyme. The only available report to date is concerned with 
the effect of naringin, which caused a decrease in PON1 arylesterase activity after incubation 
with isolated PON1 enzyme [13]; therefore all the data presented here are novel. The only 
other reports we are aware of describe the effects of phenolic compounds such as resveratrol, 
quercetin, punicalagin and ellagic acid on PON-1 enzyme secretion using the Huh7 cell line 
[30,33]. We attempted to use the HepG2 cell line to study the effect of treatments on enzyme 
secretion, but we were not able to detect any secreted or cell-based PON1 activity in our 
laboratory (Supplementary information 1). 
PON1 lactonase is the physiologically relevant activity that is associated with its 
biological functions [26,58,59]. Impairing the lactonase activity of PON1, e.g., via mutations of 
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its catalytic dyad, diminished the ability of the enzyme to prevent LDL oxidation, reduced 
HDL-mediated cholesterol efflux, and abolished lysophosphatidylcholine (LPC) formation 
from phospholipid in macrophages, suggesting that the actual biological antiatherogenic 
functions of PON1 may be mediated by its lactonase activity [59]. However, paraoxonase and 
arylesterase were the only activities that had been reported previously from studies of 
polyphenols on PON1. To the best of our knowledge, the current study is the first to examine 
the effect of anthocyanins on PON1 lactonase activity and therefore provides new information 
regarding effects of anthocyanins on PON1 activity and by association with HDL function. 
Although the data presented here does not support the notion that direct interactions between 
anthocyanins and/or their metabolites affect the lactonase or arylesterase activity of PON1, it 
is not conclusive. The purified enzyme used here is not in its native environment which would 
include the presence of HDL and the ApoA1 protein, and this may affect the enzyme structural 
conformation and its stability and therefore its activity [60–64]. In theory it would be possible 
to use instead serum as a source of PON1. However, this may prove problematic because 
serum may contain other compounds such as lipoproteins that may bind with anthocyanins 
and conceal or inhibit their effects [65–67]. 
On the other hand, cyanidin decreased PON1 lactonase activity, but at super 
physiological concentrations and not at lower more physiological concentrations. However, 
the negative effect of cyanidin may be physiologically unimportant. In fact, cyanidin was not 
detected in serum in humans after consumption of 13C-labelled C3G. Only traces of cyanidin 
conjugates were detected in urine in the same study suggesting that the existence of cyanidin 
in serum in concentrations higher than 0.1 µM is not achievable [38]. Furthermore, cyanidin 
is extremely unstable at high pH, with about 50% instantaneous loss of the parent structure at 
pH 7.4, which was lower than the pH of the assay buffer (pH = 8) used in the current study. 
This suggests that the reduction in PON1 lactonase activity was not mediated directly by 
cyanidin but may though one or more of its intermediates [68]. 
As far as the authors are aware, this is the first study to report the interaction between 
anthocyanins and their metabolites, PON1 genotype and PON1 activities. None of the 
previous reports that investigated the effects of anthocyanins and other polyphenols on PON1 
activities have considered the association between PON1 polymorphisms and its activity 
[27,28]. Here we used two enzyme isoenzymes that correspond with two functional Q192R 
polymorphisms, PON-QQ and PON-RR. At high concentrations, cyanidin decreased PON1 
lactonase activity of the PON-RR isoenzyme, but it increased the lactonase activity of PON-
QQ. These observations support the notion that individuals respond differently to treatment 
according to their PON1 genotype, and therefore the genetic variance should be taken into 
account. Although both phenotypes responded similarly to the other 
anthocyanins/metabolites, this does not preclude that these metabolites may interact and 
affect the enzyme activities with other genotypes other than the Q192R genotype. In a 
previous nutrigenomic study, a significant association between anthocyanin intake and 
increased HDL levels was reported in participants with some PON1 genotypes but not with 
others [69]. The study investigated interactions between SNPs in the PON1 gene and 
polyphenols intake on HDL and other biomarkers of CVD risk. Of 18 independent tagging 
SNPs that were tested, four SNPs (rs854549, rs854552, rs854571, and rs854572) showed a 
significant association with increased circulating HDL levels in people consuming higher 
quantities of polyphenols and anthocyanins [69]. At present there is no commercial source of 
purified isoenzymes corresponding to these genotypes to understand how these genotypes 
respond to anthocyanin treatments. However, undertaking a human intervention with large 
population and categorizing the participants into different group based on their genotype and 
studying the enzyme activities after anthocyanin intervention would provide a better insight 
into the interaction between anthocyanins, PON1 activities and PON1 genotype. 
 334 
 
Although the data presented in this report are novel, there are several limitations. 
Measuring the effects of the polyphenols on promoter activity rather than gene expression 
(transcript levels) is one weakness. The reporter assay may not faithfully recapitulate the 
native chromosome environment [70]. The treatments may affect the stability of mRNA or 
other posttranscriptional regulators of the PON1 gene without affecting the promotor activity, 
which will not be detected using the reporter assay. In addition, the effects of the anthocyanins 
and their metabolites on enzyme secretion has not been investigated in the current study due 
the authors not having a suitable model. It is possible that the treatments do not change PON1 
gene expression or the activity of the enzyme, but instead affect cell permeability or the 
cellular transporters that would lead to an increase in PON1 enzyme levels in serum. In our 
hands, HepG2 cells did not secrete detectable quantities of the enzyme, excluding its use as a 
suitable model for this purpose. Should a fit-for-purpose cultured cell model be available, 
future work should focus on the effect of anthocyanins and their metabolites on PON1 enzyme 
secretion to ensure that this potential mechanism of actions is also investigated. 
In conclusion, the novel data presented in this study do not support the notion that 
anthocyanins and/or their metabolites significantly affect PON1 gene promoter activity or 
change the activities of PON1 isoenzymes. Even though some statistically significant changes 
were detected, the changes were very modest and probably lack clinical importance. 
However, it is feasible that these compounds alternatively affect PON1 secretion or interact 
with different PON1 genotypes rather than those were reported here, and this should be 
considered in future studies. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, PON1 gene 
expression and enzyme activity in HepG2 cell. Figure S1: Secreted PON1 arylesterase activity using 
HepG2 cell, Figure S2: Cell-based PON1 arylesterase activity using HepG2 cell. 
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Abstract: Atherosclerosis, the main contributor to coronary heart disease, is 
characterised by an accumulation of lipids such as cholesterol in the arterial 
wall. Reverse cholesterol transport (RCT) reduces cholesterol via its 
conversion into bile acids (BAs). During RCT in non-hepatic peripheral 
tissues, cholesterol is transferred to high-density lipoprotein (HDL) particles 
and returned to the liver for conversion into BAs predominantly via the rate-
limiting enzyme, cholesterol 7 α-hydroxylase (CYP7A1). Numerous reports 
have described that polyphenol induced increases in BA excretion and 
corresponding reductions in total and LDL cholesterol in animal and in-vitro 
studies, but the process whereby this occurs has not been extensively 
reviewed. There are three main mechanisms by which BA excretion can be 
augmented: (1) increased expression of CYP7A1; (2) reduced expression of 
intestinal BA transporters; and (3) changes in the gut microbiota. Here we 
summarise the BA metabolic pathways focusing on CYP7A1, how its gene is 
regulated via transcription factors, diurnal rhythms, and microRNAs. 
Importantly, we will address the following questions: (1) Can polyphenols 
enhance BA secretion by modulating the CYP7A1 biosynthetic pathway? (2) 
Can polyphenols alter the BA pool via changes in the gut microbiota? (3) 
Which polyphenols are the most promising candidates for future research? We 
conclude that while in rodents some polyphenols induce CYP7A1 expression 
predominantly by the LXRα pathway, in human cells, this may occur through 
FXR, NF-KB, and ERK signalling. Additionally, gut microbiota is important 
for the de-conjugation and excretion of BAs. Puerarin, resveratrol, and 
quercetin are promising candidates for further research in this area. 
Keywords: atherosclerosis; reverse cholesterol transport; diurnal rhythms; microRNA; 
ASBT; flavonoid; phenolic acid; catechin; anthocyanin 
 
1. Introduction 
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Atherosclerosis, the main contributor to coronary heart disease, is characterised by an 
accumulation of lipids in the arterial wall [1]. Polyphenols have been shown to confer 
beneficial effects against cardio-metabolic diseases. Among the mechanisms proposed for 
their beneficial effects is the alteration of bile acid metabolism. Here, we give a comprehensive 
review of research on the molecular mechanisms through which polyphenols exert their 
beneficial effects focusing on CYP7A1 and bile acid metabolism. The key points raised in this 
review include: 
1. Polyphenols have been shown to have a wide range of beneficial effects, of note red wine, 
rich in flavonoids, phenolic polymers and resveratrol are promising as possible targets 
for further investigation. 
2. As well as giving a state-of- the-art review on the mechanisms through which 
polyphenols exert their beneficial effects focussing on CYP7A1 and bile acid metabolism, 
critical points that will be of benefit to clinical nutritionists, academic experts in the area 
of bioactive food compounds, and possible stakeholders have also been raised in this 
review namely; 
a. While polyphenols do have effects on bile acid metabolism, it should be born in 
mind that species differences, time of cull, dose, and length of treatment can also 
affect the results and as such, may lead to discrepancies between studies. As such, 
there is a need to standardise animal studies, ensuring that these factors are correctly 
reported. 
b. Polyphenols confer their beneficial effects partly through altering the microbiome, 
thus they could have useful prebiotic-like functions. 
c. There is a lack of data on the effects conferred by the parent compound versus those 
of their metabolic products, and future studies should aim to determine the effects 
of both the parent compounds and their metabolites, with particular emphasis on 
the gut microbiota. 
d. Further studies are required in humans to substantiate the mechanisms proposed 
using animal and cell culture models. 
1.1. Reverse Cholesterol Transport 
The reverse cholesterol transport (RCT) pathway removes excess cholesterol from the 
peripheral system including from lipid laden macrophages, thus preventing foam cell 
accumulation during atherosclerosis development. In this process, cholesterol is returned to 
the liver where it is converted into BAs predominantly via the cytochrome P450 enzyme, 
cholesterol 7 α-hydroxylase (CYP7A1), for subsequent excretion into the faeces (Figure 1). 
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Figure 1. The enterohepatic re-circulation of bile acids via reverse cholesterol transport. 
Cholesterol laden macrophages in the arterial wall deliver cholesterol via the ABCA1 
transporter to lipid free apoA-I, preventing foam cell formation and also forming nascent 
HDL particles. Further lipidation of the nascent HDLs occurs via ABCG1. Cholesterol is 
delivered to the liver from mature HDL particles via specific HDL cholesterol efflux (CE) 
uptake by a scavenger receptor class B type I (SR-BI). In the liver, cholesterol is converted into 
BAs predominantly by the CYP7A1 neutral (classic) pathway. The BAs travel via the bile duct 
to the intestine, where they are de-conjugated via the bacteria and excreted or re-circulated 
(95%), usually in their conjugated form via passive diffusion or via active transport via the 
apical sodium dependent BA transporter (ASBT). 
In humans, approximately 500 mg/day of cholesterol is converted into bile acids (Bas) in 
the liver and lost in the faeces [2]. Two pathways, namely the neutral (classic) and the 
alternative (acidic) pathways, are involved in cholesterol metabolism, with CYP7A1 being the 
rate-limiting enzyme in the former, and CYP7A1 being responsible for cholesterol metabolism 
in the latter. Both pathways result in the formation of the primary BAs chenodeoxycholic acid 
(CDCA) and cholic acid (CA), the neutral pathway being the most predominant [3]. The acidic 
pathway only contributes 9% and 25% of total BAs in humans and mice, respectively [4]. The 
biochemistry of BA biosynthesis is reviewed elsewhere [2,5] and is summarised in Figure 2. 
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Figure 2. A summary of the main enzymes involved in the classic and alternative bile acid 
biosynthesis pathways. The classic pathway is controlled by the rate limiting enzyme CYP7A1 
and the alternative pathway is controlled by CYP27A1; both pathways culminate in the 
production of cholic acid (CA) and chenodexoycholic acid (CDCA), the ratio of which 
depends on the activity of CYP8B1. Briefly, bile-acid biosynthesis begins with the 
modification of the ring structure of cholesterol, which involves oxidation and shortening of 
the side chain [2]. In the classic pathway, cholesterol is converted into 7 α-hydroxycholesterol 
by CYP7A1 and in subsequent steps, cytochrome P450 Family 8 Subfamily B Member 1a 
(CYP8B1) and sterol 27-hydroxylase (CYP27A1) are required for the synthesis of cholic acid 
(CA). Without CYP8B1, the product is chenodeoxycholic acid (CDCA), which is formed via 
the activity of CYP27A1 alone. The acidic pathway (or alternative pathway) is initiated by 
CYP27A1 and relies on 25-hydroxycholesterol 7-alpha-hydroxylase (CYP7B1) to produce 
CDCA. 
Before excretion into bile, primary BAs are conjugated with amino acids glycine and to a 
lesser degree taurine in humans [6]. In rodents, taurine is almost exclusively used for 
conjugation [6]. This increases solubility, minimises passive absorption, and makes the BAs 
resistant to cleavage by pancreatic carboxypeptidase. BAs are secreted from the gallbladder 
via the bile duct into the intestine and can be metabolised into their respective secondary BAs 
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via the gut microbiota, which are also responsible for de-conjugation. Conjugated BAs are 
actively exported from the liver via the bile salt export pump (BSEP)/ABCB11, which in 
humans preferentially transports conjugated BAs, but can also transport unconjugated BAs 
[7]. The main function of BAs is to facilitate digestion in the gut and their synthesis 
inadvertently regulates lipid concentrations. A list of all known BAs and their abbreviations 
is given in Supplementary Table S1. BAs are reabsorbed in the intestine by either passive 
diffusion or by active transport, which occurs via the apical sodium BA transporter (ASBT) in 
the terminal portion of the ileum [8]. Once reabsorbed, BAs travel through the hepatic portal 
vein and are returned to the liver via specific transporters, with approximately 95% of BAs 
being recirculated back to the gallbladder in a process termed enterohepatic circulation, and 
the rest is excreted in the faeces (Figure 1). Typically, cholesterol synthesis equals its secretion 
as BAs; however, this equilibrium can be disturbed during disease states or by diet [9]. 
1.2. Regulation of CYP7A1 by Dietary Cholesterol, Circadian Rhythm, Transcription Factors, and 
microRNAs 
Diet can regulate BA synthesis, particularly the intake of a cholesterol rich diet. In wild-
type mice, feeding a high cholesterol diet stimulated BA synthesis by activating LXRα to 
induce CYP7A1 gene transcription [10–12]. Cholesterol treatment of HepG2 cells also 
moderately induces CYP7A1 gene expression [13]. In contrast, another study using HepG2 
cells, cholesterol dose dependently decreased CYP7A1 expression [14], which is supported by 
a mouse study [15]. Although it has been suggested that mice have a different response to 
cholesterol when compared to humans, here, comparable effects were observed on BA pool 
size, faecal BA excretion, and plasma cholesterol levels between humans, transgenic mice, and 
wild-type CYP7A1 mice. This suggests that another mechanism other than LXR signalling 
alters BAs on a high cholesterol diet, perhaps the microbiota [16]. There are also differences 
between rodents and humans, for example LXRα-CYP7A1 signalling, is redundant in humans 
due to the lack of LXRE in the human CYP7A1 gene promoter, but this pathway is well known 
in rodent models. Nevertheless, FXR signalling is homologous between mice and humans and 
is a well-studied mechanism of CYP7A1 control. It is logical that cholesterol, the substrate for 
CYP7A1, would increase CYP7A1 levels, but the data published to date are equivocal and may 
depend on the presence of a functional LXRα receptor. 
One key mechanism is the circadian regulation of CYP7A1. Cyp7a1 levels in mice have 
been shown to peak mid-morning to noon, although this is also influenced by the fed and non-
fed state [17]. This is particularly problematic when animals treated with different diets are 
culled at different times over the day as this would dramatically alter the results and lead to 
erroneous interpretation [17]. The circadian control of Cyp7a1, along with other clock 
associated genes, has also been shown to parallel changes in triglyceride and total cholesterol 
[18]. A summary of circadian genes involved in the regulation of Cyp7a1 is shown in Table 1. 
Cyp7a1 is also regulated by microRNAs, which are non-coding RNAs of 15–25 bases that bind 
to complementary sequences in the 3′-UTR regions of target mRNA to repress translation. The 
effects and targets of microRNAs on Cyp7a1 and cholesterol metabolism are also summarised 
in Table 1. The concept that diet can regulate BA synthesis is not a new one, in fact fibre is well 
known to regulate BA synthesis [19–23], however, the idea that bio-actives within food, 
particularly polyphenols, can increase CYP7A1 without increased food consumption is an 
exciting field and will be considered in the following sections. 
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Table 1. A summary of the transcription factors and microRNAs involved in Cyp7a1 gene regulation in humans and rodents. 
Factor Humans/Human Cell Lines Rodents Ref. 
Farnesoid X receptor, retinoic acid receptor and 
small heterodimer partner (FXR-RXR 
and SHP) 
FXR is highly expressed in both the liver and ileum tissue. 
Ligand binding to FXR allows translocation from the 
cytoplasm to the nucleus to bind RXR at FXR-response 
elements. FXR is not able to bind to CYP7A1 but can bind to 
the promoter of the SHP gene. SHP represses CYP7A1 gene 
expression by binding to human α-fetoprotein transcription 
factor (FTF). FXR-RXR complex also binds illeal FGF19 
(humans) or FGFR4 (mice) translocates to the liver, activates 
FGR4 which inhibits c CYP7A1 transcription. 
The same as humans, 
however, FTF is called liver 
receptor homolog-1 (LRH-1) in 
mice. 
[24–
26] 
Pregnane X receptor (PXR) 
PXR activation by specific bile acids such as lithocholic acid 
(LCA) leads to the repression of bile acid synthesis by 
binding and inactivating the transcription factor, hepatocyte 
nuclear factor 4 alpha (HNF4α) so that it can no-longer bind 
to its transcriptional co-activator, proliferator-activated 
receptor γ co-activator 1-α (PGC1α) to induce CYP7A1 
transcription. 
 [27] 
Liver X receptor α (LXRα) 
LXRα cannot bind to the human CYP7A1 promoter due to an 
alteration of the DR4 motif in the BARE-I sequence. 
Therefore, in humans LXRα does not play a role in the 
regulation of CYP7A1 gene expression.  
Unlike in humans, LXRα can 
directly bind to the Cyp7a1 
promoter to upregulate 
expression.  
[28] 
Hepatocyte nuclear factor 4 alpha/Peroxisome 
proliferator-activated receptor γ co-activator 1-α 
(HNF4α /PGC1α) 
HNF4α is a transcription factor that upregulates CYP7A1 by 
directly binding to its promoter along with the trans-activator 
PGC-1α.  
Same as humans. 
[29–
32] 
Peroxisome Proliferator Activated Receptor Alpha 
(PPARα) 
In vitro PPARα over-expression in human liver cells has been 
shown to reduce CYP7A1gene expression. However, when 
activators of PPARα where added to non-over-expressing 
cells a moderate amount of inhibition was observed.  
PPARα knock out mice did not 
show altered Cyp7a1 levels.  
[31,3
3] 
Peroxisome Proliferator Activated Receptor gamma 
(PPARγ) 
PPARγ activation induced CYP7A1 expression in HepG2 
cells  
 [34] 
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Forkhead box protein O1 (FoxO1) 
FoxO1 is an in-direct suppressor of CYP7A1, there is no 
binding site for FoxO1 on the human CYP7A11 promoter. 
FoxO1 inhibits CYP7A1 by inhibiting expression of HNF-4α 
and PGC-1α TFs.  
FoxO1 has the opposite 
function in mice and 
upregulates Cyp7a1 directly by 
binding to its promoter.  
[35,3
6] 
Nuclear receptor subfamily 1, group D, member 1 
(NR1D1 or Rev-Erba) 
NR 
Competes for the promoter of 
the clock gene Bmal1 and 
mediate the circadian 
regulation of Cyp7a1 
[37,3
8]. 
Per1 and Per2  NR 
Genetic ablation in mice 
disrupts normal BA control, 
increases serum BA and in 
parallel reduces dbp and 
Cyp7a1 expression in both rats 
and mice 
[39,4
0]. 
D site albumin promoter binding protein (DBP) 
Gain-of-function studies have shown that DBP serves as a 
circadian activator of CYP7A1 transcription. 
Cyp7a1 peaks after dark 
[41–
43] 
Enhancer binding protein C/EBPβ-LAP Binds cyp7a1 promoter site at DBP  [39] 
miR-33  
Located in the intron sequence 
of SREBP and regulates Cyp7a1 
expression possibly 
synergistically to control 
hepatic cholesterol metabolism 
and BA synthesis 
[44–
47] 
miR-144-3p and miR-99a-3p 
Target CYP7A1 and other non-alcoholic fatty liver disease 
related genes 
 [44] 
miR-122 and miR-422 
Cyp7a1 also has recognition sequences for miR-122 and miR-
422 in its 3′-UTR. A synthetic miR-122 mimic inhibits 
CYP7A1expression in vitro and miR-122 inhibition has 
shown the opposite effect 
 [45] 
miR-24 and miR-34 
Indirectly decrease CYP7A1 by decreasing HNF4α 
transcription factor 
 [48] 
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miR-17 Leads a reduction in CYP7A1 mRNA expression  
Reduces Cyp7a1 mRNA 
expression accompanied by 
hepatic steatosis 
[30]. 
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2. Current Status of Knowledge: Polyphenols That Regulate Bile Acid Synthesis and 
CYP7A1 
Numerous studies have assessed the effects of polyphenols on BA excretion and CYP7A1 
expression and the mechanisms by which they alter BA excretion and CYP7A1expression have 
been summarised in Supplementary Table S2; these were mostly obtained from rodent studies 
showing a depletion of hepatic cholesterol when fed polyphenols, which in some instances is 
linked to an increase in CYP7A1 activity and LXRα signalling. Polyphenols are subdivided 
into different categories: flavonoids, isoflavonoids, lignans, stilbenes, phenolic acids, and 
phenolic polymers (Supplementary Figure S1). It is worth noting that all types of polyphenols 
are only partially bioavailable and subject to both phase-2 conjugation and catabolism by the 
gut microbiota, and the reader is referred to some excellent reviews of the bioavailability and 
metabolism of polyphenols and how these processes can affect their biological activities [49–
53]. Currently, evidence for whether the known effects of polyphenols on BA metabolism and 
CYP7A1 are mediated by the parent polyphenols or their metabolites, or a combination of 
both is limited; this is an important area for future research. There are multiple pathways 
through which polyphenols confer their beneficial effects including those involved in 
inflammation. These have been substantially reviewed elsewhere [54,55] Another biological 
activity of polyphenols is as antioxidant molecules that have the potential to mop up free 
radicals. Although this has been somewhat challenging to prove unequivocally in humans, it 
is notable that there is a significant body of evidence to show that consumption of specific 
polyphenols such as those in olive oil can effectively reduce the levels of oxidised LDL [56]. 
In the following sections, we review the effects of each sub-group of polyphenols on CYP7A1 
expression, BA metabolism/excretion, and comment on the mechanism of action. We then 
further discuss the emerging research that polyphenols can mediate cholesterol efflux and 
microbial changes in the gut, subsequently modulating bile acid excretion. 
2.1. Flavonoids 
Flavonoids are water soluble polyphenolic molecules that consist of six major subgroups: 
flavanols (catechins), anthocyanins, flavonols, flavanones, and flavones (see Supplementary 
Figure S1). The effects of flavonoids on the HDL delivery of cholesterol to the liver via RCT 
have been recently reviewed [57], however, the effects of polyphenols on bile acid biosynthesis 
and efflux was not described. 
2.1.1. Flavanols 
Flavanol-rich green tea has been shown to increase BA excretion, however, the link to 
CYP7A1 is tentative. For example, Lung Chen tea has been shown to reduce serum cholesterol 
and increase faecal BA excretion in hypercholesteraemic rats, without altering Cyp7a1 enzyme 
activity [58]. Cyp7a1 gene expression was not changed in C57BL mice fed green tea extract 
(GTE) over six weeks [59]. Despite this, there was an increase in circulating BAs and excreted 
faecal cholesterol, although this was only apparent once normalised to the amount of faeces 
excreted per day as the mice on the GTE produced more faeces overall [15]. Interestingly, in 
the same study, GTE dramatically increased Cyp27a1 mRNA expression in mice fed a high 
cholesterol diet, but not in mice fed a normal chow diet; indicating a shift from the neutral 
pathway to the acidic pathway only in the presence of high cholesterol [15]. Several studies 
have shown an increase in Cyp7a1 expression in response to catechin treatment. For example, 
in rats, epigallocatechin gallate (EGCG) decreased bile acid-independent bile flow but not 
excretion, whilst increasing Cyp7a1 mRNA expression and increasing circulating BAs [60]. 
EGCG increased Cyp7a1 protein levels in C57BL/6 mouse livers, however, BAs were not 
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measured [61]. Finally, an in vitro study using HepG2 cells has shown that catechins increase 
CYP7A1mRNA levels with epicatechin gallate showing the greatest fold induction [62]. In 
contrast, EGCG is also known to be an activator of FXR signalling [63], which would in turn 
supress CYP7A1expression. Studies in our lab confirm a reduction of CYP7A1 gene expression 
in human liver HepG2 cells treated with 5 µM EGCG in the absence of serum, which is 
consistent with the hypothesis that EGCG is an activator of farnesoid X receptor (FXR) 
signalling (unpublished data). Interestingly, in the presence of chenodeoxycholic acid, another 
FXR inhibitor, EGCG acts as a suppressor of FXR signalling in vitro [63]. CYP7A1 levels were 
not measured, but it would be fascinating to explore the role of EGCG on CYP7A1expression 
in the presence and absence of FXR inhibitors. 
2.1.2. Anthocyanins 
There are very limited data on the effects of anthocyanins on BAs. In one study, red 
pericarp glutinous rice, rich in anthocyanins, induced Cyp7a1 expression when fed to 
hypercholesterolemic C57BL/6 mice when compared to brown rice [64]. A decrease in hepatic 
cholesterol was also observed although faecal cholesterol or BAs were not measured [64]. 
Lingonberries, which contain high levels of anthocyanins, have been shown to increase Cyp7a1 
expression and decrease atherosclerotic plaque and triglyceride concentration in ApoE-/- mice 
on a high fat diet [65]. The relative faecal abundance of the bacterial genera Bacteroides, 
Parabacteroides, and Clostridium were also increased [65]. In type-2 diabetic mice, Buckwheat 
sprouts, which contain cyanidin 3-O-glucoside (C-3-G) [66] and C-3-G alone, increased faecal 
BAs and Cyp7a1 mRNA expression in the liver whilst correspondingly decreasing serum 
cholesterol, liver cholesterol, and triglycerides and consequently reduced atherosclerosis 
[67,68]. However, buckwheat protein has also been investigated as the active cholesterol 
lowering component [69]. High doses of polyphenol-rich Lonicera caerulea berry extract, 
which contains mainly anthocyanins, significantly upregulated Cyp7a1 gene expression, 
reduced the expression of SREBP-1C, SREBP2, miR-33, and miR-122 and caused a reduction 
in cholesterol, LDL, and triglyceride in Sprague Dawley rats [70]. To our knowledge, all the 
published anthocyanin data that have examined changes in BA levels or Cyp7a1 expression 
have utilised mouse models. However, human cells may respond differently, as in mouse 
primary hepatocytes, C-3-G treatment increased Cyp7a1 expression in an LXRα dependent 
way [68]. Indeed, using HepG2 cells, we showed that C-3-G does not increase CYP7A1 mRNA 
expression (data unpublished), perhaps because human cells do not possess functional LXRα. 
2.1.3. Flavonols 
Quercetin, a flavonol found in capers, has been shown to elevate hepatic Cyp7a1 as well 
as LXRα at both mRNA and protein levels in male Wistar rats along with increased secretion 
of BAs and total hepatic BAs [71]. Importantly, quercetin also increased the expression of 
hepatic ATP binding cassette transporter G1 (ABCG1) mRNA and protein expression, 
indicating that quercetin may be involved in the regulation of hepatic cholesterol efflux [71]. 
Black bean seed coat extract predominantly containing quercetin 3-O-glucoside significantly 
stimulated the expression of Cyp7a1 protein in the liver and faecal BAs in C57BL mice [72]. A 
combination of quercetin and leucodelphinidin or quercetin with Banyan tree, derived 
leucopelargonin and leucocyanin significantly increased hepatic and faecal BAs in 
hypercholesteraemic rats and correspondingly reduced L-LDL cholesterol with the former 
also increasing HDL [73,74]. Overall, there is some evidence from animal studies that 
quercetin alone or in combination with other flavonoids can induce BA excretion via induction 
of CYP7A1. Other flavonols such as kaempferol have been shown to increase hepatic CYP7A1, 
faecal cholesterol, and BAs through mechanisms that may involve its binding to LXRα [75]. 
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Human interventions and in vitro studies are still required to examine the role of quercetin 
and kaempferol on Cyp7a1 and lipid metabolism. 
2.1.4. Flavanones, Flavones, and Isoflavones 
Naringin (a flavanone) occurs naturally in citrus fruits, especially in grapefruit, where it 
is responsible for the fruit’s bitter taste. Naringin, has been shown to induce LDL-receptor and 
CYP7A1 expression in HepG2 cells through the NF-κB and ERK signalling pathway as well as 
through PPARy, which occurs in a dose-dependent manor [76,77]. Its aglycone naringenin has 
been shown to be a partial agonist of LXRα in cells transfected with a reporter construct [76]. 
In contrast, using computer modelling of tetrahydro-flavanones (cryptochinones A–D), it was 
shown that flavanones may behave as FXR agonists to decrease CYP7A1 mRNA expression 
[78]. The only one study that investigated the effects of flavones from a leaf extract of 
Xanthosoma sagittifolium showed no effects on total Bas, but reduced secondary BAs in rats 
[79,80]. 
When administered to mice and rats, an isoflavonoid puerarin (from arrowroot) increases 
hepatic Cyp7a1 expression and suppresses serum and hepatic cholesterol, although in HepG2 
cells, no changes were observed [81–83]. Additionally, Xuezhikang, an isoflavone-rich extract 
of red-yeast-rice and Erythrina lysistemon also rich in isoflavones, increased hepatic Cyp7a1 
expression and BA excretion in high-fat fed mice and in ovariectomised rats, respectively 
[84,85]. The bacterial isoflavone metabolite equol has also been shown to alter BA metabolism 
by increasing hepatic CYP7A1 mRNA levels in the chicken embryos liver [86]. Soymilk and 
fermented soymilk, which contain both isoflavones, bioactive proteins, and peptides, have 
also been shown to attenuate hepatic cholesterol and triglycerides levels and increase hepatic 
Cyp7a1 gene expression in Sprague Dawley rats [87]. It is not clear whether the effects can be 
attributed to either the flavonoids or the proteins/peptides or both, as soy protein alongside a 
high-fat diet also increased hepatic Cyp7a1 mRNA in male Syrian Golden hamsters [88]. In 
addition, soy protein isolate has been shown to induce Cyp7a1 hepatic expression and reduce 
hepatic cholesterol in rats [89]. The only study in humans showed no effects [83]. 
2.2. Stillbenes 
The anti-atherosclerotic effects of resveratrol (3,5,4′-trihydroxy-trans-stilbene), which is 
found in the skin of grapes, blueberries, raspberries, and mulberries, have been widely studied 
in mouse models and human cell lines [90]. In mice on a high fat diet and in HepG2 cells, 
resveratrol increased CYP7A1 mRNA expression with activity being increased in the former 
[91]. Similar results were observed in HepG2 cells treated with resveratrol or resveratrol-
glucuronides along with a concurrent decrease in cholesterol content and an increase in bile 
salt export protein (BSEP), respectively [92]. In alpha-Naphthylisothiocyanate (ANIT) induced 
liver injury in rats, resveratrol restored FXR and Cyp7a1 expression and BA secretion [93]. 
Donryu rats implanted with an ascites hepatoma cell line and given resveratrol showed a 
dose-dependent reduction in serum cholesterol and excreted BAs [94]. Thus, supporting the 
evidence that resveratrol or its metabolites (aglycone and glucuronide), which are bioavailable 
in bile and plasma, 4 to 8 h after administration, may be functional bio-actives [95]. Resveratrol 
may confer its beneficial effects through FXR signalling targeting SIRT1, which acetylates FXR 
and prevents its binding with RXRα, consequently inhibiting its binding and activation of the 
Cyp7a1 repressor Shp [96,97]. Resveratrol has also been shown to alter the gut microbiota 
profile in C57BL/6J and ApoE-/- mice as well as bile salt hydrolase activity and de-conjugation, 
thus increasing faecal excretion. This was associated with the repression of enterohepatic FXR 
and FGF15 signalling and increased Cyp7a1 expression and hepatic BA synthesis [98]. In 
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antibiotic treated mice, resveratrol has no such effects, indicating the importance of gut 
microbiota in resveratrol mediated effects [98]. 
2.3. Phenolic Acids and Phenolic Polypmers 
Phenolic acids such as vanillic, caffeic, ferulic, and gallic acid are found in high 
concentrations in berries, tea, whole grains, and wine. A fermented Chinese tea, which 
contains a range of phenolic acids including catechin and gallic acid, has been shown to reduce 
LDL cholesterol in a 3-month double-blind randomised study of health and 
hypercholesterolemic patients, although BA levels were not measured [99–101]. Similarly, in 
hypercholesteraemic rats, an 8-week administration of the tea increased faecal BAs, but not 
Cyp7a1 expression [58]. A separate study showed decreases in serum LDL and total cholesterol 
in hypercholesteraemic rats after 3-weeks of feeding [102]. Indeed, a phenolic acid, 
chlorogenic acid, found in green tea, increased in Cyp7a1 mRNA expression in 129/Sv mice, 
indicating that at least some of the phenolic acid components are bioactive [103]. 
The beneficial effects of some phenolic polymers found in raisins, grapes, and wine (high 
in fibre but also tannins (proanthocyanidins)) in humans are however questionable as two 
human studies from the same lab showed that consuming 80–120 g raisins over a two to nine 
week period decreased total faecal BAs, and in another study, when tartaric acid was fed to 
participants, no effects on BAs were observed [104–106]. In contrast, 2% tannin polymers from 
raisins significantly increased faecal BAs and lowered LDL cholesterol in mice, although 
tannin monomers did not have any effect [107]. Using an in vitro study, Camire et al. proposed 
that the fibre in chopped raisins act as a BA sequestrant to prevent enterohepatic re-
circulation, although the role of polymeric tannins cannot be ruled out as gallic acid does 
directly bind to taurocholic, taurodeoxycholic, and glycodeoxycholic BAs in vitro, and ellagic 
acid has been shown to induce genes involved in BA synthesis in mice [108–110]. It is therefore 
evident that some raisin constituents may promote BA secretion in rodents, tannin polymers 
(but not monomers) being among them, although their effects in humans is yet to be assessed. 
2.4: Grape Juice, Wine and Grape Seed Extract 
In-vivo and vitro effects of grapes, wine, and grape seed extract (GPSE) on BA secretion 
have recently been reviewed with moderate increase in Cyp7a1 after GPSE treatments of 
hamsters on a 0.1% cholesterol diet while red wine procyanidins induced hepatic Cyp7a1 in 
Wistar rats along with reduced LDL-C [111–113]. Grape juice fed to rats also increased 
primary BA but reduced secondary BA in the intestinal contents. Interestingly faecal counts 
of Lactobacillus and Bifdobaceterium were also increased [114]. In FXR knockout mice, GPSE 
induced faecal BA output and downregulated genes involved in intestinal BA absorption and 
transport. This correlated with increased Cyp7a1 mRNA expression in the liver, decreased 
circulating LDL cholesterol, and decreased intestinal Fgf15 expression [115]. In contrast, fisetin 
a flavonol from red wine, decreased Cyp7a1 mRNA expression in Sprague Dawley rats, when 
compared to controls of mice fed a high fat diet [116]. Despite this, the rats still exhibited 
decreased plasma total cholesterol and LDL-cholesterol, along with decreased hepatic 
cholesterol content [116]. Perhaps the alternative pathway regulated by CYP27A1 may be 
responsible for altered BA secretion in this instance. Procyanidins may also have long-term 
effects; for example, in the alteration of reverse cholesterol transport in the adult offspring 
after intake of grape procyanidins during gestation and lactation [117]. Overall, the evidence 
suggests GPSE induces Cyp7a1 mRNA expression and BA secretion into faeces. There is less 
evidence for wine and grape juice, although the existing publications support the same trend 
presented with GPSE. Once again, studies in humans are lacking. 
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3. Polyphenol Mediated Mechanisms of Action 
Understanding the mechanisms through which polyphenols modulate CYP7A1 to 
regulate cholesterol and bile acid metabolism is important and this review has highlighted 
that multiple pathways may be involved. These include regulation through the NF-Kβ/ERK 
and SIRT-RXR-FXR (LXR) signalling pathways, modification of circadian rhythm associated 
genes, reverse cholesterol transport, and bile salt hydrolyses (Figure 3). While there is 
limited experimental data on the effects of polyphenols on microRNAs and 
CYP7A1expression, using a database that predicts the target for microRNAs in messenger 
RNA in rats, several microRNAs have been recognised to target CYP7A1, and some of these 
microRNAs have been shown to be modulated by polyphenol supplementation (Figure 3). 
Polyphenols have also been shown to regulate intestinal BA transporters and alter the gut 
microbial composition (Figure 3) to regulate the excretion of BAs as will be discussed in 
Sections 3.1 and 3.2. 
 
 
Figure 3. Putative mechanisms through which polyphenols modulate CYP7A1 to promote 
cholesterol metabolism and bile acid deconjugation, consequently attenuating atherosclerosis 
plaque development. Resveratrol, epigallocatechin gallate (EGCG), and quercetin increase 
cyp7a1 by employing SIRT1 to acetylate FXR/LXRα; preventing its dimerisation with RXR, 
which then inhibits its binding and activation of CYP7A1 repressor [77,93]. Resveratrol can 
activate circadian proteins [118,119] and genes that subsequently upregulate cyp7a1 and 
together with C-3-G, procyanidins, and naringin, can downregulate or upregulate certain 
microRNAs to promote CYP7A1 expression [45,120–123]. Alternatively, these may also 
increase bile acid hydrolases and certain gut microbiota species involved in the deconjugation 
and excretion of bile acids [124–126]. Dashed lines indicate mechanisms not completely 
known. 
3.1. Control of the Apical Sodium Dependent Bile Acid Transporter (ASBT) by Polyphenols 
ASBT is expressed in the ileum and the terminal portion of the small intestine, and is 
responsible for the re-circulation of 95% of BAs back to the liver [127]. Blocking BA 
enterohepatic circulation by interrupting the ASBT pathway increases hepatic BA synthesis to 
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compensate for BAs lost in the faeces [128]. Consequently, the concentration of liver 
cholesterol decreases causing the activation of compensatory mechanisms to maintain cellular 
cholesterol homeostasis such as increased hepatic uptake of LDL cholesterol, thereby, 
reducing circulating cholesterol levels [128]. Therefore, ASBT is an attractive therapeutic 
target to lower LDL cholesterol [129]. Inhibition of ASBT by SC-435, a potent ASBT inhibitor, 
was found to increase feacal BA excretion, upregulate Cyp7a1 gene expression, decrease total 
cholesterol, and reduce the aortic lesion area in Apo E-/- mice [128]. Dietary cholesterol has 
direct effects on ASBT function and expression [130]. In vitro, 25-hydroxycholesterol, and to a 
lesser extent 22-and 24-hydroxycholesterol, reduced ASBT function and mRNA levels in 
Caco2 cells [131]. Moreover, 25-hydroxycholesterol significantly reduced the relative activity 
of the human ASBT promoter in a dose-dependent manner [131]. On the other hand, 100 µM 
cholesterol produced no inhibitory effect on sodium-dependent taurocholate uptake into 
COS-7 cells that were transiently transfected with ASBT [132]. In vivo, feeding 1% cholesterol 
to C57BL/6J female mice for two weeks decreased ASBT mRNA abundance by 54% when 
compared to control, while there was no change in ASBT protein expression in Sprague 
Dawley rats fed with 2% cholesterol for 10 days [132,133]. It is unlikely that the differences in 
these two studies were due to doses given, as in the later study, a much higher dose was given, 
which should be more effective than a 1% cholesterol dose. Possibly, the feeding duration 
could have caused these differences. However, in the later study using rats, changes in other 
genes such as cyp7a1 were observed, indicating that there was ample feeding time to alter gene 
expression. As the time of cull was not specified in the later study, circadian gene expression 
changes may explain the observed differences [134]. Species differences could not be ruled out 
either, as in the same study that used rats, 2% cholesterol significantly increased ASBT protein 
expression in rabbits. Although cholesterol is not a dietary bioactive, the study results are 
applicable as polyphenols may alter cholesterol levels, which can further alter gene 
expression. However, for cholesterol, the results were varied, with a trend towards an 
enhanced cholesterol diet leading to a decrease in the expression of ASBT. Several reports 
have investigated the effects of dietary bioactives on the active transport of conjugated BAs 
via ASBT and these are summarised in Supplementary Table S3 The evidence that 
polyphenols such as resveratrol alter the gut microbiota to increase faecal BAs is further 
explored in the following sections of the review. 
3.2. Changes in Gut Microbiota Can Increase Bile Acid Excretion: Action of Polyphenols 
Microbial metabolism and de-conjugation of BAs lead to increased diversity within the 
BA pool and in general, a more hydrophobic population. Increasing the hydrophobic nature 
of the BAs makes them less readily re-absorbed and more easily excreted into faeces. De-
conjugation of BAs is catalysed by bile salt hydrolase (BSH) enzymes and genes coding for 
BSH have been detected in the main bacterial genera: Firmicutes, Bacteroidetes, and 
Actinobacteria [135]. In fact, BSH is enriched in the gut microbiota and helps the bacteria 
survive and colonise the gastrointestinal tract [136]. De-conjugated primary BAs that are not 
re-absorbed by the enterocytes enter the colon, where they are metabolised through 7-
dehydroxylation into secondary BAs. 7-dehydroxylation of the primary BAs, CDCA, and CA 
can occur due to accessibility of the hydroxyl group, leading to DCA and LCA production. 
Bacteria that have 7-dehydroxylation activity are members of the Firmicutes phylum 
(Clostridium and Eubacterium) and these bacteria have a BA-inducible (BAI) gene. The bacteria 
are essential for the formation of secondary BAs and this is demonstrated in germ free mice, 
which have lower levels of secondary BAs and a smaller BA pool [137,138]. Germ-free animals 
accumulate cholesterol at higher levels [139], have higher levels of conjugated BAs, and 
significantly reduced excretion of faecal BAs [138,140]. 
   
 
   
 
355 
 
The gut microbiota can also regulate BA metabolism by reducing the levels of tauro beta-
muricholic acid (tbMCA), a naturally occurring FXR antagonist, and FXR antagonism 
increases Cyp7a1 expression [137]. This has been further confirmed in a separate study, where 
an anti-oxidant, tempol, was used to suppress FXR signalling, which increased the levels of 
tbMCA [141]. Specifically, tempol decreased the genera Lactobacillus and Clostridium, which 
was accompanied by decreased BSH activity [141]. Oral feeding of Lactobacillus plantarum to 
mice resulted in significant reduction in LDL-C, increased faecal BA excretion, increased 
hepatic BA synthesis, and increased gene and protein expression of Cyp7a1 [142]. Recently, 
the glycine conjugate of bMCA (GbMCA) has also been found to be an FXR antagonist, which 
in contrast to TbMCA, was found to be resistant to faecal microbial BSH [143]. However, at 
present, it is not known whether TbMCA or GbMCA can antagonise FXR signalling in humans 
and how the human microbiota, which is more adapted to glycine conjugated BAs, 
metabolises GbMCA. 
Human dietary interventions have shown that certain probiotics can reduce blood 
cholesterol by altering the microbial environment to increase BAs in the faeces [144,145]. The 
Lactobacilus reuteri strain, NCIMB 30242, which is known for its BSH activity reduced 
cholesterol levels in hypercholesterolaemic participants (>100) when fed an encapsulated form 
in a yoghurt. In a second study using the same strain of bacteria, but lyophylised, they found 
similar results and most importantly found that the participants had higher levels of de-
conjugated BAs in their faeces [145]. In addition, live Lactobacillus reuteri with BSH activity 
when fed to pigs on a high fat, high cholesterol, low fibre diet reduced total and LDL-
cholesterol concentrations [146]. Therefore, the interesting question is whether diet can alter 
the composition of the microbiota to decrease cholesterol levels. 
Polyphenols have recently emerged as modulators of the gut microbiota [147]. Tea 
polyphenols have been shown to modulate the composition of the gut microbial community 
through the inhibition of pathogenic bacteria (Clostridium perfringens, Clostridium difficile, and 
Bacteroides) [148]. In the same study, no changes to the beneficial bacteria (Clostridium, 
Bifidobacterium, and Lactobacillus) were found [148], whereas, rats fed a diet containing tea 
polyphenols or gallotannins had reduced amounts of secondary BAs in the faeces, which 
suggests a reduction in bacteria with BSH activity [149]. Accordingly, in a study using rats, 
the supplementation of a high fat diet with catechin, curcumin, caffeic acid, rutin, ellagic acid, 
or quercetin reduced the concentration of secondary BAs in the faeces [150]. This suggests that 
the amount of de-conjugating bacteria were also reduced in the rats on these diets [150]. 
However, when tea flavan-3-ol monomers such as catechin were fed to humans, there was an 
enhanced growth of members of Clostridium coccoides, particularly Eubacterium rectale, which 
are known to break down BAs to secondary BAs [151]. Interestingly, Eubacterium rectale spp. 
has been shown to play a probiotic role of butyrate synthesis from carbohydrates [152–154] 
and other members of the Clostridium coccoides family are known to have high levels of BA 7α-
dehydroxylating activity, which break down primary BAs to secondary BAs [153]. 
A human intervention study has shown that consumption of red wine polyphenols 
significantly increased the number of Bacteroides, Bifidobacterium, Enterococcus, Prevotella, 
Bacteroides uniformis, Eggerthellalenta, and Blautia coccoides-E. rectale. Correspondingly, total 
cholesterol was significantly decreased and most importantly, changes in cholesterol 
concentrations were linked to changes in the Bifidobacteria number, Bifidobacteria were 
probiotic, and some groups had BSH activity, although BSH activity was not measured [152]. 
This corresponded to a study in rats supplemented with a de-alcoholised, proanthocyanidin-
rich red wine extract over 16-weeks, where the bacterial composition changed from a 
predominance of Bacteroides, Clostridium, and Propionibacterium to a prevalence of Bacteroides, 
Lactobacillus, and Bifidobacterium [155]. Interestingly, in another study, red wine tannins had 
no effect on the conversion of primary to secondary BAs in the faeces of rats [156]. 
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In a human intervention study, the consumption of a wild blueberry drink, rich in 
polyphenols significantly increased the amount of Bifidobacterium, some Bifidobacteria are 
known to have BSH activity [157]. Proanthocyanidin-rich extract from grape seeds fed to 
healthy adults for two weeks also significantly increased the number of intestinal Bifidobacteria 
[158]. In addition, resveratrol, which is found in wine and grapes, also increased faecal counts 
of Bifidobacterium and increased Lactobacillus in a rat model, and in humans, it increased α-
diversity such as Barnesiella levels that are associated with gut health and may improve 
cholesterol metabolism [159,160]. In one study, which substituted the water fed to rats for 
grape, apple, or beetroot juice, a higher concentration of primary BAs but lower concentration 
of secondary BAs was found in the intestinal contents along with increased amounts of 
cholesterol and its metabolites. Intriguingly, this corresponded to increased faecal counts of 
bacteria with BSH activity, Lactobacillus and Bifidobacterium [114]. Raspberry pomace 
containing seeds fed to rats on a high fat diet also reduced the amount of secondary BAs (LCA 
and DCA) in the cecum, but interestingly, the seedless fraction did not have the same effect 
[161]. Grape seed flour has been shown to alter the gut microbiota of male Golden Syrian 
hamsters. Hamsters were fed a high-fat (HF) control diet or a HF diet supplemented with 10% 
partially defatted grape seed flour. The Chardonnay diet altered the numbers of total bacteria 
and relative abundances of Bifidobacterium, Lactobacillus, and Firmicutes in the faeces, which 
were significantly lower than the control group. This was accompanied by decreased intestinal 
FGF15 expression and increased liver Cyp7a1 gene expression [162]. It was suggested that 
alteration of the intestinal microbiota may regulate BA metabolism, but BAs were not 
measured in this study. 
4. Conclusions 
4.1. The Limitations of Existing Models 
Rodent models are useful for studying the effects of polyphenols on faecal BAs, liver, and 
circulating cholesterol levels, but the evidence that this occurs through the regulation of 
CYP7A1 in humans should be examined with caution, as human cells lack a LXRα response 
element in the human CYP7A1 promoter. Nevertheless, the effects of polyphenols on FXR 
signalling are similar in mice and humans with studies showing that polyphenols affect this 
signalling pathway in both species [96,97]. The reverse cholesterol transport pathway and the 
NF-κB and ERK signalling pathway are also both inducible by polyphenols in humans and 
mice [71,77,163,164], providing a degree of confidence that effects observed in mouse models 
would also be observed in humans. Thus, indicating great potential for observations in rodent 
models to inform future translational studies in human. Human cell lines are the obvious next 
best choice for functional studies, but previous research has shown that cell density can affect 
the expression of CYP7A1mRNA [165], and it has been shown that CYP7A1 expression is 
dependent on hepatocyte differentiation [166]. Specifically, cells which are more terminally 
differentiated are more responsive to hormones or BA conjugates when compared to less 
differentiated cells [13]. CYP7A1 mRNA levels significantly increased in HepG2 cells cultured 
over time [14]. In addition, the presence of Fetal Bovine Serum (FBS) inhibits 
CYP7A1expression due to the presence of bovine BAs [14]. The removal of serum was shown 
to stimulate CYP7A1 mRNA levels in HepG2 cells [13]. A factor in the serum such as calf BAs 
may be directly repressing expression of Cyp7a1. Alternatively, serum may influence 
hepatocyte differentiation, as serum-free medium has been found to promote a more 
differentiated phenotype than serum-containing medium [167,168]. Additionally, the 
presence of LDL cholesterol can affect the impact on CYP7A1. For example, when HepG2 cells 
were incubated in serum free medium with or without a red grape juice (RGJ) extract, different 
results were observed. In cells exposed to LDL-C, RGJ caused a marked reduction in the 
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expression of CYP7A1 expression, however, when LDL-C was absent, increased CYP7A1 
levels were observed on treatment with RGJ [169]. Therefore, care in the interpretation of both 
human and animal studies is required. Additionally, cells lines do not represent a multi-organ 
regulation of cholesterol and bile acid metabolism as do animal studies. Another factor that 
may greatly lead to disparities between experiments may be the concentrations of polyphenols 
used, some of which may not be physiologically relevant. 
4.2. The Most Promising Polyphenol Candidates for Future Studies 
Puerarin, an isoflavonoid, is a promising candidate for further studies. Rodent studies 
from three separate labs have shown that puerarin increases hepatic Cyp7a1 expression [81–
83]. However, when liver HepG2 cells were treated with increasing doses of puerarin, there 
was no effect, highlighting the disparity between human and animal studies [83]. The 
predominant mechanism for BA induction via puerarin in mice appears to be LXRα driven, 
which suggests that BA induction may not occur in human cells via the same pathway. This 
suggests that BA induction via polyphenols is not always LXRα driven. Quercetin has also 
been shown to regulate cholesterol metabolism via LXRα signalling as well as reverse 
cholesterol transport, which also occurs in humans, making it a promising candidate for 
further studies in humans [163]. There are documented mechanisms whereby polyphenols 
can induce CYP7A1 expression that are not driven by LXRα. For example, NF-κB and ERK 
signalling induces CYP7A1expression in human cells treated with naringin, a flavanone-7-O-
glycoside [77]. In addition, attenuated FXR signalling by resveratrol, a stilbene, has been 
shown to induce CYP7A1 mRNA expression in human HepG2 liver cells [91,92,97]. In 
conclusion, there is some promising research that polyphenols may regulate CYP7A1 
expression. In addition, modification of the gut bacteria appears to be an important factor in 
the enhancement of BAs in the faeces, through the enrichment of bacteria with BSH activity. 
Red wine, rich in phenolic polymers and resveratrol, has been particularly well documented 
at increasing beneficial bacteria [152,155,159]. In particular, resveratrol increased levels of 
Lactobacillus and Bifidobacterium in mice and bacterial α-diversity in humans. These bacteria 
have enhanced BSH activity, which enables increased BA de-conjugation to promote faecal 
excretion of BAs [98]. Further studies are required to ascertain whether the parent polyphenols 
or their metabolites are responsible for the alterations in the gut microbiota and whether the 
effects seen in animal studies can be replicated in humans to inform future clinical studies. 
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